Name,MOA,Target,Disease Area,Indication,SMILES,Phase
"((2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyltriphosphoric acid",,,,,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O,
(+)-borneol,gaba receptor agonist,"GABRA1, TRPA1, TRPM8, TRPV3",neurology/psychiatry,postherpetic neuralgia,O[C@@H]1[C@](C2(C)C)(C)CC[C@]2([H])C1,Launched
(+)-matrine,opioid receptor agonist,,,,O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34,Phase 2
(+)-sk&f 10047 hydrochloride,sigma receptor agonist,,,,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,Phase 1
(-)-huperzine a,acetylcholinesterase inhibitor,,,,C\C=C1\[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|,Phase 2
"(d-ala2,d-leu5)-enkephalin",opioid receptor agonist,,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
"(e)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)vinyl)-6-(dimethylamino)-1-methylquinolin-1-ium 4,4'-methylenebis(3-hydroxy-2-naphthoate)",,,,,CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1,
(R)-(-)-apomorphine,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A",neurology/psychiatry,Parkinson's Disease,"CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31",Launched
(R)-(-)-rolipram,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D, PDE5A",,,"COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1",Phase 1
(R)-baclofen,benzodiazepine receptor agonist,"GABBR1, GABBR2",,,"NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1",Phase 3
(r)-ketorolac,cyclooxygenase inhibitor,"CDC42, RAC1",,,OC(=O)[C@@H]1CCn2c1ccc2C(=O)c1ccccc1,Phase 3
(S)-(+)-rolipram,phosphodiesterase inhibitor,"PDE4B, PDE4D",,,"COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1",Phase 1
(2s)-2-amino-5-({(1r)-2-[(carboxymethyl)amino]-1-[(nitrososulfanyl)methyl]-2-oxoethyl}amino)-5-oxopentanoic acid,nitric oxide stimulant,,,,N[C@@H](CCC(=O)N[C@@H](CS[NH2+][O-])C(=O)NCC(O)=O)C(O)=O,Phase 1
"(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-5,6,10,12a-tetrahydroxy-6-methyl-1,3,11,12-tetraoxo-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodecahydro-2-naphthacenecarboxamide hydrate",,,,,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,
"(5z,8z,11z,14z,17z)-methyl icosa-5,8,11,14,17-pentaenoate",,,,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC,
"[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate",,,,,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,
"[sar9,met(o2)11]-substance-p",tachykinin antagonist,TACR1,,,CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O,Preclinical
A-1070722,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,"COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1",Preclinical
A-1120,retinoid receptor ligand,RBP4,,,"OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F, OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F",Preclinical
A-317491,purinergic receptor antagonist,P2RX3,,,"OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12",Preclinical
A-33903,,,,,"CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|",Phase 2
A-366,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,"COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|",Preclinical
A-381393,dopamine receptor antagonist,,,,Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1,Preclinical
A-412997,dopamine receptor agonist,DRD4,,,"Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1",Preclinical
A-438079,purinergic receptor antagonist,P2RX7,,,"Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl",Preclinical
A-485,histone acetyltransferase inhibitor,,,,"CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1, CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1",Preclinical
A-582941,nicotinic receptor agonist,CHRNA7,,,"CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1",Preclinical
A-61603,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",,,"CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|",Preclinical
A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",,,"Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1",Preclinical
A-7,calmodulin antagonist,,,,"NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",Preclinical
A-769662,AMPK activator,,,,"Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12",Preclinical
A-784168,transient receptor potential channel antagonist,TRPV1,,,"FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|",Preclinical
A-803467,sodium channel blocker,SCN10A,,,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
A-804598,purinergic receptor antagonist,P2RX7,,,"C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1",Preclinical
A-839977,purinergic receptor antagonist,P2RX7,,,"Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1",Preclinical
A-867744,acetylcholine receptor allosteric modulator,"CHRNA3, CHRNA4, CHRNA7",,,"CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O",Preclinical
A-887826,sodium channel blocker,SCN10A,,,"CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1",Preclinical
A-922500,diacylglycerol O acyltransferase inhibitor,DGAT1,,,"OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1",Preclinical
A-939572,stearoyl-CoA desaturase inhibitor,SCD,,,"CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1",Preclinical
A-967079,transient receptor potential channel antagonist,TRPA1,,,"CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1",Preclinical
A-987306,histamine receptor antagonist,"ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2",,,"Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|",Preclinical
AA-29504,GABA receptor positive allosteric modulator,"GABRA1, GABRA4, GABRB3",,,"CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N",Preclinical
AAI101,lactamase inhibitor,,,,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O,Phase 3
AB-423,HBV capsid assembly inhibitor,,,,CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1,Preclinical
ab-680,cd antagonist,NT5E,oncology,pancreatic cancer,C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]3O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]3O)c4ccccc4F,Phase 1
abacavir,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|",Launched
abafungin,sterol methyltransferase inhibitor,,,,Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|,Phase 3
abamectin,benzodiazepine receptor agonist,"GABBR1, GABBR2",infectious disease,gastrointestinal parasites,"[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|",Launched
abamectin (avermectin b1a shown),benzodiazepine receptor agonist,,infectious disease,gastrointestinal parasites,CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
abametapir,metalloproteinase inhibitor,MMP9,,,"Cc1ccc(nc1)-c1ccc(C)cn1, Cc1ccc(nc1)-c1ccc(C)cn1",Phase 3
abarelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Phase 3
ABBV-744,bromodomain inhibitor,,,,CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O,Phase 1
ABC-294640,sphingosine kinase inhibitor,SPHK2,,,"Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|",Phase 2
abc294640 hcl,sphingosine kinase inhibitor,,,,Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2,Phase 2
abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1",Launched
abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|",Launched
abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|",Launched
abt 418,,,,,CN1CCC[C@H]1c2onc(C)c2,Preclinical
ABT-072,RNA polymerase inhibitor,,,,COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O,Phase 2
ABT-202,acetylcholine receptor agonist,,,,"N[C@H]1CCN(C1)c1cccnc1 |&1:1|, N[C@H]1CCN(C1)c1cccnc1 |&1:1|",Phase 1
ABT-239,histamine receptor antagonist,"HRH1, HRH2, HRH3",,,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,Phase 1
abt-418 (hydrochloride),nicotinic receptor agonist,"CHRNA4, CHRNA7, HTR3A",neurology/psychiatry,alzheimer's disease,CN1CCC[C@H]1c1cc(C)no1.Cl |a:5|,Preclinical
ABT-491,platelet activating factor receptor antagonist,PTAFR,,,"CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C",Phase 1
ABT-639,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I",,,"Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F",Phase 2
ABT-702,adenosine kinase inhibitor,ADK,,,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
ABT-724,dopamine receptor agonist,DRD4,,,"C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1",Phase 2
ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
ABT-751,tubulin polymerization inhibitor,TUBB,,,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
ABX-1431,monoacylglycerol lipase inhibitor,,,,FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F,Phase 2
ABX464,antiviral,,,,FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1,Phase 2
ab928,adenosine receptor antagonist,"ADORA2A, ADORA2B",oncology,non-small cell lung cancer (nsclc),Cc1c(cccc1c2cc(nc(N)n2)c3cn(Cc4cccc(n4)C(C)(C)O)nn3)C#N,Phase 2
AC-186,estrogen receptor agonist,ESR2,,,"Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F",Preclinical
AC-261066,retinoid receptor agonist,RARB,,,"CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1",Preclinical
AC-264613,PAR agonist,F2RL1,,,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
AC-55541,PARP inhibitor,PARP2,,,"C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|",Preclinical
AC-55649,retinoid receptor agonist,"RARA, RARB",,,"CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O",Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",,,"CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1",Preclinical
AC-7954-(+/-),urotensin receptor agonist,UTS2R,,,"CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|",Preclinical
acadesine,AMPK activator,,,,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N",Phase 3
acalabrutinib,Bruton's tyrosine kinase (BTK) inhibitor,BTK,hematologic malignancy,mantle cell lymphoma (MCL),"CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12",Launched
acalisib,PI3K inhibitor,"PIK3CB, PIK3CD",,,"C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1",Phase 1
acamprosate,glutamate receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5",neurology/psychiatry,abstinence from alcohol,"CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O",Launched
acarbose,glucosidase inhibitor,"AMY2A, MGAM",endocrinology,diabetes mellitus,"C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|",Launched
ACDPP,glutamate receptor antagonist,GRM5,,,"CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1",Preclinical
acebilustat,leukotriene inhibitor,,,,[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2,Phase 2
acebutolol,adrenergic receptor antagonist,ADRB1,cardiology,"hypertension, ventricular arrhythmias","CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O",Launched
acebutolol hydrochloride,adrenergic receptor antagonist,CES2,Cardiology,angina pectoris,"CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(c1)C(C)=O |&1:12,r|",Launched
acecainide,polarization inhibitor,SCN5A,,,"CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1",Phase 3
aceclidine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",ophthalmology,glaucoma,"CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|",Launched
aceclidine hcl,acetylcholine receptor agonist,,ophthalmology,glaucoma,CC(=O)OC1CN2CCC1CC2,Launched
aceclofenac,prostanoid receptor antagonist,PTGS2,rheumatology,"rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia","OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl",Launched
acedapsone,,,infectious disease,leprosy,"CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1, CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1",Launched
acedoben,,,,,"CC(=O)Nc1ccc(cc1)C(O)=O, CC(=O)Nc1ccc(cc1)C(O)=O",Phase 2
acefylline,adenosine receptor agonist,ADORA1,pulmonary,asthma,"Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O",Launched
aceglutamide,,,gastroenterology,peptic ulcer disease (PUD),"CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O",Launched
acelarin,anticancer agent,,,,"C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|",Phase 2/Phase 3
acemetacin,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,osteoarthritis,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1",Launched
aceneuramic-acid,,"CES1, SELE, SELP",,,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,Phase 3
acenocoumarol,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),"CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|, CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|",Launched
acepromazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,sedative,"CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O",Launched
acesulfame-potassium,,,,,"CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|",Phase 3
acetanilide,hydrogen peroxide decomposition inhibitor,,,,"CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1",Preclinical
acetarsol,,,gastroenterology,diarrhea,"CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O",Launched
acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,"CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O",Launched
acetohexamide,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
acetohydroxamic-acid,urease inhibitor,MMP12,infectious disease,urinary tract infections,"CC(=O)NO, CC(=O)NO",Launched
acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,"CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1",Launched
acetriazoic-acid,,,,,"CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I",Preclinical
acetyl-farnesyl-cysteine,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV),"CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O",Launched
acetyl-l-leucine,,,neurology/psychiatry,vertigo,"CC(C)C[C@H](NC(C)=O)C(O)=O, CC(C)C[C@H](NC(C)=O)C(O)=O",Launched
acetyl-11-keto-beta-boswellic-acid,lipoxygenase inhibitor,"HSD11B1, HSD11B2",,,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|",Phase 2
acetylcholine,acetylcholine receptor agonist,"ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2","neurology/psychiatry, gastroenterology, pulmonary","drowsiness, fatigue, headache, indigestion, chest congestion","CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C",Launched
acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,,,,"CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O",Preclinical
acetylspiramycin,other antibiotic,,,,"[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|",Preclinical
acexamic-acid,5 alpha reductase inhibitor,GAST,dermatology,wound healing,"CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O",Launched
acifran,cholesterol inhibitor,"HCAR2, HCAR3",,,"C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|",Phase 3
acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
acitazanolast,mediator release inhibitor,,allergy,allergic rhinitis,"OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1",Launched
acitretin,retinoid receptor agonist,"RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3",dermatology,psoriasis,"COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C",Launched
acivicin,gamma glutamyltransferase inhibitor,CTPS1,,,"N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|, N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|",Phase 2
aclarubicin,topoisomerase inhibitor,"TOP1, TOP2A",hematologic malignancy,acute myeloid leukemia (AML),"CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC, CC[C@@]1(O)C[C@@H](O[C@H]2C[C@@H]([C@@H](O[C@H]3C[C@@H](O)[C@@H](O[C@H]4CCC(=O)[C@@H](C)O4)[C@@H](C)O3)[C@@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@@H]1C(=O)OC |&1:2,&2:5,&3:7,&4:9,&5:10,&6:12,&7:14,&8:16,&9:18,&10:23,&11:26,&12:29,&13:53,r|, CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC",Launched
aclidinium,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)","OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1, OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1",Launched
acolbifene,estrogen receptor antagonist,,,,CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|,Phase 3
acotiamide,acetylcholinesterase inhibitor,"ACHE, CHRM1, CHRM2",gastroenterology,dyspepsia,COc1cc(O)c(cc1OC)C(=O)Nc2nc(cs2)C(=O)NCCN(C(C)C)C(C)C,Launched
acoziborole,antitrypanosomal,,,,CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12,Preclinical
ACPC,glutamate receptor antagonist,,,,"NC1(CC1)C(O)=O, NC1(CC1)C(O)=O",Phase 1
acriflavine,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,"Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12",Launched
acriflavinium,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,"C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, C[n+]1c2cc(N)ccc2cc2ccc(N)cc12",Launched
acrisorcin,other antifungal,,infectious disease,fungal infection,CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12,Launched
acrivastine,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1",Launched
acrizanib,vegfr inhibitor,,ophthalmology,macular degeneration,CNCc1cc(Oc2ccc3n(ccc3c2)C(=O)Nc2cc(n(C)n2)C(F)(F)F)ncn1,Phase 2
acrylate,mucus protecting agent,,,,[Na].OC(=O)C=C,Phase 3
ACT-132577,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),"NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",Launched
ACT-462206,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1",Phase 1
act-709478,calcium channel blocker,CACNA1G,neurology/psychiatry,epilepsy,FC(F)(F)C1(CC1)c1ccc(CC(=O)Nc2ccn(Cc3ccc(cn3)C#N)n2)cc1,Phase 2
actarit,interleukin receptor agonist,,rheumatology,rheumatoid arthritis,"CC(=O)Nc1ccc(CC(O)=O)cc1, CC(=O)Nc1ccc(CC(O)=O)cc1",Launched
ACTB-1003,"FGFR inhibitor, VEGFR inhibitor","KDR, TEK",,,"COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1",Phase 1
actinomycin d,rna polymerase inhibitor,,oncology,"wilm's tumor, ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma","CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2CCCN2C1=O |&1:3,&2:7,&3:29,&4:30,&5:35,&6:48,&7:55,&8:65,&9:70,&10:83,r|",Launched
actinomycin-d,RNA polymerase inhibitor,,oncology,"Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma","CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O",Launched
actinonin,,,infectious disease,gram-negative bacterial infections,CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO,Preclinical
actinoquinol,,,,,"CCOc1ccc(c2cccnc12)S(O)(=O)=O, CCOc1ccc(c2cccnc12)S(O)(=O)=O",Preclinical
acumapimod,p38 MAPK inhibitor,,,,Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1,Phase 1
ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",,,"ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1",Phase 1/Phase 2
acyclovir,DNA polymerase inhibitor,PNP,infectious disease,"genitial herpes, shingles, chicken pox","Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1",Launched
AC1NDSS5,,,,,"CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC, CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC",Phase 1
AC260584,cholinergic receptor agonist,,,,CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1,Preclinical
AD-5467,aldose reductase inhibitor,AKR1B1,,,"CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|",Phase 2
adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
adaprev,TGF beta receptor inhibitor,"AKR1B1, GPI, HK1, M6PR, PYGM",,,"O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|, O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|",Phase 3
adaptavir,CC chemokine receptor antagonist,CCR5,,,"C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O",Phase 2
adarotene,retinoid receptor agonist,"RARB, RARG",,,"OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Phase 1
adatanserin,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR2A",,,"O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2",Phase 2
adavivint,WNT pathway inhibitor,,,,CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1,Phase 1
ADD-233089,benzodiazepine receptor agonist,,,,"Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1",Phase 1
adefovir,DNA polymerase inhibitor,,infectious disease,hepatitis B,"Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12",Launched
adefovir-dipivoxil,DNA polymerase inhibitor,,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
adelmidrol,anti-inflammatory agent,,dermatology,dermatitis,"OCCNC(=O)CCCCCCCC(=O)NCCO, OCCNC(=O)CCCCCCCC(=O)NCCO",Launched
ademetionine,"methyltransferase stimulant, phosphodiesterase inhibitor",,neurology/psychiatry,"depression, attention-deficit/hyperactivity disorder (ADHD)","C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",Launched
adenine,protein synthesis stimulant,"ACACB, ACP1, APRT, MTAP, PECR, SRPK2",,,"Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12",Preclinical
adenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4",cardiology,Wolff-Parkinson-White Syndrome (WPW),"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
adenosine 5-monophosphate,adenosine receptor agonist,,,,Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
adenosine-phosphate,adenosine receptor agonist,"ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4",,,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
adenosine-triphosphate,adenosine receptor agonist,"ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7",,,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",Phase 2
adiphenine,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms,"CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1",Launched
adipic-acid,solute carrier family member inhibitor,SLC22A6,,,OC(=O)CCCCC(O)=O,Preclinical
adiporon,adiponectin receptor agonist,"ADIPOR1, ADIPOR2",,,"O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1",Preclinical
ADL5859,opioid receptor agonist,OPRD1,,,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|",Phase 2
adomeglivant,glucagon receptor antagonist,,,,Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C,Preclinical
adoprazine,"dopamine receptor antagonist, serotonin receptor agonist","DRD2, HTR1A",,,"Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1",Phase 2
adrafinil,adrenergic receptor agonist,,neurology/psychiatry,fatigue,"ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|",Launched
adrenalone,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage,"CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1",Launched
adrenosterone,11-beta hydroxysteroid dehydrogenase inhibitor,"HSD11B1, HSD11B2",,,"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",Preclinical
adriforant (hydrochloride),histamine receptor antagonist,HRH4,dermatology,dermatitis,NC1=NC(N2C[C@H](NC)CC2)=CC(NCC3CC3)=N1.[H]Cl.[H]Cl.[H]Cl,Phase 2
ADX-10059,glutamate receptor negative allosteric modulator,GRM5,,,"Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1",Phase 2
ADX-47273,glutamate receptor modulator,GRM5,,,"Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1",Preclinical
AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",,,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
AEG3482,HSP inducer,,,,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
afalanine,dopamine receptor agonist,DRD2,,,"CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O",Phase 3
afamelanotide,"melatonin receptor agonist, melanocyte-stimulating hormone mimetic","MC1R, MC3R, MC4R, MC5R",dermatology,erythropoietic protoporphyria (epp),"CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O, CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O",Launched
afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
afimoxifene,estrogen receptor antagonist,"ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ",,,CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Phase 2
afloqualone,acetylcholine receptor antagonist,,neurology/psychiatry,sedative,"Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O",Launched
AFN-1252,FABI inhibitor,,,,"CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1, CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1",Phase 2
afobazole,anxiolytic,,neurology/psychiatry,anxiety,"CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1, CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1",Launched
afoxolaner,gaba receptor antagonist,GABRA1,infectious disease,flea control,FC(F)(F)CNC(=O)CNC(=O)c1ccc(C2=NOC(C2)(c3cc(Cl)cc(c3)C(F)(F)F)C(F)(F)F)c4ccccc14,Launched
AF38469,sortilin inhibitor,SORT1,,,"Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1",Preclinical
AG-1024,insulin growth factor receptor inhibitor,IGF1R,,,"CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O, CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O",Preclinical
AG-14361,PARP inhibitor,PARP1,,,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
AG-490,"EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3",,,"Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O",Preclinical
AG-555,tyrosine kinase inhibitor,CDK2,,,Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O,Preclinical
AG-556,tyrosine kinase inhibitor,,,,"Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O",Preclinical
AGI-5198,isocitrate dehydrogenase inhibitor,IDH1,,,"Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|",Preclinical
AGI-6780,isocitrate dehydrogenase inhibitor,IDH2,,,"FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1",Preclinical
AGM-1470,cell cycle inhibitor,METAP2,,,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|",Phase 2
agmatine,nitric oxide synthase inhibitor,"ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH",,,"NCCCCNC(N)=N, NCCCCNC(N)=N, NCCCCNC(N)=N",Phase 3
AGN-192403,imidazoline receptor ligand,NISCH,,,"CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|",Preclinical
AGN-194310,retinoid receptor antagonist,"RXRA, RXRB, RXRG",,,"CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|",Phase 3
AGN-195183,retinoid receptor agonist,RARA,,,"CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1, CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1",Phase 1/Phase 2
agomelatine,"melatonin receptor agonist, serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B",neurology/psychiatry,depression,"COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1",Launched
AGP-103,membrane permeability inhibitor,,,,"CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O",Launched
AH-7614,free fatty acid receptor antagonist,FFAR4,,,"Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12",Preclinical
AH11110,adrenergic receptor ligand,ADRA1B,,,"O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|",Preclinical
AH6809,prostanoid receptor antagonist,"PTGDR, PTGER1, PTGER2, PTGER3",,,"CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O",Preclinical
AI-10-49,core binding factor inhibitor,CBFB,,,"FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1, FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1",Preclinical
AIM-100,tyrosine kinase inhibitor,TNK2,,,"C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1",Preclinical
ajmaline,sodium channel blocker,"KCNH2, KCNQ1","cardiology, Tachycardias, cardiology, Tachycardias","wolff-parkinson-white syndrome (wpw), atrial fibrillation (af), Wolff-Parkinson-White Syndrome (WPW), atrial fibrillation (af)","[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, [H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O, CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O",Launched
AJ76-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4",,,"CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C",Preclinical
AK-7,SIRT inhibitor,SIRT2,,,"Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1",Preclinical
AKBA,lipoxygenase inhibitor,ALOX5,,,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|",Phase 3
aklomide,,,infectious disease,coccidiosis,"NC(=O)c1ccc(cc1Cl)[N+]([O-])=O, NC(=O)c1ccc(cc1Cl)[N+]([O-])=O",Launched
AL-8697,p38 MAPK inhibitor,MAPK14,,,"Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1",Preclinical
alacepril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O",Launched
alafosfalin,bacterial cell wall synthesis inhibitor,,,,"C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O, C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O",Phase 1
alagebrium,glycosylation inhibitor,,,,"Cc1sc[n+](CC(=O)c2ccccc2)c1C, Cc1sc[n+](CC(=O)c2ccccc2)c1C",Phase 2/Phase 3
alanine,,,,,"C[C@@H](N)C(O)=O |&1:1,r|",Launched
alanosine,antimetabolite,,,,N[C@@H](CN(O)[N+][O-])C(O)=O,Phase 2
alantolactone,"apoptosis stimulant, STAT inhibitor",STAT3,,,"C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|",Preclinical
alaproclate,serotonin receptor antagonist,SLC6A4,,,"C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|, C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|",Phase 2
alarelin,gonadotropin releasing factor hormone receptor antagonist,GNRH1,,,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1",Launched
albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
albendazole-oxide,anthelmintic agent,,infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|, CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|",Launched
albuterol,adrenergic receptor agonist,ADRB2,pulmonary,asthma,"CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NCC(O)c1ccc(O)c(CO)c1",Launched
alcaftadine,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis,"CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12, CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12",Launched
alclofenac,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis,"OC(=O)Cc1ccc(OCC=C)c(Cl)c1, OC(=O)Cc1ccc(OCC=C)c(Cl)c1",Launched
alclometasone dipropionate,glucocorticoid receptor agonist,NR3C1,Dermatology,corticosteroid-responsive dermatoses,"[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C |c:37,t:33|",Launched
alclometasone-dipropionate,glucocorticoid receptor agonist,"CYP3A4, NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|",Launched
alcuronium,muscle relaxant,"CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7",neurology/psychiatry,muscle relaxant,"OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|",Launched
alda-1,aldehyde dehydrogenase activator,ALDH2,,,"Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1",Preclinical
aldose reductase-in-1,aldose reductase inhibitor,AKR1B1,cardiology,cardiomyopathy,OC(=O)CC1=NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c4nccnc14,Phase 3
aldoxorubicin,topoisomerase inhibitor,TOP2A,,,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|",Phase 3
alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
aleglitazar,ppar receptor agonist,"PPARA, PPARG",endocrinology,diabetes mellitus,CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1,Phase 3
alendronate,bone resorption inhibitor,"ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS",orthopedics,osteoporosis,"NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,,,"CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|",Preclinical
alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
alfadolone-acetate,benzodiazepine receptor agonist,,,,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,Phase 2
alflutinib,protein tyrosine kinase inhibitor,EGFR,oncology,non-small cell lung cancer (nsclc),CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C,Phase 2
alfuzosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",urology,benign prostatic hyperplasia (BPH),"COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|",Launched
algestone acetophenide,,,endocrinology,contraceptive,CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1,Launched
algestone-acetophenide,,,endocrinology,contraceptive,CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|,Launched
alibendol,antispasmodic,,gastroenterology,bile stimulation,"COc1cc(CC=C)cc(C(=O)NCCO)c1O, COc1cc(CC=C)cc(C(=O)NCCO)c1O",Launched
alicapistat,calpain inhibitor,"CAPN1, CAPN2",neurology/psychiatry,alzheimer's disease,O=C(N[C@H](Cc1ccccc1)C(=O)C(=O)NC1CC1)[C@H]1CCC(=O)N1Cc1ccccc1 |&1:3|,Phase 1
alimemazine,"histamine receptor agonist, histamine receptor antagonist",HRH1,"neurology/psychiatry, allergy, pulmonary","sedative, urticaria, itching, cough suppressant","C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|",Launched
alinidine,bradycardic effect ,,,,Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|,Phase 3
alisertib,Aurora kinase inhibitor,AURKA,,,"COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|",Phase 3
aliskiren-hemifumarate,renin inhibitor,REN,cardiology,hypertension,"COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC",Launched
alisporivir,cyclophilin inhibitor,,,,[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C,Phase 3
alizapride,dopamine receptor antagonist,,gastroenterology,nausea,"COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15,r|",Launched
alizapride hcl,dopamine receptor antagonist,,gastroenterology,nausea,COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C,Launched
alizarin,,,,,"Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O",Preclinical
alk2-in-1,alk inihibitor,ALK,oncology,glioma,CCOC1(CCN(CC1)C(C)C)c1ccc(nc1)-c1cc2c(ccnn2c1)N1CCN(CC1)C(=O)O[C@@H]1CCOC1,Phase 1
allantoin,cosmetic,,dermatology,skin protectant,"NC(=O)N[C@H]1NC(=O)NC1=O |r|, NC(=O)N[C@H]1NC(=O)NC1=O |r|",Launched
allicin,cytokine production inhibitor,"TRPA1, TRPV1",,,"C=CCS[S@@](=O)CC=C |&1:4,r|, C=CCS[S@@](=O)CC=C |&1:4,r|",Phase 2
allopurinol,xanthine oxidase inhibitor,XDH,"rheumatology, urology","gout, kidney stones","O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12",Launched
allopurinol-riboside,"anti-leishmanial agent, phosphorylase inhibitor, anti-leishmanial agent, phosphorylase inhibitor",,,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|, OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O",Phase 2
allylestrenol,steroidal progestin,"ESR1, PGR, SLC6A9",obstetrics/gynecology,premature labor,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|,Launched
allylisothiocyanate,TRPV agonist,TRPA1,,,"C=CCN=C=S, C=CCN=C=S",Preclinical
allylthiourea,nitrification inhibitor,,,,"NC(=S)NCC=C, NC(=S)NCC=C, NC(=S)NCC=C",Preclinical
alminoprofen,cyclooxygenase inhibitor,"PTGS1, PTGS2",cardiology,edema,CC(C(=O)O)c1ccc(NCC(=C)C)cc1,Preclinical
almitrine,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD),"Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1",Launched
almonertinib,egfr inhibitor,EGFR,oncology,non-small cell lung cancer (nsclc),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C4CC4)c5ccccc35,Phase 2
almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1",Phase 3
almotriptan,serotonin receptor agonist,"HTR1B, HTR1D",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12",Launched
aloe-emodin,anticancer agent,CASP8,,,OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,Preclinical
alofanib,fgfr inhibitor,FGFR2,oncology,ovarian cancer,Cc1cc(c(NS(=O)(=O)c2cccc(c2)C(O)=O)cc1-c1cccnc1)[N+]([O-])=O,Phase 1
alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
alogliptin benzoate,dipeptidyl peptidase inhibitor,,endocrinology,diabetes mellitus,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O,Launched
aloin,angiogenesis inhibitor,,,,"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12",Preclinical
aloperine,,,,,"C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|, C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|",Preclinical
alosetron,serotonin receptor antagonist,HTR3A,,,"Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C",Withdrawn
alovudine,DNA synthesis marker,,,,Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O,Phase 2
aloxistatin,protease inhibitor,CTSG,,,"CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C",Phase 3
alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",oncology,breast cancer,"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F",Launched
alpha-asarone,"cytochrome P450 inhibitor, HMGCR inhibitor",HMGCR,,,COc1cc(OC)c(\C=C\C)cc1OC,Preclinical
alpha-D-glucopyranose,,,,,OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O,Preclinical
alpha-glucosyl-hesperidin,antioxidant,,,,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1,Preclinical
alpha-linolenic-acid,omega 3 fatty acid stimulant,"ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1",,,"CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O",Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-),histamine receptor agonist,HRH3,,,"C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1",Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+),histamine receptor agonist,HRH3,,,"C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1",Preclinical
alpha-methylserotonin,serotonin receptor agonist,"HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4",,,C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|,Preclinical
alpha-tochopherol,antioxidant,,endocrinology,vitamin E deficiency,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|",Launched
alpha-tochopheryl-acetate,antioxidant,,endocrinology,vitamin E deficiency,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|",Launched
alpidem,benzodiazepine receptor agonist,GABRA1,,,"CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1",Withdrawn
alprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,angina pectoris,"CC(C)NCC(O)COc1ccccc1CC=C, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|",Launched
alprostadil,prostanoid receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR",cardiology,congenital heart defects,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",Launched
alrestatin,aldose reductase inhibitor,AKR1B1,,,"OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
ALS-8112,,,,,"Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1",Phase 1
ALS-8176,RNA polymerase inhibitor,,,,CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O,Phase 1
altanserin,serotonin receptor antagonist,HTR2A,,,"Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1",Phase 2
althiazide,diuretic,,cardiology,hypertension,"NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|",Launched
altinicline,nicotinic receptor agonist,"CHRNA4, CHRNB2",,,"CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C",Phase 2
altiratinib,"MET inhibitor, VEGFR inhibitor","KDR, MET, TEK",,,"Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1",Phase 1
altrenogest,progestogen hormone,PGR,endocrinology,estrus,"C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|",Launched
altretamine,DNA synthesis inhibitor,,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
alverine,muscle relaxant,HTR1A,gastroenterology,"irritable bowel syndrome, diverticular disease","CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1",Launched
alvespimycin,HSP inhibitor,HSP90AA1,,,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|",Phase 2
alvimopan,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,postoperative ileus,"C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1",Launched
alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",,,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
ALX-40-4C,CC chemokine receptor antagonist,,,,CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O,Preclinical
ALX-5407,glycine transporter inhibitor,SLC6A9,,,"CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O",Phase 1
AM-1241,cannabinoid receptor agonist,"CNR1, CNR2",,,"CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|",Preclinical
AM-24,lipoxygenase inhibitor,ALOX5,,,"Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I",Phase 2
AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",,,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
AM-281,cannabinoid receptor antagonist,"CNR1, CNR2, GPR55",,,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1",Preclinical
AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",,,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1",Preclinical
AM-580,retinoid receptor agonist,RARA,,,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
AM-630,cannabinoid receptor antagonist,"CNR1, CNR2",,,"COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12",Preclinical
AM-92016,potassium channel blocker,GRIN1,,,"CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|",Preclinical
amantadine,glutamate receptor antagonist,"DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A","infectious disease, neurology/psychiatry","influenza A virus infection, Parkinson's Disease","NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2",Launched
ambazone,DNA damage inducer,,,,"NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N",Phase 1
ambenonium,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,"CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl",Launched
ambrisentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),"COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1, COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1",Launched
ambroxol,sodium channel blocker,CYP3A4,pulmonary,bronchitis,"Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|",Launched
amcasertib,kinase inhibitor,,,,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C,Phase 2
amcenestrant,,ESR1,oncology,breast cancer,OC(=O)c1ccc2c(CCCC(c3ccc(Cl)cc3Cl)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1 |c:20|,Phase 3
amcinonide,glucocorticoid receptor agonist,NR3C1,"Dermatology, dermatology","dermatitis, corticosteroid-responsive dermatoses","CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|, CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|, CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:27,t:23|",Launched
AMD-3465,CC chemokine receptor antagonist,CXCR4,,,"C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1",Preclinical
amdinocillin,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, gram-negative bacterial infections","CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O",Launched
AMD11070,CC chemokine receptor antagonist,"CCR5, CXCR4",,,"NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12",Phase 3
ameltolide,anticonvulsant,,,,"Cc1cccc(C)c1NC(=O)c1ccc(N)cc1, Cc1cccc(C)c1NC(=O)c1ccc(N)cc1",Preclinical
amenamevir,helicase primase inhibitor,,,,"Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1, Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1",Phase 1
ametantrone,anticancer agent,,,,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12,Preclinical
amezinium,adrenergic receptor agonist,ADRB2,cardiology,hypotension,"COc1cc(N)cn[n+]1-c1ccccc1, COc1cc(N)cn[n+]1-c1ccccc1",Launched
amfebutamone hcl,dopamine reuptake inhibitor,,neurology/psychiatry,depression,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,Launched
amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1",Launched
amflutizole,xanthine oxidase inhibitor,XDH,,,"Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O",Phase 2
amg 333,transient receptor potential channel antagonist,TRPM8,neurology/psychiatry,migraine headache,OC(=O)c1ccc(nc1)C(=O)N[C@@H](c1ccc(OC(F)(F)F)c(F)c1)c1ncccc1F |a:12|,Phase 1
AMG-PERK-44,PERK inhibitor,EIF2AK4,,,"Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N",Preclinical
AMG-176,MCL1 inhibitor,,,,CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|,Phase 1
AMG-208,tyrosine kinase inhibitor,MET,,,"COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1",Phase 1
AMG-232,MDM inhibitor,MDM2,,,"CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1",Phase 2
AMG-319,PI3K inhibitor,PIK3CD,,,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1",Phase 2
AMG-337,MET inhibitor,MET,,,"COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1",Phase 2
AMG-487,CC chemokine receptor antagonist,,,,"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1",Phase 2
AMG-487-(+/-),CC chemokine receptor antagonist,CXCR3,,,"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|",Phase 2
AMG-510,K-Ras inhibitor,,,,"CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F, CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F",Phase 1/Phase 2
AMG-517,TRPV antagonist,TRPV1,,,"CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1",Phase 1
AMG-548,MAP kinase inhibitor,"MAPK11, MAPK12, MAPK13, MAPK14",,,"Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O",Phase 1
AMG-837,free fatty acid receptor agonist,FFAR1,,,"CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1",Phase 1
AMG-925,"CDK inhibitor, FLT3 inhibitor","CDK4, CDK6, FLT3",,,"C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|",Phase 1
AMG-9810,TRPV antagonist,TRPV1,,,"CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1",Preclinical
AMG319,PI3K inhibitor,PIK3CD,,,"C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|",Phase 2
AMG458,MET inhibitor,MET,,,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12",Phase 1
AMI-1,protein arginine N-methyltransferase inhibitor,PRMT1,,,"Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O, Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O",Preclinical
amibegron,adrenergic receptor agonist,ADRB3,,,"CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1",Phase 3
amidopyrine,analgesic agent,,dermatology,dermatitis herpetiformis (DH),"CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O",Launched
amifampridine,potassium channel blocker,,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"Nc1ccncc1N, Nc1ccncc1N",Launched
amiflamine,monoamine oxidase inhibitor,"MAOA, SLC6A2",,,"C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|, C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|",Phase 1
amifostine,reducing agent,"ALPPL2, ENPP1",nephrology,renal toxicity,"NCCCNCCSP(O)(O)=O, NCCCNCCSP(O)(O)=O",Launched
amikacin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O",Launched
amiloride,sodium channel blocker,"AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2",cardiology,"hypertension, congestive heart failure","NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N",Launched
amineptine,dopamine receptor agonist,"SLC6A2, SLC6A4",,,"OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12",Withdrawn
aminocaproic-acid,plasminogen activator inhibitor,"LPA, PLAT, PLG",hematology,fibrinolytic bleeding,"NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O",Launched
aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|",Launched
aminoguanidine,nitric oxide synthase inhibitor,"AKR1B1, NOS2, TIMP3",,,"NN=C(N)N, NN=C(N)N, NN=C(N)N",Phase 3
aminohydroxybutyric-acid,,,neurology/psychiatry,epilepsy,"NC[C@@H](O)CC(O)=O |&1:2,r|, NC[C@@H](O)CC(O)=O |&1:2,r|",Launched
aminolevulinic-acid-benzyl-ester,,,,,"NCC(=O)CCC(=O)OCc1ccccc1, NCC(=O)CCC(=O)OCc1ccccc1",Phase 1
aminomethyltransferase,nitric oxide synthase inhibitor,NOS2,,,"C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|",Preclinical
aminopentamide,acetylcholine receptor antagonist,CHRM1,gastroenterology,"acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea",CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,Launched
aminophylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A",pulmonary,"asthma, bronchitis, emphysema","Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O",Launched
aminopterin,dihydrofolate reductase inhibitor,"DHFR, SLC46A1",,,"Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1",Phase 3
aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5",,,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
aminosalicylate,cyclooxygenase inhibitor,"ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2",gastroenterology,"inflammatory bowel disease, ulcerative colitis","Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1",Launched
aminothiadiazole,inosine monophosphate dehydrogenase inhibitor,"ADORA3, IMPDH1",,,"Nc1nncs1, Nc1nncs1, Nc1nncs1",Phase 2
aminothiazole,cyclin D inhibitor,NOS2,,,"Nc1nccs1, Nc1nccs1, Nc1nccs1",Preclinical
amiodarone,potassium channel blocker,"ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2",cardiology,ventricular arrhythmias,"CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1",Launched
amiprilose,CD antagonist,,,,CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO,Phase 3
amiselimod,sphingosine 1-phosphate receptor modulator,,,,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,Phase 2
amisulpride,dopamine receptor antagonist,DRD2,neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|",Launched
amitifadine,serotonin transporter (SERT) inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,"Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|, Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|",Phase 3
amitraz,adrenergic receptor agonist,"ADRA1A, ADRA2A",infectious disease,generalized demodicosis,"CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C, CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C",Launched
amitriptyline,"norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,"CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12",Launched
amlexanox,histamine receptor modulator,"FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13","dental, pulmonary, ophthalmology, allergy","aphthous ulcers, asthma, conjunctivitis, allergic rhinitis","CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O",Launched
amlodipine,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1",cardiology,"hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)","CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|",Launched
amlodipine besylate (norvasc),calcium channel blocker,,cardiology,"hypertension, chronic stable angina, vasospastic angina, coronary artery disease (cad)",CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC,Launched
ammonium glycyrrhizinate,thrombin inhibitor,,dermatology,cosmetic,C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O,Launched
ammonium-glycyrrhizinate,thrombin inhibitor,"HSD11B1, HSD11B2, SLCO1B1, SLCO1B3",dermatology,cosmetic,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|,Launched
ammonium-lactate,,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris","N.C[C@@H](O)C(O)=O |&1:2,r|, N.C[C@@H](O)C(O)=O |&1:2,r|",Launched
ammonium-perfluorocaprylate,Pim kinase inhibitor,PIM1,,,"OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F",Phase 1
AMN-082,glutamate receptor modulator,GRM7,,,"C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1",Preclinical
amodiaquine,histamine receptor agonist,HNMT,infectious disease,malaria,"CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O",Launched
amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",,,"CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23",Phase 3
amorolfine,membrane integrity inhibitor,,infectious disease,onychomycosis,"CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|",Launched
amoxapine,norepinephrine reputake inhibitor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|",Launched
amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
AMPA-(RS),glutamate receptor agonist,GRIN1,,,"Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|",Preclinical
AMPA-(S),glutamate receptor agonist,"GRIA2, GRIN1",,,"Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O",Preclinical
ampalex,glutamate receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,"O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1",Phase 2
amperozide,dopamine receptor antagonist,"FAAH, HTR2A",neurology/psychiatry,psychosis,"CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1",Launched
amphotericin-b,membrane permeability enhancer,,infectious disease,fungal infection,"C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|",Launched
ampicillin,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
ampiroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|",Launched
amprenavir,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1",Launched
amprolium,thiamine uptake blocker,,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
ampyrone,cyclooxygenase inhibitor,,,,"Cc1c(N)c(=O)n(-c2ccccc2)n1C, Cc1c(N)c(=O)n(-c2ccccc2)n1C",Preclinical
amrinone,phosphodiesterase inhibitor,"PDE3A, PDE3B, PDE4B, TNF",cardiology,congestive heart failure,"Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1",Launched
amrubicin,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,small cell lung cancer,"CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1",Launched
amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
amthamine,histamine receptor agonist,HRH2,,,"Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN",Preclinical
amtolmetin-guacil,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C",Launched
amuvatinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor","KIT, MET",,,"S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12",Phase 2
amxt-1501 tetrahydrochloride,ornithine decarboxylase inhibitor,"ODC1, TPO",oncology,neuroblastoma,CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](N)C(=O)NCCCNCCCCNCCCN.Cl.Cl.Cl.Cl,Phase 1
amygdalin,caspase activator,CASP3,,,"OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
amyl-nitrite,atrial natriuretic peptide receptor agonist,,,,CCCCCO[NH2+][O-],Preclinical
amyleine,local anesthetic,,,,"CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|",Preclinical
amylene-hydrate,local anesthetic,,,,"CCC(C)(C)O, CCC(C)(C)O",Preclinical
amylmetacresol is a component of strepsis mixture,sodium channel blocker,SCN2A,otolaryngology,sore throat,CCCCCC1=C(C=C(C=C1)C)O,Launched
amyloid p-in-1,beta amyloid inhibitor,APP,neurology/psychiatry,alzheimer's disease,O=C(CCCCC(=O)N1CCC[C@@H]1C(=O)OCOC(=O)OC2CCOCC2)N3CCC[C@@H]3C(=O)OCOC(=O)OC4CCOCC4,Phase 1
AMZ30,protein phosphatase inhibitor,,,,[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1,Preclinical
AM095,lysophosphatidic acid receptor antagonist,,,,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Preclinical
AM211,prostaglandin inhibitor,,,,CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1,Preclinical
AM679,"cannabinoid receptor agonist, lipoxygenase inhibitor","ALOX5AP, CNR1, CNR2",,,COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1,Preclinical
ANA-12,tropomyosin receptor kinase inhibitor,NTRK2,,,"O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|",Preclinical
anabasine,acetylcholine receptor agonist,,,,"C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|",Preclinical
anacetrapib,cholesteryl ester transfer protein inhibitor,CETP,,,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,Phase 3
anacetrapib (mk-0859),cholesteryl ester transfer protein inhibitor,,,,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,Phase 3
anagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N",Launched
anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|",Launched
anamorelin,growth hormone secretagogue receptor agonist,GHSR,,,"CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N",Phase 3
anandamide,cannabinoid receptor agonist,"CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1",,,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO",Phase 2
anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
andarine,androgen receptor modulator,AR,,,"CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1",Phase 1
andrographolide,tumor necrosis factor production inhibitor,"IL1B, IL6, NFKB1, NFKB2, TNF",,,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12,Phase 2
androstenone,steroid,,,,"C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|",Preclinical
androsterone,androgen receptor agonist,,,,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O",Preclinical
anecortave-acetate,angiogenesis inhibitor,,ophthalmology,macular degeneration,"CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25,t:15|",Launched
anethole,glutathione transferase stimulant,,,,"COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1",Launched
anethole-trithione,glutathione transferase stimulant,,dental,xerostomia,"COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1",Launched
anguidine,"protein synthesis inhibitor, apoptosis stimulant",SLC5A1,Endocrinology,diabetes mellitus,"CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|",Preclinical
anidulafungin,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,"candidemia, fungal infection, esophageal candidiasis",CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|,Launched
aniracetam,glutamate receptor agonist,"DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A",,,"COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O",Launched
anisindione,vitamin K antagonist,GGCX,hematology,deep vein thrombosis (DVT),"COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O",Launched
anisodamine,lipid peroxidase inhibitor,ADRA1A,,,"CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|",Phase 3
anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,"COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1",Preclinical
anisotropine,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD),CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C,Launched
anisotropine methylbromide,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (pud),"CCCC(CCC)C(=O)O[C@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C |a:12,15,&1:10|",Launched
anlotinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR, PDGFRB",,,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1",Launched
anpirtoline,serotonin receptor agonist,HTR1B,,,"Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1",Phase 1
ANR-94,adenosine receptor antagonist,ADORA2A,,,"CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC",Preclinical
ansamitocin-p-3,apoptosis stimulant,,,,"[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|",Preclinical
ansofaxine,,,,,CN(C)CC(c1ccc(OC(=O)c2ccc(C)cc2)cc1)C3(O)CCCCC3,Phase 3
ansofaxine hydrochloride,dopamine-norepinephrine reuptake inhibitor,"ADRA1A, DRD2, HTR2A",neurology/psychiatry,depression,"CN(C)C[C@H](c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1.Cl |&1:4,r|",Phase 3
antagonist-g,neuropeptide receptor antagonist,MAPK8,,,"CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",Phase 1
antalarmin,corticotropin releasing factor receptor antagonist,CRHR1,,,"CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C",Preclinical
antazoline,antihistamine,HRH1,"ophthalmology, otolaryngology","conjunctivitis, nasal congestion","C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|",Launched
anthralin,DNA synthesis inhibitor,,dermatology,psoriasis,"Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12",Launched
anthraquinone,CDC inhibitor,CDC25B,,,"O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12",Preclinical
antimony potassium tartrate trihydrate,,,,,OC(=O)C1O[Sb]2OC(C(O[Sb]3OC1C(=O)O3)C(O)=O)C(=O)O2,Phase 2
antimony-potassium,,,,,[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|,Phase 2
antimonyl,,,,,"O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O, O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O",Phase 1
antimycin-A,ATP synthase inhibitor,CYCS,,,CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O,Preclinical
antineoplaston a10,p53 activator,"DPM1, LGALS1",oncology,brainstem glioma,O=C(Cc1ccccc1)N[C@H]2CCC(=O)NC2=O,Phase 2
antioxine,,,,,"CC(C)c1ccc(C)c(O)c1, CC(C)c1ccc(C)c(O)c1",Launched
AN2718,leucyl-tRNA synthetase inhibitor,,,,"OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12",Phase 1
AP-18,transient receptor potential channel antagonist,TRPA1,,,"C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O",Preclinical
apabetalone,apolipoprotein expression enhancer,BRD3,,,"COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1",Phase 3
apafant,platelet activating factor receptor antagonist,PTAFR,,,"Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|",Phase 3
apalutamide,androgen receptor antagonist,,oncology,prostate cancer,"CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F",Launched
apararenone,mineralocorticoid receptor antagonist,,,,CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1,Preclinical
apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",,,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
APC-100,"androgen receptor antagonist, anti-inflammatory agent",AR,,,"Cc1c(C)c2OC(C)(C)CCc2c(C)c1O, Cc1c(C)c2OC(C)(C)CCc2c(C)c1O",Phase 1/Phase 2
APcK-110,KIT inhibitor,"KIT, STAT3",,,"COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1",Preclinical
APD597,glucose dependent insulinotropic receptor agonist,GPR119,,,"COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C, COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C",Phase 1
APD668,glucose dependent insulinotropic receptor agonist,GPR119,,,"CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O",Phase 1
aphidicolin,RNA synthesis inhibitor,,,,"C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO",Phase 1
API-001,sigma receptor antagonist,SIGMAR1,,,"Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1",Phase 2
API-1,AKT inhibitor,"AKT1, AKT2, AKT3",,,"NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O",Preclinical
apigenin,"casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1",,,"Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1",Preclinical
apixaban,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)","COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O",Launched
apocynin,NADPH oxidase inhibitor,NOX4,,,"COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O",Phase 1
apomorphine hydrochloride,dopamine receptor agonist,,neurology/psychiatry,parkinson's disease,CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31,Launched
apoptosis-activator-II,carboxylesterase inhibitor,"BCHE, CES1",,,"Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl",Preclinical
APR-246,p53 activator,TP53,,,"COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|",Phase 3
apraclonidine,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C",ophthalmology,"glaucoma, intraocular pressure","Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|, Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|",Launched
apramycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O,Launched
apramycin sulfate,bacterial 30s ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,CN[C@H]1[C@@H](O)[C@H]2O[C@@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O,Launched
apratastat,"matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9",,,"CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1",Phase 2
apremilast,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D","dermatology, rheumatology","psoriasis, psoriatic arthritis","CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O",Launched
aprepitant,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting",C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,Launched
apricitabine,nucleoside reverse transcriptase inhibitor,,,,Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,Phase 3
aprindine,voltage-gated sodium channel blocker,"CALM1, SCN5A",cardiology,cardiac arrythmia,"CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1, CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1",Launched
apronal,cytochrome P450 modulator,,,,"CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|",Preclinical
aptiganel,glutamate receptor antagonist,GRIN1,,,"CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12",Phase 3
APTO-253,kr√ºppel-like factor expression enhancer,KLF4,,,"Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21",Phase 1
APY-29,serine/threonine kinase inhibitor,ERN1,,,"C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1",Preclinical
apyramide,cyclooxygenase inhibitor,,,,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1,Preclinical
APY0201,phosphoinositide dependent kinase inhibitor,"IL12A, IL12B, PIKFYVE",,,"Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1",Preclinical
AP1903,,MTOR,,,"CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1, CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1",Phase 1/Phase 2
AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",,,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C",Phase 2
AQ-RA741,acetylcholine receptor antagonist,CHRM2,,,"CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1",Preclinical
AQ-13,antimalarial agent,,,,CCN(CC)CCCNc1ccnc2cc(Cl)ccc12,Phase 2
AQW-051,nicotinic receptor agonist,,,,Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1,Preclinical
AR-A014418,glycogen synthase kinase inhibitor,GSK3B,,,"COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1",Preclinical
AR-C155858,monocarboxylate transporter inhibitor,"SLC16A1, SLC16A7",,,"CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O",Preclinical
AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,,,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
ar-13324 m1 metabolite,protein kinase c inhibitor,"PRKCA, ROCK1",ophthalmology,macular degeneration,NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1,Phase 1
AR-42,HDAC inhibitor,HDAC1,,,"CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1",Phase 1
ar-9281,epoxide hydolase inhibitor,EPHX2,cardiology,hypertension,CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3,Phase 2
arachidonic-acid,cytochrome P450 inhibitor,"CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2",,,"CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",Phase 1
aramchol,stearoyl-CoA desaturase inhibitor,,,,CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1,Phase 2/Phase 3
aranidipine,l-type calcium channel blocker,CACNA1C,cardiology,hypertension,COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(=O)C)C,Preclinical
arbidol,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection,"CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12",Launched
arbutamine,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",cardiology,coronary artery disease (cad),Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2,Withdrawn
arbutin,melanin inhibitor,TYR,,,"OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2/Phase 3
ARC-239,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C",,,"COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1",Preclinical
arctigenin,MEK inhibitor,"CHUK, MAP2K1",,,"COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC",Preclinical
arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",,,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
ardeparin,thrombin inhibitor,SERPIND1,,,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,Withdrawn
arecaidine-but-2-ynyl-ester,acetylcholine receptor agonist,CHRM2,,,CC#CCOC(=O)C1=CCCN(C)C1 |t:7|,Preclinical
arecaidine-propargyl-ester,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|",Preclinical
arecoline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|",Phase 1
argatroban,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT),"C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|",Launched
argireline,neurotransmitter release inhibitor,,,,CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O,Phase 3
arglabin,farnesyltransferase inhibitor,"FNTA, NFKB1",,,"CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|",Launched
arimoclomol,superoxide dismutase inhibitor,"HSPA1A, SOD1",neurology/psychiatry,amyotrophic lateral sclerosis (als),O[C@@H](CO\N=C(/Cl)\c1ccc[n+]([O-])c1)CN2CCCCC2,Phase 3
aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
aripiprazole-lauroxil,serotonin receptor agonist,,neurology/psychiatry,schizophrenia,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12,Launched
arofylline,phosphodiesterase inhibitor,PDE4A,,,"CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O, CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O",Phase 3
arotinolol,adrenergic receptor antagonist,ADRB3,"cardiology, neurology/psychiatry","hypertension, tremors","CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|",Launched
ARQ-092,AKT inhibitor,AKT2,,,"Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1",Phase 1
ARQ-621,kinesin-like spindle protein inhibitor,KIF11,,,"NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F",Phase 1
ARRY-334543,EGFR inhibitor,ERBB2,,,"C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|",Phase 2/Phase 3
arsanilic-acid,,LYZ,,,"Nc1ccc(cc1)[As](O)(O)=O, Nc1ccc(cc1)[As](O)(O)=O",Phase 1
arsenic trioxide diethanolamine salt,apoptosis stimulant,,gastroenterology,diarrhea,O[AsH]O[AsH]O,Launched
arsenic-trioxide,apoptosis stimulant,"AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1",gastroenterology,diarrhea,O=[As]O[As]=O,Launched
artelinic acid,antimalarial agent,,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](OCc3ccc(cc3)C(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 |a:1,4,5,7,20,22,26,27|",Preclinical
artemether,antimalarial agent,ATP1A1,infectious disease,malaria,"CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3",Launched
artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
artemotil,,,infectious disease,malaria,"CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3",Launched
artesunate,DNA synthesis inhibitor,,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
articaine,local anesthetic,,neurology/psychiatry,local anesthetic,"CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|, CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|",Launched
arundic-acid,astrocyte modulating agent,"PTGS2, S100B",,,"CCCCCC[C@@H](CCC)C(O)=O, CCCCCC[C@@H](CCC)C(O)=O",Phase 2/Phase 3
ARV-825,bromodomain inhibitor,BRD4,,,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|",Preclinical
AS-1269574,glucose dependent insulinotropic receptor agonist,GPR119,,,"Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1",Preclinical
AS-1892802,rho associated kinase inhibitor,ROCK1,,,"OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1",Preclinical
AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,,,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
AS-2034178,free fatty acid receptor agonist,FFAR1,,,"OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F",Preclinical
AS-2444697,interleukin inhibitor,IRAK4,,,"Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1",Preclinical
AS-252424,PI3K inhibitor,PIK3CG,,,"Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1",Preclinical
AS-604850,PI3K inhibitor,"PIK3CA, PIK3CG",,,FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1,Preclinical
AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",,,"OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F",Phase 2
AS-77,potassium channel blocker,"KCNA3, KCNA5, KCNN4",,,"O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1",Phase 1
ASA-404,angiogenesis inhibitor,,,,"Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C, Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C",Phase 3
asapiprant,prostaglandin inhibitor,,,,CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1,Preclinical
asaraldehyde,cyclooxygenase inhibitor,PTGS2,,,"COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC",Preclinical
ASC-J9,androgen receptor enhancer,AR,,,"COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC",Phase 2
asciminib,Bcr-Abl kinase inhibitor,,,,O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1,Phase 2
ascomycin,calcineurin inhibitor,FKBP1A,,,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|,Preclinical
ascorbic-acid,antioxidant,"SLC23A1, SLC23A2",endocrinology,scurvy,"OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|",Launched
asenapine,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A",neurology/psychiatry,"schizophrenia, bipolar disorder","[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|, [H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|",Launched
asenapine maleate,"dopamine receptor antagonist, serotonin receptor antagonist",,neurology/psychiatry,"schizophrenia, bipolar disorder",CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21,Launched
asiatic-acid,apoptosis stimulant,PYGM,,,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",Preclinical
asimadoline,opioid receptor agonist,OPRK1,,,CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1,Phase 3
asivatrep,transient receptor potential channel antagonist,,,,CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F,Phase 3
ASP-2535,glycine transporter inhibitor,SLC6A9,,,"CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12",Phase 1
ASP-6537,cyclooxygenase inhibitor,,,,COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1,Preclinical
ASP-9521,aldo-keto reductase inhibitor,,,,COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1,Preclinical
aspartame,,"TAS1R2, TRPV1",,,"COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O",Launched
aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
ASP3026,ALK tyrosine kinase receptor inhibitor,ALK,,,"COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",Phase 1
asp5878,fgfr inhibitor,FGFR3,,,OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1,Phase 1
AST-1306,EGFR inhibitor,"EGFR, ERBB2",,,"Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1",Phase 1
astaxanthin,antioxidant,,,,"C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9,34|",Launched
astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",,,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
astilbin,"nuclear factor erythroid derived, like (NRF2) activator",,,,C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,Preclinical
astragaloside-a,anti-inflammatory agent,,,,"CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C, CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C",Preclinical
ASTX660,apoptosis inhibitor,,,,C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1,Phase 1/Phase 2
asunaprevir,HCV inhibitor,,,,"COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12",Phase 3
asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",,,"CN(C)C(=N)NCCC[C@H](N)C(O)=O, CN(C)C(=N)NCCC[C@H](N)C(O)=O",Phase 1
AT-1015,serotonin receptor antagonist,HTR2A,,,"O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|",Preclinical
AT-406,IAP antagonist ,,,,"CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C, CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C",Phase 1
AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",,,"Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1",Phase 2
AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",,,"O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1",Phase 2
ataluren,"CFTR channel agonist, dystrophin stimulant",DMD,"genetics, pulmonary","duchenne muscular dystrophy (DMD), cystic fibrosis","OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F, OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F",Launched
atamparib,parp inhibitor,TIPARP,oncology,carcinoid tumors,C[C@@H](COCCC(=O)N1CCN(CC1)c2ncc(cn2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F,Phase 1
atazanavir,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C",Launched
ATB-346,cyclooxygenase inhibitor,PTGER2,,,"COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|",Phase 2
atenolol-(+),adrenergic receptor antagonist,,,,"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1",Preclinical
atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2, LTF, PLA2G2E",cardiology,"hypertension, angina pectoris","CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|",Launched
atenolol-(-),adrenergic receptor antagonist,,cardiology,hypertension,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Launched
atglistatin,adipose triglyceride lipase inhibitor,,,,"CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C",Preclinical
aticaprant,opioid receptor antagonist,,,,Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1,Phase 2
atipamezole,adrenergic receptor antagonist,,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",,,"CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1",Phase 2
atizoram,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",,,"COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1",Phase 2
atm-3507,tropomyosin receptor kinase inhibitor,TPM3,oncology,ovarian cancer,CN1CCN(CCCn2c(C)c(C)c3cc(Oc4cccc(c4)C(=O)N5CCN(CCc6ccc(F)cc6)CC5)ccc23)CC1,
ATN-161,integrin antagonist,"ITGA5, ITGAV, ITGB1, ITGB3",,,"CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O",Phase 2
atomoxetine,norepinephrine transporter inhibitor,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD),"CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1",Launched
atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
atosiban,oxytocin receptor antagonist,"AVPR1A, AVPR1B, AVPR2, OXT, OXTR","Birth, neurology/psychiatry, cardiology, endocrinology","premature labor, stroke, angina pectoris, myocardial infarction, hyperlipidemia","CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|",Launched
atovaquone,mitochondrial electron transport inhibitor,,infectious disease,pneumonia,"Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|",Launched
atp,purinergic receptor activator,,Cardiology,cardiac arrythmia,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,Phase 3
ATPA,glutamate receptor agonist,GRIK1,,,"CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|",Preclinical
atr inhibitor 2,atr kinase inhibitor,ATR,oncology,ovarian cancer,Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(CC1)C(=O)N1CCN(CC1)C1COC1,Phase 2
atractylenolide-i,JAK inhibitor,,,,"[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|",Preclinical
atracurium,acetylcholine receptor antagonist,,"critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7,&2:20,&3:37,&4:51|",Launched
atracurium besylate,acetylcholine receptor antagonist,,"critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant",COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC,Launched
atrasentan,endothelin receptor antagonist,EDNRA,,,"CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1",Phase 3
atropine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",ophthalmology,"cycloplegia, mydriasis, amblyopia","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",Launched
atropine-oxide,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,"C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|",Preclinical
atuveciclib,CDK9 inhibitor,,,,COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1,Phase 1
AT13148,protein kinase inhibitor,"AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3",,,"NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1",Phase 1
AT13387,HSP inhibitor,HSP90AA1,,,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",,,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
auranofin,NFkB pathway inhibitor,"IKBKB, PRDX5, TRPA1",rheumatology,rheumatoid arthritis,"CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O",Launched
aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,,,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
aurothioglucose,PKC inhibitor,PRKCI,rheumatology,rheumatoid arthritis,"OC[C@H]1OC(S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O",Launched
AUT-1,potassium channel activator,,,,CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1,Preclinical
autotaxin-modulator-1,autotaxin inhibitor,ENPP2,,,"C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|, C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|",Preclinical
AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,"CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C",Phase 1
AV-608,tachykinin antagonist,TACR1,,,"FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12",Phase 2
avacopan,complement inhibitor,,,,Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F,Phase 2
avadomide,antitumor agent,,,,"Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|",Phase 2
avagacestat,gamma secretase inhibitor,PSEN1,,,"NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1",Phase 2
avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
avapritinib,KIT inhibitor,,,,Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1,Launched
avasimibe,ACAT inhibitor,CES1,,,"CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C",Phase 3
avatrombopag,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia,"OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1, OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1",Launched
AVE-0991,angiotensin receptor agonist,MRGPRX1,,,"CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1",Preclinical
AVE-3085,nitric oxide synthase stimulant,,,,FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1,Preclinical
AVex-73,sigma receptor agonist,,,,"CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|",Preclinical
avibactam,beta lactamase inhibitor,,infectious disease,"intra-abdominal infections, urinary tract infections, pyelonephritis","NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O",Launched
avilamycin,other antibiotic,,infectious disease,gram-positive bacterial infections,[H][C@]12COC(O[C@@H]3O[C@H](COC)[C@@H](O[C@@H]4O[C@H](C)[C@H](OC)[C@H](O[C@H]5C[C@@]6(C)OC7(C[C@@H](O)[C@H](O[C@H]8C[C@@H](O)[C@H](OC(=O)C9=C(C)C(Cl)=C(O)C(Cl)=C9OC)[C@@H](C)O8)[C@@H](C)O7)O[C@]6([H])[C@@H](C)O5)[C@H]4O)[C@H](O)[C@@H]3OC)[C@H](OC(=O)C(C)C)[C@]1([H])O[C@@]1(O2)O[C@H](C)[C@@](O)(C(C)=O)[C@]2([H])OCO[C@@]12[H],Launched
avitinib,EGFR inhibitor,,,,CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F,Phase 2
AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",,,"COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1",Phase 2
AVN-492,serotonin receptor antagonist,,,,"CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1, CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1",Preclinical
AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",,,"CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1",Phase 2
avobenzone,topical sunscreen agent,,dermatology,"cosmetic, sunscreen lotion","COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C",Launched
avoralstat,kallikrein inhibitor,,,,COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1,Phase 3
avridine,immunostimulant,,,,CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO,Preclinical
AX-024,cytokine production inhibitor,,,,COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|,Preclinical
axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1",Launched
AY-9944,hedgehog pathway modulator,,,,"Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|",Preclinical
AZ-10417808,caspase inhibitor,CASP3,,,"[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1",Preclinical
AZ-10606120,purinergic receptor antagonist,P2RX7,,,"OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1",Preclinical
AZ-12080282,hedgehog pathway inhibitor,DHH,,,"Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1",Preclinical
AZ-628,RAF inhibitor,"BRAF, RAF1",,,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
AZ-7371,antibacterial ,,,,COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C,Preclinical
azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
azacyclonol,histamine receptor antagonist,HRH1,,,"OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1",Preclinical
azaguanine-8,purine antagonist,PNP,,,"Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1",Preclinical
azalomycin-B,bacterial 50S ribosomal subunit inhibitor,,,,"CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|",Preclinical
azaperone,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,sedative,"Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1",Launched
azapropazone,cyclooxygenase inhibitor,PTGS2,,,"CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|, CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|",Withdrawn
azaserine,purine antagonist,,,,N[C@@H](COC(=O)C[N+]#N)C(O)=O,Preclinical
azasetron,serotonin receptor antagonist,"HTR3A, HTR3B",infectious disease,genitial herpes,"CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|, CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|",Launched
azatadine,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12",Launched
azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O",Launched
azd-0364,erk1 and erk2 phosphorylation inhibitor,MAPK1,oncology,non-small cell lung cancer (nsclc),COC[C@H]1Cn2cc(nc2C(=O)N1Cc1ccc(F)c(F)c1)-c1nc(Nc2ccnn2C)ncc1C,Preclinical
azd-4017,11-beta hydroxysteroid dehydrogenase inhibitor,"GGT1, HSD11B1",endocrinology,obesity,CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@@H](CC(O)=O)C1 |a:23|,Phase 2
azd-7648,dna protein kinase inhibitor,PRKDC,oncology,melanoma,Cc1cc2ncnn2cc1Nc1ncc2n(C)c(=O)n(C3CCOCC3)c2n1,Phase 1/Phase 2
AZD0156,ATM kinase inhibitor,,,,CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1,Phase 1
AZD1080,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,"O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N",Phase 1
AZD1208,Pim kinase inhibitor,"PIM1, PIM2, PIM3",,,"N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1",Phase 1
AZD1283,purinergic receptor antagonist,P2RY12,,,"CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1",Preclinical
AZD1390,ATM kinase inhibitor,,,,"CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O, CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O",Phase 1
AZD1446,acetylcholine receptor agonist,"CHRNA4, CHRNB2",,,"Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|",Phase 2
AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",,,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1",Phase 1
azd1940,cannabinoid receptor agonist,"CNR1, CNR2",neurology/psychiatry,acute pain,CCS(=O)(=O)Nc1ccc2n(CC3CCC(F)(F)CC3)c(nc2c1)C(C)(C)C,Preclinical
AZD1981,CRTH receptor antagonist,PTGDR2,,,"CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12",Phase 2
AZD2014,mTOR inhibitor,MTOR,,,"CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",Phase 2
azd2098,ccr antagonist,CCR4,pulmonary,asthma,O=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=CN=C2OC)=O,Preclinical
AZD2461,PARP inhibitor,,,,"COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F",Phase 1
AZD2858,glycogen synthase kinase inhibitor,GSK3B,,,"CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1",Preclinical
AZD3264,IKK inhibitor,IKBKB,,,"Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1, Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1",Preclinical
AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",,,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
AZD3514,androgen receptor modulator,AR,,,"CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|",Phase 1
AZD3759,EGFR inhibitor,EGFR,,,"COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C, COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C",Phase 2/Phase 3
AZD3839,beta-secretase inhibitor,BACE1,,,"NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|",Phase 1
AZD3965,monocarboxylate transporter inhibitor,SLC16A1,,,"CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O, CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O",Phase 1
AZD3988,diacylglycerol kinase inhibitor,DGAT1,,,"OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|",Preclinical
AZD4282,glutamate receptor antagonist,"AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9",,,"NCC(O)=O, NCC(O)=O",Phase 1
AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",,,"COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1",Phase 2/Phase 3
AZD4573,CDK9 inhibitor,,,,CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1,Phase 1
AZD4635,adenosine receptor antagonist,,,,Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1,Phase 1/Phase 2
AZD5069,CC chemokine receptor antagonist,CXCR2,,,C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,Phase 2
AZD5153,bromodomain inhibitor,,,,[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|,Phase 1
AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",,,"NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1",Phase 3
azd5423,glucocorticoid receptor modulator,"BGLAP, NR3C1",pulmonary,chronic obstructive pulmonary disease (copd),"COc1cccc(c1)[C@@H](Oc1ccc2n(ncc2c1)-c1ccc(F)cc1)[C@H](C)NC(=O)C(F)(F)F |a:8,26|",Phase 2
AZD5438,CDK inhibitor,KCNH2,,,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
AZD5582,XIAP inhibitor,"BIRC2, BIRC3, XIAP",,,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1",Preclinical
AZD5991,MCL1 inhibitor,,,,Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C,Phase 1
AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
AZD6738,ATR kinase inhibitor,ATR,,,"C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|",Phase 2
AZD6765,glutamate receptor antagonist,GRIN1,,,"N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|, N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|",Phase 2
AZD7545,pyruvate dehydrogenase kinase inhibitor,PDK1,,,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1,Phase 1
AZD7594,glucocorticoid receptor modulator,,,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1,Phase 2
AZD7687,diacylglycerol O acyltransferase inhibitor,DGAT1,,,"Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|",Phase 1
AZD7762,CHK inhibitor,"CHEK1, CHEK2",,,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
AZD7986,dipeptidyl peptidase inhibitor,,,,Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1,Phase 1
AZD8055,mTOR inhibitor,MTOR,,,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",Phase 1
AZD8186,PI3K inhibitor,"PIK3CB, PIK3CD",,,"C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C",Phase 1
azd8329,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,endocrinology,obesity,CC(C)(C)c1c(cnn1-c1ccc(cc1)C(O)=O)C(=O)NC1C2CC3CC(C2)CC1C3,Phase 1
AZD8330,MEK inhibitor,MAP3K1,,,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
AZD8797,CC chemokine receptor antagonist,,,,CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12,Preclinical
AZD8835,PI3K inhibitor,"PIK3CA, PIK3CD",,,"CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO",Phase 1
AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",,,"CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC",Phase 2
AZD9056,purinergic receptor antagonist,,,,OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2,Phase 2
AZD9272,glutamate receptor antagonist,GRM5,,,"Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N",Preclinical
AZD9496,estrogen receptor agonist,ESR1,,,"C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F",Phase 1
AZD9668,elastase inhibitor,ELANE,,,"Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C",Phase 2
azelaic-acid,tyrosinase inhibitor,"AKR1D1, SRD5A2, TYR",dermatology,rosacea,"OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O",Launched
azelastine,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|",Launched
azeliragon,RAGE receptor antagonist,AGER,,,"CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1",Phase 3
azelnidipine,calcium channel blocker,CACNA1C,cardiology,hypertension,"CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|",Launched
azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
azilsartan-medoxomil,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
azimilide,potassium channel blocker,KCNA5,,,"CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1",Phase 3
azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
azlocillin,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
azlocillin sodium salt,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections",CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O,Launched
AZM-475271,SRC inhibitor,SRC,,,"COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1",Preclinical
azodicarbonamide,DNA synthesis inhibitor,,,,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
azomycin-(2-nitroimidazole),protein synthesis inhibitor,,,,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
azosemide,electrolyte reabsorption inhibitor,"SLC12A1, SLC12A2",cardiology,edema,"NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl",Launched
aztreonam,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
azvudine (hydrochloride),nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (hiv-1),"Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2F)c(=O)n1.Cl |a:5,7,13,15|",Phase 3
AZ191,DYRK inhibitor,DYRK1B,,,"COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1",Preclinical
AZ20,ATR kinase inhibitor,"ATR, MTOR",,,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
AZ3146,monopolar spindle 1 kinase inhibitor,,,,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
AZ505,histone lysine methyltransferase inhibitor,SMYD2,,,"Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12",Preclinical
AZ5104,EGFR inhibitor,EGFR,,,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12,Preclinical
AZ7550,insulin growth factor receptor inhibitor,,,,CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C,Phase 1
AZ960,JAK inhibitor,JAK2,,,"C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
A0001,,,,,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|",Phase 2
A12B4C3,polynucleotide kinase/phosphatase inhibitor,PNKP,,,"CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|",Preclinical
A205804,ICAM1 expression inhibitor,"ICAM1, SELE",,,"Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1",Preclinical
A61603,adrenergic receptor agonist,ADRA1A,,,"CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|",Preclinical
A66,PI3K inhibitor,PIK3CA,,,"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C",Preclinical
A740003,purinergic receptor antagonist,P2RX7,,,"COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|",Preclinical
A77636,dopamine receptor agonist,CALY,,,"NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2",Preclinical
A922500,diacylglycerol O acyltransferase inhibitor,DGAT1,,,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,Preclinical
bacampicillin,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections","CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|",Launched
bacitracin,bacterial cell wall synthesis inhibitor,IDE,infectious disease,first-aid antibiotic,"CCC(C)C(N)C1=NC(CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC, CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|, CCC(C)C(N)C1=NC(CS1)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NCCCCC1NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)C(CCCN)NC1=O)C(C)CC",Launched
bacitracin (zinc),bacterial cell wall synthesis inhibitor,,infectious disease,first-aid antibiotic,[Zn++].CCC(C)C(N)C1=NC(CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC,Launched
bacitracin zinc,bacterial cell wall synthesis inhibitor,,infectious disease,first-aid antibiotic,CC[C@H](C)[C@H](N)C1=NCC(S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)[C@H](C)CC,Launched
bacitracin-zinc,bacterial cell wall synthesis inhibitor,,infectious disease,first-aid antibiotic,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|,Launched
baclofen,benzodiazepine receptor agonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",neurology/psychiatry,"multiple sclerosis, spasms","NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|, NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|",Launched
BADGE,PPAR receptor antagonist,PPARG,,,"CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|",Preclinical
bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",,,"CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1",Phase 2
bafilomycin-a1,ATPase inhibitor,,,,"[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|, [H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|",Preclinical
BAG-956,phosphoinositide dependent kinase inhibitor,PIK3CG,,,"Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1",Preclinical
baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",,,"Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1",Preclinical
baicalin,beta glucuronidase inhibitor,PREP,neurology/psychiatry,anxiety,"O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
bakuchiol,DNA polymerase inhibitor,HIF1A,,,"CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1",Phase 2
balaglitazone,"insulin sensitizer, PPAR receptor partial agonist",PPARG,,,"Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|",Phase 3
balapiravir,RNA polymerase inhibitor,,,,"CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]",Phase 2
balicatib,cathepsin inhibitor,CTSK,,,"CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N",Phase 2
balofloxacin,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,"CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|",Launched
balovaptan,vasopressin receptor antagonist,"AVPR1A, AVPR2, HTR2B, OXTR",,,CN1CC2=NN=C([C@H]3CC[C@H](OC4=NC=CC=C4)CC3)[N@]2[C@]5=CC=C(Cl)C=C5C1,Phase 3
baloxavir,endonuclease inhibitor,,,,[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12,Phase 3
baloxavir-marboxil,endonuclease inhibitor,,infectious disease,influenza A virus infection,[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12,Launched
balsalazide,cyclooxygenase inhibitor,"ALOX5, PPARG, PTGS1, PTGS2",gastroenterology,ulcerative colitis,OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O,Launched
balsalazide disodium,cyclooxygenase inhibitor,,gastroenterology,ulcerative colitis,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O,Launched
bamaquimast,proton pump inhibitor,,,,CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O,Preclinical
bambuterol,adrenergic receptor agonist,"ADRB2, BCHE",pulmonary,asthma,"CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C, CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)[C@@H](O)CNC(C)(C)C |&1:18,r|",Launched
BAM7,BAX activator,BAX,,,"CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|",Preclinical
BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,,,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
banoxantrone,topoisomerase inhibitor,TOP2A,,,C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12,Phase 1/Phase 2
barasertib,Aurora kinase inhibitor,"AURKA, AURKB",,,"CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O",Phase 2/Phase 3
barasertib-HQPA,Aurora kinase inhibitor,AURKB,,,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1",Phase 2/Phase 3
bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",,,"CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|",Phase 1
bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",,,"COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|",Phase 3
baricitinib,JAK inhibitor,"JAK1, JAK2",rheumatology,rheumatoid arthritis,"CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12",Launched
barium-6-O-phosphonato-D-glucose,,,,,O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O,Preclinical
barnidipine,calcium channel blocker,,cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|",Launched
basic-fuchsin,,,,,"CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|",Preclinical
basimglurant,glutamate receptor antagonist,GRM5,,,"Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1",Phase 2
basmisanil,GABA receptor inverse agonist,,,,Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1,Phase 2
batabulin,tubulin polymerisation inhibitor,TUBB,oncology,breast cancer,O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(F)=C2)=O,Phase 1
batefenterol,"acetylcholine receptor antagonist, adrenergic receptor agonist",,,,COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12,Phase 2
batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",,,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
bavisant,histamine receptor antagonist,HRH3,,,"O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1",Phase 2
BAX-channel-blocker,cytochrome C release inhibitor,BAX,,,O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|,Preclinical
bay 2416964,antitumor agent,AHR,oncology,non-small cell lung cancer (nsclc),C[C@@H](CO)NC(=O)c1cc(nn(-c2cnn(C)c2)c1=O)-c1ccc(Cl)cc1,Phase 1
BAY-K-8644-(+/-),L-type calcium channel blocker,,,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|",Preclinical
BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,,,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|",Preclinical
BAY-W-9798,antioxidant,,,,"COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|",Phase 2
BAY-11-7082,NFkB pathway inhibitor,RELA,,,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BAY-11-7085,NFkB pathway inhibitor,NFKBIA,,,"CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N, CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BAY-1251152,CDK9 inhibitor,,,,COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|,Phase 1
BAY-1436032,isocitrate dehydrogenase inhibitor,,,,C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12,Phase 1
BAY-1895344,ATR kinase inhibitor,,,,C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,Phase 1
BAY-2402234,dihydroorotate dehydrogenase inhibitor,,,,"CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O, CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O",Phase 1
BAY-41-2272,guanylyl cyclase activator,"GUCY1A3, GUCY1B3",,,"Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12",Preclinical
BAY-60-6583,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N",Preclinical
BAY-60-7550,phosphodiesterase inhibitor,PDE2A,,,COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC,Preclinical
BAY-61-3606,SYK inhibitor,SYK,,,"COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1",Preclinical
BAY-8002,monocarboxylate transporter inhibitor,,,,OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1,Preclinical
BAY-85-8050,,,,,"N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|",Phase 1
bay-85-8501,elastase inhibitor,ELANE,,,"CN1[C@@H](C(C#N)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1S(C)(=O)=O)C#N |a:2,t:5|",Phase 2
BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,,,"Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1",Phase 1
BAY1125976,AKT inhibitor,,,,NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1,Phase 1
BAY1217389,kinase inhibitor,,,,COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F,Phase 1
bazedoxifene,selective estrogen receptor modulator (SERM),"ESR1, ESR2","orthopedics, endocrinology","osteoporosis, menopause","Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12",Launched
BAZ2-ICR,bromodomain inhibitor,ZNF215,,,"Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1",Preclinical
BC-11,urokinase inhibitor,PLAU,,,"NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O",Preclinical
BCI-540,glutamate receptor agonist,,,,"Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C",Phase 2
BCTC,TRPV antagonist,TRPV1,,,"CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1",Preclinical
BCX-1470,"complement inhibitor, serine protease inhibitor",CFD,,,"NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1",Phase 1
BD-1008,sigma receptor antagonist,,,,"CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1, CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1",Preclinical
BD-1047,adrenergic receptor antagonist,SIGMAR1,,,"CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1",Preclinical
BD-1063,sigma receptor antagonist,SIGMAR1,,,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,Preclinical
BE-2254,adrenergic receptor antagonist,ADRA1A,,,"Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|",Phase 2
BEBT-908,PI3K inhibitor,,,,CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Preclinical
beclabuvir,antiviral,,,,COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|,Phase 2
beclamide,anticonvulsant,,neurology/psychiatry,"sedative, seizures","ClCCC(=O)NCc1ccccc1, ClCCC(=O)NCc1ccccc1",Launched
beclomethasone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,"C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|",Launched
beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|",Launched
bedaquiline,ATPase inhibitor,,infectious disease,tuberculosis,"COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12",Launched
befuraline,,,,,O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1,Phase 2
begacestat,gamma secretase inhibitor,PSEN1,,,"OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F",Phase 1
bekanamycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),"ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1",Launched
belizatinib,receptor tyrosine protein kinase inhibitor,,,,CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|,Preclinical
belotecan,topoisomerase inhibitor,,,,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O,Phase 3
belvarafenib,raf inhibitor,"ARAF, BRAF, NRAS",oncology,melanoma,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12,Phase 1
belzutifan,hif modulator,EPAS1,oncology,renal cell carcinoma (rcc),CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13,Launched
bemegride,chemoreceptor agonist,GABRA1,critical care,poison antidote,"CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1",Launched
bemesetron,serotonin receptor antagonist,"HTR3A, HTR3B",,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|",Phase 3
bemotrizinol,,,dermatology,sunscreen lotion,"CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|, CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|",Launched
bempedoic-acid,AMPK inhibitor,ACLY,,,"CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O",Launched
benactyzine,butyrylcholinesterase inhibitor,,,,CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,Preclinical
benaxibine,,,,,OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,Phase 1
benazepril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O",Launched
bendamustine,DNA inhibitor,,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
bendazac,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain",OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,Launched
bendazol,nitric oxide synthase stimulant,,,,C(c1nc2ccccc2[nH]1)c1ccccc1,Launched
bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|",Launched
benethamine,,,,,C(Cc1ccccc1)NCc1ccccc1,Preclinical
benfluorex,gluconeogenesis inhibitor,HMGCR,,,C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|,Withdrawn
benfluorex hydrochloride,gluconeogenesis inhibitor,,,,"CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1, CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1",
benfluralin,,"CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1",,,"CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O, CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O",Phase 3
benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
benidipine,calcium channel blocker,"CACNA1C, CACNA1G",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1",Launched
benperidol,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,"Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O",Launched
benproperine,antitussive,SCN5A,pulmonary,cough suppressant,"C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|, C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|",Launched
benserazide,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O",Launched
bentiromide,,HPN,gastroenterology,pancreas diagnostic agent,"OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1",Launched
benurestat,urease inhibitor,,,,"ONC(=O)CNC(=O)c1ccc(Cl)cc1, ONC(=O)CNC(=O)c1ccc(Cl)cc1",Phase 1
benzalkonium,cationic surfactant,,dermatology,"abrasions, superficial cuts","CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1",Launched
benzamil,sodium channel blocker,"ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1",,,"NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N",Phase 2
benzbromarone,chloride channel blocker,ABCC1,rheumatology,gout,"CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1",Launched
"benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]",,,,,"CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|",Preclinical
benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
benznidazole,DNA synthesis inhibitor,,infectious disease,Chagas disease,[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1,Launched
benzo[d]thiazole-2(3H)-thione,,,,,"S=c1[nH]c2ccccc2s1, S=c1[nH]c2ccccc2s1",Phase 1
benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
benzoclidine,,,,,"O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|",Preclinical
benzofenac,,,,,"OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1",Phase 1
benzoic-acid,food preservative,"DAO, HRSP12, PRDX5, RAB9A",infectious disease,tinea pedis,"OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1",Launched
benzoin,,CES1,,,"O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|",Preclinical
benzonatate,local anesthetic,SCN5A,pulmonary,cough suppressant,"CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC, CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC",Launched
benzoquinonium-dibromide,cholinergic receptor antagonist,CHRNA1,,,"CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|",Preclinical
benzotript,CCK receptor antagonist,"CCKAR, CCKBR",,,"OC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1",Phase 1
benzoxiquine,antiinfective drug,,,,O=C(Oc1cccc2cccnc12)c1ccccc1,Preclinical
benzoyl-peroxide,oxidizing agent,,dermatology,acne vulgaris (AV),"O=C(OOC(=O)c1ccccc1)c1ccccc1, O=C(OOC(=O)c1ccccc1)c1ccccc1",Launched
benzoylpas,,,,,"OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O",Preclinical
benzquinamide,dopamine receptor agonist,"DRD2, PTGS2",gastroenterology,nausea,CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(=O)C,Withdrawn
benzthiazide,carbonic anhydrase inhibitor,CA2,cardiology,"hypertension, edema","NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl",Launched
benztropine mesylate,acetylcholine receptor antagonist,,neurology/psychiatry,"extrapyramidal symptoms (eps), parkinson's disease",CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,Launched
benztropine-mesylate,acetylcholine receptor antagonist,"CHRM1, HRH1, SLC6A3",neurology/psychiatry,"extrapyramidal symptoms (EPS), Parkinson's Disease",CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1,Launched
benzydamine,prostanoid receptor antagonist,,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
benzyl-alcohol,local anesthetic,,infectious disease,virus herpes simplex (HSV),"OCc1ccccc1, OCc1ccccc1",Launched
benzyl-benzoate,lipase inhibitor,LIPE,allergy,sweet itch,"O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1",Launched
benzyl-isothiocyanate,methylazoxymethanol acetate inhibitor,,,,"S=C=NCc1ccccc1, S=C=NCc1ccccc1",Preclinical
benzyldimethylhexadecylammonium,cationic surfactant,,,,"CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1",Preclinical
benzyldimethyloctylammonium,,,,,CCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
benzylpenicillin,penicillin binding protein inhibitor,,infectious disease,"celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia","CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
bephenium-hydroxynaphthoate,anthelmintic agent,,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
bepotastine,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1",Launched
bepridil,calcium channel blocker,KCNQ4,cardiology,angina pectoris,"CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1",Launched
berberine,LDL receptor activator,LDLR,,,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Launched
bergapten,,,,,"COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12",Phase 3
bergenin,interleukin inhibitor,"IL1B, TNF",,,"COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O",Preclinical
besifloxacin,bacterial DNA gyrase inhibitor,,ophthalmology,conjunctivitis,"N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1",Launched
besifovir,antiviral,GPT,infectious disease,hepatitis b,Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1,Phase 3
BET-BAY-002,bromodomain inhibitor,,,,"Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|",Preclinical
beta-amyloid-synthesis-inhibitor,beta amyloid synthesis inhibitor,APP,,,Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,Preclinical
beta-carotene,,,,,"C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|",Launched
beta-CCB,benzodiazepine receptor ligand,"GABRA1, GABRG2",,,"CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21, CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21",Launched
beta-elemene,apoptosis stimulant,"MMP2, MMP9",,,"CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C, CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C",Launched
beta-funaltrexamine,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,"COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45",Preclinical
beta-glycerophosphoric-acid,,,,,OCC(CO)OP(O)(O)=O,Preclinical
beta-hydroxy-beta-methylbutyrate,protein synthesis stimulant,MTOR,,,CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O,Launched
beta-hydroxybutyrate,,HCAR2,,,CC(O)CC(O)=O,Phase 1
beta-lapachone,topoisomerase inhibitor,TOP1,,,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|",Phase 2
beta-naphthol,,,,,Oc1ccc2ccccc2c1,Preclinical
betahistine,"histamine receptor agonist, histamine receptor antagonist","HRH1, HRH3",neurology/psychiatry,Meniere's disease,"CNCCc1ccccn1, CNCCc1ccccn1, CNCCc1ccccn1",Launched
betaine,nitric oxide donor,,metabolism,homocystinuria,"C[N+](C)(C)CC(O)=O, C[N+](C)(C)CC(O)=O",Launched
betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",
betamethasone acetate,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,Launched
betamethasone sodium phosphate,,,,,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O,
betamethasone-acetate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|",Launched
betamethasone-butyrate-propionate,,,rheumatology,rheumatoid arthritis,"CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18,t:14|",Launched
betamethasone-dipropionate,anti-inflammatory agent,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|",Launched
betamethasone-phosphate,,,rheumatology,rheumatoid arthritis,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|",Launched
betamethasone-valerate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|",Launched
betamipron,panipenem uptake inhibitor,,nephrology,renal toxicity,"OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1",Launched
betaxolol,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|",Launched
betaxolol hydrochloride,adrenergic receptor antagonist,,ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,Launched
betazole,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic,NCCc1ccn[nH]1,Launched
bethanechol,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",urology,urinary retention,C[C@@H](C[N+](C)(C)C)OC(N)=O |r|,Launched
bethanechol chloride,,,,,CC(C[N+](C)(C)C)OC(N)=O,
BETP,GLP receptor positive allosteric modulator,GLP1R,,,"CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|",Preclinical
betrixaban,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT),"COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1",Launched
betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,,,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
bevantolol,adrenergic receptor antagonist,,cardiology,"angina pectoris, hypertension","COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|, COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|",Launched
bevenopran,opioid receptor antagonist,,,,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O,Phase 1
bevirimat-dimeglumine,HIV capsid assembly inhibitor,,,,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 2
bexagliflozin,solute carrier family member inhibitor,,,,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1,Phase 3
bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C",Launched
bezafibrate,PPAR receptor agonist,"PPARA, PPARD, PPARG",cardiology,cholesterol,"CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O",Launched
BFH772,VEGFR inhibitor,,,,OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1,Phase 2
BGP-15,PARP inhibitor,,,,"O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|",Phase 2
BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",,,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BHQ,ATPase inhibitor,ATP2A1,,,"CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C",Preclinical
BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",,,"CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|",Preclinical
BI-224436,HIV integrase inhibitor,,,,"Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O",Phase 1
BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",,,"CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O",Phase 2
BI-409306,phosphodiesterase inhibitor,,,,Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1,Phase 1
BI-78D3,JNK inhibitor,MAPK8,,,"[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1",Preclinical
BI-847325,"Aurora kinase inhibitor, MEK inhibitor","AURKA, AURKB, AURKC, MAP2K1, MAP2K2",,,"CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1",Phase 1
BIA-10-2474,Fatty acid hydrolase inhibitor,,,,CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1,Preclinical
biapenem,bacterial cell wall synthesis inhibitor,,infectious disease,"bacterial septicemia, pneumonia, urinary tract infections","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|",Launched
BIBN4096,calcitonin antagonist,"CALCA, CALCRL, RAMP1",,,"NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1",Phase 2
BIBR-1532,telomerase inhibitor,TERT,,,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BIBU-1361,EGFR inhibitor,EGFR,,,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",,,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|",Launched
bicifadine,"dopamine reuptake inhibitor, serotonin receptor antagonist",,,,"[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|",Phase 3
bictegravir,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F,Launched
bicuculline methochloride,gaba receptor antagonist,,null,epilepsy,C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21,Preclinical
bicuculline-(+),GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1",,,CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21,Preclinical
bicuculline-methochloride-(-),GABA receptor antagonist,,,,C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21,Preclinical
bicyclol,NFkB pathway inhibitor,"HSPA1A, HSPB1",infectious disease,"hepatitis B, hepatitis C","COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO",Launched
bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
bifendate,,,infectious disease,"hepatitis B, hepatitis C","COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC",Launched
bifonazole,sterol demethylase inhibitor,,infectious disease,"tinea pedis, tinea cruris","c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|",Launched
BIIB021,HSP inhibitor,HSP90AA1,,,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
biib068,bruton's tyrosine kinase (btk) inhibitor,BTK,,,CC(C)OC1CN(C1)C(=O)NCc1ccc(cc1C)-c1ccnc(Nc2cnn(C)c2)n1,Phase 1
bilastine,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1, CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1",Launched
bilobalide,GABA receptor modulator,"GLRA1, GLRA2, GLRB, HTR3A, HTR3B",,,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123,Preclinical
bimatoprost,prostanoid receptor agonist,"AKR1C3, PTGER1, PTGER3, PTGFR",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension, intraocular pressure, glaucoma, ocular hypertension","CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1",Launched
bimosiamose,p selectin inhibitor,"ICAM1, SELE, SELP",pulmonary,chronic obstructive pulmonary disease (copd),"OC[C@H]1O[C@H](Oc2ccc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)cc2-c2cccc(CC(O)=O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |a:2,4,21,23,26,28,30,56,58,60|",Phase 2
BIMU-8,serotonin receptor agonist,HTR4,,,"CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|",Preclinical
BINA,glutamate receptor positive allosteric modulator,GRM2,,,"Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|",Preclinical
bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",,,"CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O",Phase 2
binimetinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO",Launched
BIO-1211,integrin antagonist,"ITGA4, ITGB1",,,"CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O",Phase 2
BIO-5192,integrin inhibitor,"ITGA4, ITGB1",,,"CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O",Preclinical
biotin,vitamin B,"ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6",,,"OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12",Launched
bipenamol,dipeptidyl peptidase inhibitor,CTSC,,,"NCc1ccccc1Sc1ccccc1CO, NCc1ccccc1Sc1ccccc1CO",Phase 2
biperiden,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",neurology/psychiatry,Parkinson's Disease,"O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|",Launched
biperiden hcl,acetylcholine receptor antagonist,,neurology/psychiatry,parkinson's disease,OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1,Launched
birinapant,XIAP inhibitor,"BIRC2, XIAP",,,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BIRT-377,lymphocyte function-associated antigen negative modulator,ICAM1,,,"CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1",Preclinical
bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,,,"Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O",Phase 2
bisacodyl,laxative,,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
bisantrene,topoisomerase inhibitor,,,,"C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|",Phase 2
bisindolylmaleimide-IX,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",,,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|",Preclinical
bismuth subcitrate potassium,,,gastroenterology,duodenal ulcer disease,OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O,Launched
bismuth(III)-trifluoromethanesulfonate,direct substitution catalyst,,,,[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F,Preclinical
bismuth-oxalate,,,,,[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O,Preclinical
bismuth-subcitrate-potassium,,,gastroenterology,duodenal ulcer disease,"OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4,&2:15|",Launched
bismuth-subgallate,nitric oxide synthase inhibitor,NOS1,gastroenterology,internal deoderant,O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O,Launched
bismuth-subsalicylate,antacid,,gastroenterology,diarrhea,"O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1",Launched
bisoctrizole,,,,,"CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1, CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1",Phase 2
bisoprolol,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,"CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|",Launched
bisphenol-A,synthetic estrogen,"AR, ESR1, ESR2, ESRRG, PPARG",,,"CC(C)(c1ccc(O)cc1)c1ccc(O)cc1, CC(C)(c1ccc(O)cc1)c1ccc(O)cc1",Phase 1
bithionol,autotaxin inhibitor,"ESR1, ESR2, MCL1",,,"Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O",Withdrawn
bitopertin,glycine transporter inhibitor,"SLC6A5, SLC6A9",,,"C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F",Phase 3
bitoscanate,anthelmintic agent,,,,"S=C=Nc1ccc(cc1)N=C=S, S=C=Nc1ccc(cc1)N=C=S",Preclinical
bivalirudin,thrombin inhibitor,F2,cardiology,angina pectoris,"CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O",Launched
BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BIX-02188,MEK inhibitor,MAP2K5,,,"CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1",Preclinical
BIX-02189,MEK inhibitor,"MAP2K5, MAPK7",,,"CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1",Preclinical
BL-5583,hypercalcaemic agent,,,,"OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1",Preclinical
blebbistatin-(+/-),ATPase inhibitor,"MYH14, MYH2",,,"Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|",Preclinical
blebbistatin-(-),ATPase inhibitor,,,,"Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|",Preclinical
bleomycetin,EGFR expression inhibitor,,,,"C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN",Launched
bleomycin,"dna damage inducer, DNA synthesis inhibitor",,"Oncology, hematologic malignancy, pulmonary, oncology","pancreatic cancer, non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma","C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C, [H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O",Launched
bleomycin (sulfate),,,,,CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)C(CC(N)=O)NCC(N)C(N)=O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C,
bleomycin sulfate,dna synthesis inhibitor,,"hematologic malignancy, pulmonary, oncology","non-hodgkin lymphoma (nhl), hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma",C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C,Launched
blonanserin,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1",Launched
BLU9931,FGFR inhibitor,FGFR4,,,"COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1",Preclinical
BLZ945,CSF1R inhibitor,,,,CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1,Phase 1/Phase 2
BML-190,cannabinoid receptor inverse agonist,CNR2,,,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1",Preclinical
BML-284,WNT agonist,,,,"COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1",Preclinical
BMS-CCR2-22,CC chemokine receptor antagonist,CCR2,,,"CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F",Preclinical
BMS-182874,endothelin receptor antagonist,EDNRA,,,"CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C",Phase 2
BMS-191011,potassium channel activator,KCNMA1,,,"Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F",Preclinical
BMS-191095,"KATP activator, potassium channel agonist",,,,"CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N",Phase 1
BMS-207940,endothelin receptor antagonist,,,,CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C,Preclinical
BMS-214662,farnesyltransferase inhibitor,,,,O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1,Phase 1
BMS-265246,CDK inhibitor,"CDK1, CDK2",,,"CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BMS-299897,gamma secretase inhibitor,,,,"C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O",Phase 1
BMS-309403,fatty acid binding protein inhibitor,FABP4,,,"CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1",Preclinical
BMS-345541,IKK inhibitor,"CHUK, IKBKB",,,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",,,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BMS-470539,melanocortin receptor agonist,MC1R,,,"CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1",Preclinical
BMS-536924,IGF-1 inhibitor,"AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB",,,"Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1",Preclinical
BMS-566419,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",,,"CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F",Preclinical
BMS-582949,p38 MAPK inhibitor,,,,CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C,Phase 2
BMS-587101,integrin antagonist,"ITGAL, ITGB2",,,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,Phase 2
BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",,,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BMS-626529,HIV attachment inhibitor,,,,"COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12, COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12",Phase 3
BMS-626531,p38 MAPK inhibitor,,,,Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1,Phase 1
BMS-649,retinoid receptor agonist,RXRA,,,"CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O",Preclinical
BMS-688521,"ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist",ICAM1,,,CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1,Preclinical
BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",,,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BMS-707035,HIV integrase inhibitor,,,,"Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O, Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O",Phase 2
BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",,,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BMS-770767,11-beta-HSD1 inhibitor,,,,O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|,Phase 2
BMS-777607,"AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor","AXL, MERTK, MET, MST1R, TYRO3",,,"CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1",Phase 1/Phase 2
BMS-779788,LXR agonist,,,,CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O,Phase 1
BMS-806,HIV attachment inhibitor,,,,"COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12",Phase 1
BMS-813160,CC chemokine receptor antagonist,,,,CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C,Phase 2
BMS-817378,"c-Met inhibitor, VEGFR inhibitor","KDR, MET",,,"Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",Phase 1
BMS-833923,smoothened receptor antagonist,SMO,,,"CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1",Phase 2
BMS-863233,CDC inhibitor,"CDC7, PIM1",,,"Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1",Phase 1/Phase 2
BMS-906024,gamma secretase inhibitor,,,,CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|,Phase 1
BMS-911543,JAK inhibitor,,,,CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1,Phase 1/Phase 2
BMS-935177,Bruton's tyrosine kinase (BTK) inhibitor,,,,Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O,Preclinical
BMS-983970,notch signaling inhibitor,,,,"NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|",Phase 1
BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,,,C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1,Phase 2
BMS-986142,Bruton's tyrosine kinase (BTK) inhibitor,,,,Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O,Phase 2
BMS-986158,bromodomain inhibitor,,,,"Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O, Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O",Phase 1/Phase 2
BMS-986195,Bruton's tyrosine kinase (BTK) inhibitor,,,,CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12,Phase 1
BMS-986205,"indoleamine 2,3-dioxygenase inhibitor",,,,[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1,Phase 3
BMY-14802,sigma receptor antagonist,HTR1A,,,"O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|",Phase 2
BMY-45778,IP1 prostacyclin receptor agonist,PTGIR,,,"OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1",Preclinical
BMY-7378,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A",,,"COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1",Preclinical
BNC105,tubulin polymerization inhibitor,,,,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,,Preclinical
boceprevir,HCV inhibitor,"CMA1, CTSA, CTSF, CTSK, CTSL, CTSS",infectious disease,hepatitis C,"CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|",Launched
bonaphthone,,,,,"Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|, Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|",Phase 3
bopindolol,adrenergic receptor antagonist,,cardiology,"hypertension, coronary artery disease (CAD)","Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|, Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|, Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|",Launched
bornyl acetate,apoptosis stimulant,,,,CC(=O)O[C@@H]1C[C@@H]2CC[C@@]1(C)C2(C)C,Preclinical
bornyl-acetate,,,,,"CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|, CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|",Preclinical
boronophenylalanine,,,,,"N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O",Phase 2
bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BOS-172722,monopolar spindle 1 kinase inhibitor,,,,CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C,Phase 1
bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1",Launched
bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BP-554,serotonin receptor agonist,HTR1A,,,"C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1",Preclinical
BP-897,dopamine receptor agonist,"ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B",,,"COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1",Phase 2
bq-123,endothelin receptor antagonist,,,,CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C,Phase 2
BQ-123,endothelin receptor antagonist,EDNRA,,,[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C,Phase 2
BQ-788,endothelin receptor antagonist,EDNRB,,,"CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O",Phase 1
BQU57,Ras GTPase inhibitor,"RALA, RALB",,,"Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|",Preclinical
BRD4770,histone lysine methyltransferase inhibitor,EHMT2,,,"COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1",Preclinical
BRD7389,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3",,,"O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23",Preclinical
BRD9876,kinesin inhibitor,KIF11,,,"CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N",Preclinical
brefeldin-A,protein synthesis inhibitor,"ARF1, CYTH2",,,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|",Preclinical
bremelanotide,melanocortin receptor agonist,"MC1R, MC2R, MC3R, MC4R, MC5R",neurology/psychiatry,hypoactive sexual desire disorder,"CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O",Launched
brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,,,"Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F",Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",,,"CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21",Phase 2
bretylium,norepinephrine inhibitor,ATP1A1,cardiology,"ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)","CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br",Launched
brexpiprazole,dopamine receptor partial agonist,DRD2,neurology/psychiatry,"depression, schizophrenia","O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1",Launched
briciclib,cyclin D inhibitor,CCND1,,,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1",Phase 1
brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
brilliant-green,,,infectious disease,antiseptic,"CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC",Launched
brimonidine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|",Launched
brincidofovir,antiviral,,,,CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O,Phase 3
brinzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA5A, CA7",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension","CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O",Launched
brivanib,"FGFR inhibitor, VEGFR inhibitor","CYP3A4, FGFR1, FLT1, KCNH2, KDR",,,"C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C",Phase 3
brivanib-alaninate,"FGFR inhibitor, VEGFR inhibitor",FGFR3,,,"C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N",Phase 3
brivudine,DNA directed DNA polymerase inhibitor,,infectious disease,shingles,"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2,4,&1:6|",Launched
brl-15572,5-ht1d receptor antagonist,HTR1D,,,OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1,Preclinical
BRL-15572,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",,,"O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|",Preclinical
BRL-26314,cholesterol inhibitor,LPL,,,"OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|",Phase 1
BRL-37344,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,"C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1",Phase 2
BRL-44408,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C",,,"C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|",Preclinical
BRL-50481,phosphodiesterase inhibitor,"PDE7A, PDE7B",,,"CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",Preclinical
BRL-52537,opioid receptor agonist,OPRK1,,,"Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|",Preclinical
BRL-54443,serotonin receptor agonist,"HTR1E, HTR1F",,,"CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12",Preclinical
brofaromine,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,COc1cc(Br)c2oc(cc2c1)C3CCNCC3,Phase 1
brolitene,muscle relaxant,RYR1,rheumatology,lumbago,"OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1",Launched
bromantan,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",,neurology/psychiatry,neurasthenia,"Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1",Launched
bromebric-acid,"DNA synthesis inhibitor, purine antagonist",,,,COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O,Preclinical
bromfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1",Withdrawn
bromhexine,mucolytic agent,,pulmonary,chest congestion,"CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1",Launched
bromindione,anticoagulant,,,,"Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O",Phase 2
bromisoval,anti-inflammatory agent,,,,"CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|",Preclinical
bromocriptine,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7","endocrinology, neurology/psychiatry","hyperprolactinemia, Parkinson's Disease, acromegaly","CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|",Launched
bromodiphenhydramine,histamine receptor antagonist,HRH1,Allergies,allergic rhinitis,"CN(C)CCO[C@H](c1ccccc1)c1ccc(Br)cc1 |&1:6,r|",Launched
bromopride,dopamine receptor antagonist,DRD2,gastroenterology,"nausea, vomiting, gastroesophageal reflux disease (GERD)","CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC",Launched
bromosporine,bromodomain inhibitor,,,,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
bromperidol,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1",Launched
brompheniramine,histamine receptor antagonist,HRH1,"allergy, otolaryngology","allergic rhinitis, common cold",CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|,Launched
brompheniramine maleate,histamine receptor antagonist,,"allergy, otolaryngology","allergic rhinitis, common cold",CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,Launched
bronopol,,,obstetrics/gynecology,mastitis,"OCC(Br)(CO)[N+]([O-])=O, OCC(Br)(CO)[N+]([O-])=O",Launched
bropirimine,interferon inducer,,,,"Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1",Phase 3
broxaldine,,,,,"Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1",Preclinical
broxaterol,adrenergic receptor agonist,ADRB2,,,"CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|",Phase 3
broxuridine,antimetabolite,,,,"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O",Phase 2
broxyquinoline,antiprotozoal agent,,,,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
bruceantin,protein synthesis inhibitor,,,,"COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|",Phase 2
brucine,glycine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,"COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC",Preclinical
BS-181,CDK inhibitor,CDK7,,,"CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12",Preclinical
BT-11,cAMP stimulant,,,,O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1,Phase 2
BTB06584,ATPase inhibitor,ATP5F1,,,"[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1",Preclinical
BTB1,mitotic kinesin inhibitor,KIF18A,,,"[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1",Preclinical
BTK-IN-1,Bruton's tyrosine kinase (BTK) inhibitor,,,,"Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|",Preclinical
BTS,,,,,"Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1",Preclinical
BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,"CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|",Withdrawn
BTS-71321,,,,,"CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1, CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1",Phase 2
BTS-72664,GABA receptor antagonist,GABBR1,,,"C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|",Phase 1
BTT-3033,integrin inhibitor,"ITGA2, ITGB1",,,"CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1",Preclinical
BTZ043-racemate,DPRE1 inhibitor,,,,"C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|, C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|",Phase 1/Phase 2
BU-224,imidazoline receptor ligand,"MAOA, MAOB",,,"C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|",Preclinical
BU-239,"imidazoline receptor agonist, imidazoline receptor ligand",,,,"C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|",Preclinical
bucetin,analgesic agent,,,,"CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|, CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|",Withdrawn
bucillamine,immunosuppressant,,rheumatology,rheumatoid arthritis,"CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O",Launched
bucladesine,"adenosine receptor agonist, camp stimulant, adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",Launched
bucladesine (sodium),,,,,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",
buclizine,histamine receptor antagonist,HRH1,neurology/psychiatry,migraine headache,"CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|, CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|",Launched
budesonide,glucocorticoid receptor agonist,NR3C1,gastroenterology,Crohn's disease,"CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|",Launched
budipine,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease,"CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1, CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1",Launched
bufexamac,cyclooxygenase inhibitor,"HDAC10, HDAC6",,,"CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1",Withdrawn
buflomedil,"adrenergic receptor antagonist, calcium channel blocker",ADRA1A,cardiology,peripheral artery disease (PAD),"COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1",Launched
bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
bunazosin,adrenergic receptor antagonist,ADRA1A,ophthalmology,"glaucoma, intraocular pressure","CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1, CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1",Launched
buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",,,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
buparvaquone,antiprotozoal agent,,infectious disease,protozoan infection,"CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|, CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|",Launched
buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
bupicomide,adrenergic receptor antagonist,ADRB1,,,"CCCCc1ccc(nc1)C(N)=O, CCCCc1ccc(nc1)C(N)=O",Phase 1
bupivacaine,sodium channel blocker,"KCNA5, SCN10A",neurology/psychiatry,"peripheral nerve block, caudal epidural block, lumbar epidural block","CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|",Launched
bupivacaine hydrochloride,sodium channel blocker,,neurology/psychiatry,"peripheral nerve block, caudal epidural block, lumbar epidural block",CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,Launched
bupranolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3","cardiology, ophthalmology","hypertension, glaucoma","Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|",Launched
bupropion,dopamine reuptake inhibitor,"SLC6A2, SLC6A3",neurology/psychiatry,depression,"C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|",Launched
buramate,antiepileptic,,,,"OCCOC(=O)NCc1ccccc1, OCCOC(=O)NCc1ccccc1",Preclinical
burixafor,cc chemokine receptor antagonist,CXCR4,hematologic malignancy,multiple myeloma,Nc1cc(nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1)N1CCN(CCP(O)(O)=O)CC1.Br.Br |r|,Phase 2
buserelin,gonadotropin releasing factor hormone receptor agonist,,"oncology, obstetrics/gynecology","prostate cancer, endometriosis",CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,Launched
buspirone,serotonin receptor agonist,"DRD2, HTR1A",neurology/psychiatry,generalized anxiety disorder (GAD),"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1",Launched
busulfan,DNA inhibitor,,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
butabindide,tripeptidyl peptidase inhibitor,TPP2,,,"CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC",Preclinical
butacaine,local anesthetic,,neurology/psychiatry,local anesthetic,"CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1",Launched
butaclamol,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A",,,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,Phase 2
butaclamol (+),dopamine receptor antagonist,,,,CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34,Phase 2
butalbital,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,"headache, muscle relaxant","CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O, CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O",Launched
butamben,sodium channel blocker,,,,"CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1",Withdrawn
butaprost,prostaglandin receptor agonist,,,,CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,Preclinical
butein,"EGFR inhibitor, SRC inhibitor",ACE,,,"Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1",Preclinical
butenafine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12",Launched
buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,,,"CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|, CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|",Phase 1
butibufen,cyclooxygenase inhibitor,,,,"CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|",Withdrawn
butoconazole,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis,"Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|, Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|",Launched
butoconazole nitrate,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis,Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,Launched
butofilolol,adrenergic receptor antagonist,,,,"CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|",Phase 2
butyl-paraben,DNA synthesis inhibitor,,,,"CCCCOC(=O)c1ccc(O)cc1, CCCCOC(=O)c1ccc(O)cc1",Preclinical
butylated-hydroxyanisole,antioxidant,,,,"COc1ccc(O)c(c1)C(C)(C)C, COc1ccc(O)c(c1)C(C)(C)C",Preclinical
butylated-hydroxytoluene,carbonic anhydrase inhibitor,CA2,,,"Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Phase 1
butylidenephthalide,cyclooxygenase inhibitor,,,,CCC\C=C1/OC(=O)c2ccccc12,Phase 1/Phase 2
butylphthalide,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke,"CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|, CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|",Launched
butylscopolamine bromide,cholinergic receptor antagonist,,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
butylscopolamine-bromide,cholinergic receptor antagonist,,gastroenterology,abdominal pain,"CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:4,TLB:3:4:7.8.9:11.13,12:11:4:7.8.9,12:13:4:7.8.9,THB:5:4:7.8.9:11.13,14:8:4:11.13|",Launched
BU226,imidazoline receptor ligand,,,,"C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|",Preclinical
BVD-523,MAP kinase inhibitor,,,,"CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1",Phase 2
BVT-2733,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,,,CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1,Preclinical
BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",,,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|, CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|",Preclinical
bvt948,tyrosine phosphatase inhibitor,,,,"CC1(C)[C@H]2C(=NC1=O)c1ccccc1C(=O)C2=O |r,c:4|",Preclinical
BW-A4C,lipoxygenase inhibitor,ALOX5,,,"CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1, CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1",Phase 1
BW-B70C,lipoxygenase inhibitor,ALOX5,,,"C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|",Preclinical
BW-180C,opioid receptor agonist,"OPRD1, OPRM1",,,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BW-348U87,antiviral,,,,C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,Preclinical
BW-373U86,opioid receptor agonist,OPRD1,,,"CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1",Preclinical
BW-616U,monoamine oxidase inhibitor,MAOA,,,"CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1, CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1",Preclinical
BW-723C86,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",,,"C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|",Preclinical
BX-795,IKK inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",,,"Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1",Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",,,"Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1, Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1",Preclinical
BYK-204165,PARP inhibitor,PARP1,,,"Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12",Preclinical
C-021,CC chemokine receptor antagonist,CCR4,,,"COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1",Preclinical
C-1,protein kinase inhibitor,PRKCA,,,"O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12",Preclinical
C-751,,,,,CCOC(=O)c1cnc[nH]1,Preclinical
CA-4948,kinase inhibitor,,,,Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1,Phase 1
cabagin,,,gastroenterology,dyspepsia,"C[S+](C)CC[C@H](N)C(O)=O, C[S+](C)CC[C@H](N)C(O)=O",Launched
cabaletta,pharmacological chaperone,,,,"OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
cabazitaxel,microtubule inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,prostate cancer,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|,Launched
cabergoline,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7",endocrinology,hyperprolactinemia,"CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1",Launched
cabotegravir,HIV integrase inhibitor,,,,"C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12, C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12",Phase 3
cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET, RET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
CaCCinh-A01,calcium-activated chloride channel inhibitor,CLCA1,,,"CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|",Preclinical
cadazolid,antibacterial ,,,,OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1,Phase 3
cadralazine,adrenergic receptor antagonist,,cardiology,hypertension,"CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|, CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|",Launched
cafestol,pregnane X receptor agonist,,,,"C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3, C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3",Launched
caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",,,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,,,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
caffeine,"adenosine receptor antagonist, phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3",neurology/psychiatry,"fatigue, drowsiness","Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12",Launched
calcifediol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,"C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
calcipotriol,vitamin D receptor agonist,VDR,dermatology,psoriasis,"C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
calcitonin,calcitonin agonist,,orthopedics,osteoporosis,[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|,Launched
calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
calcium-gluceptate,,,,,"OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O",Launched
calcium-levofolinate,,,,,"Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
Calhex-231,calcium sensing receptor negative allosteric modulator,CASR,,,"C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12",Preclinical
calpeptin,calpain inhibitor,,,,"CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
camicinal,motilin receptor agonist,MLNR,,,"C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1",Phase 2
CaMKII-IN-1,calcium/calmodulin dependent protein kinase inhibitor,"AKT1, CAMK2A, CAMK4, MYLK",,,"Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12",Preclinical
camobucol,anti-inflammatory agent,,,,CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C,Preclinical
camostat-mesilate,protease inhibitor,PRSS1,gastroenterology,pancreatitis,"CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1",Launched
camphor-(+),,,,,"CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2",Phase 2
camphor-(1R),TRPV activator,TRPV1,,,"CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2",Phase 1
camptothecin,topoisomerase inhibitor,TOP1,,,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
camptothecin-20(s)-o-propionate,anticancer agent,TOP1,oncology,breast cancer,CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O,Phase 1
camylofine-chlorhydrate,,,gastroenterology,abdominal pain,"CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|",Launched
canagliflozin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,"Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",Launched
candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Launched
candesartan-cilexetil,angiotensin receptor antagonist,,cardiology,"hypertension, congestive heart failure, hypertension","CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|",Launched
candicidin,fungal ergosterol inhibitor,,infectious disease,vulvovaginal candidiasis,"C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38,40,42,44,46,&1:1,&2:3,&3:5,&4:18,&5:21,&6:24,&7:30,&8:32,&9:33,&10:36,&11:62,&12:67,t:49,51,53,55,57,59,61|",Launched
canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",,,"Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl",Phase 3
cangrelor,purinergic receptor antagonist,,cardiology,myocardial infarction,CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O,Launched
canrenone,mineralocorticoid receptor antagonist,NR3C2,,,"C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|",Withdrawn
cantharidin,protein phosphatase inhibitor,,dermatology,blisters,"C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O",Launched
capadenoson,adenosine receptor agonist,ADORA1,,,"Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N",Phase 2
capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
capobenic-acid,,,,,COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O,Preclinical
capreomycin,protein synthesis inhibitor,,infectious disease,tuberculosis,"C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|, C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|",Launched
capreomycin (sulfate),,,,,CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1,
capreomycin sulfate [4mm],protein synthesis inhibitor,,infectious disease,tuberculosis,"NCCC[C@@H](N)CC(=O)NC[C@H]1NC(=O)[C@@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)C(NC1=O)C=NC(N)=O)[C@H]1CCN=C(N)N1 |&1:4,&2:11,&3:15,&4:21,&5:27,&6:40,&7:35,w:35.35,t:44|",Launched
capromorelin,growth hormone secretagogue receptor agonist,,,,CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|,Preclinical
caprylic-acid,,,,,"CCCCCCCC(O)=O, CCCCCCCC(O)=O",Launched
capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
capsazepine,TRPV agonist,"TRPV1, TRPV4",,,"Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1",Preclinical
captamine,,,,,"CN(C)CCS, CN(C)CCS",Preclinical
captan,,,,,"ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r,c:10|",Phase 1
captopril,angiotensin converting enzyme inhibitor,"ACE, LTA4H, MMP2, MMP9","cardiology, endocrinology, nephrology","hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy","C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O",Launched
caracemide,ribonucleotide reductase inhibitor,RRM1,,,"CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC",Phase 2
caramiphen,cholinergic receptor antagonist,"CHRM1, CHRM2",neurology/psychiatry,Parkinson's Disease,"CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1",Launched
carazolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,"angina pectoris, cardiac arrythmia, hypertension, myocardial infarction","CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|",Launched
carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
carbadox,other antibiotic,,"infectious disease, gastroenterology","dysentry, enteritis","COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]",Launched
carbamazepine,carboxamide antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|",Launched
carbaril,acetylcholinesterase inhibitor,,,,"CNC(=O)Oc1cccc2ccccc12, CNC(=O)Oc1cccc2ccccc12",Launched
carbarsone,antiprotozoal agent,,infectious disease,amebiasis,"NC(=O)Nc1ccc(cc1)[As](O)(O)=O, NC(=O)Nc1ccc(cc1)[As](O)(O)=O",Launched
carbazochrome,,,hematology,hemorrhage,"CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|",Launched
carbendazim,"microtubule inhibitor, tubulin polymerization inhibitor","TP53, TUBB",infectious disease,fungicide,"COC(=O)Nc1nc2ccccc2[nH]1, COC(=O)Nc1nc2ccccc2[nH]1",Launched
carbenicillin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|",Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3","gastroenterology, dental","peptic ulcer disease (PUD), mouth inflammation",CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|,Launched
carbenoxolone sodium,11-beta hydroxysteroid dehydrogenase inhibitor,,"gastroenterology, dental","peptic ulcer disease (pud), mouth inflammation",CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O,Launched
carbetapentane,acetylcholine receptor antagonist,CHRM2,"otolaryngology, pulmonary","common cold, nasal congestion, bronchitis","CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1",Launched
carbetocin,oxytocin receptor agonist,OXTR,hematology,hemorrhage,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O",Launched
carbidopa,aromatic L-amino acid decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,"C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O",Launched
carbimazole,antithyroid agent,TPO,endocrinology,hyperthyroidism,"CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S",Launched
carbinoxamine,histamine receptor antagonist,HRH1,"allergy, ophthalmology, otolaryngology, dermatology","allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism",CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|,Launched
carbinoxamine maleate,histamine receptor antagonist,,"allergy, ophthalmology, otolaryngology, dermatology","allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism",CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,Launched
carboplatin,"DNA alkylating agent, DNA inhibitor",,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
carboprost,prostanoid receptor agonist,PTGER1,hematology,postpartum hemorrhage (pph),O=C(O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@](O)(C)CCCCC,Launched
carboxyamidotriazole,calcium channel blocker,CXCL8,,,"NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N",Phase 3
carboxylosartan,angiotensin antagonist,AGTR1,,,"CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Phase 1
carboxypyridine-disulfide,,,,,"OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1",Phase 2
carcainium chloride,antitussive,,infectious disease,pneumonia,O=C(NC1=CC=CC=C1)C[N+](C)(C)CC(NC2=CC=CC=C2)=O.[Cl-],Preclinical
cardiogenol-C,cardiomyogenesis inducer,,,,"COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1",Preclinical
cardionogen-1,WNT signaling inhibitor,CTNNB1,,,"C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1",Preclinical
carebastine,histamine receptor antagonist,HRH1,,,"CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1",Phase 1
carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,"CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1",Launched
carglumic-acid,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia,"NC(=O)N[C@@H](CCC(O)=O)C(O)=O, NC(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
caricotamide,NADPH quinone oxidoreductase inhibitor,NQO2,,,"NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|",Phase 2
cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,,,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
cariprazine,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,schizophrenia,"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|",Launched
carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
carmoterol,adrenergic receptor agonist,ADRB2,,,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Phase 2
carmoxirole,dopamine receptor agonist,DRD2,,,"OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|",Phase 2
carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma","[O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl",Launched
carnitine-(D/L),,,,,"C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|",Phase 3
carnosine,antiglycating agent,,,,"NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|",Phase 2
caroverin,cytochrome P450 inhibitor,,,,"CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O, CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O",Phase 3
caroxazone,monoamine oxidase inhibitor,"MAOA, MAOB",,,"NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O",Withdrawn
carprofen,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,"C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|",Launched
carsalam,analgesic agent,,,,"O=c1[nH]c(=O)c2ccccc2o1, O=c1[nH]c(=O)c2ccccc2o1",Preclinical
carteolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"intraocular pressure, glaucoma, ocular hypertension",CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,Launched
carteolol hydrochloride,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",Cardiology,angina pectoris,"CC(C)(C)NC[C@@H](O)COc1cccc2NC(=O)CCc12 |&1:6,r|",Launched
carumonam,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, gram-negative bacterial infections",NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,Launched
carvedilol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,"myocardial infarction, hypertension, myocardial infarction, hypertension","COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
carvedilol phosphate,,,,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,Launched
carzenide,,"CA1, CA12, CA14, CA2, CA6, CA9",,,NS(=O)(=O)c1ccc(cc1)C(O)=O,Preclinical
casanthranol-variant,,,gastroenterology,constipation,"OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O",Launched
casin,GTPase inhibitor,CDC42,,,"OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|",Preclinical
caspofungin,"bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,"candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection",[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O,Launched
caspofungin (acetate),,,,,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)c1ccc(O)cc1)[C@H](O)CCN,
caspofungin acetate,,,,,CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN,
castanospermine,glucosidase inhibitor,"GAA, GBA",,,"O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12",Phase 2
catharanthine,tubulin polymerization inhibitor,,,,"CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|",Preclinical
cathepsin-inhibitor-1,cathepsin inhibitor,"CTSB, CTSL, CTSV",,,"Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C",Preclinical
CAY10505,PI3K inhibitor,PIK3CG,,,"Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1",Preclinical
CB-03-01,androgen receptor antagonist,AR,,,"CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|",Phase 3
CB-10-277,DNA synthesis inhibitor,,,,"CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O",Phase 1
cb-103,notch signaling inhibitor,NOTCH1,oncology,breast cancer,CC(C)(C)c1ccc(Oc2ccc(N)cn2)cc1,Phase 1/Phase 2
cb-1158,arginase inhibitor,"ARG1, ARG2, IFNLR1",oncology,bladder cancer,C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(=O)O,Phase 1
CB-5083,valosin-containing protein inhibitor,VCP,,,"Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O",Phase 1
CB-839,glutaminase inhibitor,GLS,,,"FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1",Phase 2
CBiPES,glutamate receptor positive allosteric modulator,GRM2,,,"CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N",Preclinical
cbl0137,histone chaperone inhibitor,,,,CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O,Phase 1
cbp/p300-in-4,bromodomain inhibitor,"CREBBP, EP300",genetics,duchenne muscular dystrophy (dmd),CO[C@H]1CC[C@@H](CC1)n1c(nc2cc(ccc12)-c1c(C)noc1C)[C@@H]1CCCC(=O)N1c1ccc(F)c(F)c1,
CBS-1114,lipoxygenase inhibitor,ALOX5,,,NC(=NNc1ccccc1)c1ccccc1,Phase 1
CC-115,"DNA protein kinase inhibitor, mTOR inhibitor",MTOR,,,"CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|",Phase 2
CC-223,mTOR inhibitor,MTOR,,,"CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|",Phase 2
CC-401,JNK inhibitor,MAPK8,,,C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1,Phase 1
CC-90003,MAP kinase inhibitor,,,,COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1,Phase 1
cc-92480,ubiquitin ligase inhibitor,CRBN,hematologic malignancy,multiple myeloma,Fc1cc(ccc1N2CCN(Cc3ccc(COc4cccc5C(=O)N(Cc45)[C@H]6CCC(=O)NC6=O)cc3)CC2)C#N,Phase 1
CC-930,JNK inhibitor,,,,"O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1",Phase 2
CCG-1423,apoptosis stimulant,"RHOC, SRF",,,"C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|",Preclinical
CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",,,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
CCG-63802,G protein signaling inhibitor,RGS4,,,"Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1",Preclinical
CCG-63808,G protein signaling inhibitor,RGS4,,,"Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O",Preclinical
CCMI,acetylcholine receptor allosteric modulator,CHRNA7,,,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
CCMQ,homoquinolinic acid binding inhibitor,,,,"OC(=O)Cc1cc2ccccc2nc1C(O)=O, OC(=O)Cc1cc2ccccc2nc1C(O)=O",Preclinical
ccr1 antagonist 9,ccr antagonist,CCR1,rheumatology,rheumatoid arthritis,O=C(C1=CN=CC2=C1C=NN2C3=CC=C(F)C=C3)NCC4=CC(S(=O)(C)=O)=NC=C4,Preclinical
ccr2 antagonist 3,potassium channel blocker,KCNJ3,cardiology,cardiac arrythmia,CC1=C(F)C=CC(C(N(C)[C@@H](C(C)C)CN2CC(O)C2)=O)=C1,Phase 2
CCT-031374,WNT signaling inhibitor,CTNNB1,,,"O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|",Preclinical
CCT018159,HSP inhibitor,"HSP90AA1, HSP90AB1",,,"CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O",Preclinical
CCT128930,AKT inhibitor,,,,"NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12",Preclinical
CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1",Preclinical
CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1",Preclinical
CCT196969,RAF inhibitor,,,,"CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1, CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1",Preclinical
CCT245737,kinase inhibitor,,,,FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1,Preclinical
CC4,nicotinic receptor agonist,CHRNB2,,,"O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12",Preclinical
CD-1530,retinoid receptor agonist,RARG,,,"OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2",Preclinical
CD-437,retinoid receptor agonist,RARG,,,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
CDBA,,,,,"OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|",Phase 3
CDK1-5-inhibitor,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3B",,,"Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12",Preclinical
CDK9-IN-6,CDK inhibitor,CDK9,,,"COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1",Preclinical
CDPPB,glutamate receptor positive allosteric modulator,GRM5,,,"O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N",Preclinical
ce-245677,tie tyrosine kinase inhibitor,"NTRK1, NTRK2, TEK",oncology,breast cancer,O=C(NC1=CC=C(Cl)C=C1Cl)NC2=CC(C(C3=CN(C(C)C)C4=NC=NC(N)=C43)=O)=CC=C2OC,Phase 1
cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",,,"CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|",Phase 3
cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",,,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1",Phase 3
cedrol,,,,,"C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|, C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|",Phase 2
cedrol-(+),sedative,,,,"C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O, C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O",Phase 2
cefaclor,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis","N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|",Launched
cefadroxil,bacterial cell wall synthesis inhibitor,"SLC15A1, SLC15A2, SLC22A6, SLC22A8","infectious disease, otolaryngology, infectious disease, otolaryngology","urinary tract infections, skin infections, tonsillitis, pharyngitis, urinary tract infections, skin infections, tonsillitis, pharyngitis","CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O",Launched
cefalonium,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|",Launched
cefamandole,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, urinary tract infections, respiratory tract infections","Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|",Launched
cefamandole-nafate,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, urinary tract infections, respiratory tract infections","Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|",Launched
cefathiamidine,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|, CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|",Launched
cefazolin,bacterial cell wall synthesis inhibitor,PON1,infectious disease,"urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections","Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|",Launched
cefcapene-pivoxil,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, pneumonia, urinary tract infections","CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|",Launched
cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|",Launched
cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|",Launched
cefepime,"penicillin binding protein inhibitor, bacterial cell wall synthesis inhibitor",A1BG,"infectious disease, Infectious disease","pneumonia, urinary tract infections, skin infections, intra-abdominal infections, gram-negative bacterial infections","CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:19|",Launched
cefetamet,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, pulmonary","ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|",Launched
cefetamet-pivoxil,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|",Launched
cefiderocol,antibacterial ,,,,[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|,Launched
cefixime,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, pulmonary","urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis","Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|",Launched
cefmenoxime,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|,Launched
cefmenoxime hydrochloride,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,Launched
cefmetazole,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, skin infections","CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|",Launched
cefminox,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|, CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|",Launched
cefodizime,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, skin infections, gonorrhea","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|",Launched
cefonicid,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|",Launched
cefoperazone,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|",Launched
ceforanide,penicillin binding protein inhibitor,,infectious disease,gram-negative bacterial infections,"NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|",Launched
cefoselis,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|",Launched
cefotaxime,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|",Launched
cefotetan,"bacterial cell wall synthesis inhibitor, penicillin binding protein inhibitor",PBP,"infectious disease, Infectious disease","urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis, gram-positive bacterial infections","CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|",Launched
cefotetan disodium,,,,,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:30|,Launched
cefotiam,bacterial cell wall synthesis inhibitor,,infectious disease,"bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections","CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|",Launched
cefotiam-cilexetil,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|, C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|, C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|",Launched
cefoxitin,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections","CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|",Launched
cefozopran,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|",Launched
cefpiramide,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|",Launched
cefpirome,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|",Launched
cefpodoxime,bacterial cell wall synthesis inhibitor,,"otolaryngology, infectious disease, pulmonary","pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis","COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|",Launched
cefprozil,bacterial cell wall synthesis inhibitor,,"otolaryngology, infectious disease, pulmonary","pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis","C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|",Launched
cefradine,bacterial cell wall synthesis inhibitor,CYP3A4,"infectious disease, otolaryngology","respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia","CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|",Launched
cefsulodin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|",Launched
ceftaroline-fosamil,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, pneumonia",CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|,Launched
ceftazidime,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis","CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|",Launched
ceftazidime pentahydrate,,,,,CC(C)(O\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O,
ceftibuten,bacterial cell wall synthesis inhibitor,,"pulmonary, otolaryngology","bronchitis, otitis, pharyngitis, tonsillitis","Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|",Launched
ceftiofur,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, respiratory tract infections","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|",Launched
ceftizoxim,bacterial cell wall synthesis inhibitor,,infectious disease,"respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|",Launched
ceftobiprole,antiinfective drug,,,,[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|,Phase 3
ceftriaxone,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|",Launched
cefuroxime,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|",Launched
cefuroxime-axetil,bacterial cell wall synthesis inhibitor,,otolaryngology,"pharyngitis, tonsillitis, otitis, sinusitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|",Launched
celecoxib,cyclooxygenase inhibitor,"CA12, PDPK1, PTGS2","rheumatology, endocrinology","osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)","Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F",Launched
celgosivir,glucosidase inhibitor,,,,[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O,Phase 2
celiprolol,adrenergic receptor antagonist,"ADRA2A, ADRB1, ADRB2",genetics,Ehlers-Danlos syndrome (EDS),"CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|, CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|",Launched
cenerimod,sphingosine 1-phosphate receptor modulator,,,,CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1,Phase 2
cenicriviroc,CC chemokine receptor antagonist,,,,CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|,Phase 3
cenisertib,aurora kinase inhibitor,"AURKB, KDR",oncology,pancreatic cancer,[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H],Phase 1
cenobamate,"GABA receptor modulator, voltage-gated sodium channel blocker",,,,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,Launched
centanafadine,dopamine reuptake inhibitor,,,,C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1,Phase 3
centazolone,monoamine oxidase inhibitor,,,,"Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O",Phase 1
centhaquin,analgesic agent,,,,Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1,Phase 1
centpropazine,inositol monophosphatase inhibitor,,,,"CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|",Phase 3
CEP-32496,RAF inhibitor,"BRAF, RAF1",,,"COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC",Phase 1/Phase 2
CEP-33779,JAK inhibitor,JAK2,,,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,,,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl",Phase 1
CEP-40783,AXL kinase inhibitor,,,,COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC,Preclinical
cephalexin,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections","CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|",Launched
cephalomannine,DNA polymerase inhibitor,,,,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|",Preclinical
cephalosporin-c-zn,bacterial cell wall synthesis inhibitor,,,,CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|,Preclinical
cephalothin,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, surgical prophylaxis","CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|",Launched
cephapirin,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|",Launched
cepharanthine,NFkB pathway inhibitor,,,,"COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34",Phase 2
cephradine,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, respiratory tract infections, urinary tract infections","CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7,11,&1:4,c:17,t:1,14|",Launched
ceralasertib,atr kinase inhibitor,ATR,Oncology,breast cancer,C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@](C)(=N)=O,Phase 3
ceramide,"phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator",,dermatology,cosmetic,"CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O, CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O",Launched
ceritinib,ALK tyrosine kinase receptor inhibitor,"ALK, FLT3, IGF1R, INSR, TSSK1B",oncology,non-small cell lung cancer (NSCLC),"CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1",Launched
cerulenin,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,"C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O",Launched
ceruletide,CCK receptor agonist,CCKAR,,,[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,Preclinical
cetaben,"ACAT inhibitor, cholesterol inhibitor",PPARA,,,"CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O",Phase 2
cetilistat,triacylglycerol lipase inhibitor,PNLIP,,,"CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1",Phase 3
cetirizine,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|",Launched
cetrimonium,,,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
cetrorelix,gonadotropin releasing factor hormone receptor antagonist,"GNRHR, LHCGR",endocrinology,premature luteinizing hormone surges,"CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",Launched
cetylpyridinium,,,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
cevimeline,acetylcholine receptor agonist,CHRM3,rheumatology,sjogren's syndrome,"C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|",Launched
cevimeline hydrochloride,acetylcholine receptor agonist,,rheumatology,sjogren's syndrome,C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,Launched
cevipabulin,"microtubule stimulant, tubulin polymerization inhibitor, microtubule stimulant, tubulin polymerization inhibitor",TUBB,,,"CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F, [H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F",Phase 1
CE3F4,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,,,"C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|",Preclinical
CFI-400945,serine/threonine kinase inhibitor,,,,COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1,Phase 2
CFI-402257,dual specificity protein kinase inhibitor,,,,Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|,Phase 1/Phase 2
CFM-1571,guanylate cyclase activator,,,,"COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1",Preclinical
CFM-2,glutamate receptor antagonist,,,,"COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|, COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|",Preclinical
CFTRinh-172,chloride channel blocker,CFTR,,,"OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1",Preclinical
CF102,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12",Phase 2
CG-400549,FABI inhibitor,,,,"Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O",Phase 2
CGH2466,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",,,"Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1",Preclinical
CGK-733,"ATM kinase inhibitor, ATR kinase inhibitor","ATM, ATR",,,"[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|",Preclinical
CGM097,MDM inhibitor,MDM2,,,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
cgp 55845,gaba receptor antagonist,,Neurology,depression,C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,Preclinical
CGP-12177,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,"CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|",Phase 1
CGP-13501,GABA receptor modulator,GABBR1,,,"CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C",Preclinical
CGP-20712A,adrenergic receptor antagonist,"ADRB1, ADRB3",,,"CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|",Preclinical
CGP-25454A,dopamine receptor antagonist,,,,CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC,Preclinical
CGP-37157,"mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor",SLC8A1,,,"Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|",Preclinical
CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|",Phase 1
CGP-39551,NMDA receptor antagonist,,,,"CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|",Preclinical
CGP-52411,EGFR inhibitor,EGFR,,,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
CGP-53353,"EGFR inhibitor, PKC inhibitor","EGFR, PRKCB",,,"Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1",Preclinical
CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|",Preclinical
CGP-55845,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,"C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",Preclinical
CGP-57380,MAP kinase inhibitor,"AURKB, LCK, MKNK1, MKNK2, SGK1",,,"Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12",Preclinical
CGP-60474,CDK inhibitor,"CDK1, CDK2",,,"OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1",Preclinical
CGP-71683,neuropeptide receptor antagonist,NPY5R,,,"Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|",Preclinical
CGP-74514,CDK inhibitor,CDK1,,,"CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12",Preclinical
CGP-78608,glutamate receptor antagonist,,,,"C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O, C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O",Preclinical
CGP-7930,GABA receptor modulator,GABBR1,,,"CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Preclinical
CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1",Preclinical
CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",,,"COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O",Phase 1
CGS-21680,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,Preclinical
CGS-9896,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2",,,"Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O, Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O",Preclinical
CH-170,,,,,"Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1, Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1",Phase 1
CH-5183284,fibroblast growth factor inhibitor,"FGFR1, FGFR2, FGFR3",,,"Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N",Phase 2
CHC,monocarboxylate transporter inhibitor,SLC16A1,,,"OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N",Preclinical
chenodeoxycholic-acid,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist","HSD11B1, NR1H4","cardiology, gastroenterology","cerebral cholesterosis, gallstones","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
CHF5074,gamma secretase modulator,PSEN1,,,"OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1, OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1",Phase 2
chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,,,"COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|",Preclinical
chidamide,HDAC inhibitor,"HDAC10, HDAC3",hematologic malignancy,peripheral T-cell lymphoma (PTCL),"Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1",Launched
chiniofon,antiprotozoal agent,,infectious disease,amebiasis,"Oc1c(I)cc(c2cccnc12)S(O)(=O)=O, Oc1c(I)cc(c2cccnc12)S(O)(=O)=O",Launched
CHIR-124,CHK inhibitor,CHEK1,,,"Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1",Preclinical
CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",,,"Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O",Preclinical
CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",,,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
chloralose,,,,,OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl,Preclinical
chlorambucil,DNA inhibitor,,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl, OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl",Launched
chloramine-T,,,infectious disease,bacterial gill disease,"Cc1ccc(cc1)S(=O)(=O)NCl, Cc1ccc(cc1)S(=O)(=O)NCl",Launched
chloramphenicol,bacterial 50S ribosomal subunit inhibitor,CD55,"infectious disease, endocrinology","meningitis, fever, cholera","OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O",Launched
chloramphenicol palmitate,protein synthesis inhibitor,,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
chloramphenicol-palmitate,protein synthesis inhibitor,,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
chloramphenicol-sodium-succinate,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O, O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O",Launched
chlorazanil,,,,,Nc1ncnc(Nc2ccc(Cl)cc2)n1,Preclinical
chlorcyclizine,histamine receptor antagonist,,allergy,allergic rhinitis,"CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|",Launched
chlorfenson,other antifungal,,,,Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1,Phase 2
chlorhexidine,membrane integrity inhibitor,,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis","NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1",Launched
chlorindanol,,,,,"Oc1ccc(Cl)c2CCCc12, Oc1ccc(Cl)c2CCCc12",Preclinical
chlorindione,,,,,"Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O",Preclinical
chlorisondamine-diiodide,acetylcholine receptor antagonist,CHRNA1,,,"C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl",Preclinical
chlormadinone acetate,5 alpha reductase inhibitor,,endocrinology,"hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea",CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,Launched
chlormadinone-acetate,5 alpha reductase inhibitor,PGR,endocrinology,"hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",Launched
chlormerodrin,sodium/potassium/chloride transporter inhibitor,"ALDH5A1, SLC12A1",urology,urinary frequency,COC(CNC(=O)N)C[Hg]Cl,Withdrawn
chlormethine (hydrochloride),,,,,CN(CCCl)CCCl,
chlormezanone,GABA receptor modulator,GABRA1,,,"CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|",Withdrawn
chlormidazole,fungal lanosterol demethylase inhibitor,,infectious disease,fungal infection,"Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1",Launched
chlorobutanol,,,neurology/psychiatry,"anesthetic, sedative","CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl",Launched
chlorocresol,ryanodine receptor activator,,infectious disease,first-aid antiseptic,"Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl",Launched
chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
chlorophyllin,cytochrome p450 inhibitor,,"urology, Infectious disease","urinary incontinence, hepatitis b","CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C, CCc1c(C)c2=Cc3c(C=C)c(C)c4C=c5c(C)c(CCC(O)=O)c6=C7C(C(O)=O)C(=O)c8c(C)c9C=c1n2[Cu](n34)(n9c78)n56",Phase 1
chlorophyllin-copper,cytochrome P450 inhibitor,,,,"CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|",Phase 1
chloroprocaine,sodium channel blocker,"ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3",neurology/psychiatry,local anesthetic,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,Launched
chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma","CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1",Launched
chloroquine,antimalarial agent,MRGPRX1,infectious disease,"malaria, amebiasis","CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|",Launched
chlorothiazide,diuretic,"CA1, CA2, CA4, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|",Launched
chlorothymol,,,,,"CC(C)c1cc(Cl)c(C)cc1O, CC(C)c1cc(Cl)c(C)cc1O",Launched
chlorotrianisene,estrogenic hormone,"ESR1, ESR2","endocrinology, oncology","menopause, prostate cancer","COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1",Launched
chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
chloroxoquinoline,,,,,"Clc1ccc2c(c1)[nH]ccc2=O, Clc1ccc2c(c1)[nH]ccc2=O",Launched
chloroxylenol,ATP synthase inhibitor,,infectious disease,skin infections,"Cc1cc(O)cc(C)c1Cl, Cc1cc(O)cc(C)c1Cl",Launched
chlorphenamine,histamine receptor antagonist,,allergy,"allergic rhinitis, urticaria",CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|,Launched
chlorphenesin,muscle relaxant,,neurology/psychiatry,"muscle relaxant, sedative","OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|, OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|",Launched
chlorpheniramine maleate,histamine receptor antagonist,,allergy,"allergic rhinitis, urticaria",CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,Launched
chlorphenoxamine,histamine receptor antagonist,,,,CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|,Preclinical
chlorphensin-carbamate,muscle relaxant,,neurology/psychiatry,spasms,"NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5,r|",Launched
chlorproguanil,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,"CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1",Launched
chlorpromazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5","neurology/psychiatry, gastroenterology, hematology, infectious disease","schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus","CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12",Launched
chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
chlorpropham,antiviral,,,,"CC(C)OC(=O)Nc1cccc(Cl)c1, CC(C)OC(=O)Nc1cccc(Cl)c1",Phase 1
chlorprothixene,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"schizophrenia, bipolar disorder","CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12",Launched
chlorpyrifos,acetylcholinesterase inhibitor,ACHE,,,"CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl",Launched
chlorquinaldol,other antibiotic,,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
chlortetracycline,protein synthesis inhibitor,,ophthalmology,conjunctivitis,"[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|, [H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|",Launched
chlortetracycline hcl,protein synthesis inhibitor,,ophthalmology,conjunctivitis,CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,Launched
chlorthalidone,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1","cardiology, gastroenterology, rheumatology, nephrology","hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure","NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|",Launched
chlorzoxazone,bacterial 30S ribosomal subunit inhibitor,"KCNMA1, KCNN4",neurology/psychiatry,muscle relaxant,"Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1",Launched
cholecalciferol,,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
cholesterol,,RORA,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|,Preclinical
cholic-acid,bile acid,"ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B","gastroenterology, neurology/psychiatry, genetics","bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",Launched
choline,acetylcholine precursor,"ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2",,,"C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO",Phase 3
choline alfoscerate,acetylcholine precursor,,CNS disorders,alzheimer's disease,C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO,Launched
choline-alfoscerate,acetylcholine precursor,,,,C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO,Launched
CHPG,glutamate receptor agonist,GRM5,,,"N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|",Preclinical
CHR-6494,serine/threonine kinase inhibitor,GSG2,,,"CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1",Preclinical
chromanol-(+/-),potassium channel blocker,,,,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,Preclinical
"chromanol-293B-(-)-[3R,4S]",potassium channel blocker,,,,"CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N, CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N",Preclinical
chromium-picolinate,insulin sensitizer,,endocrinology,diabetes mellitus,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1",Launched
chromocarb,antispasmodic,,,,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
chrysin,breast cancer resistance protein inhibitor,"AKR1B1, CDK6, CYP19A1, CYP1B1",,,"Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1",Phase 1
chrysophanic-acid,EGFR inhibitor,"EGFR, MTOR",,,"Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",Preclinical
chs-828,nampt inhibitor,"A1BG, NAMPT",Oncology,lung cancer,Clc1ccc(OCCCCCC\N=C(\NC#N)Nc2ccncc2)cc1,Phase 1
chuanxiongzine,,,,,"Cc1nc(C)c(C)nc1C, Cc1nc(C)c(C)nc1C",Phase 2
CH223191,aryl hydrocarbon receptor antagonist,AHR,,,Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1,Preclinical
CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
CH55,retinoid receptor binder,"RARA, RARB",,,"CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O",Preclinical
CI-844,,,,,"O(c1ccccc1)c1cccnc1, O(c1ccccc1)c1cccnc1",Phase 2
CI-923,acetylcholine receptor antagonist,,,,"CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|, CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|",Phase 1
CI-953,voltage-gated sodium channel blocker,,,,Cc1cccc(Cl)c1NC(=O)Nc1ccncc1,Phase 1
CI-966,GAT inhibitor,SLC6A1,,,"OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|",Phase 1
CI-976,ACAT inhibitor,"ACAT1, CES1",,,"CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC",Phase 1
ciaftalan-zinc,reactive oxygen species stimulant,,,,"[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|",Phase 1
cianidanol,fatty acid synthase inhibitor,PTGS1,,,"O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1",Withdrawn
cibenzoline,sodium channel blocker,,cardiology,cardiac arrythmia,"C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|",Launched
ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,"CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|",Launched
ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
cicloprofen,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|",Preclinical
CID-16020046,G protein-coupled receptor antagonist,GPR55,,,"Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|",Preclinical
CID-2011756,protein kinase inhibitor,PKD1,,,"Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1",Preclinical
CID-2745687,G protein-coupled receptor antagonist,GPR35,,,"COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F",Preclinical
CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,,,"OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|, OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|",Preclinical
cidofovir,DNA polymerase inhibitor,,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
ciglitazone,PPAR receptor agonist,PPARG,,,"CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|",Phase 2
cilastatin,dehydropeptidase inhibitor,DPEP1,,,"CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O",Launched
cilazapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure","CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O",Launched
cilazapril monohydrate,angiotensin converting enzyme inhibitor,,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O,Launched
cilengitide,integrin antagonist,"ITGAV, ITGB3",,,"CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O",Phase 3
cilnidipine,calcium channel blocker,CACNA1B,cardiology,hypertension,"COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|",Launched
cilofexor,FXR agonist,,,,OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl,Phase 3
cilomilast,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4D",,,"COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N, COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|",Phase 3
cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",,,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
cilostazol,phosphodiesterase inhibitor,"PDE3A, PDE3B",cardiology,claudication,"O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1",Launched
ciluprevir,serine protease inhibitor,,,,"COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|",Preclinical
CIM-0216,transient receptor potential channel agonist,TRPM3,,,"Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|",Preclinical
cimaterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,"CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|",Preclinical
cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N",Launched
cimetropium,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,"C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|, C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|",Launched
cimlanod,nitric oxide donor,,cardiology,congestive heart failure,Cc1oc(cc1)S(=O)(=O)NO,Phase 2
cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia","C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12",Launched
cinaciguat,guanylate cyclase activator,"GUCY1A3, GUCY1B3",,,"OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O",Phase 2
cinalukast,leukotriene receptor antagonist,CYSLTR1,,,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
cinanserin,serotonin receptor antagonist,HTR2A,,,"CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1",Preclinical
cinchocaine,sodium channel blocker,"CALM1, SCN10A, SCN5A",neurology/psychiatry,local anesthetic,"CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1",Launched
cinchonidine,P glycoprotein inhibitor,,,,"O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",Phase 1
cinchonine,P glycoprotein inhibitor,CYP2D6,,,O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12,Preclinical
cinchophen,analgesic agent,,rheumatology,gout,"OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1",Launched
cinepazet,vasodilator,,,,CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1,Launched
cinepazide,calcium channel activator,,,,"COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC",Withdrawn
cinflumide,muscle relaxant,,,,Fc1cccc(\C=C\C(=O)NC2CC2)c1,Phase 2
cinnamaldehyde,"aldose reductase inhibitor, TRPV agonist",TRPA1,,,O=C\C=C\c1ccccc1,Preclinical
cinnarazine,calcium channel blocker,,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
cinobufotalin,anticancer agent,,,,[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1,Phase 1
cinoctramide,,,,,"COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC",Preclinical
cinoxacin,topoisomerase inhibitor,,infectious disease,urinary tract infections,"CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12",Launched
cinoxate,,,dermatology,sunscreen lotion,"CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1",Launched
CINPA-1,CAR antagonist,"NR1H4, NR1I3, PPARG",,,"CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1",Preclinical
cinromide,,,,,"CCNC(=O)\C=C\c1cccc(Br)c1, CCNC(=O)\C=C\c1cccc(Br)c1",Phase 3
cintirorgon,ROR agonist,,,,CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O,Phase 1/Phase 2
cintriamide,,,,,COc1cc(\C=C\C(N)=O)cc(OC)c1OC,Preclinical
cipamfylline,phosphodiesterase inhibitor,,,,Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1,Phase 2
cipargamin,antimalarial agent,,,,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21,Phase 2
cipemastat,metalloproteinase inhibitor,"ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9",,,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,Phase 3
ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|",Launched
ciprofloxacin,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis,"OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
ciproxifan,histamine receptor antagonist,"ADRA2A, ADRA2C, HRH3, HRH4, HTR3A",,,"O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1",Preclinical
CIQ,glutamate receptor potentiator,"GRIN2C, GRIN2D",,,"COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|",Preclinical
cirazoline,adrenergic receptor agonist,ADRA1A,,,"C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|",Preclinical
cis-aconitic-acid,,ACO2,,,"OC(=O)C\C(=C\C(O)=O)C(O)=O, OC(=O)C\C(=C\C(O)=O)C(O)=O",Preclinical
cis-ACPD,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM7, GRM8",,,"[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|",Preclinical
"cis-exo-camphanediol-2,3",nitric oxide stimulant,NOS3,,,CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O,Phase 1
cis-urocanic acid,serotonin receptor agonist,,,,OC(=O)\C=C/c1cnc[nH]1,Phase 2
cis-urocanic-acid,serotonin receptor agonist,HTR2A,,,"OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1",Phase 2
"cis-9,trans-11-conjugated-linoleic-acid",,,,,"CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O",Launched
cisapride,serotonin receptor agonist,"HTR2A, HTR3A, HTR4, KCNH2",,,"COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC",Withdrawn
cisatracurium,acetylcholine receptor antagonist,CHRNA2,"neurology/psychiatry, critical care","muscle relaxant, endotracheal intubation","COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC",Launched
cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),"ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|",Launched
citarinostat,HDAC inhibitor,,,,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl,Phase 1
CITCO,constitutive androstane receptor (CAR) agonist,NR1I3,,,"Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1",Preclinical
citicoline,"glutathione transferase stimulant, membrane permeability enhancer","ACHE, SLC1A2","neurology/psychiatry, ophthalmology","stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma","C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|",Launched
citiolone,"lipotropic, mucolytic agent",,,,"CC(=O)N[C@H]1CCSC1=O |&1:4,r|",Preclinical
citric-acid,coagulation factor inhibitor,"AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2",,,OC(=O)CC(O)(CC(O)=O)C(O)=O,Preclinical
CJ-033466,serotonin receptor agonist,HTR4,,,"CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1",Preclinical
CJ-13610,lipoxygenase inhibitor,,,,Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1,Phase 2
CK-101,EGFR inhibitor,,,,"OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F, OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F",Preclinical
CK-636,actin related protein inhibitor,"ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5",,,"Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1",Preclinical
CKD-712,NFkB pathway inhibitor,"JAK2, STAT1",,,"Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|",Phase 1
CKI-7,casein kinase inhibitor,CSNK1G2,,,"NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12, NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12",Preclinical
CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",,,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
CL-225385,,,,,"O=C(CC#N)c1ccccc1, O=C(CC#N)c1ccccc1",Phase 2
cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,"Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1",Launched
clamikalant,ATP-sensitive potassium channel antagonist,,,,CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC,Preclinical
clanfenur,anticancer agent,,,,CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1,Preclinical
clarithromycin,bacterial 50S ribosomal subunit inhibitor,CYP3A4,"otolaryngology, pulmonary, infectious disease","pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC",Launched
clascoterone,androgen receptor antagonist,AR,dermatology,acne vulgaris (av),CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO,Withdrawn
clavulanate,beta lactamase inhibitor,,otolaryngology,otitis,"OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O, OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O",Launched
clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,"COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1",Launched
clemastine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1",Launched
clemizole,HCV inhibitor,,allergy,allergic rhinitis,"Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1",Launched
clenbuterol,adrenergic receptor agonist,"ABCC8, ADRB2, KCNJ11",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|,Launched
clenbuterol hydrochloride,adrenergic receptor agonist,,pulmonary,"chronic obstructive pulmonary disease (copd), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
cleviprex,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1S",cardiology,hypertension,"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|",Launched
clevudine,DNA polymerase inhibitor,,infectious disease,hepatitis B,"Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O, Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O",Launched
clidinium,acetylcholine receptor antagonist,"CHRM1, CHRM3",gastroenterology,"peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis","C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|",Launched
climbazole,enzyme inducer,,dermatology,"dandruff, eczema","CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|, CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|, CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|",Launched
clinafloxacin,bacterial DNA gyrase inhibitor,,,,"N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|",Phase 3
clinafloxacin (pd127391),bacterial dna gyrase inhibitor,,,,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1,Phase 3
clindamycin,protein synthesis inhibitor,,infectious disease,"respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections","CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O",Launched
clindamycin palmitate hcl,bacterial 50s ribosomal subunit inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections",CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl,Launched
clindamycin-palmitate,bacterial 50S ribosomal subunit inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections",CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl,Launched
clindamycin-phosphate,protein synthesis inhibitor,,obstetrics/gynecology,bacterial vaginosis,"CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O",Launched
clinofibrate,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia,"CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|, CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|",Launched
clioquinol,chelating agent,OPRK1,,,"Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12",Withdrawn
clobenpropit,histamine receptor antagonist,"HRH1, HRH2, HRH3, HRH4",,,"Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1",Preclinical
clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|",Launched
clobetasone-butyrate,corticosteroid agonist,NR3C1,dermatology,"eczema, psoriasis, dermatitis","CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|, CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|",Launched
clobutinol,antitussive,,,,"C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|, C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|",Withdrawn
clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|",Launched
clodronic-acid,bone resorption inhibitor,"SLC25A4, SLC25A5, SLC25A6","orthopedics, endocrinology, hematologic malignancy","osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma","OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O",Launched
clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
clofazimine,GK0582 inhibitor,,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
clofedanol,histamine receptor antagonist,HRH1,pulmonary,cough suppressant,"CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|",Launched
clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
clofibric-acid,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O",Launched
clofilium,potassium channel blocker,"KCNA5, KCNH1",,,"CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1",Phase 2
clofoctol,protein synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
clomesone,DNA inhibitor,,,,CS(=O)(=O)CS(=O)(=O)OCCCl,Phase 1
clomethiazole,"GABA receptor antagonist, GABA receptor modulator",GABRA1,neurology/psychiatry,"Parkinson's Disease, sedative, muscle relaxant","Cc1ncsc1CCCl, Cc1ncsc1CCCl, Cc1ncsc1CCCl",Launched
clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
clomipramine,serotonin transporter (SERT) inhibitor,"GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,obsessive compulsive disorder (OCD),"CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12",Launched
clonidine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, neurology/psychiatry","hypertension, attention-deficit/hyperactivity disorder (ADHD)","Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|",Launched
clonixin,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, infectious disease","rheumatoid arthritis, soft tissue infection",Cc1c(Cl)cccc1Nc1ncccc1C(O)=O,Preclinical
clonixin-lysinate,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,"NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O",Launched
clopamide,sodium/chloride cotransporter inhibitor,,cardiology,hypertension,"CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O",Launched
cloperastine,antitussive,,pulmonary,cough suppressant,"Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|, Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|, Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|",Launched
cloperastine-fendizoate,potassium channel antagonist,,,,,Preclinical
clopidogrel,purinergic receptor antagonist,P2RY12,"cardiology, neurology/psychiatry","myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)","COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl",Launched
clopidol,,,infectious disease,coccidiosis,"Cc1[nH]c(C)c(Cl)c(=O)c1Cl, Cc1[nH]c(C)c(Cl)c(=O)c1Cl",Launched
cloprostenol-(+/-),prostaglandin receptor agonist,"PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R",obstetrics/gynecology,endometriosis,"O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O",Launched
cloranolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,hypertension,CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|,Launched
clorgiline,monoamine oxidase inhibitor,MAOA,,,"CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C",Phase 2
clorofene,,,,,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Launched
clorotepine,"adrenergic receptor antagonist, dopamine receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6",neurology/psychiatry,psychosis,"CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|, CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|",Launched
clorprenaline,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,asthma,"CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|, CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|",Launched
clorsulon,glycolysis inhibitor,,infectious disease,"gastrointestinal roundworms, lungworms, liver flukes, lice, mites","Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O",Launched
closantel,"chitinase inhibitor, NFkB pathway inhibitor, chitinase inhibitor, nfkb pathway inhibitor",,infectious disease,liver flukes,"Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|, Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|",Launched
clotiapine,,,neurology/psychiatry,psychosis,"CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|",Launched
clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
cloxacillin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl",Launched
cloxyquin,potassium channel activator,KCNK18,,,"Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12",Preclinical
clozapine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7",neurology/psychiatry,schizophrenia,"CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|",Launched
CL316243,adrenergic receptor agonist,"ADRB3, UCP1, UCP2, UCP3",,,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,Phase 2
CM-4620,calcium release activated channel modulator,,,,Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl,Phase 2
CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",,,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
cndac,,,,,NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N,Phase 2
cndac (hydrochloride),antineoplastic agent,"ATP8A2, BRCA2, RAD51D",hematologic malignancy,acute myeloid leukemia (aml),"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1.Cl |a:5,7,10,12|",Phase 1/Phase 2
CNQX,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N",Phase 1
CNX-2006,EGFR inhibitor,EGFR,,,"COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F",Preclinical
CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,"CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1",Preclinical
CO-101244,glutamate receptor antagonist,GRIN2B,,,"Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1",Preclinical
CO-102862,sodium channel blocker,"SCN4A, SCN9A",,,"NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1",Phase 1
cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),"CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1",Launched
cobimetinib,MEK inhibitor,MAP2K1,oncology,melanoma,"OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1",Launched
coenzyme-A,,"ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5",,,"CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|, CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|",Launched
coenzyme-I,,"AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH",,,"NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|",Phase 2
coenzyme-Q10,,,,,"COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|",Launched
COH29,ribonucleotide reductase inhibitor,,,,Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1,Phase 1
colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
colforsin,adenylyl cyclase activator,"ADCY2, ADCY5",,,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|",Phase 2
colforsin-daproate,adenylyl cyclase activator,,,,"CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C",Launched
colfosceril-palmitate,pulmonary surfactant,,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|",Launched
colistimethate,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections,[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O,Launched
colistimethate sodium,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections,"CCC(C)C1NC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(CCNC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(CCNCS(O)(=O)=O)NC1=O)C(C)O)NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)CCCCC(C)C)C(C)O)C(C)CC, CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O",Launched
colistin,bacterial permeability inducer,,infectious disease,"gram-negative bacterial infections, gram-negative bacterial infections","CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|, CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|, CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|",Launched
colistin (sulfate),,,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,
colistin sulfate,,,,,"CCC(C)C1NC(=O)C(NC(=O)C(CCN)NC(=O)C(CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC1=O)C(C)O)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)CCCCC(C)C)C(C)O)C(C)CC, CC(C)CCCCC(=O)N[C@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CCN)C(=O)N[C@@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)C(C)C)[C@@H](C)O",
colistin-b-sulfate,,,,,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,
combretastatin-A-4,tubulin polymerization inhibitor,,,,"COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O",Phase 2
compound-w,beta-secretase inhibitor,BACE1,,,"OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1",Preclinical
compound-401,DNA dependent protein kinase inhibitor,"MTOR, PRKDC",,,"O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1",Preclinical
compound-58112,,,,,"COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1, COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1",Preclinical
conivaptan,vasopressin receptor antagonist,"AVPR1A, AVPR2",endocrinology,hyponatremia,"Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1, Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1",Launched
convallatoxin,cardiac glycoside,,,,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|,Preclinical
copanlisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,follicular lymphoma,"COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|",Launched
copper-histidine,,"SLC15A3, SLC15A4, SLC38A5",,,"N[C@H](Cc1cnc[nH]1)C(O)=O, N[C@H](Cc1cnc[nH]1)C(O)=O",Phase 3
COR-170,cannabinoid receptor inverse agonist,CNR2,,,"CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1",Preclinical
cordycepin,DNA inhibitor,,,,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O",Phase 1/Phase 2
corosolic-acid,"PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1",,,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",Phase 2
CORT-108297,glucocorticoid receptor antagonist,,,,CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|,Preclinical
corticosterone,mineralocorticoid receptor agonist,"HSD11B1, NCOA1, NR3C2",,,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|",Preclinical
cortisone,glucocorticoid receptor agonist,NR3C1,"gastroenterology, rheumatology, dermatology, gastroenterology, rheumatology, dermatology","ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema, ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema","C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|",Launched
cortisone-acetate,glucocorticoid receptor agonist,NR3C1,"pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease","asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|",Launched
cortodoxone,androgen receptor antagonist,AR,,,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|",Phase 3
costunolide,telomerase inhibitor,,,,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|",Preclinical
cot-inhibitor-1,MAPK-interacting kinase inhibitor,MAP3K8,,,"Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl",Preclinical
cot-inhibitor-2,MAPK-interacting kinase inhibitor,MAP3K8,,,"CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1",Preclinical
COTI-2,anticancer agent,,,,S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1,Phase 1
cotinine,nicotine metabolite,,,,"CN1[C@@H](CCC1=O)c1cccnc1, CN1[C@@H](CCC1=O)c1cccnc1",Phase 2
coumarin,vitamin K antagonist,"CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6","gastroenterology, pulmonary","ulcerative colitis, asthma, celiac disease","O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1",Launched
coumophos,cholinesterase inhibitor,,,,"CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1",Preclinical
"CP-105,696",leukotriene receptor antagonist,,,,O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O,Preclinical
CP-316819,glycogen phosphorylase inhibitor,PYGL,,,"CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",Preclinical
CP-339818,potassium channel blocker,KCNA3,,,CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12,Preclinical
CP-376395,corticotropin releasing factor receptor antagonist,CRHR1,,,"CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C",Phase 1
CP-471474,matrix metalloprotease inhibitor,"MMP1, MMP13, MMP2, MMP3, MMP9",,,"CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO",Preclinical
CP-532623,cholesteryl ester transfer protein inhibitor,CETP,,,CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F,Phase 1
CP-547632,kinase inhibitor,,,,NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F,Phase 2
CP-640186,acetyl-CoA carboxylase inhibitor,"ACACA, ACACB",,,"O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1, O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1",Preclinical
CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",,,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,,,"COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1",Phase 2
CP-775146,PPAR receptor agonist,PPARA,,,"CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1",Preclinical
CP-91149,glycogen phosphorylase inhibitor,PYGL,,,"CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",Preclinical
CP-93129,serotonin receptor agonist,HTR1A,,,"O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|",Preclinical
CP-94253,serotonin receptor agonist,HTR1B,,,"CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|",Preclinical
"CP-945,598",cannabinoid receptor antagonist,CNR1,,,"CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O",Phase 3
CP-99994,tachykinin antagonist,TACR1,,,"COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1",Phase 2
CPA-inhibitor,carboxypeptidase inhibitor,"CPA1, CPA2",,,"ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|",Preclinical
CPCCOEt,glutamate receptor antagonist,GRM1,,,"CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|",Preclinical
CPI-0610,bromodomain inhibitor,BRD4,,,"Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|",Phase 2
CPI-1189,tumor necrosis factor release inhibitor,TNF,,,"CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C",Phase 2
CPI-1205,EZH2 inhibitor,,,,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,Phase 1/Phase 2
CPI-169,histone lysine methyltransferase inhibitor,EZH2,,,CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12,Preclinical
CPI-203,bromodomain inhibitor,BRD4,,,"Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|",Preclinical
CPI-360,histone lysine methyltransferase inhibitor,EZH2,,,"COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12, COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12",Preclinical
CPI-444,adenosine receptor antagonist,,,,Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12,Phase 1/Phase 2
CPI-613,pyruvate dehydrogenase inhibitor,PDHA1,,,"OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|",Phase 3
CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1",Phase 2
CPSI-1306-(+/-),macrophage migration inhibiting factor inhibitor,MIF,,,"Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|",Preclinical
CQS,,,,,Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1,Preclinical
creatine,,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",,,"CN(CC(O)=O)C(N)=N, CN(CC(O)=O)C(N)=N",Launched
creatinine,,,,,"CN1CC(=O)NC1=N, CN1CC(=O)NC1=N, CN1CC(=O)NC1=N",Preclinical
creatinol-phosphate,,,,,"CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N",Launched
crenigacestat,notch signaling inhibitor,,,,C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O,Preclinical
crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",,,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 3
cresol,,,,,"Cc1ccc(O)cc1, Cc1ccc(O)cc1",Launched
cresopirine,,,,,"CC(=O)Oc1c(C)cccc1C(O)=O, CC(=O)Oc1c(C)cccc1C(O)=O",Preclinical
cridanimod,progesterone receptor agonist,PGR,infectious disease,influenza A virus infection,"OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12",Launched
crisaborole,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",dermatology,dermatitis,"OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12",Launched
crisdesalazine,free radical scavenger,,,,OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O,Preclinical
crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
crizotinib-(S),MTH1 inhibitor,NUDT1,,,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
crocin,microtubule inhibitor,"BCL2, BIRC5, CCND1, TPPP",endocrinology,hyperglycemia,O[C@@H]([C@H](O)[C@H]1O)[C@H](O[C@H]1OC(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=O)=O)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO,Launched
croconazole,bacterial cell wall synthesis inhibitor,,infectious disease,fungal infection,"Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1, Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1",Launched
crolibulin,tubulin polymerization inhibitor,,,,COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|,Phase 1/Phase 2
cromakalim,,KCNJ8,,,"CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N",Phase 2
cromoglicic-acid,immunosuppressant,"KCNMA1, S100P","pulmonary, ophthalmology, allergy, gastroenterology","asthma, conjunctivitis, urticaria, ulcerative colitis","OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O",Launched
crotamiton,antipruritic,,infectious disease,scabies,"CCN(C(=O)\C=C\C)c1ccccc1C, CCN(C(=O)\C=C\C)c1ccccc1C",Launched
CRT0044876,,,,,"OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1",Preclinical
cryptotanshinone,"acetylcholinesterase inhibitor, STAT inhibitor",STAT3,,,"C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|",Preclinical
crystal violet,other antibiotic,,,,CN(C)c1ccc(cc1)[C+](c1ccc(cc1)N(C)C)c1ccc(cc1)N(C)C,Launched
crystal-violet,other antibiotic,,,,"CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12,15|",Launched
CR8-(R),CDK inhibitor,CCNA2,,,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
CS-110266,dopamine receptor agonist,SLC6A3,,,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
CS-917,fructose biphosphate inhibitor,FBP1,,,"CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O",Phase 2
CT-7758,integrin antagonist,ITGA4,,,"OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|",Phase 2
CTEP,glutamate receptor antagonist,GRM5,,,"Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1",Preclinical
CTS-1027,metalloproteinase inhibitor,"MMP1, MMP13, MMP2, MMP3, MMP9",,,"ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1",Phase 2
CTS21166,beta-secretase inhibitor,BACE1,,,"CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O",Phase 1
CT7001,CDK inhibitor,,,,CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,Phase 1/Phase 2
CU-CPT-4a,toll-like receptor inhibitor,TLR3,,,"OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl",Preclinical
CU-T12-9,toll-like receptor agonist,"TLR1, TLR2",,,"CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O",Preclinical
CUDC-101,EGFR inhibitor,"EGFR, ERBB2",,,"COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO",Phase 1
CUDC-427,apoptosis inhibitor,XIAP,,,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1",Phase 1
CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",,,"COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1",Phase 2
CUR-61414,smoothened receptor antagonist,"DHH, IHH, SMO",,,COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1,Phase 1
curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",,,"COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O",Launched
curcumol,JAK inhibitor,"JAK1, JAK2, JAK3",,,"CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C",Phase 1
cutamesine,sigma receptor agonist,SIGMAR1,,,"COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC",Phase 2
CV-1808,adenosine receptor agonist,ADORA2A,,,"Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Preclinical
CVT-10216,aldehyde dehydrogenase inhibitor,ALDH2,,,"CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O",Phase 1
CW-008,PKA activator,PRKACA,,,"COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1",Preclinical
CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",,,"OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21",Phase 1/Phase 2
CX-516,glutamate receptor modulator,,,,"O=C(N1CCCCC1)c1ccc2OCOc2c1, O=C(N1CCCCC1)c1ccc2OCOc2c1",Phase 2/Phase 3
CX-5461,RNA polymerase inhibitor,,,,"CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O, CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O",Phase 1
CXD101,HDAC inhibitor,,,,Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N,Phase 1/Phase 2
cyacetacide,,,,,"NNC(=O)CC#N, NNC(=O)CC#N",Preclinical
cyamemazine,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C, HTR7",neurology/psychiatry,"schizophrenia, anxiety","C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|",Launched
cyanocobalamin,"methylmalonyl CoA mutase stimulant, vitamin B",MUT,"hematology, infectious disease, gastroenterology","anemia, fish tapeworm infestation, celiac disease","C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|",Launched
cyanopindolol,adrenergic receptor antagonist,"ADRB1, HTR1A, HTR1D",,,"CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|",Phase 2
cyclamic-acid,,,,,"OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1",Preclinical
cyclandelate,calcium channel blocker,,"cardiology, rheumatology","claudication, arteriosclerosis, Raynaud's disease","C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|",Launched
cyclic-AMP,,"CNGA3, TRPM7",,,"Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|, Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|",Preclinical
cyclizine,histamine receptor modulator,"HRH1, SULT1E1","gastroenterology, neurology/psychiatry","nausea, vomiting, vertigo, motion sickness","CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
cyclobenzaprine,"adrenergic receptor agonist, serotonin receptor agonist",HTR2A,neurology/psychiatry,spasms,"CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|",Launched
cyclocreatine,creatine kinase substrate,,,,NC1=NCCN1CC(O)=O |t:1|,Phase 1
cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",,,,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
cycloheximide,protein synthesis inhibitor,RPL3,,,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
cyclopamine,hedgehog pathway inhibitor,,,,"C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|",Preclinical
cyclopenthiazide,thiazide diuretic,,cardiology,"hypertension, congestive heart failure","NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|",Launched
cyclopentolate,acetylcholine receptor antagonist,,ophthalmology,"mydriasis, cycloplegia","CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|, CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|",Launched
cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|",Launched
cyclopiazonic acid,endoplasmic reticulum calcium atpase inhibitor,,,,CC(=O)[C@H]1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |&1:3|,Preclinical
cyclopiazonic-acid,ATPase inhibitor,ATP2A1,,,"CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|",Preclinical
cycloserine-(D),bacterial cell wall synthesis inhibitor,GRIN1,infectious disease,"tuberculosis, tuberculosis","N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O",Launched
cyclosporin-A,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","rheumatology, dermatology","rheumatoid arthritis, psoriasis","CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
cyclothiazide,glutamate receptor modulator,"CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|",Launched
cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O",Launched
cyclovirobuxin-D,calcium channel modulator,,,,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
CycLuc1,,,,,OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|,Preclinical
CYC065,CDK inhibitor,,,,CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,Phase 1
CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",,,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
CYM-50260,sphingosine 1-phosphate receptor agonist,S1PR4,,,"FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1",Preclinical
CYM-50358,sphingosine 1-phosphate receptor antagonist,S1PR4,,,"Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl",Preclinical
CYM-50769,neuropeptide receptor antagonist,NPBWR1,,,"COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1",Preclinical
CYM-5442,sphingosine 1-phosphate receptor agonist,S1PR1,,,"CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|",Preclinical
CYM-5520,sphingosine 1-phosphate receptor agonist,S1PR2,,,"Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1",Preclinical
CYM-5541,sphingosine 1-phosphate receptor agonist,S1PR3,,,"O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1",Preclinical
cypermethrin,,,infectious disease,flea control,"CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|",Launched
cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|",Launched
cyproterone,,,,,CC(=O)[C@@]1(O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@]12C,
cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",Launched
cyromazine,,,,,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
cysteamine,tissue transglutaminase inhibitor,"NPY2R, SST",metabolism,cystinosis,"NCCS, NCCS",Launched
cysteamine hcl,,,,,Cl.NCCS,
CYT-997,tubulin polymerization inhibitor,TUBB,,,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
cytidine,,UCK2,,,"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
cytisine,acetylcholine receptor agonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4",neurology/psychiatry,nicotinism,"O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12",Launched
cytochalasin-B,microtubule inhibitor,ACTB,,,"C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|",Phase 2
cytochlor,,,,,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
cyt387,JAK inhibitor,"JAK1, JAK2, JAK3",,,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
CY208-243,dopamine receptor agonist,CALY,,,"CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",Phase 2
CZC-54252,leucine rich repeat kinase inhibitor,LRRK2,,,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1",Preclinical
CZC24832,PI3K inhibitor,PIK3CG,,,"CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1",Preclinical
C106,,,,,"CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|",Phase 3
C11-Acetate,,"ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN",,,[Y+3],Phase 3
C188-9,STAT inhibitor,,,,COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12,Preclinical
C34,toll-like receptor inhibitor,TLR4,,,"CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O",Preclinical
C646,histone acetyltransferase inhibitor,EP300,,,"CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|",Preclinical
"D,L-mevalonic-acid-lactone",,,,,"C[C@@]1(O)CCOC(=O)C1 |&1:1,r|",Preclinical
"d,l-3-hydroxybutyric acid",hydroxycarboxylic acid receptor agonist,"HCAR2, HDAC2, HDAC3",,,C[C@@H](O)CC(O)=O |&1:1|,Phase 1
D-(+)-maltose,,MGAM,,,"OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
D-alpha-tocopheryl-succinate,,,,,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1",Launched
D-delta-tocopherol,,,,,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1",Launched
d-fructose,,,,,OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO,
D-limonene,,,,,"CC(=C)[C@@H]1CCC(C)=CC1 |c:7|, CC(=C)[C@@H]1CCC(C)=CC1 |c:7|",Phase 1
D-phenylalanine,enkephalinase inhibitor,"CCBL1, CRH, HCAR3",,,"N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O",Preclinical
d-pinitol,,,,,CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,
D-serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",,,"N[C@H](CO)C(O)=O, N[C@H](CO)C(O)=O",Launched
D-157495,decapping scavenger enzyme inhibitor,,,,Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1,Preclinical
D-3263,transient receptor potential channel agonist,,,,COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1,Phase 1
D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",,,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1",Preclinical
D-64131,microtubule inhibitor,TUBB,,,"COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1",Preclinical
D-7193,,,,,"CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O, CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O",Phase 2
DAA-1106,benzodiazepine receptor agonist,TSPO,,,"COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1",Preclinical
dabigatran,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1",Launched
dabigatran-etexilate,thrombin inhibitor,F2,"neurology/psychiatry, hematology","stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)","CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1",Launched
dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
dabuzalgron,adrenergic receptor agonist,ADRB3,urology,urinary incontinence,Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O |t:5|,Phase 1
dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O",Launched
dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
daclatasvir,HCV inhibitor,,infectious disease,hepatitis C,"COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C",Launched
dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1",Launched
dactinomycin,RNA polymerase inhibitor,POLR2A,oncology,"testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)","CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O",Launched
daidzein,estrogen receptor agonist,"ESRRA, ESRRB, ESRRG, TRPC5",,,"Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",Phase 2
daidzin,antioxidant,ALDH2,,,OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O,Phase 1
dalargin,opioid receptor agonist,OPRM1,,,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|",Phase 2
dalbavancin,bacterial cell wall synthesis inhibitor,PNLIP,infectious disease,skin infections,"CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2, CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2",Launched
dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,,,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
dalfampridine,potassium channel blocker,"KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2",neurology/psychiatry,multiple sclerosis,"Nc1ccncc1, Nc1ccncc1, Nc1ccncc1, Nc1ccncc1",Launched
dalfopristin,antibacterial ,,,,"[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|",Preclinical
daltroban,thromboxane receptor antagonist,TBXA2R,,,"OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1, OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1",Phase 3
daminozide,KDM2A inhibitor,"KDM2A, KDM7A, PHF8",,,"CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O",Preclinical
danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema","C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|",Launched
danegaptide,gap junction modulator,,,,"NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1, NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1",Phase 2
danirixin,CC chemokine receptor antagonist,CXCR2,,,"Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1",Phase 2
danofloxacin,bacterial DNA gyrase inhibitor,,pulmonary,bovine respiratory disease (BRD),"CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1",Launched
danoprevir,HCV inhibitor,,,,"CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|",Phase 3
dantrolene,calcium channel blocker,"RYR1, RYR3","neurology/psychiatry, endocrinology","spasms, malignant hyperthermia (MH)","[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1",Launched
dantron,laxative,,,,"Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12",Withdrawn
danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",,,"CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
dapagliflozin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,"CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1",Launched
dapansutrile,anti-inflammatory agent,,,,CS(=O)(=O)CCC#N,Phase 2
daphnetin,protein kinase inhibitor,,,,"Oc1ccc2ccc(=O)oc2c1O, Oc1ccc2ccc(=O)oc2c1O",Preclinical
dapiprazole,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",ophthalmology,mydriasis,"Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1",Launched
dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",,,"Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1",Phase 3
dapoxetine,selective serotonin reuptake inhibitor (SSRI),"HTR1A, HTR1B, HTR2C, SLC6A4",urology,premature ejaculation (PE),"CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1",Launched
daprodustat,hypoxia inducible factor inhibitor,EGLN1,,,"OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O",Phase 3
dapsone,bacterial antifolate,DHFR,"dermatology, infectious disease","dermatitis herpetiformis (DH), leprosy","Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1, Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1",Launched
DAPT,gamma secretase inhibitor,,,,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1",Preclinical
daptomycin,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, endocarditis, skin infections, endocarditis","CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O, [H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O",Launched
darapladib,phospholipase inhibitor,PLA2G7,,,"CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1",Phase 3
darglitazone,PPAR receptor antagonist,PPARG,,,"Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1, Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1",Phase 2
darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
darolutamide,androgen receptor antagonist,AR,oncology,"breast cancer, prostate cancer","C[C@@H](Cn1ccc(n1)c2ccc(c(c2)Cl)C#N)NC(=O)c3cc([nH]n3)C(C)O, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|",Launched
darunavir,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1",Launched
darusentan,endothelin receptor antagonist,EDNRA,,,"COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1",Phase 3
dasabuvir,HCV inhibitor,,infectious disease,hepatitis C,"COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1",Launched
dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
dasotraline,dopamine-norepinephrine-serotonin reuptake inhibitor,,,,N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12,Phase 3
DAU-5884,acetylcholine receptor antagonist,CHRM3,,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O",Preclinical
daucosterol,apoptosis stimulant,,,,"CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|",Phase 2
daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
dauricine,nfkb pathway inhibitor,"GORASP1, PTGR1",oncology,colorectal cancer,COc1cc2CCN(C)[C@H](Cc3ccc(Oc4cc(C[C@H]5N(C)CCc6cc(OC)c(OC)cc56)ccc4O)cc3)c2cc1OC,Preclinical
dazmegrel,thromboxane synthase inhibitor,TBXAS1,,,"Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O, Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O",Phase 2
dazoxiben,thromboxane synthase inhibitor,TBXAS1,,,OC(=O)c1ccc(OCCn2ccnc2)cc1,Phase 2
DBeQ,ATPase inhibitor,CASP3,,,"C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1",Preclinical
DBPR-211,cannabinoid receptor antagonist,,,,FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,Preclinical
DBPR108,dipeptidyl peptidase inhibitor,DPP4,,,"CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N",Phase 1
DC-260126,free fatty acid receptor antagonist,FFAR1,,,"CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1",Preclinical
DCC-2618,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","KIT, PDGFRA",,,"Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1",Phase 1
DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",,,"CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O",Preclinical
DCP-LA,protein kinase activator,,,,"CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|",Preclinical
DCPIB,"chloride channel blocker, gap junction modulator, glutamate inhibitor",SLC1A2,,,"CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|",Preclinical
ddd107498 (succinate),antimalarial agent,,infectious disease,malaria,Fc1ccc2nc(cc(C(=O)NCCN3CCCC3)c2c1)-c1ccc(CN2CCOCC2)cc1.OC(=O)CCC(=O)O,Phase 1
DDR1-IN-1,discoidin domain receptor inhibitor,"DDR1, DDR2",,,"CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1",Preclinical
deazaguanine,DNA synthesis inhibitor,,,,Nc1cc2[nH]cnc2c(O)n1,Preclinical
Debio-0932,HSP inhibitor,,,,CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C,Phase 1
debrisoquin,adrenergic neuron blocker,SLC6A2,cardiology,hypertension,"NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1",Launched
decamethonium,acetylcholine receptor agonist,"ACHE, CHRNA2",neurology/psychiatry,muscle relaxant,"C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C",Launched
decamethoxine,antiseptic,,,,"CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|",Phase 2
decernotinib,"protein tyrosine kinase inhibitor, JAK inhibitor","JAK2, JAK3",Immunology,rheumatoid arthritis,"CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F",Phase 2/Phase 3
decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
declopramide,cell cycle inhibitor,,,,CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1,Preclinical
decloxizine,histamine receptor antagonist,,,,OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,Preclinical
decoglurant,glutamate receptor modulator,"GRM2, GRM3",neurology/psychiatry,depression,NC1=NC=C(C#CC2=C3N=C(C4=CC=C(C(F)(F)F)C=C4)C=C(C(F)(F)F)N3N=C2)C=C1,Phase 2
decoquinate,antiprotozoal agent,,infectious disease,coccidiosis,"CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O",Launched
defactinib,focal adhesion kinase inhibitor,PTK2,,,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload","OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O",Launched
deferasirox-iron-chelate,,,,,OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21,Launched
deferiprone,chelating agent,UGT1A6,hematology,"transfusional hemosiderosis, thalassemia, iron overload","Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C",Launched
deferoxamine-mesylate,chelating agent,,hematology,"acute iron intoxication, iron overload","CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN",Launched
deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,"CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|",Launched
deforolimus,mTOR inhibitor,MTOR,,,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|",Phase 3
degarelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer,"CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",Launched
dehydroacetic-acid,,,,,"CC(=O)c1c(O)cc(C)oc1=O, CC(=O)c1c(O)cc(C)oc1=O",Preclinical
dehydrocholate,,,,,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|",Preclinical
dehydrocholate-acid,,,,,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O",Preclinical
dehydrocorydaline,acetylcholinesterase inhibitor,ACHE,,,"COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC",Phase 3
dehydroepiandrosterone,protein synthesis stimulant,"ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1",endocrinology,menopause,"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|",Launched
dehydroepiandrosterone-sulfate,"androgen receptor agonist, estrogen receptor agonist","AR, ESR1, ESR2",endocrinology,menopause,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|,Launched
delafloxacin,antiinfective drug,,,,Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12,Phase 3
delamanid,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis,"C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O, C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O, C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O",Launched
delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",,,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
delapril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1",Launched
delavirdine,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1",Launched
delcasertib,PKC inhibitor,,,,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O,Phase 1
delgocitinib,JAK inhibitor,,,,C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12,Phase 2
delivert,angiotensin receptor agonist,"AGTR1, AGTR2",critical care,sepsis,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O",Launched
delpazolid,antibacterial,,,,CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|,Phase 2
delphinidin,membrane permeability inhibitor,GLO1,,,"Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1",Phase 2
delta-tocotrienol,HMGCR inhibitor,HMGCR,,,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1",Phase 1
deltarasin,phosphodiesterase inhibitor,KRAS,,,"C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1",Preclinical
demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma","CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C",Launched
demeclocycline,bacterial 30S ribosomal subunit inhibitor,,"endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis","[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11,&2:21|",Launched
demeclocycline hcl,,,,,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,
denatonium-benzoate,,,,,"CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1, CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1",Preclinical
denopamine,adrenergic receptor agonist,,cardiology,angina pectoris,COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC,Launched
denotivir,antiviral,,infectious disease,"virus herpes simplex (HSV), skin infections","Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1",Launched
deoxyarbutin,tyrosinase inhibitor,,,,"Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|, Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|",Preclinical
deoxycholic-acid,"biliverdin reductase A activator, G protein-coupled receptor agonist","FPR1, GPBAR1",endocrinology,submental fat,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",Launched
deoxycorticosterone-acetate,progestogen hormone,NR3C2,,,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|",Preclinical
deoxyepinephrine,"adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2",,,"CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1",Preclinical
deprodone propionate,anti-inflammatory agent,"ALOX5AP, CHRNB4",dermatology,eczema,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)C,Launched
deptropine,histamine receptor antagonist,HRH1,,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|",Preclinical
dequalinium,PKC inhibitor,"KCNN1, KCNN3",infectious disease,first-aid antiseptic,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
deracoxib,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,"COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F, COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F",Launched
derazantinib,tyrosine kinase inhibitor,,,,COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1,Phase 2
deserpidine,angiotensin converting enzyme inhibitor,"ACE, SLC18A2",cardiology,hypertension,"CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1",Launched
desidustat,hypoxia inducible factor prolyl hydroxylase inhibitor,,,,OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O,Preclinical
desipramine,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1",neurology/psychiatry,depression,"CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12",Launched
desisobutyryl-ciclesonide,cytochrome P450 inhibitor,,allergy,allergic rhinitis,"[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13,t:9|",Launched
deslanoside,Na/K-ATPase inhibitor,"ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2",cardiology,"congestive heart failure, cardiac arrythmia","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|",Launched
desloratadine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1",Launched
deslorelin,gonadotropin releasing factor hormone receptor agonist,,,,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,Phase 2
desmethylclozapine,acetylcholine receptor agonist,HTR2C,,,"Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|, Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|",Phase 2
desmopressin (acetate),vasopressin receptor agonist,,"endocrinology, urology","central diabetes insipidus, nocturnal enuresis",NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O,Launched
desmopressin-acetate,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR","endocrinology, urology","central diabetes insipidus, nocturnal enuresis",NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|,Launched
desogestrel,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,"CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|",Launched
desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",Launched
desoximetasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|",Launched
desoxycorticosterone-pivalate,corticosteroid agonist,NR3C2,endocrinology,Addison's disease,"CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|, CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|",Launched
desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",,,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|",Preclinical
desoxymetasone,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,Launched
desoxypeganine,"acetylcholinesterase inhibitor, monoamine oxidase inhibitor",ACHE,,,"C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|",Phase 1
desvenlafaxine,"serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI), serotonin‚Äö√§√¨norepinephrine reuptake inhibitor (snri)","SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|",Launched
detomidine,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative,"Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C",Launched
deucravacitinib,tyrosine kinase inhibitor,TYK2,gastroenterology,crohn's disease,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc3cccc(c3OC)c4ncn(C)n4,Launched
deutetrabenazine,vesicular monoamine transporter inhibitor,SLC18A2,neurology/psychiatry,huntington's disease,[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Launched
devazepide,CCK receptor antagonist,,,,"CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|",Preclinical
dexamethasone,glucocorticoid receptor agonist,"ANXA1, NOS2, NR0B1, NR3C1, NR3C2","endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology, endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (dh), nephrotic syndrome, psoriasis","C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",Launched
dexamethasone palmitate,glucocorticoid receptor agonist,NR3C1,rheumatology,rheumatoid arthritis,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Phase 3
dexamethasone sodium phosphate,glucocorticoid receptor agonist,,Lung diseases,acute respiratory distress syndrome,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|, C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O",
dexamethasone-acetate,glucocorticoid receptor agonist,,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|",Launched
dexbrompheniramine,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C,Withdrawn
dexchlorpheniramine,histamine receptor antagonist,,"allergy, cardiology","allergic conjunctivitis, allergic rhinitis, urticaria, angioedema","CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1",Launched
dexfosfoserine,membrane integrity inhibitor,"CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2",,,"N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O",Preclinical
dexlansoprazole,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), erosive esophagitis (EE)","Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1",Launched
dexloxiglumide,CCK receptor antagonist,CCKAR,,,"CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1, CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1",Phase 3
dexmedetomidine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,sedative,"C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C",Launched
dexniguldipine,calmodulin antagonist,ADORA3,,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",Phase 2
dexpanthenol,,,gastroenterology,paralytic ileus,"CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)[C@@H](O)C(=O)NCCCO",Launched
dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
dextran,,,"hematology, critical care","thrombosis, hypovolemia","OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",Launched
dextromethorphan,"glutamate receptor antagonist, sigma receptor agonist","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4",pulmonary,cough suppressant,"COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1",Launched
dextrorotation-nimorazole-phosphate-ester,antiinfective drug,,,,Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O,Preclinical
dextrose,,,endocrinology,hypoglycemia,"OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O",Launched
dextrothyroxine,,,null,cholesterol,N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O,Launched
DFB,glutamate receptor agonist,GRM5,,,"Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1",Preclinical
DG-172,PPAR receptor inverse agonist,PPARD,,,"CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1",Preclinical
DG051,leukotriene synthesis inhibitor,,,,OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1,Preclinical
DH-97,melatonin receptor antagonist,MTNR1B,,,"CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",Preclinical
DHBP,ryanodine receptor blocker,,,,"CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1, CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1",Preclinical
diacerein,interleukin inhibitor,IL1B,rheumatology,osteoarthritis,"CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O",Launched
diacetamate,,,,,"CC(=O)Nc1ccc(OC(C)=O)cc1, CC(=O)Nc1ccc(OC(C)=O)cc1",Preclinical
diadenosine-tetraphosphate,adenosine kinase inhibitor,"P2RY13, P2RY2",,,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|",Phase 1
dianhydrogalactitol,DNA alkylating agent,,,,"O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1",Phase 3
diarylpropionitrile,estrogen receptor agonist,ESR2,,,"Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|",Preclinical
diatrizoate,contrast agent,,radiology,mri contrast agent,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,Launched
diatrizoic-acid,,,radiology,contrast agent,"CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I",Launched
diaveridine,dihydrofolate reductase inhibitor,,infectious disease,coccidiosis,"COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC",Launched
diazoxide,potassium channel activator,"ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3",endocrinology,hypoglycemia,"CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|",Launched
dibekacin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1,Launched
dibenzepine,norepinephrine reputake inhibitor,,,,"CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O, CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O",Preclinical
dibenzothiophene,,,,,"c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21",Preclinical
dibutyl-phthalate,,TRPA1,,,"CCCCOC(=O)c1ccccc1C(=O)OCCCC, CCCCOC(=O)c1ccccc1C(=O)OCCCC",Preclinical
dicarbine,dopamine receptor ligand,,,,CN1CCC2Nc3ccc(C)cc3C2C1,Preclinical
dichlorisone-acetate,,,,,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|",Phase 2
dichloroacetate,pyruvate dehydrogenase kinase inhibitor,,,,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
dichlorophen,anticestodal agent,,infectious disease,"hookworm, tapeworm","Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O",Launched
dichlorvos,acetylcholinesterase inhibitor,,,,"COP(=O)(OC)OC=C(Cl)Cl, COP(=O)(OC)OC=C(Cl)Cl",Launched
diclazuril,antiprotozoal agent,,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|",Launched
diclofenac,cyclooxygenase inhibitor,"AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A","rheumatology, neurology/psychiatry","rheumatoid arthritis, osteoarthritis, migraine headache","OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl",Launched
diclofenamide,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA4, CA7","ophthalmology, neurology/psychiatry","glaucoma, epilepsy","NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O, NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O",Launched
diclofensine,dopamine reuptake inhibitor,"DRD1, MAOA, MAOB",,,"COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|",Phase 3
dicloralurea,,,,,"O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|, O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|",Preclinical
dicloxacillin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl",Launched
dicoumarol,NADPH inhibitor,"CRYZ, NQO1, VKORC1",hematology,deep vein thrombosis (DVT),"Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12, Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12",Launched
dicyclohexylamine,,,,,"C1CCC(CC1)NC1CCCCC1, C1CCC(CC1)NC1CCCCC1",Preclinical
dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
didanosine,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1),"OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O",Launched
dideoxyadenosine,nucleoside reverse transcriptase inhibitor,,,,"Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1",Phase 1
didox,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer,"ONC(=O)c1ccc(O)c(O)c1, ONC(=O)c1ccc(O)c(O)c1",Launched
dienestrol,estrogen receptor agonist,ESR1,endocrinology,menopause,"C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1",Launched
dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis","C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|",Launched
diethylcarbamazine,lipoxygenase inhibitor,"ALOX5, PTGS1",infectious disease,filariasis,"CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1",Launched
diethylstilbestrol,estrogen receptor agonist,"ESR1, ESR2, ESRRB, ESRRG",,,"CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1",Withdrawn
diethyltoluamide,ionotropic receptor IR40a activator,,dermatology,sunscreen lotion,"CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1",Launched
difamilast,phosphodiesterase inhibitor,PDE4A,dermatology,dermatitis,CCOc1ccccc1C(=O)NCc2coc(n2)c3ccc(OC(F)F)c(OC(C)C)c3,Phase 3
difelikefalin,opioid receptor agonist,OPRK1,nephrology,uremic pruritus,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O |a:4,8,19,31|",Launched
difenpiramide,"cyclooxygenase inhibitor, prostaglandin inhibitor",,neurology/psychiatry,pain relief,O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1,Launched
diflorasone diacetate,glucocorticoid receptor agonist,NR3C1,"Dermatology, dermatology","psoriasis, corticosteroid-responsive dermatoses","[H][C@@]12C[C@H](C)[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C |r,c:35,t:31|, [H][C@@]12C[C@H](C)[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C |r,c:35,t:31|",Launched
diflorasone-diacetate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,,Launched
difloxacin,bacterial DNA gyrase inhibitor,,infectious disease,"skin infections, urinary tract infections","CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1",Launched
diflunisal,prostanoid receptor antagonist,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F, OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F",Launched
difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,"CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|",Launched
diftalone,cyclooxygenase inhibitor,,endocrinology,thyroiditis,"O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12, O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12",Launched
digitoxigenin,ATPase inhibitor,ATP1A1,,,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|",Preclinical
digitoxin,ATPase inhibitor,"ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2",cardiology,"congestive heart failure, cardiac arrythmia","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|",Launched
digoxigenin,steroid,,,,"C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|",Preclinical
digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)","[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|, [H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|",Launched
dihomo-gamma-linolenic-acid,prostanoid receptor agonist,"PTGS1, PTGS2",,,"CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O",Phase 2
dihydrexidine,dopamine receptor agonist,"DRD1, DRD2, DRD3, DRD4, DRD5",,,"Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O",Phase 2
dihydroartemisinin,antimalarial agent,,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",neurology/psychiatry,"senile dementia, cerebrovascular insufficiency","CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
dihydroergotamine,serotonin receptor agonist,"ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,"CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
dihydromyricetin,,,,,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
dihydrostreptomycin,bacterial 30S ribosomal subunit inhibitor,,,,"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO, CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO",Withdrawn
dihydrostreptomycin [5mm],bacterial 30s ribosomal subunit inhibitor,,Infectious disease,tuberculosis,CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO,Withdrawn
dihydrotachysterol,vitamin analog,VDR,"orthopedics, endocrinology","rickets, hypocalcemia, osteomalacia","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|",Launched
dihydroxyacetone,,,dermatology,skin protectant,OCC(=O)CO,Launched
dihydroxyphenylglycine,glutamate receptor agonist,"GRM1, GRM5",,,"N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|",Preclinical
diiodothyropropionic-acid,thyroid hormone stimulant,,,,OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1,Phase 2
dilazep,adenosine reuptake inhibitor,SLC29A1,cardiology,coronary heart disease,"COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1",Launched
dilmapimod,p38 MAPK inhibitor,,,,Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12,Phase 1
diloxanide,protein synthesis inhibitor,,infectious disease,amebiasis,"CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1, CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1",Launched
diltiazem,calcium channel blocker,"CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5",cardiology,"hypertension, angina pectoris","COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O",Launched
DIM-C-pPhCO2Me,nuclear receptor antagonist,,,,COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12,Preclinical
dimaprit,histamine receptor agonist,"HRH2, HRH3, HRH4",,,"CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N",Preclinical
dimemorfan,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant,"CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31",Launched
dimenhydrinate,histamine receptor antagonist,HRH1,"neurology/psychiatry, gastroenterology","motion sickness, nausea, vomiting",Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1,Launched
dimercaprol,chelating agent,,neurology/psychiatry,metal toxicity,"OC[C@@H](S)CS |&1:2,r|, OC[C@@H](S)CS |&1:2,r|, OC[C@@H](S)CS |&1:2,r|",Launched
dimercaptosuccinic-acid,chelating agent,DNMT1,neurology/psychiatry,metal toxicity,"OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O",Launched
dimesna,tubulin polymerization inhibitor,,,,"OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O",Phase 3
dimethadione,oxazolidine antiepileptic,,,,CC1(C)OC(=O)NC1=O,Preclinical
dimethicone,,,dermatology,cosmetic,C[Si](C)(C)O[Si](C)(C)C,Launched
dimethindene-(S)-(+),acetylcholine receptor antagonist,HRH1,,,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|",Preclinical
dimethisoquin,local anesthetic,,neurology/psychiatry,local anesthetic,"CCCCc1cc2ccccc2c(OCCN(C)C)n1, CCCCc1cc2ccccc2c(OCCN(C)C)n1",Launched
dimethyl-fumarate,"nuclear factor erythroid derived, like (NRF2) activator",KEAP1,neurology/psychiatry,multiple sclerosis,"COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC",Launched
dimethyl-isosorbide,cosmetic moisturizer,,,,"CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|",Preclinical
dimetindene,"cholinergic receptor antagonist, histamine receptor antagonist",HRH1,allergy,allergic rhinitis,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|",Launched
dimetridazole,bacterial DNA inhibitor,,infectious disease,protozoan infection,"Cc1ncc(n1C)[N+]([O-])=O, Cc1ncc(n1C)[N+]([O-])=O",Launched
diminazene-aceturate,angiotensin converting enzyme activator,"AOC1, PRDX5, PRSS1",,,"NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1",Phase 3
dimpylate,acetylcholinesterase inhibitor,ACHE,infectious disease,flea control,"CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C",Launched
dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",,,"CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO",Phase 3
dinitolmide,,,infectious disease,coccidiosis,"Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O, Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O",Launched
dinoprost,prostacyclin analog,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R",obstetrics/gynecology,labor induction,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O",Launched
dinoprostone,prostanoid receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R",,,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",Withdrawn
dinotefuran,,,,,[O-][N+](=O)NC(=N/C)\NCC1CCOC1,Launched
dioscin,apoptosis stimulant,CXCR3,,,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|,Preclinical
diosgenin,steroid,,,,"C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|",Preclinical
diosmetin,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic,"COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1",Launched
diosmin,"aryl hydrocarbon receptor agonist, capillary stabilizing agent",AHR,"cardiology, hematology, dermatology","chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome","COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1",Launched
dioxybenzone,topical sunscreen agent,,,,"COc1ccc(C(=O)c2ccccc2O)c(O)c1, COc1ccc(C(=O)c2ccccc2O)c(O)c1",Preclinical
dipeptamin,,,,,"C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O",Launched
diperodon,local anesthetic,,,,"O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|",Preclinical
diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,"C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1",Launched
diphencyprone,immunostimulant,,,,"O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1",Phase 2
diphenhydramine,histamine receptor antagonist,HRH1,neurology/psychiatry,headache,"CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1",Launched
diphenidol,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,vertigo,"OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1",Launched
diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",,,"[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|",Preclinical
diphenylguanidine,,,,,"N=C(Nc1ccccc1)Nc1ccccc1, N=C(Nc1ccccc1)Nc1ccccc1",Preclinical
diphenylpyraline,dopamine reuptake inhibitor,"HRH1, SLC6A3",allergy,allergic rhinitis,"CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1",Launched
dipivefrine,adrenergic receptor agonist,,ophthalmology,"glaucoma, intraocular pressure",CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|,Launched
dipraglurant,glutamate receptor negative allosteric modulator,GRM5,,,"Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1",Phase 2
DIPT,"dopamine reuptake inhibitor, serotonin reuptake inhibitor","HTR1A, HTR2A, HTR2C",,,CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,Launched
dipyridamole,phosphodiesterase inhibitor,"ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1",cardiology,"coronary artery disease (CAD), peripheral artery disease (PAD), hypertension","OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO",Launched
dipyrocetyl,chelating agent,,"endocrinology, neurology/psychiatry","fever, pain relief","CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O, CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O",Launched
diquafosol,purinergic receptor activator,,,,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O,Phase 3
dirithromycin,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O",
diroximel-fumarate,anti-inflammatory agent,,,,"COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O, COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O",Phase 3
disodium-sebacate,,HBB,,,OC(=O)CCCCCCCCC(O)=O,Phase 1
disopyramide,sodium channel blocker,"CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A",cardiology,"ventricular tachycardia (VT), ventricular arrhythmias","CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|",Launched
disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
dithranol,DNA synthesis inhibitor,,dermatology,psoriasis,Oc1cccc2cc3cccc(O)c3c(O)c12,Launched
ditiocarb-sodium-trihydrate,immunostimulant,"CA1, CA2, CA4",,,"CCN(CC)C(S)=S, CCN(CC)C(S)=S",Phase 3
ditolylguanidine,sigma receptor agonist,"GRIN1, GRIN2A, GRIN2B, SIGMAR1",,,"Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C",Preclinical
dixanthogen,,,,,"CCOC(=S)SSC(=S)OCC, CCOC(=S)SSC(=S)OCC",Preclinical
dixyrazine,antipsychotic,,,,"C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|",Preclinical
dizocilpine-(+),glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21",Preclinical
dizocilpine-(-),glutamate receptor antagonist,,,,"C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21",Phase 1
dl-cystine,,,,,"N[C@@H](CSSC[C@@H](N)C(O)=O)C(O)=O |&1:1,&2:6,r|",
dl-tboa,excitatory amino acid transporter inhibitor,"EAAT1, EAAT2, EAAT3",,,"N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O |&1:1,2|",Preclinical
DMAB-anabaseine,adrenergic receptor agonist,CHRNA7,,,"CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|",Preclinical
DMeOB,glutamate receptor modulator,GRM5,,,"COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1",Preclinical
DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,,,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
DMH4,VEGFR inhibitor,KDR,,,"C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1",Preclinical
DMNB,DNA dependent protein kinase inhibitor,,,,"COc1cc(C=O)c(cc1OC)[N+]([O-])=O, COc1cc(C=O)c(cc1OC)[N+]([O-])=O",Preclinical
DMP-543,acetylcholine release enhancer,,,,"Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1",Phase 2
DMP-777,elastase inhibitor,MPO,,,"CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1",Phase 2
DMPS,chelating agent,,,,"OS(=O)(=O)C[C@@H](S)CS |&1:5,r|",Phase 1
DMSO,control vehicle,,,,CS(C)=O.CS(C)=O,Preclinical
dm4,tubulin inhibitor,"CD19, MSLN, SDC1, TUBB",hematologic malignancy,multiple myeloma,CO[C@@H]1\C=C\C=C(/C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)[C@]3(C)O[C@H]3[C@H](C)[C@@H]4C[C@@]1(O)NC(=O)O4,
DNQX,glutamate receptor antagonist,"GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B",,,"[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O",Preclinical
dobutamine,adrenergic receptor agonist,"ADRB1, ADRB2",cardiology,congestive heart failure,"CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1",Launched
docebenone,lipoxygenase inhibitor,ALOX5,,,"CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|, CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|",Phase 2
docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|",Launched
doconexent,PPAR receptor agonist,"FFAR1, PTGS1, PTGS2",,,"CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O",Launched
doconexent-ethyl-ester,omega 3 fatty acid stimulant,,endocrinology,hypertriglyceridemia,"CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC",Launched
docosanol,lipase clearing factor inhibitor,TLR7,dental,cold sore,"CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO",Launched
docusate,laxative,,gastroenterology,constipation,"CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|, CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|",Launched
dodecyl-sulfate,,LYZ,,,CCCCCCCCCCCCOS(O)(=O)=O,Preclinical
dofequidar,"MRP inhibitor, P glycoprotein inhibitor",ABCB1,,,"OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1, OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1",Phase 3
dofequidar fumarate,mrp inhibitor,"ABCB1, ABCC1",,,"O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1 |&1:1,r|",Phase 3
dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",,,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
dolasetron,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting","O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12",Launched
dolastatin-10,tubulin polymerization inhibitor,TUBB,,,"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C",Phase 2
dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
dolutegravir (gsk1349572),hiv integrase inhibitor,,infectious disease,human immunodeficiency virus (hiv-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
domiphen,,,,,"CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1",Preclinical
domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
donepezil,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,Alzheimer's disease,"COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|",Launched
donitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6",,,"NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12",Phase 2
dopamine,dopamine receptor agonist,"DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4","cardiology, neurology/psychiatry","ventricular arrhythmias, depression, headache, tremors","NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1",Launched
doramapimod,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK13, MAPK14",,,"Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C",Phase 2
doramectin,,,infectious disease,gastrointestinal roundworms,"[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,58,t:6,37,68|, CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O",Launched
doravirine,non-nucleoside reverse transcriptase inhibitor,,,,Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O,Launched
doripenem,bacterial cell wall synthesis inhibitor,DPEP1,infectious disease,"intra-abdominal infections, urinary tract infections, pyelonephritis","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|",Launched
dorsomorphin,AMPK inhibitor,"ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC",,,"C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1",Preclinical
dorzagliatin,glucokinase activator,GCK,endocrinology,diabetes mellitus,CC(C)C[C@H](N1CC(=CC1=O)Oc2ccccc2Cl)C(=O)Nc3ccn(C[C@@H](O)CO)n3,Phase 2
dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
dorzolamide hcl,carbonic anhydrase inhibitor,,ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
dosulepin,"norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4",neurology/psychiatry,depression,"CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12",Launched
dotinurad,urate transporter inhibitor,SLC22A12,nephrology,hyperuricemia,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl,Launched
DOTMP,,,,,OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1,Preclinical
dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",,,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
doxapram,potassium channel blocker,,"pulmonary, neurology/psychiatry","respiratory depression, central nervous system depression, acute hypercapnia (AHC)","CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|",Launched
doxazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|",Launched
doxazosin mesylate,adrenergic receptor antagonist,,"urology, cardiology","benign prostatic hyperplasia (bph), hypertension",COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1,Launched
doxepin,histamine receptor antagonist,"HRH1, SLC6A2, SLC6A4",neurology/psychiatry,"depression, anxiety","CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12",Launched
doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
doxofylline,adenosine receptor antagonist,"ADORA1, PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,asthma,"Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O",Launched
doxorubicin,"topoisomerase inhibitor, dna polymerase inhibitor",TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma",COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,Launched
doxycycline,"bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor",MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|",Launched
doxycycline hcl,"bacterial 30s ribosomal subunit inhibitor, metalloproteinase inhibitor",,dental,periodontitis,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12,Launched
doxycycline hyclate,bacterial 30s ribosomal subunit inhibitor,,Infectious disease,gram-negative bacterial infections,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |&1:12,c:22|",Launched
doxylamine,histamine receptor antagonist,HRH1,neurology/psychiatry,sedative,"CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1",Launched
doxylamine succinate,histamine receptor antagonist,HRH1,Allergies,allergic conjunctivitis,"CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1 |&1:6,r|",Launched
DpC,,,,,CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1,Phase 1
DPC-681,HIV protease inhibitor,,,,"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1",Phase 1
DPCPX,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1",Phase 1
DPI-201106,sodium channel activator,ADRB2,,,"O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|",Phase 2
DPO-1,potassium channel blocker,KCNA5,,,"CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1",Preclinical
DPPE,histamine receptor antagonist,"ABCB1, HRH1",,,"CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1",Phase 3
DQP-1105,glutamate receptor antagonist,"GRIN2C, GRIN2D",,,"Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|",Preclinical
DR-2313,PARP inhibitor,"PARP1, PARP3",,,"Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1",Preclinical
DR-4485,serotonin receptor antagonist,HTR7,,,"Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|",Preclinical
DRF053-(R),CDK inhibitor,CSNK1A1,,,"CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
drofenine,,,neurology/psychiatry,spasms,"CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|, CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|",Launched
droloxifene,selective estrogen receptor modulator (SERM),ESR1,,,CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,Phase 3
dromostanolone-propionate,androgen receptor modulator,AR,oncology,breast cancer,"CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|, CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|",Launched
dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),"CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12",Launched
droperidol,dopamine receptor antagonist,"ADRA1A, DRD2, DRD3, DRD4, HTR2A",gastroenterology,"nausea, vomiting","Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|",Launched
dropropizine,antitussive,,pulmonary,cough suppressant,"OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|",Launched
drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|",Launched
drotaverine,phosphodiesterase inhibitor,,obstetrics/gynecology,labor induction,"CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|",Launched
droxicam,cyclooxygenase inhibitor,PTGS1,rheumatology,"rheumatoid arthritis, osteoarthritis","CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O",Launched
droxidopa,norepinephrine precursor,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH","cardiology, neurology/psychiatry","hypertension, Parkinson's Disease","N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O",Launched
droxinostat,HDAC inhibitor,"HDAC6, HDAC8",,,"Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO",Preclinical
ds-1971a,voltage-gated sodium channel blocker,SCN9A,neurology/psychiatry,peripheral neuropathy,O=S(C1=CC(Cl)=C(O[C@@H]2[C@@H](C3=CC=NN3C)CCCC2)C=C1F)(NC4=NC=NC=C4)=O,Phase 2
DSM265,dihydroorotate dehydrogenase inhibitor,,,,Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F,Phase 2
DSPC,,,,,"CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|",Preclinical
DSR-6434,toll-like receptor agonist,TLR7,,,"CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1",Preclinical
DS2-(806622),,,,,"Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1",Preclinical
dtp3,dual specificity protein kinase inhibitor,MAP2K7,hematologic malignancy,multiple myeloma,CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N,
DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",,,"N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O",Phase 1
duloxetine,"norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy","CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1",Launched
DUP-697,cyclooxygenase inhibitor,PTGS2,,,"CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1",Phase 1
dusquetide,,,,,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N,Phase 3
dusquetide (tfa),immunostimulant,SQSTM1,dental,mucositis,C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O,Phase 2
dutasteride,5 alpha reductase inhibitor,"SRD5A1, SRD5A2, SRD5A3",urology,benign prostatic hyperplasia (BPH),"C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|",Launched
duvelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1",Launched
DVD-111,,,,,"CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1, CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1",Phase 2
DWK-1339,beta amyloid aggregation inhibitor,,,,COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1,Preclinical
dxd,topoisomerase inhibitor,TOP1,oncology,breast cancer,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](NC(=O)CO)c(c3Cn1c2=O)c45,
dyclonine,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,local anesthetic,"CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1",Launched
dydrogesterone,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|",Launched
dynasore,dynamin inhibitor,"DNM1, DNM1L, DNM2",,,"Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O",Preclinical
dynole-34-2,dynamin inhibitor,DNM1,,,"CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N",Preclinical
dyphylline,"adenosine receptor antagonist, phosphodiesterase inhibitor",PDE4A,pulmonary,"asthma, bronchitis, emphysema","Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|",Launched
DY131,estrogen-related receptor agonist,"ESRRB, ESRRG",,,"CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1",Preclinical
D609,phospholipase inhibitor,,,,"SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21",Preclinical
d609,phospholipase inhibitor,,Neurology,alzheimer's disease,"SC(=S)O[C@@H]1C[C@@H]2C[C@H]1[C@H]1CCC[C@@H]21 |&1:4,&2:6,8,&3:9,13|",Preclinical
E-2001,antioxidant,,,,Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1,Preclinical
E-2012,gamma secretase modulator,"APH1A, APH1B, PSENEN",,,"COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1",Phase 1
E-4031,potassium channel blocker,"KCNH1, KCNH2",,,"Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1",Phase 1
E-64,"calpain inhibitor, cysteine protease inhibitor",CTSS,,,"CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N, CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N",Preclinical
e-64,,,,,CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N,
e-7386,,"CREBBP, CTNNB1",oncology,colorectal cancer,[H][C@]12CN(Cc3cccc(n3)N3CC(C3)N3CCN(CC)CC3)C(=O)[C@H](Cc3ccc(O)cc3F)N1C(=O)CN(CC=C)N2C(=O)NCc1ccccc1,Phase 1
eact,calcium-activated chloride channel inhibitor,ANO1,,,"COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1",Preclinical
EB-47,PARP inhibitor,PARP1,,,"Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1",Preclinical
ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria","CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1",Launched
EBPC,aldose reductase inhibitor,AKR1B1,,,"CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|",Preclinical
ebrotidine,histamine receptor antagonist,HRH2,,,"NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1",Withdrawn
ebselen,"cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor",ALB,,,"O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1",Phase 2/Phase 3
EC-144,HSP inhibitor,"HSP90AA1, HSP90AB1",,,"COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C",Preclinical
EC-23,retinoid receptor agonist,"RARA, RARB, RARG",,,"CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O",Preclinical
ecabapide,,,,,"CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1",Phase 3
ecabet,"gastrin inhibitor, urease inhibitor",NOXO1,ophthalmology,dry eye syndrome,"CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O, CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O",Launched
ecamsule triethanolamine,,,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
ecamsule-triethanolamine,,,dermatology,"skin protectant, sunscreen lotion","CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3,6,&2:22,25,r|",Launched
echinomycin,DNA intercalating agent,,,,"[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|",Phase 2
econazole,"lanosterol demethylase inhibitor, sterol demethylase inhibitor","NPY1R, NPY2R, TRPM2, TRPV5",infectious disease,"tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis","Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|",Launched
ecothiopate,acetylcholinesterase inhibitor,BCHE,ophthalmology,glaucoma,[I-].O=P(OCC)(OCC)SCC[N+](C)(C)C,Launched
ectoine,anti-inflammatory agent,,,,"CC1=NCC[C@H](N1)C(O)=O |t:1|, CC1=NCC[C@H](N1)C(O)=O |t:1|",Launched
ec5026,epoxide hydolase inhibitor,EPHX2,neurology/psychiatry,pain relief,CC[C@H](C)C(=O)N1CCC(CC1)NC(=O)Nc1ccc(OC(F)(F)F)c(F)c1,Phase 1
edaglitazone,PPAR receptor agonist,PPARG,,,"Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|",Phase 2
edaravone,nootropic agent,BCL2,neurology/psychiatry,stroke,"Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1",Launched
edasalonexent,NFkB pathway inhibitor,,,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O,Phase 3
edelfosine,phospholipase inhibitor,,,,"CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|",Phase 2
editol,,,,,"C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|, C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|",Preclinical
EDO-S101,HDAC inhibitor,,,,Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl,Phase 1/Phase 2
edonerpic-maleate,beta amyloid inhibitor,,,,OC1CN(CCCOCCc2ccc3sccc3c2)C1,Preclinical
edoxaban,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)","CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1",Launched
edoxudine,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV),"CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O, CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O",Launched
edrophonium,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,"CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1",Launched
EDTMP,chelating agent,,,,"OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O, OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O",Preclinical
EED226,polycomb protein inhibitor,EED,,,"CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12, CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12",Preclinical
efaproxiral,hemoglobin oxygen release stimulant,"HBA1, HBB",,,"Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1",Phase 3
efaroxan,adrenergic receptor antagonist,ADORA2A,,,"CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1",Phase 2
efatutazone,PPAR receptor agonist,PPARG,,,"Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|",Phase 2
efavirenz,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),"FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1",Launched
efinaconazole,"lanosterol demethylase inhibitor, fungal lanosterol demethylase inhibitor",CYP51A1,"infectious disease, Infectious disease","onychomycosis, fungal infection","C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|, C[C@@H](N1CCC(=C)CC1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",Launched
efletirizine,antihistamine,,,,OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1,Phase 3
eflornithine,ornithine decarboxylase inhibitor,"ARG2, ODC1",dermatology,facial hair reduction,"NCCCC(N)(C(F)F)C(O)=O |&1:4|, NCCCC(N)(C(F)F)C(O)=O |&1:4|",Launched
efloxate,vasodilator,,,,CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1,Preclinical
efonidipine,calcium channel blocker,,cardiology,hypertension,"CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|, CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|",Launched
efonidipine hydrochloride monoethanolate,,,,,CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1,
EF5,cytochrome P450 activator,,,,[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F,Phase 2
EGF816,EGFR inhibitor,EGFR,,,"CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12",Phase 2
eglumetad,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM8",,,"N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",Phase 2
EG00229,neuropilin receptor antagonist,NRP1,,,"NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O",Preclinical
EHop-016,Ras GTPase inhibitor,"RAC1, RAC3",,,"CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12",Preclinical
EIPA,"sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor","ADRA2A, ASIC1, PKD2L1",,,"CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N",Preclinical
EIT-hydrobromide,nitric oxide synthase inhibitor,"NOS2, NOS3",,,"CCSC(N)=N, CCSC(N)=N",Preclinical
EI1,histone lysine methyltransferase inhibitor,EZH2,,,CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O,Preclinical
elacestrant,estrogen receptor degrader,,,,"CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1, CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1",Phase 3
elacridar,P glycoprotein inhibitor,ABCB1,,,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
elactocin,exportin antagonist,XPO1,,,,Phase 1
elacytarabine,antineoplastic agent,DCK,,,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O,Phase 3
elafibranor,PPAR receptor agonist,"PPARA, PPARD, PPARG",,,"CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1",Phase 3
elagolix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,,"COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O, COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O",Launched
elamipretide,,CRLS1,ophthalmology,macular degeneration,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N,Phase 3
elbasvir,HCV inhibitor,,infectious disease,hepatitis C,"COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C",Launched
eldecalcitol,bone formation stimulant,VDR,,,[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C,Phase 3
eleclazine,late sodium current inhibitor,,,,FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1,Phase 3
elemene,VEGFR inhibitor,,,,CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C,Phase 3
elenbecestat,beta secretase inhibitor,BACE1,neurology/psychiatry,alzheimer's disease,FC1=CC=C(NC(C2=NC=C(C(F)F)N=C2)=O)C=C1[C@@]3(N=C(N)SC4)[C@@]4([H])[C@@H](C)OC3,Phase 3
elesclomol,oxidative stress inducer,HSPA1A,,,"CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1",Phase 3
eletriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",neurology/psychiatry,migraine headache,"CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12",Launched
elexacaftor,cystic fibrosis transmembrane conductance regulator inhibitor,CFTR,pulmonary,cystic fibrosis,CC1(C)C[C@H](C)CN1C2=C(C(NS(C3=CN(C)N=C3C)(=O)=O)=O)C=CC(N4C=CC(OCC(C)(C(F)(F)F)C)=N4)=N2,Launched
eliglustat,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,"CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1",Launched
elinogrel,purinergic receptor antagonist,P2RY12,,,"CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F",Phase 2
eliprodil,glutamate receptor antagonist,"GRIN1, GRIN2B",,,"O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|",Phase 3
ellagic-acid,"glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor","CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK",,,"Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O",Phase 2
ELN-441958,bradykinin receptor antagonist,BDKRB1,,,"Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1",Preclinical
eltanexor,exportin inhibitor,,,,NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1,Preclinical
eltanolone,GABA receptor positive allosteric modulator,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",,,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Phase 3
eltoprazine,serotonin receptor agonist,"HTR1A, HTR1B",,,"C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12",Phase 2
eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease, hematology, infectious disease","anemia, hepatitis C, thrombocytopenia, anemia, hepatitis c, thrombocytopenia","CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
elubrixin,cc chemokine receptor antagonist,CXCR2,pulmonary,cystic fibrosis,Oc1c(NC(=O)Nc2cccc(F)c2Cl)ccc(Cl)c1S(=O)(=O)N1CCNCC1.Cc1ccc(cc1)S(=O)(=O)O,Phase 2
eluxadoline,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O,Launched
elvitegravir,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C, COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C",Launched
elx-02,,,,,C[C@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@H](O)[C@@H]1O,Phase 1
emamectin,GABA receptor agonist,,,,"[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|",Preclinical
embelin,"HCV inhibitor, XIAP inhibitor",XIAP,,,"CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|",Preclinical
EMD-1214063,hepatocyte growth factor receptor inhibitor,MET,,,"CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1",Phase 2
EMD-386088,serotonin receptor agonist,HTR6,,,"Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|",Preclinical
EMD-53998,phosphodiesterase inhibitor,TNNC1,,,"COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|",Phase 1
EMD-66684,angiotensin receptor antagonist,AGTR1,,,"CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Preclinical
EMD534085,kinesin inhibitor,,,,[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F,Preclinical
emedastine,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1",Launched
emeramide,antioxidant,,,,SCCNC(=O)c1cccc(c1)C(=O)NCCS,Phase 2
emetine,protein synthesis inhibitor,RPS2,,,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
emiglitate,alpha glucoside inhibitor,,,,CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1,Preclinical
emixustat,retinoid isomerohydrolase inhibitor,,,,NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,Phase 3
emodepside,nematocide,,,,[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O,Phase 1
emodin,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,,,"Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1",Preclinical
emorfazone,"anti-inflammatory agent, cyclooxygenase inhibitor",,dental,mouth inflammation,CCOc1c(cnn(C)c1=O)N1CCOCC1,Launched
emoxipin,,,,,"CCc1nc(C)ccc1O, CCc1nc(C)ccc1O",Phase 3
empagliflozin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",endocrinology,diabetes mellitus,"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1",Launched
emricasan,caspase inhibitor,"CASP1, CASP3, CASP7",,,"C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F",Phase 2
emtricitabine,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1, Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1",Launched
enalapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O",Launched
enalaprilat,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",Launched
enarodustat,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1,hematology,anemia,OC(=O)CNC(=O)c1c(O)cc(CCc2ccccc2)n3ncnc13,Phase 3
enasidenib,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),"CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F",Launched
enbucrilate,,,dermatology,"skin lacerations, tissue adhesive",CCCCOC(=O)C(=C)C#N,Launched
enciprazine,GABA receptor modulator,GABRA1,,,"COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|",Phase 3
encorafenib,"RAF inhibitor, serine/threonine kinase inhibitor","BRAF, CCND1",oncology,melanoma,"COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C, C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC",Launched
endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",,,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|",Preclinical
endoxifen,estrogen receptor antagonist,ESR1,,,"CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1",Phase 2
enflurane,membrane permeability inhibitor,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9",neurology/psychiatry,anesthetic,"FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|",Launched
enilconazole,sterol demethylase inhibitor,"CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2",infectious disease,skin infections,"Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|",Launched
eniluracil,dihydropyrimidine dehydrogenase inhibitor,"AOX1, DPYD, XDH",,,"O=c1[nH]cc(C#C)c(=O)[nH]1, O=c1[nH]cc(C#C)c(=O)[nH]1",Phase 3
eniporide,sodium/hydrogen antiport inhibitor,,,,Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1,Preclinical
enisamium-iodide,,,,,"C[n+]1ccc(cc1)C(=O)NCc1ccccc1, C[n+]1ccc(cc1)C(=O)NCc1ccccc1",Launched
ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",,,"CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1",Phase 2
enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",hematologic malignancy,acute myeloid leukemia (AML),"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
enoxacin,topoisomerase inhibitor,TOP2A,infectious disease,"urinary tract infections, gonorrhea","CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1",Launched
enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,"CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C",Launched
enoxolone,gap junction modulator,HSD11B1,"gastroenterology, otolaryngology","peptic ulcer disease (PUD), common cold","CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|",Launched
enprofylline,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B",,,"CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O",Phase 3
enrofloxacin,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,"CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1",Launched
ensartinib,alk inihibitor,ALK,oncology,non-small cell lung cancer (nsclc),C[C@@H](Oc1cc(nnc1N)C(=O)Nc2ccc(cc2)C(=O)N3C[C@@H](C)N[C@@H](C)C3)c4c(Cl)ccc(F)c4Cl,Phase 2
entacapone,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease,"CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N",Launched
entasobulin,tubulin polymerization inhibitor,,,,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1,Preclinical
entecavir,"DNA replication inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,hepatitis B,"Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1, Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1",Launched
entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",,,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
entrectinib,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor","ALK, NTRK1, NTRK2, NTRK3, ROS1",oncology,non-small cell lung cancer (NSCLC),"CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1",Launched
enzacamene,,,,,CC1=CC=C(C=C1)/C=C/2\C3CCC(C2=O)(C3(C)C)C,Launched
enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F",Launched
enzastaurin,PKC inhibitor,"AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG",,,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|",Phase 3
EN460,endoplasmic reticulum oxidation inhibitor,ERO1A,,,"OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|",Preclinical
EO-1428,p38 MAPK inhibitor,"MAPK11, MAPK14",,,"Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl",Preclinical
epacadostat,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,"NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1",Phase 3
epalrestat,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy,"C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1",Launched
eperezolid,bacterial 30S ribosomal subunit inhibitor,,,,"CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1",Phase 1
eperisone,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,"amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury","CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|, CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|",Launched
epetraborole,leucyl-tRNA synthetase inhibitor,,,,NC[C@H]1OB(O)c2c1cccc2OCCCO,Preclinical
ephedrine,adrenergic receptor agonist,"ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity","CN[C@@H](C)[C@H](O)c1ccccc1, CN[C@@H](C)[C@H](O)c1ccccc1",Launched
ephedrine-(racemic),adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF","cardiology, pulmonary, neurology/psychiatry, endocrinology","hypotension, asthma, narcolepsy, obesity","CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|, CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|",Launched
epi-001,ppar receptor modulator,AR,oncology,prostate cancer,OCC(O)COC1=CC=C(C(C)(C2=CC=C(OCC(O)CCl)C=C2)C)C=C1,Preclinical
epiandrosterone,steroid,G6PD,,,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
epicatechin-gallate-(-),bacterial DNA gyrase inhibitor,"BACE1, FASN",,,"Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1",Phase 2
epiestriol,estrogen receptor agonist,,"endocrinology, obstetrics/gynecology, infectious disease","menopause, vaginal atrophy, urinary tract infections","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O, CC12CCC3C(CCc4cc(O)ccc34)C1C[C@H](O)[C@@H]2O",Launched
epigallocatechin-(-),,,,,O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1,Phase 2
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,"ELANE, EP300, FASN, KAT2B, MMP14, MMP2",,,"Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1",Phase 2/Phase 3
epinastine,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,"NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|, NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|",Launched
epinephrine,"adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
epirizole,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"COc1cc(C)nn1-c1nc(C)cc(OC)n1, COc1cc(C)nn1-c1nc(C)cc(OC)n1",Launched
epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
epitalon,,,,,C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O,Withdrawn
epitalon (tfa),,TERT,ophthalmology,retinitis pigmentosa (rp),"C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O.OC(=O)C(F)(F)F |a:1,6,15|",Withdrawn
epitiostanol,androgen receptor agonist,AR,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O",Launched
eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|",Launched
epomediol,cholesterol inhibitor,CYP7A1,neurology/psychiatry,itching,"CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|",Launched
epoprostenol,prostacyclin analog,"P2RY12, PTGER1, PTGER4, PTGIR, PTGIS",cardiology,hypertension,"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O",Launched
epoprostenol sodium,prostacyclin analog,,Lung diseases,acute respiratory distress syndrome,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H]2O\C(C[C@H]12)=C/CCCC(O)=O,Launched
"epothilone b (epo906, patupilone)","microtubule stabilizing agent, tubulin polymerization inhibitor",,,,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
epothilone-A,microtubule stabilizing agent,,,,"C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",Preclinical
epothilone-B,"microtubule stabilizing agent, tubulin polymerization inhibitor",TUBB,,,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
epothilone-D,"microtubule stabilizing agent, tubulin polymerization inhibitor",TUBB,,,"C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|",Phase 2
EPPTB,trace amine associated receptor antagonist,TAAR1,,,"CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1",Preclinical
eprazinone,mucolytic agent,,pulmonary,bronchospasm,"CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|",Launched
eprinomectin,benzodiazepine receptor agonist,,infectious disease,"gastrointestinal roundworms, lungworms, gastrointestinal roundworms, lungworms","[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4,64,t:6,42,72|, CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C",Launched
epristeride,5 alpha reductase inhibitor,,,,"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|",Preclinical
eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,"Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1",Launched
eprodisate,"amyloid protein inhibitor, antiamyloidogenic agent",SAA1,,,"OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O",Phase 3
eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (acs), percutaneous coronary intervention (pci), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)","NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O",Launched
EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,,,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1",Phase 1
EPZ004777,histone lysine methyltransferase inhibitor,DOT1L,,,"CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12",Preclinical
EPZ005687,histone lysine methyltransferase inhibitor,EZH2,,,Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,Preclinical
EPZ011989,histone lysine methyltransferase inhibitor,EZH2,,,"CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|",Preclinical
EPZ015666,protein arginine N-methyltransferase inhibitor,PRMT5,,,"O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1",Preclinical
EPZ020411,protein arginine N-methyltransferase inhibitor,PRMT6,,,"CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|",Preclinical
equilin,estrogen receptor agonist,HSD17B1,,,"C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|",Preclinical
equol,estrogen receptor agonist,"ESR1, ESR2",,,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,,,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
ER-50891,retinoid receptor antagonist,RARA,,,"CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1",Preclinical
erastin,ion channel antagonist,VDAC2,,,"CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|",Preclinical
eravacycline,"antibacterial, bacterial 30s ribosomal subunit inhibitor",,infectious disease,gram-positive bacterial infections,"[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29,&2:22|, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(F)cc(NC(=O)CN5CCCC5)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N",Launched
erbstatin-analog,"EGFR inhibitor, tyrosine kinase inhibitor",EGFR,,,COC(=O)\C=C\c1cc(O)ccc1O,Preclinical
ercalcitriol,vitamin D receptor agonist,VDR,,,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Phase 1
erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",,,"COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1",Launched
erdosteine,mucolytic agent,,"pulmonary, infectious disease","bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections","OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|",Launched
ergocalciferol,vitamin analog,VDR,"endocrinology, orthopedics","hypoparathyroidism, rickets, hypophosphatemia","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
ergoloid mesylate,serotonin receptor antagonist,"ADRA1A, ADRB1, DRD1, HTR1A",neurology/psychiatry,senile dementia,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,Launched
ergonovine,"adrenergic receptor agonist, serotonin receptor agonist","ADRA1A, HTR1E",hematology,postpartum hemorrhage (PPH),C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|,Launched
ergonovine maleate,"adrenergic receptor agonist, serotonin receptor agonist",,hematology,postpartum hemorrhage (pph),CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,Launched
ergosterol,vitamin D precursor,,,,"CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|",Preclinical
ergotamine,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2",neurology/psychiatry,migraine headache,"CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|, CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|",Launched
ergotamine tartrate,adrenergic receptor antagonist,,neurology/psychiatry,migraine headache,CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)C3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,Launched
eribulin,microtubule inhibitor,,oncology,breast cancer,"[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58,50:49:44:51.53,50:51:44:48.49.56.58,53:54:46.48.49.58:41.43.59,59:56:44:51.53|",Launched
ERK5-IN-1,MAP kinase inhibitor,MAPK7,,,"COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1",Preclinical
erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
ertapenem,bacterial cell wall synthesis inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis","C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|",Launched
erteberel,estrogen receptor agonist,"ESR1, ESR2",,,"Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12",Phase 2
ertugliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,Launched
erythritol,,,,,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
erythromycin,NFkB pathway inhibitor,MLNR,infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,"ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1",infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
erythromycin-ethylsuccinate,"cytochrome P450 inhibitor, protein synthesis inhibitor","ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1",infectious disease,"listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma","CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C",Launched
erythrosine,coloring agent,,,,Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I,Preclinical
esaprazole,,,,,"O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1",Phase 2
esaxerenone,mineralocorticoid receptor antagonist,,,,Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O,Preclinical
escin,nitric oxide synthase stimulant,,dermatology,varicose veins,"CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|, C\C=C(\C)C(=O)O[C@@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CCC4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)C5CC[C@@]34C)C2CC1(C)C",Launched
escitalopram,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,"depression, generalized anxiety disorder (GAD)","CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|",Launched
escitalopram oxalate,selective serotonin reuptake inhibitor (ssri),,neurology/psychiatry,depression,CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,Launched
esculin,antioxidant,,,,"OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O",Phase 1
eseroline-(-),acetylcholinesterase inhibitor,"OPRD1, OPRM1",,,CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21,Preclinical
ESI-09,EPAC inhibitor,"RAPGEF3, RAPGEF4",,,"CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N",Preclinical
eslicarbazepine-acetate,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12, CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12",Launched
esmolol,adrenergic receptor antagonist,ADRB1,cardiology,"ventricular tachycardia (VT), hypertension","COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|, COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|",Launched
esmolol hcl,adrenergic receptor antagonist,,cardiology,"ventricular tachycardia (vt), hypertension",COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,Launched
esomeprazole,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)","COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C",Launched
esonarimod,antirheumatic drug,,,,"CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|",Preclinical
estetrol,selective estrogen receptor modulator (SERM),ESR1,,,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,Phase 3
estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
estradiol cypionate,estrogen receptor agonist,,endocrinology,"hypoestrogenism, menopause","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1 |a:1,18,&1:4,&2:5,&3:15|",Launched
estradiol-acetate,estrogen receptor agonist,ESR1,"endocrinology, obstetrics/gynecology","menopause, vaginal atrophy",CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,Launched
estradiol-benzoate,contraceptive agent,ESR1,,,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O,Preclinical
estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
estradiol-valerate,estrogen receptor agonist,ESR1,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, hypoestrogenism, menopause, vaginal atrophy","CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C",Launched
estradiol-3-O-sulfamate,steryl sulfatase inhibitor,,,,C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O,Phase 2
estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2","oncology, Oncology","prostate cancer, breast cancer",C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O,Launched
estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,"C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O",Launched
estriol,estrogen receptor agonist,"ESR1, ESR2","endocrinology, obstetrics/gynecology, infectious disease","menopause, vaginal atrophy, urinary tract infections","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O",Launched
estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",endocrinology,menopause,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
estropipate,estrogen receptor agonist,"ESR1, ESR2","orthopedics, endocrinology, obstetrics/gynecology, orthopedics, endocrinology, obstetrics/gynecology","osteoporosis, menopause, vaginal atrophy, hypoestrogenism, osteoporosis, menopause, vaginal atrophy, hypoestrogenism","C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O, C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O",Launched
etacrynic-acid,sodium/potassium/chloride transporter inhibitor,"ATP1A1, SLC12A1","cardiology, gastroenterology, nephrology, rheumatology","hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome","CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl",Launched
etafenone,calcium channel blocker,,,,"CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1",Launched
etamsylate,hemostatic agent,,hematology,hemorrhage,"Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O",Launched
etanidazole,bacterial cell wall synthesis inhibitor,,,,"OCCNC(=O)Cn1ccnc1[N+]([O-])=O, OCCNC(=O)Cn1ccnc1[N+]([O-])=O",Phase 3
etazolate,phosphodiesterase inhibitor,"GABRB3, PDE4A",,,"CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C",Phase 2
ETC-159,"beta catenin inhibitor, porcupine inhibitor",PORCN,,,"Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O",Phase 1
ETC-206,MAPK-interacting kinase inhibitor,,,,O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1,Phase 1
etebenecid,uricosuric blocker,,,,CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O,Preclinical
etelcalcetide,calcium-sensing receptor agonist,CASR,endocrinology,hyperparathyroidism,C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C,Launched
eterobarb,anticonvulsant,,,,"CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1, CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1",Phase 2
ethacizin,anticonvulsant,,cardiology,"ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)","CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1",Launched
ethacridine-lactate-monohydrate,DNA intercalating agent,,,,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
ethambutol,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis,"CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO",Launched
ethamivan,respiratory stimulant,,,,"CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1",Preclinical
ethanolamine-oleate,immunostimulant,"F12, FABP4, FFAR1, FFAR4, PLD2",gastroenterology,esophageal varices,NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O,Launched
ethaverine,calcium channel blocker,,neurology/psychiatry,"muscle relaxant, spasms","CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC",Launched
ethenzamide,analgesic agent,,"neurology/psychiatry, endocrinology, otolaryngology","headache, fever, common cold","CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O",Launched
ethimizol,,,,,"CCn1cnc(C(=O)NC)c1C(=O)NC, CCn1cnc(C(=O)NC)c1C(=O)NC",Phase 1
ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
ethionamide,mycolic synthesis inhibitor,,infectious disease,tuberculosis,"CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S",Launched
ethisterone,progestogen hormone,TYR,endocrinology,amenorrhea,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C",Launched
ethopabate,antiprotozoal agent,,infectious disease,coccidiosis,"CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC",Launched
ethosuximide,succinimide antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,epilepsy,"CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|, CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|",Launched
ethotoin,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,"CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|",Launched
ethoxyquin,antioxidant,,,,"CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|, CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|",Preclinical
ethoxzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9","ophthalmology, gastroenterology","glaucoma, duodenal ulcer disease","CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O",Launched
ethyl pyruvate,tnf production inhibitor,"HMGB1, TNF",gastroenterology,pancreatitis,CC(C(OCC)=O)=O,Phase 2
ethyl-paraben,,,,,"CCOC(=O)c1ccc(O)cc1, CCOC(=O)c1ccc(O)cc1",Preclinical
ethyl-pyruvate,tumor necrosis factor production inhibitor,,,,"CCOC(=O)C(O)=C, CCOC(=O)C(O)=C",Phase 2
ethyl-vanillin,,,,,"CCOc1cc(C=O)ccc1O, CCOc1cc(C=O)ccc1O",Preclinical
ethyl-2-(carbamoyloxy)benzoate,,,,,CCOC(=O)c1ccccc1OC(N)=O,Phase 1
ethylenediaminetetraacetic-acid,PKC inhibitor,,neurology/psychiatry,metal toxicity,"OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O",Launched
ethylnorepinephrine,bronchodilator,,,,"CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|",Preclinical
ethynodiol-diacetate,,"ESR1, PGR",endocrinology,contraceptive,"CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|",Launched
ethynylcytidine,antimetabolite,,,,Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1,Preclinical
eticlopride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",,,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC",Preclinical
etidocaine,sodium channel blocker,A1BG,neurology/psychiatry,anesthetic,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C,Withdrawn
etidronic-acid,bone resorption inhibitor,"ATP6V1A, PTPRS","endocrinology, orthopedics","Paget's disease, heterotopic ossification","CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O",Launched
etifenin,renal function diagnostic agent,,,,"CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O, CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O",Preclinical
etifoxine,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA5",neurology/psychiatry,anxiety,"CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|, CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|",Launched
etifoxine (hydrochloride),,,,,CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1,
etilefrine,adrenergic receptor agonist,"ADRA1A, ADRB1","neurology/psychiatry, otolaryngology, endocrinology, pulmonary","headache, nasal congestion, fever, cough suppressant, common cold",CCNCC(O)c1cccc(O)c1,Launched
etilevodopa,dopamine receptor agonist,DRD3,,,"CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1",Phase 3
etizolam,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,"insomnia, anxiety","CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|",Launched
etodolac,cyclooxygenase inhibitor,PTGS2,rheumatology,"osteoarthritis, rheumatoid arthritis","CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|",Launched
etofenamate,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain","OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Launched
etofibrate,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia,"CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1, CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1",Launched
etofylline,adenosine receptor antagonist,ADORA1,pulmonary,"asthma, bronchitis","Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O",Launched
etofylline-clofibrate,platelet aggregation inhibitor,PPARA,endocrinology,hyperlipidemia,"Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O",Launched
etomidate,GABA receptor modulator,"ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,general anaesthetic,"CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1",Launched
etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,,,"CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1",Phase 2
etonogestrel,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|, CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C",Launched
etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer","COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
etoricoxib,cyclooxygenase inhibitor,PTGS2,rheumatology,"rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis","Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O",Launched
etosalamide,anti-inflammatory agent,,,,"CCOCCOc1ccccc1C(N)=O, CCOCCOc1ccccc1C(N)=O",Preclinical
etoxybamide,,,,,OCCCC(=O)NCCO,Phase 2
ETP-45658,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1",Preclinical
ETP-46464,ATR kinase inhibitor,,,,"CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1",Preclinical
etrabamine,dopamine receptor agonist,,,,"CN[C@H]1CCc2ncsc2C1 |&1:2,r|",Phase 2
etrasimod,sphingosine 1-phosphate receptor antagonist,,,,OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21,Phase 3
etravirine,non-nucleoside reverse transcriptase inhibitor,"CYP2C19, CYP2C9, CYP3A4",infectious disease,human immunodeficiency virus (HIV-1),"Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N",Launched
etretinate,protein synthesis inhibitor,"RARA, RXRG",,,"CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C",Withdrawn
etripamil,calcium channel blocker,CACNA1C,cardiology,ventricular tachycardia (vt),COC(=O)c1cccc(CCN(C)CCC[C@](C#N)(C(C)C)c2ccc(OC)c(OC)c2)c1,Phase 2
eucalyptol,acetylcholinesterase inhibitor,ACHE,dental,gingivitis,"CC12CCC(CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2",Launched
eucatropine,acetylcholine receptor antagonist,,,,"C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|, C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|",Preclinical
eugenol,androgen receptor antagonist,AR,dental,toothache,"COc1cc(CC=C)ccc1O, COc1cc(CC=C)ccc1O",Launched
EUK-134,catalase stimulant,"APP, SOD2",,,"COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|",Preclinical
eupatilin,mucus protecting agent,,,,"COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1",Launched
evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,,,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
evans-blue,glutamate receptor negative allosteric modulator,"GRIA1, PTPN1",,,"Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|",Launched
evatanepag,prostaglandin inhibitor,"PTGER2, PTGER4",,,"CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1",Phase 2
evenamide,voltage-gated sodium channel blocker,,,,CCCCOc1cccc(CCNCC(=O)N(C)C)c1,Phase 2
everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|",Launched
evobrutinib,Bruton's tyrosine kinase (BTK) inhibitor,,,,Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1,Phase 2
evocalcet,calcium sensitizer,,,,C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12,Phase 3
evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,,,"CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|",Preclinical
evogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)Cc2cc(F)c(F)cc2F,Phase 1
EVP-6124,acetylcholine receptor agonist,CHRNA7,,,"Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2",Phase 3
EVP4593,NFkB pathway inhibitor,,,,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
EW-7197,TGF beta receptor inhibitor,"ACVR1B, TGFBR1",,,"Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1",Phase 2
EX-527,SIRT inhibitor,SIRT1,,,"NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|",Phase 2
exalamide,membrane permeability inhibitor,,,,"CCCCCCOc1ccccc1C(N)=O, CCCCCCOc1ccccc1C(N)=O",Launched
examorelin,growth hormone releasing factor agonist,"GHRHR, GHSR",,,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,Phase 2
exatecan-mesylate,topoisomerase inhibitor,TOP1,,,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|",Launched
exenatide,GLP receptor agonist,GLP1R,endocrinology,diabetes mellitus,[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|,Launched
exendin-4,glp receptor agonist,,endocrinology,diabetes mellitus,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O,Launched
exherin,cadherin antagonist,CDH2,,,"CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O",Phase 2
exifone,nootropic agent,TYR,,,"Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O",Withdrawn
exisulind,phosphodiesterase inhibitor,PDE5A,,,"CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|",Phase 3
exo-IWR-1,WNT signaling inhibitor negative control,TNKS,,,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|",Preclinical
EXO-1,ARF inhibitor,,,,"COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1",Preclinical
ezatiostat,glutathione transferase inhibitor,GSTP1,,,"CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1",Phase 2
ezetimibe,"cholesterol inhibitor, niemann-pick c1-like 1 protein antagonist, cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist","ANPEP, NPC1L1, SOAT1","endocrinology, metabolism, endocrinology, metabolism","hyperlipidemia, hypercholesterolemia, sitosterolemia, hyperlipidemia, hypercholesterolemia, sitosterolemia","O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1",Launched
ezutromid,utrophin enhancer,UTRN,,,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,Phase 2
e1210,other antifungal,,infectious disease,cutaneous candidiasis,Nc1ncccc1c2onc(Cc3ccc(COc4ccccn4)cc3)c2,
E3330,NFkB pathway inhibitor,,,,"CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|",Preclinical
E7046,prostanoid receptor antagonist,,,,C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O,Phase 1
E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",,,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 2
E7820,angiogenesis inhibitor,,,,Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12,Phase 2
F-11440,serotonin receptor agonist,HTR1A,,,"Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O",Phase 2
F-16915,,,,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1,Preclinical
fadrozole,aromatase inhibitor,"CYP11B1, CYP19A1",oncology,breast cancer,"N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|, N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|",Launched
fagomine,glucosidase inhibitor,GLB1,,,"OC[C@H]1NCC[C@@H](O)[C@@H]1O, OC[C@H]1NCC[C@@H](O)[C@@H]1O",Phase 2
falecalcitriol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,"C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
famciclovir,DNA polymerase inhibitor,,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
famprofazone,cyclooxygenase inhibitor,,,,"CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|",Preclinical
fananserin,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,,,"Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1",Phase 2
fanetizole,neutrophil superoxide production,,,,C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1,Phase 3
fantofarone,calcium channel blocker,,,,COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC,Preclinical
fapi-4,fibroblast activation protein inhibitor,FAP,oncology,breast cancer,O=C(NCC(N1CC(F)(F)C[C@]1(C#N)[H])=O)C2=CC=NC3=CC=C(OCCCN4CCN(C(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CC4)C=C32,
farampator,ionotropic glutamate receptor agonist,,,,O=C(N1CCCCC1)c1ccc2nonc2c1,Preclinical
farnesyl-thiosalicylic-acid-amide,Ras GTPase inhibitor,HRAS,,,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O",Phase 1
faropenem,lactamase inhibitor,,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis","C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1,&2:3,&3:4,&4:7,r,c:12|",Launched
faropenem-medoxomil,lactamase inhibitor,,"otolaryngology, infectious disease, pulmonary","sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections","C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|",Launched
fasoracetam,GABA receptor antagonist,,,,O=C([C@H]1CCC(=O)N1)N1CCCCC1,Preclinical
fasudil,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1, ROCK2",neurology/psychiatry,cerebral vasospasm,"O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12",Launched
favipiravir,RNA polymerase inhibitor,,,,"NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O",Phase 3
FCE-22250,DNA directed DNA polymerase inhibitor,,,,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|",Phase 1
fce-22250,dna directed dna polymerase inhibitor,,,,COC1\C=C\OC2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)c(O)c2c(O)c3C,Phase 1
fdcyd,DNA methyltransferase inhibitor,,,,"Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1",Phase 2
febantel,anthelmintic agent,,infectious disease,gastrointestinal parasites,COCC(=O)NC1=C(C=CC(=C1)SC2=CC=CC=C2)N=C(NC(=O)OC)NC(=O)OC,Launched
febuprol,choleretic agent,,,,"CCCCOC[C@@H](O)COc1ccccc1 |&1:6,r|",Launched
febuxostat,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia,"CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O",Launched
fedovapagon,vasopressin receptor agonist,AVPR2,urology,benign prostatic hyperplasia (bph),CN(C)C(=O)[C@@H]1CCCN1C(=O)NCc2ccc(cc2C)C(=O)N3CCCCc4ccccc34,Phase 2
fedratinib,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",hematologic malignancy,myelofibrosis,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Launched
felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
felbinac,cyclooxygenase inhibitor,CTSL,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain","OC(=O)Cc1ccc(cc1)-c1ccccc1, OC(=O)Cc1ccc(cc1)-c1ccccc1",Launched
felbinac-ethyl,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,CCOC(=O)Cc1ccc(cc1)-c1ccccc1,Launched
felodipine,calcium channel blocker,CFTR,"null, cardiology","angina pectoris, hypertension","CCOC(=O)[C@H]1[C@H](C(C(=O)OC)=C(C)N=C1C)c1cccc(Cl)c1Cl |&2:6,r,c:14,t:11|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|",Launched
felypressin,vasopressin receptor agonist,,,,[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O,Preclinical
fenaclon,,,,,"ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1",Preclinical
fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
fenbufen,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1, OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1",Launched
fenclonine-(+/-),tryptophan hydroxylase inhibitor,"PAH, TPH1, TPH2",,,"N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|",Preclinical
fendiline,calcium channel blocker,HTR2B,,,"C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|",Preclinical
fenebrutinib,Bruton's tyrosine kinase (BTK) inhibitor,,,,C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1,Phase 2
fenigam,benzodiazepine receptor agonist,"GABBR1, GABBR2",neurology/psychiatry,"posttraumatic stress disorder, anxiety, depression","NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|",Launched
fenipentol,choleretic agent,,gastroenterology,bile stimulation,"CCCC[C@@H](O)c1ccccc1 |&1:4,r|, CCCC[C@@H](O)c1ccccc1 |&1:4,r|",Launched
fenobam,glutamate receptor antagonist,GRM5,,,"CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|",Phase 2
fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
fenofibric-acid,cytochrome P450 inhibitor,"CLCN1, PPARA",cardiology,dyslipidemia,"CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O",Launched
fenoldopam,dopamine receptor agonist,"DRD1, DRD4",cardiology,hypertension,"Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12",Launched
fenoldopam hydrochloride,dopamine receptor agonist,DRD1,Cardiovascular,hypertension,Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12,Launched
fenoprofen,prostaglandin inhibitor,"PTGS1, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis, rheumatoid arthritis, osteoarthritis","C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
fenoterol,adrenergic receptor agonist,ADRB2,,,"C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|",Withdrawn
fenoterol hydrobromide,adrenergic receptor agonist,,,,"C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,&2:12|",Withdrawn
fenoverine,acetylcholine receptor antagonist,,neurology/psychiatry,spasms,O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12,Launched
fenoxaprop-p-ethyl,,NOS3,,,CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1,Preclinical
fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,,,"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|",Phase 3
fenspiride,bronchodilator,,"pulmonary, otolaryngology","asthma, otitis, sinusitis, rhinopharyngitis, laryngitis","O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1",Launched
fenthion,cholinesterase inhibitor,,,,"COP(=S)(OC)Oc1ccc(SC)c(C)c1, COP(=S)(OC)Oc1ccc(SC)c(C)c1",Launched
fentiazac,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology","muscle pain, joint pain","OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1, OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1",Launched
fenticonazole,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis,"Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|",Launched
FERb-033,EGFR inhibitor,ERBB2,,,"O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1",Preclinical
ferroquine,antimalarial agent,,,,"CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|",Phase 2
ferrostatin-1,ferroptosis inhibitor,,,,"CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1",Preclinical
ferulic-acid,antioxidant,"CA1, CA12, CA14, CA2, CA4, CA6, CA9",,,"COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O",Phase 2
fesoterodine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C",Launched
fevipiprant,prostaglandin inhibitor,,,,Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O,Phase 2
fexaramine,FXR agonist,NR1H4,,,"COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1",Preclinical
fexinidazole,,,,,"CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1, CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1",Phase 3
fexofenadine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|",Launched
fezolinetant,neurokinin receptor antagonist,,,,C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1,Phase 2
FG-2216,hypoxia inducible factor prolyl hydroxylase inhibitor,"EGLN1, EGLN2, HIF1A",,,"OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O, OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O",Phase 2
FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,"EGLN1, EGLN2, EGLN3",,,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
FG-7142,GABA benzodiazepine site receptor inverse agonist,,,,"CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21",Preclinical
FGIN-1-27,inositol monophosphatase inhibitor,TSPO,,,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1",Preclinical
FGIN-1-43,benzodiazepine receptor agonist,TSPO,,,"CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1",Preclinical
FH-535,"PPAR receptor antagonist, WNT signaling inhibitor","PPARD, PPARG",,,"Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O",Preclinical
FH1,hepatocyte function enhancer,,,,"CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1",Preclinical
fiacitabine,DNA synthesis inhibitor,,,,"Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Phase 2
fidarestat,aldose reductase inhibitor,AKR1B1,,,"NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|, NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|",Phase 3
fidaxomicin,RNA polymerase inhibitor,,gastroenterology,diarrhea,"CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3,11,47,50,t:9|, CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O",Launched
filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,,,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|",Phase 3
filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",,,"O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1",Phase 3
filibuvir,non-nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis c,O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[C@@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5,Phase 2
fimasartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Launched
finafloxacin,bacterial DNA gyrase inhibitor,,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis","OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O",Launched
finasteride,5 alpha reductase inhibitor,"AKR1D1, SRD5A1, SRD5A2",endocrinology,androgenetic alopecia,"CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|",Launched
finerenone,mineralocorticoid receptor antagonist,NR3C2,nephrology,chronic kidney disease (ckd),"CCOc1ncc(C)c2NC(C)=C([C@@H](c3ccc(cc3OC)C#N)c12)C(N)=O |a:13,c:11|",Launched
fingolimod,"immunosuppressant, sphingosine 1-phosphate receptor agonist","S1PR1, S1PR5",neurology/psychiatry,multiple sclerosis,"CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1",Launched
fipexide,psychoactive drug,,,,"Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1, Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1",Withdrawn
FIPI,phospholipase inhibitor,"PLD1, PLD2",,,"Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O",Preclinical
fipronil,"chloride channel blocker, GABA gated chloride channel blocker",,infectious disease,flea control,"Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|, Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|",Launched
firategrast,integrin antagonist,ITGA4,,,"CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1",Phase 2
firocoxib,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,"CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|, CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|",Launched
firsocostat,acetyl-CoA carboxylase inhibitor,,,,COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1,Phase 2
fisetin,Aurora kinase inhibitor,"CDK6, FASN",,,"Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O",Preclinical
fisogatinib,fibroblast growth factor inhibitor,,,,COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1,Phase 1
FIT,opioid receptor agonist,OPRD1,,,CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1,Preclinical
FK-33-824,opioid receptor agonist,OPRM1,,,"C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|, C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|",Phase 2
FK-3311,cyclooxygenase inhibitor,PTGS2,,,"CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1",Phase 2
FK-409,guanylyl cyclase activator,,,,"CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|, CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|",Phase 2
FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,,"O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1",Phase 2
FK-888,tachykinin antagonist,"TACR1, TACR2",,,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
FK-962,somatostatin receptor agonist,,,,"CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1",Phase 2
flavin-adenine-dinucleotide,,"ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH",,,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|",Preclinical
flavoxate,acetylcholine receptor antagonist,"CHRM1, CHRM2",urology,"urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis","Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1",Launched
flecainide,sodium channel blocker,"KCNA5, KCNA7, SCN5A",cardiology,"ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias","FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1",Launched
fleroxacin,topoisomerase inhibitor,TOP2A,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
flesinoxan,serotonin receptor agonist,HTR1A,cardiology,hypertension,O=C(NCCN1CCN(C2=C3OC[C@@H](CO)OC3=CC=C2)CC1)C4=CC=C(F)C=C4,Preclinical
FLI-06,notch signaling inhibitor,,,,"CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|",Preclinical
flibanserin,serotonin receptor agonist,"DRD4, HTR1A, HTR2A",neurology/psychiatry,hypoactive sexual desire disorder,"FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1, FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1",Launched
flindokalner,potassium channel agonist,"KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5",,,"COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F",Phase 3
floctafenine,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|",Launched
flopropione,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms,"CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O",Launched
florbetaben,beta amyloid plaque binder,APP,neurology/psychiatry,alzheimer's disease,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCCF)C=C2)C=C1,Launched
florbetapir,beta amyloid plaque binder,APP,neurology/psychiatry,alzheimer's disease,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCCF)N=C2)C=C1,Launched
florfenicol,protein synthesis inhibitor,,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
florifenine,anti-inflammatory agent,,,,FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1,Preclinical
flortaucipir f18,pet imaging agent,"MAOA, MAOB, MAPT",neurology/psychiatry,alzheimer's disease,C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4,Launched
flosequinan,phosphodiesterase inhibitor,,,,Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|,Withdrawn
floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
FLT3-IN-1,FLT3 inhibitor,,,,CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C,Preclinical
flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1",Launched
fluciclovine (18f),pet imaging agent,,radiology,pet imaging,N[C@]1(C[C@H](F)C1)C(O)=O,Launched
flucloxacillin,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, dermatology, gastroenterology","gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia","Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl",Launched
fluconazole,sterol demethylase inhibitor,CYP51A1,infectious disease,"esophageal candidiasis, meningitis","OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F",Launched
flucytosine,other antifungal,DNMT1,infectious disease,"bacterial septicemia, endocarditis, urinary tract infections, meningitis","Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F",Launched
fludarabine,ribonucleotide reductase inhibitor,"ADA, DCK, POLA1, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
fludrocortisone-acetate,,NR3C2,endocrinology,"Addison's disease, adrenogenital syndrome","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|",Launched
fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis","CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|",Launched
flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",,,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",,,"CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Phase 3
flumazenil,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ",neurology/psychiatry,sedative,"CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21",Launched
flumecinol,,,,,"CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2,r|",Launched
flumequine,topoisomerase inhibitor,,infectious disease,urinary tract infections,"C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|",Launched
flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B","otolaryngology, infectious disease, dermatology","otitis, ear infections, corticosteroid-responsive dermatoses","C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|",Launched
flumethasone pivalate,glucocorticoid receptor agonist,NR3C1,Dermatology,dermatitis,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|",Launched
flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|",Launched
flumexadol,,,,,"FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|, FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|",Preclinical
flunarizine,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1","neurology/psychiatry, cardiology","migraine headache, vertigo, peripheral artery disease (PAD)","Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1",Launched
flunisolide,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,"CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",Launched
flunixin-meglumin,prostanoid receptor antagonist,,pulmonary,bovine respiratory disease (BRD),"Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F",Launched
fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",Launched
fluocinonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6, SMO",dermatology,"seborrheic dermatitis, eczema","CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C",Launched
fluorescein,,SLC22A6,ophthalmology,ophthalmology diagnostic,"Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1, Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1",Launched
fluorofenidone,nadph oxidase inhibitor,NOX1,pulmonary,idiopathic pulmonary fibrosis (ipf),CC1=CN(C(=O)C=C1)c2cccc(F)c2,Preclinical
fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,,Launched
fluorometholone(brd-a13133631),glucocorticoid receptor agonist,,ophthalmology,eye inflammation,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",Launched
fluorometholone-acetate,,NR3C1,ophthalmology,eye inflammation,"C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|",Launched
fluoromethylcholine,,,,,C[N+](C)(CF)CCO,Launched
fluoxetine,selective serotonin reuptake inhibitor (SSRI),"ANO1, HTR2B, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder","CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1",Launched
fluoxetine hydrochloride,serotonin transporter (sert) inhibitor,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9A, SLC6A4",Neurology,depression,"CNCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:4,r|",Launched
flupentixol,dopamine receptor antagonist,"ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A",neurology/psychiatry,"schizophrenia, depression","OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1",Launched
fluphenazine,dopamine receptor antagonist,"CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1",Launched
fluphenazine-decanoate,dopamine receptor antagonist,"DRD2, HTR1B, HTR4",neurology/psychiatry,schizophrenia,"CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1",Launched
flupirtine,glutamate receptor antagonist,"ADRA2A, KCNQ1, KCNQ2",neurology/psychiatry,pain relief,"CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N",Launched
fluprazine,serotonin receptor agonist,"HTR1A, HTR1B",,,"NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F, NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F",Phase 1
fluprednisolone,glucocorticoid receptor agonist,NR3C1,ophthalmology,contact dermatitis,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O,Withdrawn
fluralaner,"GABA receptor antagonist, gaba gated chloride channel blocker",GABRD,infectious disease,mites,"Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|, Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C2=NOC(C2)(c3cc(cc(c3)Cl)Cl)C(F)(F)F",Launched
flurandrenolide,glucocorticoid receptor agonist,NR3C1,"nephrology, nephrology, infectious disease, dermatology","chronic kidney disease (ckd), chronic kidney disease (ckd), skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
flurbiprofen-(+/-),cyclooxygenase inhibitor,,rheumatology,"rheumatoid arthritis, osteoarthritis","C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|",Launched
flurbiprofen-(S)-(+),cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1",Launched
flurbiprofen-axetil,analgesic agent,,,,"C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9,&2:1,r|",Launched
flurizan,gamma secretase inhibitor,"APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2",,,"C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1",Phase 3
flurofamide,urease inhibitor,,,,"NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1",Preclinical
flurothyl,,,,,"FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F",Preclinical
fluroxene,local anesthetic,,,,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
fluspirilene,dopamine receptor antagonist,"CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A",neurology/psychiatry,schizophrenia,"Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1",Launched
flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
flutemetamol,pet imaging agent,APP,neurology/psychiatry,alzheimer's disease,CNC1=C(F)C=C(C=C1)C1=NC2=C(S1)C=C(O)C=C2,Launched
fluticasone furoate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR",pulmonary,asthma,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F,Launched
fluticasone propionate,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF,Launched
fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|",Launched
flutrimazole,sterol demethylase inhibitor,,infectious disease,mycosis,Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|,Launched
fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
fluvoxamine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),"COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F",Launched
fmoc-L-leucine,PPAR receptor agonist,,,,"CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",Phase 2
FN-1501,tyrosine kinase inhibitor,,,,"CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1, CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1",Phase 1
folic-acid,folate receptor ligand,"FOLR2, FOLR3, SLC19A1, SLC46A1",hematology,megaloblastic anemia,"Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1, Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1",Launched
foliglurax (monohydrochloride),glutamate receptor modulator,GRM4,neurology/psychiatry,parkinson's disease,O/N=C1C=C(C2=CC3=C(C=CS3)C=N2)OC4=CC=C(CCCN5CCOCC5)C=C\14.Cl,
fomepizole,alcohol dehydrogenase inhibitor,"ADH1A, ADH1B, ADH1C, AKR1A1, CAT",critical care,poison antidote,"Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1",Launched
fomocaine,voltage-gated sodium channel modulator,,neurology/psychiatry,local anesthetic,"C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1, C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1",Launched
fondaparinux,coagulation factor inhibitor,"F10, SERPINC1",hematology,deep vein thrombosis (DVT),[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O,Launched
foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",,,"COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1",Phase 2
formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|",Launched
formononetin,alcohol dehydrogenase inhibitor,"ADH1C, SLC5A2",,,"COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",Preclinical
formoterol,adrenergic receptor agonist,ADRB2,pulmonary,"asthma, chronic obstructive pulmonary disease (COPD), bronchospasm","COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1",Launched
forodesine,purinergic receptor antagonist,PNP,hematologic malignancy,peripheral T-cell lymphoma (PTCL),"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Launched
foropafant,platelet activating factor receptor antagonist,PTAFR,,,"CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C",Phase 3
forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",,,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
fosamprenavir,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1",Launched
fosaprepitant-dimeglumine,tachykinin antagonist,TACR1,gastroenterology,"nausea, vomiting","C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",Launched
fosbretabulin,"tubulin polymerization inhibitor, ve-cadherin antagonist, tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,,,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
foscarnet,DNA polymerase inhibitor,,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
foscenvivint,wnt signaling inhibitor,"CCND1, CTNNB1",oncology,hepatocellular carcinoma (hcc),[H][C@]12[C@H](C)N(Cc3cccc4cccnc34)C(=O)[C@H](Cc3ccc(OP(O)(O)=O)cc3)N1C(=O)CN(C)N2C(=O)NCc1ccccc1,Phase 1/Phase 2
fosdagrocorat,glucocorticoid receptor agonist,NR3C1,rheumatology,rheumatoid arthritis,FC(F)(F)[C@]1(OP(O)(O)=O)C[C@]2([H])[C@](C3=CC=C(C(NC(C=CC=N4)=C4C)=O)C=C3CC2)(CC1)CC5=CC=CC=C5,Phase 2
fosfestrol,synthetic estrogen,"ESR1, ESR2",oncology,prostate cancer,CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1,Launched
fosfluconazole,other antifungal,,,,OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Preclinical
fosfomycin,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections,"C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O",Launched
fosfomycin calcium,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections,"C[C@H]1O[C@@H]1P(O)(O)=O |&1:1,&2:3|",Launched
fosfosal,phosphodiesterase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O",Launched
fosfructose,fructose diphosphate stimulant,,,,"O[C@@H]1[C@@H](COP(O)(O)=O)OC(O)(COP(O)(O)=O)[C@H]1O, O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O",Phase 3
fosifloxuridine nafalbenamide,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,C[C@H](N[P@@](=O)(OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1 |&1:3|,Phase 1
fosinopril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure","CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|",Launched
fosinoprilat,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|",Launched
foslinanib,anticancer agent,,oncology,neuroendocrine tumors of pancreatic origin (pnet),COc1ccc2[nH]c(cc(=O)c2c1OP(O)(O)=O)-c1cccc(F)c1.[NaH].[NaH],Phase 2
fosphenytoin,sodium channel blocker,SCN5A,neurology/psychiatry,"epilepsy, seizures","OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1",Launched
fostamatinib,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC",Launched
fostemsavir,antiviral,,,,COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
fotemustine,thioredoxin inhibitor,,oncology,melanoma,"CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|",Launched
foxy-5,WNT5a peptide mimetic,WNT5A,,,"CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O",Phase 2
FPA-124,AKT inhibitor,,,,,Preclinical
fpa-124,apoptosis stimulant,,,,Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O,Preclinical
FPH1-(BRD-6125),hepatocyte function enhancer,,,,"Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O, Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O",Preclinical
FPL-12495,glutamate receptor antagonist,,,,"CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|",Phase 1
FPL-55712,leukotriene receptor antagonist,,,,"CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|",Phase 1
FPL-62064,"cyclooxygenase inhibitor, lipoxygenase inhibitor",,,,"COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1",Phase 2
FPL-64176,calcium channel activator,"CACNA1C, CACNA1S",,,"COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1",Preclinical
FPS-ZM1,RAGE receptor antagonist,AGER,,,"Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1, Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1",Preclinical
FR-122047,cyclooxygenase inhibitor,,,,"COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1, COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1",Preclinical
FR-139317,endothelin receptor antagonist,EDNRA,,,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
FR-180204,MAP kinase inhibitor,"MAPK1, MAPK3",,,"Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1",Preclinical
frakefamide,opioid receptor agonist,OPRD1,neurology/psychiatry,depression,"C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N, C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O.OC(=O)C(F)(F)F |a:1,5,18,30|",Phase 2
FRAX486,serine/threonine kinase inhibitor,"PAK1, PAK2, PAK3, PAK4",,,"CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O",Preclinical
frentizole,immunosuppressant,,,,"COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1",Phase 1
freselestat,elastase inhibitor,"CELA1, ELANE",,,CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C,Preclinical
frovatriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D",neurology/psychiatry,migraine headache,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,Launched
fructose,,,,,OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O,
fruquintinib,VEGFR inhibitor,KDR,oncology,colorectal cancer,"CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12",Launched
ftaxilide,,,,,"Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O, Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O",Preclinical
ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
FT011,TGF beta receptor inhibitor,,,,COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C,Preclinical
fucoxanthin,anticancer agent,,,,[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C,Phase 2
fudosteine,mucolytic agent,,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
fulacimstat,chymotrypsin inhibitor,CTRL,endocrinology,diabetes mellitus,CN1C(=O)Oc2cc(ccc12)N3C=C(C(=O)O)C(=O)N([C@@H]4CCc5c4cccc5C(F)(F)F)C3=O,Phase 2
fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|",Launched
fumagillin,methionine aminopeptidase inhibitor,METAP2,"infectious disease, Infectious disease","microsporidiosis, fungal infection","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, [H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)[C@@]1(C)O[C@@H]1CC=C(C)C",Launched
fumonisin-B1,,CERS1,,,CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O,Preclinical
funapide,sodium channel blocker,,,,FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1,Preclinical
furagin,antibacterial,,,,[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1,Preclinical
furaltadone,bacterial DNA inhibitor,,infectious disease,gram-negative bacterial infections,"[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|, [O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|, [O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|",Launched
furaltadone hcl,bacterial dna inhibitor,,infectious disease,gram-negative bacterial infections,[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1,Launched
furamidine,protein arginine N-methyltransferase inhibitor,PRMT1,,,"NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N",Preclinical
furazolidone,bacterial DNA inhibitor,,"gastroenterology, infectious disease","diarrhea, enteritis, cholera","[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1",Launched
furegrelate,thromboxane synthase inhibitor,TBXAS1,,,"OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1",Phase 1
furosemide,diuretic,"CA2, GPR35, SLC12A1, SLC12A2","cardiology, rheumatology","edema, hypertension, congestive heart failure, nephrotic syndrome","NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl",Launched
furprofen,prostagladin inhibitor,PTGS2,neurology/psychiatry,pain relief,"C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1ccco1 |&1:1,r|",
fursultiamine,vitamin B,,metabolism,thiamine deficiency,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|",Launched
furvina,quorum sensing signaling inhibitor,,,,[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1,Preclinical
fusidic acid,bacterial 30s ribosomal subunit inhibitor,,dermatology,acne vulgaris (av),C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,Launched
fusidic-acid,bacterial 30S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV),C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O,Launched
futibatinib,FGFR inhibitor,,,,COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12,Phase 3
F351,TGF beta receptor inhibitor,TGFB1,,,"Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1",Phase 2
g-caryophyllene,acetylcholinesterase inhibitor,ACHE,,,"C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|, C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|",Preclinical
G-1,G protein-coupled receptor agonist,GPER1,,,"CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|",Preclinical
G-15,estrogen receptor antagonist,GPER1,,,"Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|",Preclinical
G-749,tyrosine kinase inhibitor,,,,CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1,Preclinical
GABA-linoleamide,benzodiazepine receptor agonist,,,,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O,Phase 2
gabapentin,calcium channel blocker,"ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","infectious disease, neurology/psychiatry","virus herpes simplex (HSV), shingles, seizures, restless leg syndrome","NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1",Launched
gabapentin-enacarbil,adrenergic receptor agonist,CACNA1G,neurology/psychiatry,"restless leg syndrome, postherpetic neuralgia","CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|, CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|",Launched
gabazine,GABA receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2",,,"COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1",Preclinical
gabexate,serine protease inhibitor,"PRSS1, TPSAB1",gastroenterology,pancreatitis,"CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1",Launched
gaboxadol,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3",,,"O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12",Phase 3
gadobutrol,radiopaque medium,,radiology,MRI contrast agent,"[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2,5|, OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2",Launched
gadodiamide,radiopaque medium,,radiology,MRI contrast agent,"CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2, CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2",Launched
gadopentetic-acid,contrast agent,PGD,radiology,contrast agent,OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,Launched
gadoterate-meglumine,radiopaque medium,,radiology,MRI contrast agent,"OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1",Launched
gadoteridol,radiopaque medium,,radiology,MRI contrast agent,"C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|, C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|",Launched
gadoxetate disodium,contrast agent,,radiology,mri contrast agent,[Na+].[Na+].[Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)N(CC([O-])=O)CC([O-])=O)C=C1,Launched
GAL-021,calcium channel blocker,,,,CCCNc1nc(NCCC)nc(n1)N(C)OC,Preclinical
galantamine,acetylcholinesterase inhibitor,"ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG",neurology/psychiatry,senile dementia,"COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|",Launched
galeterone,androgen receptor modulator,"AR, CYP17A1",,,"[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|",Phase 3
galidesivir,antiviral,,,,Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O,Phase 1
gallamine-triethiodide,acetylcholine receptor antagonist,"CHRM2, CHRNA1",neurology/psychiatry,muscle relaxant,"CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC",Launched
gallic-acid,"beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP",,,"OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1",Preclinical
gallium-triquinolin-8-olate,,,,,O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12,Phase 1
gallopamil,L-type calcium channel blocker,ATP2A2,cardiology,"hypertension, cardiac arrythmia","COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|",Launched
gambogic-acid,caspase activator,BCL2,,,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|",Phase 2
gamithromycin,antibacterial ,,,,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",,,"NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O",Preclinical
gamma-linolenic-acid,"cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2",,,"CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O",Phase 2
ganaxolone,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",,,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C",Phase 3
ganciclovir,DNA polymerase inhibitor,,infectious disease,cytomegalovirus (CMV),"Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1",Launched
ganetespib,HSP inhibitor,HSP90AA1,,,"CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O",Phase 3
ganoderic-acid-a,JAK inhibitor,,,,[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|,Preclinical
GANT-58,GLI antagonist,GLI1,,,"c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1",Preclinical
GANT-61,GLI antagonist,"GLI1, GLI2",,,"CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1",Preclinical
garenoxacin,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections,"C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1",Launched
gastrodin,,,,,"OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
gatifloxacin,bacterial DNA gyrase inhibitor,,,,"COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|",Withdrawn
gavestinel,glutamate receptor antagonist,"GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",,,"OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1",Phase 3
gavorestat,aldose reductase inhibitor,AKR1B1,,,OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2cscc12,
GBR-12783,dopamine reuptake inhibitor,,,,"C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1",Preclinical
GBR-12935,dopamine reuptake inhibitor,"AGTR1, SLC6A3",,,"C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1",Preclinical
GBR-13069,dopamine reuptake inhibitor,SLC6A3,,,"Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1",Preclinical
GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",,,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 3
GDC-0077,PI3K inhibitor,,,,C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O,Phase 1
GDC-0084,"mTOR inhibitor, PI3K inhibitor",,,,CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1,Phase 2
GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",,,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1",Phase 1
GDC-0349,Pim kinase inhibitor,PIK3CA,,,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
GDC-0575,CHK inhibitor,,,,N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12,Phase 1
GDC-0623,MEK inhibitor,,,,"OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F",Phase 1
GDC-0810,selective estrogen receptor destabilizer,ESR1,,,"CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl",Phase 2
GDC-0834,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,"CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|",Phase 1
GDC-0879,RAF inhibitor,BRAF,,,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O",Preclinical
GDC-0927,estrogen receptor antagonist,,,,"CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|, CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|",Phase 1
GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1",Phase 2
GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",,,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
GDC-0994,MAP kinase inhibitor,"MAPK1, MAPK3",,,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|, Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|",Phase 1
gedunin,HSP inhibitor,HSP90AA1,,,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|,Preclinical
gefapixant,purinergic receptor antagonist,,,,COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,Phase 3
gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
geldanamycin,HSP inhibitor,HSP90AA1,,,"CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|",Preclinical
gemcabene,ppar receptor agonist,"APOB, LPA, PCSK9, PPARA, PPARG",endocrinology,hypercholesterolemia,CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O,Phase 2
gemcadiol,antilipemic,,,,"CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO",Phase 2
gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
gemcitabine-elaidate,"apoptosis inhibitor, DNA synthesis inhibitor","CMPK1, RRM1, TYMS",,,"CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O",Phase 1
gemfibrozil,lipoprotein lipase activator,"LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1","endocrinology, cardiology","hyperlipidemia, coronary heart disease","Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1",Launched
gemifloxacin,bacterial DNA gyrase inhibitor,,"pulmonary, infectious disease","bronchitis, pneumonia","CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|, CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|",Launched
gemigliptin,dipeptidyl peptidase inhibitor,,,,N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F,Launched
gemilukast,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2",pulmonary,asthma,O=C(O)CCCN1C(C)=C(CCCC(O)=O)C2=C1C(C#CC3=CC=C(OCCCCC4=CC=CC(F)=C4C)C=C3)=CC=C2F,Phase 2
genipin,choleretic agent,,,,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|",Preclinical
geniposide,GLP receptor agonist,GLP1R,,,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|",Preclinical
geniposidic-acid,cyclooxygenase inhibitor,,,,"OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|",Preclinical
genistein,tyrosine kinase inhibitor,"CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5",,,"Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",Phase 2/Phase 3
gentamicin,bacterial 30s ribosomal subunit inhibitor,,Infectious disease,gram-negative bacterial infections,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](OC2[C@@H](N)C[C@@H](N)[C@H](OC3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,Launched
gentamycin,bacterial 50S ribosomal subunit inhibitor,HSPA8,"infectious disease, critical care","bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis",CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,Launched
gentiopicrin,glutamate receptor downregulator,GRIN2B,,,"OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|, OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|",Phase 3
genz-123346,glucosylceramidase inhibitor,UGCG,,,"CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1",Preclinical
genz-644282,topoisomerase inhibitor,TOP1,,,"CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O",Phase 1
gepefrine,adrenergic receptor agonist,,cardiology,hypotension,"C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|, C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|",Launched
gepon,,,,,"CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|, CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|",Phase 1
gepotidacin,topoisomerase inhibitor,,,,O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23,Phase 2
geranyl-farnesylacetate,mucin production enhancer,,,,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C",Phase 2
gestodene,contraceptive agent,,endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|",Launched
gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,"CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|",Launched
GF109203X,PKC inhibitor,"PDPK1, PIM1, PRKCI, PRKCZ",,,"CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|",Preclinical
GGsTop,gamma glutamyltransferase Inhibitor,GGT1,,,"COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|",Preclinical
GGTI-298,GGTase inhibitor,CDKN1A,,,"COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12",Preclinical
gilteritinib,FLT3 inhibitor,FLT3,,,"CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1",Launched
gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
ginkgolide-A,GABA receptor antagonist,"GLRA1, GLRB",,,C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
ginkgolide-B,platelet activating factor receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",,,"C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O",Phase 3
ginsenoside rd,apoptosis stimulant,,Immunology,immunostimulant,CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,Phase 3
ginsenoside rg1,solute carrier family member inhibitor,SLCO1B3,neurology/psychiatry,alzheimer's disease,[H][C@]12C(C)(C)[C@@H](O)CC[C@]1(C)[C@]3([H])[C@@]([C@@](CC[C@]4([H])[C@@](CC/C=C(C)/C)(C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)(C)[C@]4([H])[C@H](O)C3)(C)C[C@@H]2O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O,Preclinical
ginsenoside rg3,,,,,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,Phase 2
ginsenoside-C-K,"NFkB pathway inhibitor, nitric oxide synthase inhibitor",PTGS2,,,"CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",Phase 1
ginsenoside-RD,calcium channel blocker,,,,"CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|, CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|",Phase 3
ginsenoside-RE,anti-inflammatory agent,,,,[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,Phase 1
ginsenoside-RE3,"angiogenesis inhibitor, apoptosis stimulant",KCNH2,,,"CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|",Launched
givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,"CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1",Phase 3
GKA-50,glucokinase activator,GCK,,,"COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O",Preclinical
GKT137831,NADPH oxidase inhibitor,"NOX1, NOX4",,,"CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12",Phase 2
GK921,transglutaminase inhibitor,TGM2,,,"C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1",Preclinical
glafenine,"cystic fibrosis transmembrane conductance regulator inhibitor, DeltaF508-CFTR Correctors, deltaf508-cftr correctors, cystic fibrosis transmembrane conductance regulator inhibitor",CFTR,Pulmonology,pain relief,"OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |r|, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12",Withdrawn
glasdegib,hedgehog pathway inhibitor,SMO,hematologic malignancy,acute myeloid leukemia (AML),"CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N",Launched
glecaprevir,serine protease inhibitor,,infectious disease,hepatitis C,"[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|, [H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|",Launched
glesatinib,tyrosine kinase inhibitor,,,,COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1,Phase 2
gliclazide,"ATP channel blocker, insulin secretagogue",,endocrinology,diabetes mellitus,"Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|",Launched
glimepiride,insulin secretagogue,"ABCC8, KCNJ1, KCNJ11",endocrinology,diabetes mellitus,"CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|",Launched
glipizide,sulfonylurea,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,"diabetes mellitus, hyperglycemia","Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
gliquidone,sulfonylurea,"ABCC8, KCNJ10, KCNJ8",endocrinology,diabetes mellitus,"COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C",Launched
Gln-1062,cholinesterase inhibitor,,,,COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|,Preclinical
GLPG0187,integrin antagonist,,,,COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O,Phase 1
GLPG0492,androgen receptor modulator,AR,,,"CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",Phase 1
GLPG0492-R-enantiomer,androgen receptor modulator,AR,,,"CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",Phase 1
glpg0974,free fatty acid receptor antagonist,FFAR2,gastroenterology,ulcerative colitis,C[C@@]1(CCN1C(=O)c1csc2ccccc12)C(=O)N(CCCC(O)=O)Cc1cccc(Cl)c1 |a:1|,Phase 2
GLPG1837,CFTR channel potentiator,,,,CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1,Phase 2
glucaric-acid,,,,,O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O,Phase 1
gluconolactone,,LCT,,,OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O,Launched
glucosamine,glycosylated protein precursor,IL1B,"neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis, joint pain, backache","N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
glutathione,antioxidant,"ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12",,,"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O",Phase 3
glutathione disulfide,glutathione reductase (nadph) activators,"GSR, GSTM2, MGST1",ophthalmology,ocular hypertension,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,Launched
glutathione-monoisopropyl-ester,lipid peroxidase inhibitor,,,,"CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O",Phase 2
gly-gln,,,,,"NCC(=O)N[C@@H](CCC(N)=O)C(O)=O, NCC(=O)N[C@@H](CCC(N)=O)C(O)=O",Phase 2
glyburide,"ATP channel blocker, insulin secretagogue, sulfonylurea","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1",endocrinology,"diabetes mellitus, hyperglycemia","COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1",Launched
glycerol-monolaurate,beta lactamase inhibitor,,,,"CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15,r|",Launched
glycerol-phenylbutyrate,sigma receptor ligand,,,,O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1,Phase 1
glycitein,tumor necrosis factor release inhibitor,TNF,,,"COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O, COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O",Phase 3
glycol salicylate,prostaglandin inhibitor,"PTGS1, PTGS2",neurology/psychiatry,muscle pain,C1=CC=C(C(=C1)C(=O)OCCO)O,Launched
glycopyrrolate,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|, C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|",Launched
GM-1485,immunophilin ligand,FKBP1A,,,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O,Preclinical
GMX1778,NAMPT inhibitor,NAMPT,,,"Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1",Phase 1/Phase 2
gne-477,mtor inhibitor,"MTOR, PIK3CA",oncology,renal cell carcinoma (rcc),NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(CN5CCN(S(=O)(C)=O)CC5)S4)=N2)C=N1,Preclinical
GNE-7915,leucine rich repeat kinase inhibitor,,,,CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F,Preclinical
GNF-2,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,"NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",Preclinical
GNF-5,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,"OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",Preclinical
GNF-5837,growth factor receptor inhibitor,"NTRK1, NTRK2, NTRK3",,,"Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1",Preclinical
GNF-7,"glucokinase inhibitor, protein kinase inhibitor","GCK, TNK2",,,"CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C",Preclinical
GNTI,opioid receptor antagonist,"OPRK1, OPRM1",,,"NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O",Preclinical
go-6983,protein kinase inhibitor,"PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ",,,"COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|",Preclinical
golgicide-A,ARF inhibitor,GBF1,,,"Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|",Preclinical
golvatinib,VEGFR inhibitor,"KDR, MET",,,"CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1",Phase 2
gonadorelin,gonadotropin releasing factor hormone receptor agonist,GNRHR,obstetrics/gynecology,"cystic ovaries, reproductive synchrony",CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,Launched
goserelin-acetate,gonadotropin releasing factor hormone receptor agonist,"GNRHR, LHCGR","oncology, obstetrics/gynecology","prostate cancer, breast cancer, endometriosis","CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O",Launched
gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,,,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
GPBAR-A,G protein-coupled receptor agonist,GPBAR1,,,"Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12",Preclinical
GPI-1046,FKBP inhibitor,FKBP1A,,,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1,Preclinical
GPi-688,glycogen phosphorylase inhibitor,,,,"OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|, OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|",Preclinical
GPP-78,NAMPT inhibitor,NAMPT,,,"O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1",Preclinical
gprp (acetate),,"FGB, ITGA2B",hematology,thrombosis,O=C(O)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H]2N(C(CN)=O)CCC2)=O)=O)CCC1.OC(C)=O,
GPR120-modulator-1,G protein-coupled receptor modulator,FFAR4,,,"Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O, Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O",Preclinical
GP1a,cannabinoid receptor agonist,CNR2,,,"Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1",Preclinical
GP2a,cannabinoid receptor agonist,CNR2,,,"Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1",Preclinical
GR-103691,dopamine receptor antagonist,DRD3,,,"COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1",Preclinical
GR-113808,serotonin receptor antagonist,HTR4,,,"Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12",Preclinical
GR-127935,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6",,,"COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1",Preclinical
GR-135531,melatonin receptor agonist,,,,"COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1, COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1",Preclinical
GR-144053,integrin antagonist,"ITGA2B, ITGB3",,,"NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1",Preclinical
GR-159897,tachykinin antagonist,"TAC1, TACR2",,,"COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1",Preclinical
GR-235,"estrogen receptor agonist, FXR antagonist, progesterone receptor agonist",NR1H4,,,[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|,Launched
GR-79236,adenosine receptor agonist,"ADORA1, ADORA2A",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12",Phase 1
gramicidin,bacterial permeability inducer,,infectious disease,first-aid antibiotic,"CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO, CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO",Launched
gramicidin (gramicidin a shown),bacterial permeability inducer,,infectious disease,first-aid antibiotic,CC(C)CC(NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCO,Launched
gramine,norepinephrine reputake inhibitor,,,,CN(C)Cc1c[nH]c2ccccc12,Preclinical
granisetron,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting","CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|",Launched
grapiprant,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis,"CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1",Launched
grazoprevir,HCV inhibitor,,infectious disease,hepatitis C,"COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C",Launched
grepafloxacin,bacterial dna gyrase inhibitor,,infectious disease,gonorrhea,O=C(O)\C2=C\N(c1cc(c(F)c(c1C2=O)C)N3CC(NCC3)C)C4CC4,Withdrawn
griseofulvin,tubulin polymerization inhibitor,KRT12,infectious disease,"ringworm, tinea pedis","COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|",Launched
GR125487,serotonin receptor antagonist,HTR4,,,"COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1",Preclinical
GR46611,serotonin receptor agonist,HTR1D,,,"COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1",Preclinical
GS-143,ubiquitin ligase inhibitor,"BTRC, NFKBIA",,,"OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|",Preclinical
GS-39783,GABA receptor modulator,GABBR1,,,"CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O",Preclinical
GS-6201,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1",Phase 1
GS-9620,toll-like receptor agonist,TLR7,,,"CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1",Phase 2
GS-967,voltage-gated sodium channel blocker,,,,FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F,Preclinical
GS-9973,SYK inhibitor,SYK,,,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1",Phase 2
GSK-J1,histone demethylase inhibitor,KDM6B,,,"OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
GSK-J2,histone demethylase inhibitor,,,,"OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",Preclinical
GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",,,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
GSK-J5,histone demethylase control,,,,"CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",Preclinical
GSK-LSD-1,histone lysine demethylase inhibitor,KDM1A,,,"C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1",Preclinical
GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",,,"O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
gsk-626616,dual specificity protein kinase inhibitor,DYRK3,hematology,anemia,Clc1cccc(Cl)c1\N=C/2\NC(=O)\C(=C\c3ccc4nccnc4c3)\S2,Phase 1
GSK0660,PPAR receptor antagonist,PPARD,,,"COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC",Preclinical
GSK1059615,PI3K inhibitor,PIK3CG,,,"O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1",Phase 1
GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",,,"CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1",Phase 1
GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,,,"CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1",Phase 2
GSK1562590,urotensin receptor antagonist,UTS2R,,,"CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12",Preclinical
GSK163090,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D",,,"Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1",Phase 2
GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",,,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
GSK189254,histamine receptor antagonist,,,,CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1,Phase 2
GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",,,"CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O",Preclinical
GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",,,"Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1",Phase 2
GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1",Phase 1
GSK2190915,lipoxygenase inhibitor,ALOX5AP,,,"CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1, CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1",Phase 2
GSK2193874,transient receptor potential channel antagonist,TRPV4,,,"FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1",Preclinical
GSK2194069,fatty acid synthase inhibitor,FASN,,,"O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1",Preclinical
GSK2239633A,CC chemokine receptor antagonist,,,,COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12,Preclinical
gsk2245035,toll-like receptor agonist,TLR7,pulmonary,asthma,O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N,Phase 2
GSK2256098,kinase inhibitor,,,,CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl,Phase 2
GSK2256294A,epoxide hydolase inhibitor,EPHX2,,,"CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1, CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1",Phase 1
GSK2330672,bile acid transporter inhibitor,SLC10A2,,,"CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1, CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1",Phase 2
GSK2334470,phosphoinositide dependent kinase inhibitor,"AURKA, AURKB, PDPK1",,,"CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1",Preclinical
GSK239512,histamine receptor antagonist,,,,O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1,Preclinical
GSK256066,phosphodiesterase inhibitor,PDE4A,,,"COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1",Phase 2
GSK2578215A,leucine rich repeat kinase inhibitor,LRRK2,,,"Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1",Preclinical
GSK2606414,protein kinase inhibitor,"EIF2AK3, MYLK2",,,"Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12",Preclinical
GSK2636771,PI3K inhibitor,PIK3CB,,,"Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O",Phase 2
GSK2656157,PERK inhibitor,,,,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
GSK269962,rho associated kinase inhibitor,"ROCK1, ROCK2",,,"CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N",Preclinical
GSK2801,bromodomain inhibitor,"BAZ2A, BAZ2B",,,"CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O",Preclinical
GSK2816126,histone lysine methyltransferase inhibitor,EZH2,,,"CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",Phase 1
GSK2830371,protein phosphatase inhibitor,PPM1D,,,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
GSK2837808A,lactate dehydrogenase inhibitor,LDHA,,,"COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1",Preclinical
GSK2838232,HIV gag inhibitor,,,,"CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|",Phase 2
GSK2879552,histone lysine demethylase inhibitor,KDM1A,,,"OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1",Phase 1/Phase 2
GSK2881078,androgen receptor modulator,,,,C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F,Phase 2
GSK2981278,ROR modulator,,,,CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1,Phase 1/Phase 2
GSK2982772,RIPK inhibitor,,,,CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O,Phase 2
gsk2983559 (free acid),ripk inhibitor,RIPK2,gastroenterology,inflammatory bowel disease,CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O,Phase 1
GSK3117391,HDAC inhibitor,,,,ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1,Phase 1/Phase 2
GSK3179106,RET tyrosine kinase inhibitor,,,,CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1,Phase 1
GSK3326595,protein arginine N-methyltransferase inhibitor,,,,CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1,Phase 1/Phase 2
GSK356278,phosphodiesterase inhibitor,,,,CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1,Preclinical
GSK369796,potassium channel antagonist,,,,CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,Phase 1
GSK37647,free fatty acid receptor agonist,FFAR4,,,"COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C",Preclinical
GSK3787,PPAR receptor antagonist,PPARD,,,"FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1",Preclinical
GSK429286A,rho associated kinase inhibitor,ROCK1,,,"CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|",Preclinical
GSK461364,PLK inhibitor,PLK1,,,"C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F",Phase 1
GSK503,histone lysine methyltransferase inhibitor,EZH2,,,"CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",Preclinical
GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",,,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
GSK656,leucyl-tRNA synthetase inhibitor,,,,NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO,Preclinical
GSK690693,AKT inhibitor,"AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX",,,"CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N",Phase 1
GSK9027,glucocorticoid receptor agonist,NR3C1,,,"Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F",Preclinical
GSK923295,centromere associated protein inhibitor,CENPE,,,"CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1",Phase 1
GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",,,"c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12",Preclinical
GTS21,cholinergic receptor agonist,CHRNA7,,,"COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|",Phase 1/Phase 2
guacetisal,immunosuppressant,,pulmonary,cough suppressant,"COc1ccccc1OC(=O)c1ccccc1OC(C)=O, COc1ccccc1OC(=O)c1ccccc1OC(C)=O",Launched
guadecitabine,DNA methyltransferase inhibitor,,,,Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1,Phase 3
guaiacol,local anesthetic,CA2,pulmonary,cough suppressant,"COc1ccccc1O, COc1ccccc1O",Launched
guaifenesin,expectorant,,pulmonary,cough suppressant,"COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|",Launched
guanaben-acetate,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl",Launched
guanadrel,adrenergic inhibitor,,cardiology,hypertension,"NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|",Launched
guancydine,antihypertensive agent,,,,CCC(C)(C)NC(=N)NC#N,Preclinical
guanethidine,adrenergic inhibitor,SLC6A2,cardiology,hypertension,"NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1",Launched
guanfacine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl",Launched
guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N, NC(N)=N",Launched
guanidinoethyldisulfide-bicarbonate,nitric oxide synthase inhibitor,NOS2,,,NC(=N)NCCSSCCNC(N)=N,Phase 2
guanidinopropionic-acid,creatine kinase inhibitor,CKM,,,NC(=N)NCCC(O)=O,Phase 2
guanosine,,PNP,,,Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,Preclinical
Gue-1654,oxoeicosanoid receptor modulator,OXER1,,,"CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1",Preclinical
guggulsterone,"estrogen receptor agonist, fxr antagonist, progesterone receptor agonist",,,,C\C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|,Launched
gusacitinib,jak inhibitor,"CLDN23, IL13, IL36G, JAK1, SYK",dermatology,dermatitis,OC1CCN(CC1)c2ccc(Nc3nc(nc4C=NNC(=O)c34)N5CCC(CC#N)CC5)cc2,Phase 2
guvacine,GABA uptake inhibitor,"SLC6A1, SLC6A11, SLC6A12, SLC6A13",,,"OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|",Preclinical
GW-0742,PPAR receptor agonist,PPARD,,,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F",Preclinical
GW-1100,G protein-coupled receptor agonist,FFAR1,,,CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1,Preclinical
GW-1929,PPAR receptor agonist,PPARG,,,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,Preclinical
GW-2580,cFMS kinase inhibitor,CSF1R,,,"COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1",Preclinical
GW-311616,"elastase inhibitor, leukocyte elastase inhibitor",ELANE,,,"CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O",Phase 1
GW-3965,LXR agonist,"NR1H2, NR1H3",,,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
GW-405833,cannabinoid receptor agonist,CNR2,,,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
GW-4064,FXR agonist,NR1H4,,,"CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl",Preclinical
GW-438014A,neuropeptide receptor antagonist,NPY5R,,,"O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1",Preclinical
GW-441756,growth factor receptor inhibitor,NTRK1,,,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
GW-501516,PPAR receptor agonist,"PPARA, PPARD",,,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
GW-5074,"leucine rich repeat kinase inhibitor, RAF inhibitor","NTRK1, RAF1",,,"Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br",Phase 1/Phase 2
GW-542573X,calcium channel activator,KCNN1,,,"COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C",Preclinical
GW-583340,EGFR inhibitor,"EGFR, ERBB2",,,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
GW-627368,prostanoid receptor antagonist,PTGER4,,,"CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1",Preclinical
GW-6471,PPAR receptor antagonist,PPARA,,,"CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F",Preclinical
GW-7647,PPAR receptor agonist,PPARA,,,"CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O",Preclinical
GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",,,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
GW-803430,melanin inhibitor,"KCNH2, MCHR1",,,"COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1",Phase 1
GW-842166,cannabinoid receptor agonist,CNR2,,,"FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1",Phase 2
GW-843682X,PLK inhibitor,"PLK1, PLK3",,,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
GW-9508,"free fatty acid receptor agonist, G protein-coupled receptor agonist","FFAR1, FFAR4",,,"OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1",Preclinical
GW-9662,PPAR receptor antagonist,"NCOA2, PPARG, RXRA",,,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1",Preclinical
GW274150,nitric oxide synthase inhibitor,,,,CC(=N)NCCSCC[C@H](N)C(O)=O,Phase 2
gw7604,selective estrogen receptor destabilizer,ESR1,oncology,breast cancer,O=C(O)/C=C/C1=CC=C(/C(C2=CC=C(O)C=C2)=C(C3=CC=CC=C3)/CC)C=C1,Preclinical
GYKI-52466,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,"CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|",Preclinical
gynostemma-extract,calcium channel modulator,,,,"CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",Phase 2
GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,"CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1",Preclinical
G007-LK,tankyrase inhibitor,"TNKS, TNKS2",,,"CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl, CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl",Preclinical
h-ile-pro-pro-oh (hydrochloride),angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,O=C(N1[C@@H](CCC1)C(N2[C@@H](CCC2)C(O)=O)=O)[C@H]([C@@H](C)CC)N.Cl,
h-val-pro-pro-oh (tfa),angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,N[C@@H](C(C)C)C(N1CCC[C@H]1C(N2CCC[C@H]2C(O)=O)=O)=O.OC(C(F)(F)F)=O,
H-151,STING antagonist,,,,CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1,Preclinical
H-89,PKA inhibitor,"GSG2, PKIA, PRKACA",,,"Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1",Preclinical
HA-1004,calcium channel blocker,,,,"NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12",Phase 2
HA-130,autotaxin inhibitor,ENPP2,,,"OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1",Preclinical
HA-966-(R)-(+),glutamate receptor agonist,GRIA1,,,"N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O",Preclinical
HA-966-(S)-(-),glutamate receptor antagonist,GRIA1,,,"N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O",Preclinical
halazone,,,infectious disease,disinfectant,"OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl",Launched
halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl",Launched
halobetasol propionate,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|",Launched
halofantrine,antimalarial agent,KCNN4,infectious disease,malaria,"CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|, CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|",Launched
halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,"O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O",Launched
halopemide,phospholipase inhibitor,"PLD1, PLD2",,,"Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O",Phase 2
haloperidol,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1",neurology/psychiatry,"schizophrenia, Tourette's disorder","OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1",Launched
haloperidol-decanoate,psychoactive drug,"DRD2, DRD3, DRD4, HTR2A",neurology/psychiatry,schizophrenia,"CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1",Launched
haloprogin,other antifungal,,infectious disease,tinea pedis,"Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl",Launched
halothane,glutamate receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9",neurology/psychiatry,general anaesthetic,"FC(F)(F)[C@@H](Cl)Br |&1:4,r|, FC(F)(F)[C@@H](Cl)Br |&1:4,r|",Launched
harmane,monoamine oxidase inhibitor,"MAOA, MAOB",,,Cc1nccc2c3ccccc3[nH]c12,Preclinical
harringtonine,protein synthesis inhibitor,,,,"[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|, [H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|",Phase 3
ha14-1,bcl inhibitor,BCL2,Oncology,acute myeloid leukemia (aml),CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC,Preclinical
HA14-1,BCL inhibitor,BCL2,,,"CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|",Preclinical
HBED,chelating agent,,,,OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O,Phase 3
HC-030031,TRPA1 channel blocker,TRPA1,,,"CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1",Phase 1
HC-067047,transient receptor potential channel antagonist,TRPV4,,,"Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F",Preclinical
HC-070,transient receptor potential channel antagonist,,,,Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O,Preclinical
heclin,ubiquitin ligase inhibitor,"NEDD4, SMURF2, WWP1",,,"CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1",Preclinical
HEMADO,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1",Preclinical
hematoporphyrin,,,neurology/psychiatry,"depression, psychosis","C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|, C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|, C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|",Launched
hematoporphyrin (dihydrochloride),,,,,CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O,
hematoxylin,,,,,"Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O",Preclinical
hemin,"heme oxygenase activators, enzyme inducer, enzyme inducer, heme oxygenase activators","HMOX1, HMOX2","Neurology, hematology, cardiology, hematology, cardiology, Neurology","multiple sclerosis, acute intermittent porphyria (aip), hypertension, ventricular tachycardia (vt), acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT), multiple sclerosis","CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C",Phase 2
hemomex-s,,PPARG,,,"CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C",Launched
heparin (sodium salt),thrombin inhibitor,,,,CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O,Withdrawn
hepsulfam,DNA cross-linking,,,,NS(=O)(=O)OCCCCCCCOS(N)(=O)=O,Preclinical
heptaminol,vasoconstrictor,,cardiology,hypotension,"C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|",Launched
HER2-Inhibitor-1,EGFR inhibitor,,,,"Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1, Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1",Preclinical
hesperadin,Aurora kinase inhibitor,AURKB,,,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1",Preclinical
hesperetin,ACAT inhibitor,"DGAT1, MTTP, SOAT1, SOAT2",,,"COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1",Launched
hesperidin,flavanone glycoside,"AURKB, CACNA1B",,,"COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1",Launched
hetacillin,"penicillin binding protein inhibitor, bacterial cell wall synthesis inhibitor",,"obstetrics/gynecology, Infectious disease","mastitis, gram-positive bacterial infections","CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O",Withdrawn
hetacillin potassium,"bacterial cell wall synthesis inhibitor, penicillin binding protein inhibitor",,"Infectious disease, obstetrics/gynecology","gram-positive bacterial infections, mastitis",CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O,Withdrawn
hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,"Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl",Launched
hexafluronium bromide,acetylcholinesterase inhibitor,BCHE,neurology/psychiatry,muscle relaxant,[Br-].[Br-].c1cccc3c1c2c(cccc2)C3[N+](CCCCCC[N+](C6c4ccccc4c5ccccc56)(C)C)(C)C,Withdrawn
hexamethonium,cholinergic receptor antagonist,"CHRNA2, CHRNA3, CHRNA4, CHRNA6",,,"C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C",Preclinical
hexamethylenebisacetamide,"AKT inhibitor, differentiation inducer, NFKB pathway inhibitor",AKT1,,,"CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O",Phase 2
hexaminolevulinate,,,radiology,diagnostic agent,"CCCCCCOC(=O)CCC(=O)CN, CCCCCCOC(=O)CCC(=O)CN, CCCCCCOC(=O)CCC(=O)CN",Launched
hexasodium-phytate,,,,,"OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O, OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O",Phase 2
hexestrol,synthetic estrogen,"AKR1C1, ESR1, ESR2",endocrinology,hypoestrogenism,"CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1 |&1:2,&2:3,r|",Launched
hexetidine,local anesthetic,,"otolaryngology, infectious disease, dental, gastroenterology","pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis","CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|",Launched
hexonic-acid,,,,,"OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|, OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|",Preclinical
hexoprenaline,adrenergic receptor agonist,ADRB2,pulmonary,asthma,"O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|",Launched
hexylcaine,sodium channel blocker,SCN5A,neurology/psychiatry,local anesthetic,"C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|, C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|",Launched
hexylene-glycol,,"AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP",,,"C[C@@H](O)CC(C)(C)O |&1:1,r|, C[C@@H](O)CC(C)(C)O |&1:1,r|",Preclinical
hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic","CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O",Launched
higenamine,adrenergic receptor agonist,ADRB2,,,"Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|",Phase 1
hippuric-acid,,,,,OC(=O)CNC(=O)c1ccccc1,Preclinical
histamine,histamine receptor agonist,"HRH1, HRH2, HRH3, HRH4",allergy,allergic rhinitis,"NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1",Launched
HJC-0350,GTPase inhibitor,RAPGEF4,,,"Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C",Preclinical
HKI-357,EGFR inhibitor,EGFR,,,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",Phase 1
HLCL-61,protein arginine N-methyltransferase inhibitor,PRMT5,,,"CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12",Preclinical
HM-30181,P glycoprotein inhibitor,,,,COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC,Phase 1
hmn-176,plk inhibitor,"NFYA, PLK1",oncology,breast cancer,O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2/C=C/C3=CC=N(C=C3)=O)=O,Phase 1
HMN-214,PLK inhibitor,PLK1,,,"COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1, COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1",Phase 1
HOKU-81,bronchodilator,,,,CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|,Preclinical
homatropine,acetylcholine receptor antagonist,CHRM1,ophthalmology,"uveal tract inflammation, pupil dilation","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",Launched
homatropine methylbromide,acetylcholine receptor antagonist,,ophthalmology,uveal tract inflammation,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,Launched
homatropine-methylbromide,acetylcholine receptor antagonist,CHRM5,ophthalmology,uveal tract inflammation,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|",Launched
homidium,,,,,"CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",Preclinical
homochlorcyclizine,antihistamine,HRH1,allergy,allergic rhinitis,,Launched
homochlorcyclizine 2hcl,antihistamine,,allergy,allergic rhinitis,CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|,Launched
homochlorcyclizine(brd-a22769835),antihistamine,,allergy,allergic rhinitis,CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|,Launched
homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),"COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|",Launched
homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O",Preclinical
homosalate,HSP inducer,,,,"C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|",Preclinical
homoveratrylamine,monoamine oxidase inhibitor,,,,"COc1ccc(CCN)cc1OC, COc1ccc(CCN)cc1OC",Preclinical
honokiol,AKT inhibitor,"ALOX5, PTGS1, PTGS2",,,"Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O",Phase 3
hordenine,,,,,"CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1",Preclinical
HP-228,nitric oxide synthase inhibitor,,,,CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O,Preclinical
hPGDS-IN-1,prostaglandin inhibitor,,,,CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1,Preclinical
HPPH,photosensitizing agent,,,,CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|,Phase 2
HQK-1001,,,,,"CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O",Phase 2
HSR6071,antiallergic agent,,,,O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1,Preclinical
HT-2157,galanin receptor 3 antagonist,,,,FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1,Phase 1/Phase 2
HTH-01-015,protein kinase inhibitor,NUAK1,,,"CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12",Preclinical
HTHQ,antioxidant,,,,CCCCCCOc1cc(C)c(O)c(C)c1C,Preclinical
HTMT,histamine receptor agonist,HRH4,,,"C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|",Preclinical
huperzine-A,acetylcholinesterase inhibitor,ACHE,,,"C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|",Phase 2
hyaluronic-acid,,"C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN","rheumatology, urology","osteoarthritis, interstitial cystitis (IC)",CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O,Launched
hycanthone,RNA synthesis inhibitor,,infectious disease,schistosomiasis,"CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12, CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12, CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12",Launched
hydralazine,"vasodilator, myeloperoxidase inhibitor",MPO,cardiology,hypertension,"N\N=C1/N=NCc2ccccc12 |c:3|, NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, N\N=c1/[nH]ncc2ccccc12, N\N=c1/[nH]ncc2ccccc12",Launched
"hydrastine-(1R,9S)",tyrosine hydroxylase inhibitor,,,,"COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12",Preclinical
hydrastinine,hemostatic agent,,,,C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|,Preclinical
hydrochlorothiazide,thiazide diuretic,"CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3",cardiology,"hypertension, congestive heart failure","NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl",Launched
hydrocortisone,glucocorticoid receptor agonist,"ANXA1, NOS2, NR3C1, NR3C2","dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|",Launched
hydrocortisone acetate,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
hydrocortisone buteprate,glucocorticoid receptor modulator,"ANXA1, NR3C1",dermatology,dermatosis,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC,Launched
hydrocortisone hemisuccinate,,,,,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Phase 2/Phase 3
hydrocortisone valerate,glucocorticoid receptor agonist,,dermatology,corticosteroid-responsive dermatoses,CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO,Launched
hydrocortisone-acetate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|,Launched
hydrocortisone-butyrate,glucocorticoid receptor agonist,NR3C1,dermatology,"corticosteroid-responsive dermatoses, eczema","CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|",Launched
hydrocortisone-hemisuccinate,,,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|,Phase 2/Phase 3
hydrocortisone-phosphate,,,"pulmonary, gastroenterology, hematologic malignancy, ophthalmology","asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis","C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|, C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|",Launched
hydrocortisone-valerate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,"ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3","cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension","NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F",Launched
hydroquinidine,antiarrhythmic,,cardiology,cardiac arrythmia,"CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12, CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12, CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12",Launched
hydroquinone,melanin inhibitor,TYR,dermatology,dyschromia,"Oc1ccc(O)cc1, Oc1ccc(O)cc1",Launched
hydroxocobalamin,vitamin B,,,,"[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r,t:4,7,9,11,13,16|",Launched
hydroxyamphetamine,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis,"C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|",Launched
hydroxychloroquine,antimalarial agent,"TLR7, TLR9",infectious disease,malaria,"CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12",Launched
hydroxychloroquine sulfate,angiotensin converting enzyme inhibitor,ACE2,Infectious disease,human immunodeficiency virus (hiv-1),"CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:9,r|",Launched
hydroxyfasudil,rho associated kinase inhibitor,"PKIA, PRKACA, ROCK1",,,"O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1",Preclinical
hydroxyprogesterone,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth,"CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|",Launched
hydroxyprogesterone caproate,progesterone receptor agonist,,obstetrics/gynecology,spontaneous preterm birth,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,Launched
hydroxyprogesterone-acetate,progesterone receptor agonist,PGR,,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|,Launched
hydroxypropyl-beta-cyclodextrin,,,,,"C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|",Phase 2/Phase 3
hydroxysafflor-yellow-A,antitumor agent,,,,"[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|",Preclinical
hydroxystilbamidine,,,,,NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1,Launched
"hydroxytacrine-maleate-(R,S)",cholinesterase inhibitor,ACHE,,,Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|,Preclinical
hydroxytoluic-acid,,,,,"Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O",Preclinical
hydroxytyrosol,lipoxygenase inhibitor,ALOX5,oncology,breast cancer,OC1=CC=C(CCO)C=C1O,Phase 2/Phase 3
hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
hydroxyzine,antihistamine,HRH1,"neurology/psychiatry, allergy, dermatology","anxiety, urticaria, itching, dermatosis","OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|",Launched
hydroxyzine pamoate,antihistamine,,"neurology/psychiatry, allergy, dermatology","anxiety, urticaria, itching, dermatosis",OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,Launched
hygromycin-B,polypeptide synthesis inhibitor,,,,"CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|",Preclinical
hymecromone,monoamine oxidase inhibitor,"MAOA, MAOB",,,"Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12",Phase 2
hyodeoxycholic-acid,atherosclerosis formation inhibitor,,,,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Phase 1
hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
hypericin,tyrosine kinase inhibitor,,,,"Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O",Phase 3
hyperin,aldose reductase inhibitor,"ACE, AKR1B1",,,"OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|",Preclinical
hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",,,CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C,Phase 1
hypoxanthine,PARP inhibitor,PNP,,,"O=c1nc[nH]c2nc[nH]c12, O=c1nc[nH]c2nc[nH]c12",Preclinical
H2L-5765834,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",,,"OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1",Preclinical
h3b-6527,fgfr inhibitor,FGFR4,oncology,hepatocellular carcinoma (hcc),CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)c(NC(=O)C=C)c1,Phase 1
I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,"CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|",Phase 2
I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
I-BRD9,bromodomain inhibitor,BRD9,,,"CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1",Preclinical
I-BZA,,,,,"CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1",Phase 2
I-BZA2,,,,,"CCN(CC)CCNC(=O)c1ccccc1I, CCN(CC)CCNC(=O)c1ccccc1I",Phase 3
I-CBP-112,bromodomain inhibitor,"CREBBP, EP300",,,"CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1",Preclinical
IACS-10759,mitochondrial complex I inhibitor,,,,Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Preclinical
IB-MECA,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12",Phase 3
ibandronate,bone resorption inhibitor,FDPS,orthopedics,osteoporosis,"CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
IBC-293,hydroxycarboxylic acid receptor agonist,HCAR3,,,"CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O",Preclinical
iberdomide,cereblon modulator,,,,O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O,Preclinical
ibiglustat,glucosylceramidase inhibitor,,,,CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1,Preclinical
IBMX,phosphodiesterase inhibitor,"ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A",,,"CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O",Preclinical
ibotenic-acid,glutamate receptor agonist,GRIN1,,,"N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|",Preclinical
ibrolipim,lipoprotein lipase activator,LPL,,,"CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC",Phase 2
ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
ibudilast,"leukotriene receptor antagonist, phosphodiesterase inhibitor","IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","pulmonary, neurology/psychiatry","asthma, stroke","CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C",Launched
ibuprofen,cyclooxygenase inhibitor,,"neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental","headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache","CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|",Launched
ibuprofen-(S),cyclooxygenase inhibitor,"ASIC1, PTGS1, PTGS2, SLC5A8",neurology/psychiatry,pain relief,"CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O",Launched
ibuprofen-lysine,cyclooxygenase inhibitor,,cardiology,patent ductus arteriosus (PDA),"NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|",Launched
ibuprofen-piconol,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|",Launched
ibuproxam,"cyclooxygenase inhibitor, prostaglandin inhibitor",ALOX5,"endocrinology, rheumatology, neurology/psychiatry","fever, joint inflammation, pain relief",CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|,Launched
ibutamoren,growth hormone secretagogue receptor agonist,"GHR, GHSR",,,"CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1",Phase 2
ibutilide,potassium channel blocker,"CACNA1C, KCNH2",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|",Launched
ic-87114,pi3k inhibitor,"PIK3C2B, PIK3CD, PIK3CG",hematologic malignancy,acute myeloid leukemia (aml),Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc23)nc2cccc(C)c2c1=O,Preclinical
ICA-069673,voltage-gated potassium channel activator,"KCNQ2, KCNQ3",,,"Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1",Preclinical
ICA-110381,voltage-gated potassium channel activator,KCNQ2,,,"Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1",Preclinical
ICA-121431,sodium channel blocker,"SCN1A, SCN3A",,,"O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1",Preclinical
icariin,phosphodiesterase inhibitor,PDE5A,,,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",Phase 3
icaritin,PPAR receptor antagonist,PDE5A,,,"COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O",Phase 3
icatibant-acetate,bradykinin receptor antagonist,BDKRB2,cardiology,angioedema,"N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O",Launched
ICG-001,beta-catenin inhibitor,CTNNB1,,,Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
"ICI-118,551",adrenergic receptor antagonist,"ADRB2, ADRB3",,,"CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12",Phase 2
ICI-162846,histamine receptor antagonist,HRH2,,,"NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1",Phase 1
ICI-169369,serotonin receptor antagonist,,,,CN(C)CCSc1nc2ccccc2cc1-c1ccccc1,Phase 2
"ICI-185,282",thromboxane receptor antagonist,,,,"OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F",Phase 1
ICI-192605,thromboxane receptor antagonist,TBXA2R,,,"OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl",Phase 2
ICI-199441,opioid receptor agonist,"CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R",,,"CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1",Preclinical
"ICI-215,001",adrenergic receptor agonist,ADRB3,,,O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,Preclinical
ICI-63197,phosphodiesterase inhibitor,,,,"CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O",Preclinical
ICI-89406,adrenergic receptor antagonist,"ADRB1, ADRB2",,,"O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|",Phase 1
icilin,TRPV agonist,"TRPA1, TRPM8",,,"Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|, Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|",Phase 1
iclaprim,dihydrofolate reductase inhibitor,,,,"COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|",Phase 3
icomucret,mucin production enhancer,LTB4R2,,,CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O,Phase 3
icosapent,platelet aggregation inhibitor,"ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1",endocrinology,hypertriglyceridemia,"CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",Launched
icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1",Launched
iCRT-14,"beta catenin inhibitor, WNT signaling inhibitor","CTNNB1, TCF4",,,"Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1",Preclinical
IC261,casein kinase inhibitor,"CSNK1A1, CSNK1D, CSNK1E, CSNK1G2",,,"COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1",Preclinical
ID-1101,insulin sensitizer,INS,,,"C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O",Phase 1
ID-8,,,,,"COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12",Preclinical
idalopirdine,serotonin receptor antagonist,HTR6,,,"FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1",Phase 3
idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
idasanutlin,MDM inhibitor,"MDM2, TP53",,,"COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O",Phase 3
idazoxan,adrenergic receptor antagonist,"ADRA2A, PTGS2",,,"C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|",Phase 3
idebenone,calcium channel modulator,,"neurology/psychiatry, ophthalmology","Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)","COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|",Launched
idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1",Launched
IDF-11774,hypoxia inducible factor inhibitor,,,,CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2,Preclinical
IDH-305,isocitrate dehydrogenase inhibitor,,,,C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1,Phase 2
idoxuridine,"DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor",,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
ido1-in-5,"indoleamine 2,3-dioxygenase inhibitor",IDO1,oncology,renal cell carcinoma (rcc),FC1=CC=C(C(N[C@H](C)C2=CC=C(N(C(C3CCOCC3)=O)CC4)C4=C2)=O)C=C1,Phase 1
IDO5L,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,"Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1",Preclinical
IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,"C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|",Preclinical
idramantone,,,,,"[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|",Preclinical
idronoxil,XIAP inhibitor,"ENOX2, SPHK1",,,"Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|",Phase 3
IEM1460,glutamate receptor antagonist,GRIA2,,,"C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
IEM1754,glutamate receptor antagonist,GRIA1,,,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
ifenprodil,"adrenergic receptor antagonist, glutamate receptor antagonist",GRIN2B,,,"C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|",Launched
ifenprodil hemitartrate,"adrenergic receptor antagonist, glutamate receptor antagonist",,,,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,Launched
ifenprodil tartrate,glutamate receptor antagonist,"GIRK, GRIN2B, NR1A, NR2B",Pulmonology,acute resperatory distress syndrome,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,Launched
ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|",Launched
igmesine,sigma receptor agonist,SIGMAR1,,,"CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|",Phase 2
iguratimod,"cyclooxygenase inhibitor, NFkB pathway inhibitor",PTGS2,rheumatology,rheumatoid arthritis,"CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1, CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1",Launched
IKK-16,IKK inhibitor,IKBKB,,,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
IKK-2-inhibitor,"IKK inhibitor, SYK inhibitor",IKBKB,,,"NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1",Preclinical
IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,,,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
ilaprazole,proton pump inhibitor,,gastroenterology,gastroesophageal reflux disease (GERD),"COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8,r|",Launched
ilepcimide,anticonvulsant,,,,"O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1",Phase 3
ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",,,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
iloperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7",neurology/psychiatry,schizophrenia,"COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O, COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O",Launched
iloprost,"platelet aggregation inhibitor, prostanoid receptor agonist","PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R",pulmonary,pulmonary arterial hypertension (PAH),"CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|, CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|",Launched
ilorasertib,aurora kinase inhibitor,"AURKC, KDR, VEGFA",hematologic malignancy,chronic myelomonocytic leukemia (cmmol),Nc1ncc(c2cnn(CCO)c2)c3scc(c4ccc(NC(=O)Nc5cccc(F)c5)cc4)c13,Phase 3
imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
Imazodan,phosphodiesterase inhibitor,,,,O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|,Phase 1
imeglimin,gluconeogenesis inhibitor,,,,"C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|",Phase 2
imepitoin,gaba receptor agonist,GABRA2,neurology/psychiatry,epilepsy,C1COCCN1C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl,Launched
imetit,histamine receptor agonist,"HRH3, HRH4",,,"NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1",Preclinical
imexon,"apoptosis stimulant, ribonucleotide reductase inhibitor",,,,"NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|",Phase 2
imidacloprid,acetylcholine receptor antagonist,,,,"[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1, [O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1",Launched
imidafenacin,acetylcholine receptor antagonist,"CHRM1, CHRM3",neurology/psychiatry,spasms,"Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1",Launched
imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O",Launched
imidapril hcl,angiotensin converting enzyme inhibitor,,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
imidazoacridinone,anticancer agent,,,,CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31,Preclinical
imidurea,other antibiotic,,,,"OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|",Preclinical
imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",,,"CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|",Phase 1
imipenem,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis","C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|",Launched
imipramine,"norepinephrine reputake inhibitor, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4","neurology/psychiatry, urology","depression, nocturnal enuresis","CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12",Launched
imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
imirestat,aldose reductase inhibitor,,,,Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1,Preclinical
imisopasem-manganese,superoxide dismutase mimetic,,,,[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3,Preclinical
immepip,histamine receptor agonist,"HRH3, HRH4",,,"C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1",Preclinical
immethridine,histamine receptor agonist,HRH3,,,"C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1",Phase 1
impentamine,histamine receptor antagonist,HRH3,,,"NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1",Preclinical
imrecoxib,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,CCCN1CC(=C(C1=O)c1ccc(C)cc1)c1ccc(cc1)S(C)(=O)=O |c:5|,Phase 1
IMREG-1,,,,,"N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O, N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O",Phase 3
im156,ampk activator,"NDUFS1, PRKAA2",oncology,breast cancer,NC(Nc1ccc(OC(F)(F)F)cc1)=NC(=N)N1CCCC1.CC(=O)O,Phase 1
inarigivir,antiviral,,,,"CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|",Phase 2
inarigivir-soproxil,antiviral,,,,"[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|",Phase 2
INC-280,c-Met inhibitor,MET,,,"CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1",Phase 3
INCA-6,calcineurin inhibitor,NFATC1,,,"O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|",Preclinical
INCB-003284,CC chemokine receptor antagonist,,,,"COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",Phase 2
INCB-057643,bromodomain inhibitor,,,,CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O,Phase 1/Phase 2
INCB-3284,CC chemokine receptor antagonist,CCR2,,,"COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",Phase 2
incyclinide,matrix metalloprotease inhibitor,,,,"[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|",Phase 2
indacaterol,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,chronic obstructive pulmonary disease (COPD),"CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12",Launched
indalpine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,,,"C(Cc1c[nH]c2ccccc12)C1CCNCC1, C(Cc1c[nH]c2ccccc12)C1CCNCC1",Withdrawn
indapamide,thiazide diuretic,"CA2, HTR3A, KCNQ1",cardiology,"hypertension, congestive heart failure","C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|",Launched
indatraline,norepinephrine transporter inhibitor,"MAOA, MAOB",,,"CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1",Preclinical
indeglitazar,PPAR receptor agonist,"NCOA1, PPARA, PPARD, PPARG",,,COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12,Phase 2
indeloxazine,"norepinephrine reuptake inhibitor, serotonin reuptake inhibitor",,,,"C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|",Withdrawn
indibulin,tubulin polymerization inhibitor,,,,"Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1",Phase 1/Phase 2
indinavir,HIV protease inhibitor,"CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),"CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12",Launched
indiplon,benzodiazepine receptor agonist,GABRA1,,,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",,,"O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O",Phase 2/Phase 3
indirubin-3-monoxime,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B",,,"O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12",Preclinical
indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",,,"NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12",Phase 2
indium(III)-isopropoxide,,,,,[In].CC(C)O.CC(C)O.CC(C)O,Preclinical
indium-tri(2-propanolate),,,,,CC(C)O[In](OC(C)C)OC(C)C,Preclinical
indobufen,"cyclooxygenase inhibitor, platelet aggregation inhibitor","PTGS1, PTGS2",hematology,thrombosis,"CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|",Launched
indocyanine-green,contrast agent,SLCO1B1,cardiology,vascular imaging agent,"CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|",Launched
indole-3-carbinol,"aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor",AHR,,,"OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12",Phase 2/Phase 3
indole-3-pyrubate,melatonin receptor agonist,,,,OC(=O)C(O)=Cc1c[nH]c2ccccc12,Phase 2
indomethacin,cyclooxygenase inhibitor,"GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1","rheumatology, orthopedics","rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1",Launched
indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",,,"C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|",Withdrawn
indoramin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1",Launched
indotecan,topoisomerase inhibitor,"CHEK1, PDLIM7, TOP1",oncology,soft tissue sarcoma (sts),COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCN3CCOCC3)c(=O)c2cc1OC,Phase 1
indoxacarb,,,,,COC(=O)N(C(=O)N1COC2(CC3=C(C=CC(Cl)=C3)C2=N1)C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1,Launched
indoximod,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,"Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12",Phase 2
ingenol,PKC activator,"PRKCD, PRKCE",dermatology,keratosis,"[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|",Launched
ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),"C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|",Launched
INH1,Hec1 inhibitor,NDC80,,,"Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1",Preclinical
inimur,other antifungal,,,,"CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|, CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|, CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|",Launched
iniparib,PARP inhibitor,PARP1,,,"NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O",Phase 3
inosine,neurotrophic agent,"PARP1, PNP",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O",Launched
inositol,insulin sensitizer,CDIPT,obstetrics/gynecology,polycystic ovary syndrom (PCOS),"O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O",Launched
inositol-hexanicotinate,,,"dermatology, cardiology, rheumatology, neurology/psychiatry","statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)","O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1",Launched
INS316,purinergic receptor antagonist,,,,"O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|",Phase 2
INT-747,FXR agonist,,,,"CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",Phase 3
INT-767,FXR agonist,GPBAR1,,,"CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",Phase 1
integrin-antagonist-1,integrin antagonist,"ITGAV, ITGB6",,,"Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O",Phase 1
INX-08189,antiviral,,,,[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|,Phase 2
iobenguane,antineoplastic agent,,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
iocetamic-acid,radiopaque medium,,radiology,contrast agent,"C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1,r|",Launched
iodipamide,radiopaque medium,ALB,radiology,contrast agent,"OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I, OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I",Launched
iodixanol,radiopaque medium,,radiology,contrast agent,"CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|",Launched
iodoantipyrine,,,,,Cc1c(I)c(=O)n(-c2ccccc2)n1C,Preclinical
iododexetimide,acetylcholine receptor antagonist,,,,"Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|, Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|",Phase 2
iodophenpropit,histamine receptor antagonist,"HRH3, HRH4",,,Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1,Preclinical
iodoquinol,antiseptic,,infectious disease,amebiasis,"Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12",Launched
iodoxamic acid,radiopaque medium,,radiology,contrast agent,OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C1I,Withdrawn
iofendylate,radiopaque medium,,radiology,mri contrast agent,CCOC(=O)CCCCCCCCC(C)C1=CC=C(C=C1)I,Withdrawn
iohexol,radiopaque medium,,radiology,contrast agent,"CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|",Launched
iomazenil,radiopaque medium,TSPO,neurology/psychiatry,epilepsy,CCOC(=O)c1c2n(cn1)-c3cccc(c3C(=O)N(C2)C)I,Launched
iopamidol,radiopaque medium,,radiology,contrast agent,"C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I, C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I",Launched
iopanic-acid,thyroid hormone inhibitor,,,,"CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|, CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|",Withdrawn
iopodic-acid,,,radiology,contrast agent,"CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I",Launched
iopromide,radiopaque medium,,radiology,contrast agent,"COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|",Launched
iothalamic-acid-d3,radiopaque medium,,,,CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I,Preclinical
ioversol,radiopaque medium,,radiology,contrast agent,"OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|, OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|",Launched
IOWH032,CFTR channel antagonist,CFTR,,,"Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1",Phase 2
ioxaglic-acid,radiopaque medium,,radiology,contrast agent,"CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I, CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I",Launched
ioxilan,radiopaque medium,,radiology,angiography,"CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|",Launched
IOX1,histone demethylase inhibitor,"EGLN1, KDM3A, KDM4C, KDM6B",,,"OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12",Preclinical
IOX2,hypoxia inducible factor inhibitor,"EGLN1, KDM2A, KDM5C",,,"OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O",Preclinical
IPA-3,p21 activated kinase inhibitor,PAK1,,,"Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12",Preclinical
IPAG,,,,,"Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1",Preclinical
ipidacrine,acetylcholinesterase inhibitor,ACHE,,,"Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12",Phase 3
IPI549,PI3K inhibitor,,,,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,Phase 2
ipragliflozin-L-proline,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1",Launched
ipratropium,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",pulmonary,"bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|",Launched
ipratropium bromide,acetylcholine receptor antagonist,,pulmonary,"bronchospasm, chronic obstructive pulmonary disease (copd), bronchitis, emphysema",CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1,Launched
ipriflavone,bone resorption inhibitor,,orthopedics,osteoporosis,"CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O",Launched
iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",,,"CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1",Withdrawn
ipsapirone,serotonin receptor agonist,HTR1A,,,"O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12",Phase 3
irbesartan,angiotensin receptor antagonist,"AGTR1, JUN, SLC10A1","cardiology, nephrology","hypertension, diabetic nephropathy","CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|",Launched
irganox-1010,antioxidant,,,,CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C,Preclinical
iRGD-peptide,integrin signaling activator,,,,"[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O, [H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O",Preclinical
irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
IRL-2500,endothelin receptor antagonist,EDNRB,,,"CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1",Preclinical
irosustat,steroid sulfatase inhibitor,"CA2, STS",,,"NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1, NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1",Phase 2
irsogladine,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD),"Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl",Launched
isamoltane,adrenergic receptor antagonist,"HTR1A, HTR1B",,,"CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|",Phase 1
isavuconazole,"cytochrome P450 inhibitor, fungal lanosterol demethylase inhibitor","CYP3A4, CYP51A1",Infectious disease,fungal infection,"C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1cc(F)ccc1F",Launched
isavuconazonium sulfate,lanosterol demethylase inhibitor,,infectious disease,aspergillosis,C[C@@H](c1nc(cs1)c2ccc(cc2)C#N)[C@](Cn3c[n+](cn3)C(C)OC(=O)N(C)c4c(cccn4)COC(=O)CNC)(c5cc(ccc5F)F)O,Launched
isaxonine,nerve growth factor agonist,,,,"CC(C)Nc1ncccn1, CC(C)Nc1ncccn1",Withdrawn
isbufylline,phosphodiesterase inhibitor,,,,"CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12",Phase 2
isepamicin,protein synthesis inhibitor,,infectious disease,"pneumonia, peritonitis","CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O",Launched
islatravir,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (hiv-1),"Nc1nc(F)nc2n(cnc12)[C@H]1C[C@H](O)[C@@](CO)(O1)C#C |a:11,13,15|",Phase 3
ISO-1,macrophage migration inhibiting factor inhibitor,MIF,,,"COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|",Preclinical
isobutamben,local anesthetic,,,,"CC(C)COC(=O)c1ccc(N)cc1, CC(C)COC(=O)c1ccc(N)cc1",Preclinical
isobutyramide,gene expression stimulant,"HBE1, HBG1",,,"CC(C)C(N)=O, CC(C)C(N)=O",Phase 2
isocarboxazid,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,depression,"Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1",Launched
isoconazole,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections,"Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|",Launched
isodibut,aldehyde reductase inhibitor,,,,"OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23",Phase 2
isoetharine,adrenergic receptor agonist,,pulmonary,"bronchospasm, asthma","CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|",Launched
isofloxythepin,dopamine receptor antagonist,,,,"CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|",Phase 2
isoflupredone-acetate,,NR3C1,,,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|",Preclinical
isoflurane,inhaled anaesthetic,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9",neurology/psychiatry,general anaesthetic,"FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|",Launched
isoflurophate,cholinesterase inhibitor,"ACHE, BCHE",ophthalmology,glaucoma,"CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C",Launched
isoguvacine,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",,,"OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|",Preclinical
isoleucine,,,,,"CC[C@@H](C)[C@@H](N)C(O)=O |&1:2,&2:4,r|",Launched
isoliquiritigenin,guanylate cyclase activator,GABBR1,,,"Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1, Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1",Preclinical
isometheptene-mucate,,,neurology/psychiatry,headache,"CN[C@@H](C)CCC=C(C)C |&1:2,r|",Launched
isoniazid,FABI inhibitor,"CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4",infectious disease,tuberculosis,"NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1",Launched
isopentyl-4-methoxycinnamate,,,dermatology,sunscreen lotion,"COc1ccc(\C=C\C(=O)OCCC(C)C)cc1, COc1ccc(\C=C\C(=O)OCCC(C)C)cc1",Launched
isoprenaline,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3","cardiology, pulmonary","bradycardia, heart block, asthma","CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|",Launched
isopropamide-iodide,acetylcholine receptor antagonist,"CHRM3, CHRM4",gastroenterology,"peptic ulcer disease (PUD), gastrointestinal acidosis","CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C",Launched
isopropyl-myristate,,,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
isopropyl-palmitate,cosmetic moisturizer,,dermatology,cosmetic,"CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C",Launched
isoquercitrin,antioxidant,,,,"OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2/Phase 3
"Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,",,,,,"COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|, COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|",Preclinical
isosorbide,nitric oxide stimulant,,cardiology,"angina pectoris, coronary artery disease (CAD)","O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12",Launched
isosorbide-dinitrate,nitric oxide stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1",cardiology,"angina pectoris, coronary artery disease (CAD)","[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O",Launched
isosorbide-mononitrate,nitric oxide stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,"angina pectoris, coronary artery disease (CAD)","O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O",Launched
isosteviol,,,,,"C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|, C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|",Phase 2
isotiquimide,,,,,"Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|, Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|",Phase 1
isotretinoin,retinoid receptor agonist,"RARA, RARB, RARG",dermatology,acne vulgaris (AV),"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|",Launched
isovaleramide,alcohol dehydrogenase inhibitor,,,,"CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O",Phase 2
isoxepac,anti-inflammatory agent,,,,"OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1, OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1",Phase 2
isoxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|",Withdrawn
isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease","C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|, C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|",Launched
isoxsuprine hydrochloride,adrenergic receptor agonist,,"rheumatology, cardiology","raynaud's disease, arteriosclerosis, buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
ispinesib,kinesin inhibitor,KIF11,,,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
isradipine,calcium channel blocker,"CACNA1D, CACNA1F, CACNA2D1",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|",Launched
ISRIB,"eukaryotic translation initiation factor inhibitor, PERK inhibitor","EIF2A, EIF2AK3",,,"Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|",Preclinical
istaroxime,ATPase inhibitor,ATP1A1,,,"C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O",Phase 2
istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
isuzinaxib,nadph oxidase inhibitor,"NOX1, NOX4",nephrology,diabetic nephropathy,CCCc1c([nH]n(-c2ccccn2)c1=O)-c1ccccc1,Preclinical
ISX-9,neural stem cell inducer,NEUROD1,,,"O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1",Preclinical
itacitinib,JAK inhibitor,JAK1,,,"Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12",Phase 3
ITD-1,TGF beta receptor inhibitor,TGFBR2,,,"CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|",Preclinical
ITE,aryl hydrocarbon receptor agonist,AHR,,,"COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12",Preclinical
ITI214,phosphodiesterase inhibitor,PDE1A,,,"CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|",Phase 1/Phase 2
itopride,dopamine receptor antagonist,"CHRM3, DRD2","gastroenterology, neurology/psychiatry","dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia","COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1",Launched
itraconazole,cytochrome P450 inhibitor,,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis, onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26,29,&2:2|, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
ITX3,GEF inhibitor,TRIO,,,"Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1",Preclinical
ITX5061,SR-BI inhibitor,,,,COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C,Phase 1
IT1t,CC chemokine receptor antagonist,CXCR4,,,"CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|",Preclinical
IU1,ubiquitin C-terminal hydrolase inhibitor,USP14,,,"Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1",Preclinical
ivabradine,"HCN channel blocker, potassium channel blocker, sodium channel blocker","HCN1, HCN3, HCN4",cardiology,angina pectoris,"COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC, COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC",Launched
ivabradine hcl,"hcn channel blocker, potassium channel blocker, sodium channel blocker",,cardiology,angina pectoris,COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC,Launched
ivacaftor,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis,"CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C",Launched
ivermectin,benzodiazepine receptor agonist,"CHRNA7, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|",Launched
ivosidenib,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),"Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N",Launched
IWP-L6,porcupine inhibitor,PORCN,,,"O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1",Preclinical
ixabepilone,microtubule stabilizing agent,TUBB,oncology,breast cancer,"C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",Launched
ixazomib,proteasome inhibitor,,hematologic malignancy,multiple myeloma,"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O",Launched
ixazomib-citrate,proteasome inhibitor,,hematologic malignancy,multiple myeloma,"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|",Launched
JAK3-inhibitor-V,JAK inhibitor,JAK3,,,"C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1",Preclinical
JD-5037,cannabinoid receptor antagonist,,,,CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|,Preclinical
JDTic,opioid receptor antagonist,OPRK1,,,"CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1",Phase 1
JHW-007,dopamine reuptake inhibitor,SLC6A3,,,"CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1",Preclinical
JI-101,kinase inhibitor,,,,COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12,Phase 1/Phase 2
JIB04,histone lysine demethylase inhibitor,KDM4E,,,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
JK-184,hedgehog pathway inhibitor,,,,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
JLK-6,gamma secretase inhibitor,PSEN1,,,COc1oc(=O)c2cc(N)ccc2c1Cl,Preclinical
JNJ-10191584,histamine receptor antagonist,HRH4,,,"CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1",Preclinical
JNJ-10397049,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1",Preclinical
JNJ-16259685,glutamate receptor antagonist,GRM1,,,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|",Preclinical
JNJ-1661010,FAAH inhibitor,FAAH,,,"O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1",Preclinical
JNJ-17203212,TRPV antagonist,TRPV1,,,"FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1",Preclinical
JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",,,"Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12",Phase 2
JNJ-26990990,anticonvulsant,,,,NS(=O)(=O)NCc1csc2ccccc12,Phase 2
JNJ-27141491,CC chemokine receptor antagonist,CCR2,,,"CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1",Preclinical
JNJ-37822681,dopamine receptor antagonist,DRD2,,,"Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F",Phase 2
JNJ-38877605,tyrosine kinase inhibitor,MET,,,"Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1, Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1",Phase 1
JNJ-38877618,c-Met inhibitor,,,,FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1,Phase 1
JNJ-39758979,histamine receptor antagonist,,,,CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1,Phase 2
JNJ-40411813,glutamate receptor positive allosteric modulator,GRM2,,,"CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O, CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O",Phase 2
JNJ-42041935,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,,,"OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1, OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1",Preclinical
JNJ-42165279,FAAH inhibitor,FAAH,,,"FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1",Phase 2
JNJ-47965567,purinergic receptor antagonist,P2RX7,,,"O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1",Preclinical
jnj-5207852,histamine receptor antagonist,HRH3,neurology/psychiatry,epilepsy,C(COc1ccc(CN2CCCCC2)cc1)CN1CCCCC1,Phase 2
JNJ-54175446,purinergic receptor antagonist,,,,C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F,Phase 1
JNJ-63533054,G protein-coupled receptor agonist,GPR139,,,"C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1",Preclinical
JNJ-64619178,protein arginine N-methyltransferase inhibitor,,,,Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br,Phase 1
JNJ-678,RSV fusion inhibitor,,,,CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12,Phase 1
JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",,,"Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F",Preclinical
JNJ-7777120,histamine receptor antagonist,HRH4,,,"CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1",Preclinical
josamycin,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis,"CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O, [H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36,38|",Launched
JPH203,solute carrier family member inhibitor,,,,N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O,Preclinical
JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",,,"Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|",Preclinical
JTC-801,opioid receptor antagonist,OPRL1,,,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
JTE-013,lysophospholipid receptor antagonist,"P2RY10, S1PR2",,,"CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12",Preclinical
JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",,,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
JTE-907,cannabinoid receptor inverse agonist,CNR2,,,"CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12",Phase 1
JW-55,tankyrase inhibitor,"TNKS, TNKS2",,,"COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1",Preclinical
JW-642,monoacylglycerol lipase inhibitor,MGLL,,,"FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F",Preclinical
JW-67,WNT pathway inhibitor,"APC, AXIN1, GSK3B",,,"O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12",Preclinical
JW-74,"tankyrase inhibitor, WNT signaling inhibitor","TNKS, TNKS2",,,"COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1",Preclinical
JX-401,p38 MAPK inhibitor,MAPK14,,,"COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1",Preclinical
JZL-184,monoacylglucerol lipase inhibitor,MGLL,,,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
JZL-195,"FAAH inhibitor, monoacylglycerol lipase inhibitor","FAAH, MGLL",,,"[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1",Preclinical
J147,BDNF inducer,,,,COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1,Phase 1
K-MAP,,,,,"OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|, OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|",Phase 2
K-Ras(G12C)-inhibitor-12,K-Ras inhibitor,KRAS,,,"Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C",Preclinical
K-Ras(G12C)-inhibitor-6,K-Ras inhibitor,,,,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
K-strophanthidin,ATPase inhibitor,ATP1A1,,,"C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|, C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|",Phase 2
K-247,,,,,"OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|",Phase 1
k-80003,retinoid receptor antagonist,RXRA,cardiology,atherosclerosis,CC(C)c1ccc(\C=C/2\C(=C(CC(=O)O)c3cc(F)ccc23)C)cc1,Preclinical
K-858,kinesin-like spindle protein inhibitor,KIF11,,,"CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|, CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|",Preclinical
kaempferol,"bone resorption inhibitor, estrogen-related receptor inverse agonist","AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1",,,"Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
KAF-156,antimalarial agent,,,,CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN,Preclinical
kainic-acid,kainate receptor agonist,"GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5",,,"CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O",Preclinical
kakonein,"GABA receptor antagonist, serotonin receptor antagonist",,,,"OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|",Phase 2
kanamycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",Launched
karenitecin,topoisomerase inhibitor,TOP1,,,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O,Phase 3
kartogenin,chondrocyte differentiation stimulator,FLNA,,,"OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1",Preclinical
kasugamycin,bacterial 30S ribosomal subunit inhibitor,,,,C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O,Preclinical
KB-R7943,sodium/calcium exchange inhibitor,"SLC8A1, TRPC3, TRPC5, TRPC6",,,"NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1",Preclinical
KB-SRC-4,SRC inhibitor,SRC,,,"Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1",Preclinical
kb-0742,,,,,CCC(CC)c1cc(N[C@H]2CC[C@H](N)C2)n3nccc3n1,Phase 1
kb-0742 (dihydrochloride),cdk9 inhibitor,CDK9,oncology,prostate cancer,N[C@@H]1C[C@@H](NC2=CC(C(CC)CC)=NC3=CC=NN23)CC1.[H]Cl.[H]Cl,Phase 1/Phase 2
KBG,neprilysin inhibitor,MME,,,"O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|, O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|",Phase 2
KD-023,ACAT inhibitor,"ACACA, ACACB",,,"CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O, CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O",Phase 2
KD025,rho associated kinase inhibitor,ROCK2,,,"CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1",Phase 2
kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",,,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
ketanserin,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2",cardiology,hypertension,"Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1",Launched
ketoconazole,sterol demethylase inhibitor,KCNA10,dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
ketohexokinase-inhibitor-1,kinase inhibitor,,,,[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F,Preclinical
ketoprofen,cyclooxygenase inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|",Launched
ketorolac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|",Launched
ketorolac tromethamine,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,Launched
ketotifen,"histamine receptor antagonist, histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor",HRH1,"neurology/psychiatry, pulmonary","itching, asthma","CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(=C2c3ccccc3CC(=O)c4sccc24)CC1",Launched
kevetrin,p53 activator,,,,"NC(=N)SCCCC#N, NC(=N)SCCCC#N, NC(=N)SCCCC#N",Phase 1
KF-38789,P selectin inhibitor,SELP,,,"COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|",Preclinical
KG-5,RAF inhibitor,"BRAF, FLT3, KIT, PDGFRB",,,"CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1",Preclinical
KH-CB19,CDC inhibitor,"CLK1, CLK3, DYRK1A",,,"CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C",Preclinical
khellin,vasodilator,,,,"COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12",Phase 2
KHK-IN-1,hexokinase inhibitor,KHK,,,"CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1",Preclinical
KHS-101,neural stem cell inducer,TACC3,,,"CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1",Preclinical
KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",,,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|",Preclinical
KI-20227,c-Fms inhibitor,"CSF1R, KDR, KIT, PDGFRB",,,"COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|",Preclinical
KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",,,"OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12",Phase 1
kinetin,cell division inducer,,dermatology,sunburn,"C(Nc1ncnc2nc[nH]c12)c1ccco1, C(Nc1ncnc2nc[nH]c12)c1ccco1, C(Nc1ncnc2nc[nH]c12)c1ccco1",Launched
ki16198,lipoprotein antagonist,LPA,,,"COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|",Preclinical
KL-001,proteasome inhibitor,"CRY1, CRY2",,,"CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|",Preclinical
KM-0118,anticancer agent,,,,"CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C, CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C",Phase 1
KME-4,prostaglandin inhibitor,,,,CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C,Preclinical
KML29,monoacylglucerol lipase inhibitor,MGLL,,,"OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
KN-62,"calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist","AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1",,,"CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|, CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|",Preclinical
KN-93,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,,,"COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1",Preclinical
kojic acid,nfkb pathway inhibitor,NFKB1,,,OCc1cc(=O)c(O)co1,Preclinical
Ko143,BCRP inhibitor,"ABCB1, ABCC1",,,"COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O",Preclinical
KP-1212,,,,,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|,Phase 2
KPT-185,exportin antagonist,XPO1,,,"COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1",Preclinical
KPT-276,exportin antagonist,XPO1,,,"FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1",Preclinical
KPT-9274,NAMPT inhibitor,,,,Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1,Phase 1
KR-33494,cell death inhibitor ,,,,OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1,Preclinical
KRCA-0008,ALK inihibitor,ALK,,,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O",Preclinical
KRN-633,VEGFR inhibitor,"FLT1, FLT4, KDR",,,"CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl",Preclinical
KS-176,BCRP inhibitor,ABCG2,,,"OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1",Preclinical
KT-433,uricosuric agent,,,,CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1,Phase 2
KU-0063794,mTOR inhibitor,MTOR,,,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
KU-55933,ATM kinase inhibitor,"ATM, PRKDC",,,"O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1",Preclinical
KU-60019,ATM kinase inhibitor,ATM,,,"C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1",Preclinical
kuromanin,ribosyl cyclase inhibitor,CD38,,,"OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
KU14R,imidazoline receptor antagonist,,,,"CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|",Preclinical
KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",,,"O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1",Phase 1
KW-2478,HSP inhibitor,,,,"CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC",Phase 1/Phase 2
KW-3902,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|",Phase 3
KX2-391,"SRC inhibitor, tubulin polymerization inhibitor",SRC,,,"O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1",Phase 3
kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",,,"OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1",Phase 1
KY02111,WNT pathway inhibitor,DKK1,,,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
K02288,bone morphogenic protein inhibitor,BMP1,,,"COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1",Preclinical
K145,sphingosine kinase inhibitor,SPHK2,,,"CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1",Preclinical
l(-)sorbose,phosphorylase inhibitor,,,,OCC(O)C(O)C(O)C(=O)CO,Launched
L-(+)-rhamnose-monohydrate,,,,,C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,Preclinical
L-alanine,,"AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8",,,C[C@H](N)C(O)=O,Launched
L-arginine,nitric oxide precursor,"ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4","cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology","congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold","N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O",Launched
l-arginine hcl,nitric oxide precursor,,"cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology","congestive heart failure, hypertension, coronary artery disease (cad), claudication, senile dementia, erectile dysfunction, infertility, common cold",N[C@H](CCCNC(N)=N)C(O)=O,Launched
L-ascorbyl-6-palmitate,,,,,"CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|",Preclinical
L-asparagine,,"ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3",,,N[C@@H](CC(N)=O)C(O)=O,Phase 3
L-asparagine-N-hydroxy,,,,,N[C@@H](CC(=O)NO)C(O)=O,Preclinical
L-aspartic-acid,metallic radical formation stimulant,"ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13",,,"N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O",Launched
L-citrulline,nitric oxide stimulant,"ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6","cardiology, urology","hypertension, erectile dysfunction","N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|",Launched
L-cysteine,,"CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3",rheumatology,"osteoarthritis, rheumatoid arthritis",N[C@@H](CS)C(O)=O,Launched
L-cysteinesulfinic-acid,glutamate receptor agonist,"GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2",,,"N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|",Preclinical
L-cystine,,"CTNS, SLC3A1, SLC7A11, SLC7A9",,,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,Launched
L-ergothioneine,free radical scavenger,,,,"C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O, C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O",Phase 3
L-glutamic-acid,glutamate receptor agonist,"AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT",,,"N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCC(O)=O)C(O)=O",Launched
L-glutamine,,"CTPS1, GLUL, GPRC6A, PPAT","gastroenterology, dental, neurology/psychiatry, rheumatology","diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia","N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O",Launched
L-hydroxyproline,,,,,"O[C@H]1CN[C@@H](C1)C(O)=O |&1:1,&2:4,r|",Launched
L-kynurenine,aryl hydrocarbon receptor agonist,,,,N[C@@H](CC(=O)c1ccccc1N)C(O)=O,Phase 1
L-leucine,,"BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2",,,CC(C)C[C@H](N)C(O)=O,Phase 3
L-lysine,serotonin receptor agonist,"GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4",,,NCCCC[C@H](N)C(O)=O,Phase 2
L-methionine,voltage-gated calcium channel ligand,"BHMT, BHMT2, METAP2, MTR, MTRR","pulmonary, allergy, neurology/psychiatry","asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia",CSCC[C@H](N)C(O)=O,Launched
L-mimosine,"dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor","DBH, EIF5A",,,N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|,Preclinical
L-monomethylarginine,nitric oxide synthase inhibitor,"NOS1, NOS2",,,CN[C@@H](CCCNC(N)=N)C(O)=O,Phase 3
L-NAME,nitric oxide synthase inhibitor,NOS3,,,"COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O",Phase 2/Phase 3
L-NIL,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,"CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O",Preclinical
L-phenylisopropyladenosine,,,,,C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Preclinical
L-proline,glutamate receptor agonist,"EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7",,,OC(=O)[C@@H]1CCCN1,Launched
L-quisqualic-acid,glutamate receptor agonist,"FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8",,,"N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O",Preclinical
L-theanine,glutamate receptor antagonist,,,,CCNC(=O)CC[C@H](N)C(O)=O,Launched
l-theanine,glutamate receptor antagonist,,,,CCNC(=O)CCC(N)C(O)=O,Launched
L-threonine,,"TARS, TARS2, THNSL1",,,C[C@@H](O)[C@H](N)C(O)=O,Phase 2
L-valine,,,,,"CC(C)[C@@H](N)C(O)=O, CC(C)[C@@H](N)C(O)=O",Phase 2
L-152804,neuropeptide receptor antagonist,NPY5R,,,"CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|",Preclinical
L-161982,prostanoid receptor antagonist,PTGER4,,,"CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C",Preclinical
L-165041,PPAR receptor agonist,PPARD,,,"CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O",Preclinical
L-168049,glucagon receptor antagonist,GCGR,,,"CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1",Preclinical
L-365260,CCK receptor antagonist,"CCKAR, CCKBR, KCNQ1",,,"CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|",Phase 2
"l-368,899 hydrochloride",oxytocin receptor antagonist,,,,Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,Phase 1
L-368899,oxytocin receptor antagonist,"AVPR1A, AVPR2, OXTR",,,Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,Phase 1
"L-655,708",GABA receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRG2",,,"CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21",Preclinical
L-655240,thromboxane receptor antagonist,PTGES,,,"Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12",Phase 1
L-670596,prostanoid receptor antagonist,,,,"CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|",Preclinical
L-689560,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1",Preclinical
L-690330,inositol monophosphatase inhibitor,IMPA1,,,"CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O, CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O",Preclinical
L-693403,"sigma receptor agonist, sigma receptor antagonist","DRD2, SIGMAR1",,,"C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1",Preclinical
L-694247,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D",,,"CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1",Preclinical
L-701252,glutamate receptor antagonist,GRIN1,,,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,Preclinical
L-701324,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12",Preclinical
"L-732,138",tachykinin antagonist,"TACR1, TACR2",,,"CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Preclinical
L-733060,tachykinin antagonist,TACR1,,,"FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F",Preclinical
L-741742,dopamine receptor antagonist,"DRD3, DRD4, SCN1A, SCN3A",,,"Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1",Preclinical
L-745870,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7",,,"Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1",Preclinical
L-755507,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",,,"CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1",Preclinical
L-760735,tachykinin antagonist,TACR1,,,"C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",Preclinical
L-778123,farnesyltransferase inhibitor,"FNTA, FNTB, PGGT1B",,,"Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O",Phase 1
L-798106,prostanoid receptor antagonist,PTGER3,,,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
L-838417,GABA receptor partial agonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,"Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F",Preclinical
labetalol,adrenergic receptor antagonist,"ADRA1D, ADRB1, ADRB2",cardiology,hypertension,"C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|",Launched
labetalol hydrochloride,adrenergic receptor antagonist,,cardiology,hypertension,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O,Launched
lacidipine,calcium channel blocker,CACNA1C,cardiology,hypertension,"CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|",Launched
lacitol,laxative,,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
lactulose,laxative,,gastroenterology,portal-systemic encephalopathy (PSE),"OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O",Launched
laflunimus,prostagladin inhibitor,"PTGS1, PTGS2",,,"Cc1cc(NC(=O)[C@@H](C#N)C(=O)C2CC2)ccc1C(F)(F)F |&1:7,r|",Phase 2
lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD), duodenal ulcer disease, peptic ulcer disease (pud)","O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|, O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1",Launched
lamivudine,nucleoside reverse transcriptase inhibitor,,infectious disease,"human immunodeficiency virus (hiv-1), acquired immunodeficiency syndrome (aids), hepatitis b, human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B","Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn(C2CSC(CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1",Launched
lamotrigine,"serotonin receptor antagonist, sodium channel blocker","SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, bipolar disorder","Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl",Launched
lanabecestat,beta secretase inhibitor,,,,"CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|",Phase 3
lanatoside-C,cardiac glycoside,,,,"C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|",Preclinical
landiolol,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia,"CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1",Launched
lanifibranor,PPAR receptor agonist,,,,OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1,Phase 2
lanoconazole,sterol demethylase inhibitor,,infectious disease,fungal infection,"Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7,r|",Launched
lanraplenib,protein tyrosine kinase inhibitor,"A1BG, LAT, TNK1",rheumatology,lupus,Nc1cncc(n1)c2cn3ccnc3c(Nc4ccc(cc4)N5CCN(CC5)C6COC6)n2,Phase 2
lanreotide,somatostatin receptor agonist,"SSTR2, SSTR3, SSTR5",endocrinology,acromegaly,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,Launched
lansoprazole,ATPase inhibitor,"ATP4A, ATP4B",gastroenterology,heartburn,"Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |r|",Launched
lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
lapirium chloride,cationic surfactant,,infectious disease,antiseptic,CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1,Withdrawn
lappaconite,sodium channel blocker,,,,CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O,Phase 2
lappaconite hbr,sodium channel blocker,,,,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
laquinimod,immunosuppressant,CXCL2,,,"CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1",Phase 3
larazotide-acetate,tight junction regulator,,,,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O,Phase 2
laropiprant,prostanoid receptor antagonist,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R",cardiology,cholesterol,"CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12",Launched
larotrectinib,"tropomyosin receptor kinase inhibitor, alk tyrosine kinase receptor inhibitor","NTRK1, NTRK2, NTRK3",hematologic malignancy,myeloproliferative neoplasms,"O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc2cnn3ccc(nc23)N4CCC[C@@H]4c5cc(F)ccc5F",Launched
lasalocid,bacterial permeability inducer,,infectious disease,coccidiosis,CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
lasalocid sodium,bacterial permeability inducer,,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
lasmiditan,serotonin receptor agonist,,,,CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1,Launched
lasofoxifene,selective estrogen receptor modulator (SERM),"ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, Oc1ccc2[C@H]([C@H](CCc2c1)c3ccccc3)c4ccc(OCCN5CCCC5)cc4",Phase 2
las101057,adenosine receptor antagonist,ADORA2B,pulmonary,asthma,Fc1cnccc1-c1ncc(NC(=O)C2CC2)nc1-c1cccnc1,Phase 1
latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma","CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1",Launched
latanoprostene bunod,prostanoid receptor agonist,"GUCY1A1, PTGFR",ophthalmology,intraocular pressure,C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O,Launched
latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",,,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
latrunculin-B,actin polymerization inhibitor,"ACTA1, MKL1, SPIRE2",,,"C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|",Phase 1
lauric-acid,bacterial permeability inducer,"GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4",,,"CCCCCCCCCCCC(O)=O, CCCCCCCCCCCC(O)=O",Phase 3
lauric-diethanolamide,,,,,"CCCCCCCCCCCC(=O)N(CCO)CCO, CCCCCCCCCCCC(=O)N(CCO)CCO",Preclinical
laurocapram,,,,,"CCCCCCCCCCCCN1CCCCCC1=O, CCCCCCCCCCCCN1CCCCCC1=O",Phase 3
lazabemide,monoamine oxidase inhibitor,MAOB,,,"NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1",Phase 3
lazertinib,tyrosine kinase inhibitor,,,,COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1,Phase 1/Phase 2
LB-100,protein phosphatase inhibitor,,,,"CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|",Phase 2
lb-100,protein phosphatase inhibitor,PPP5C,Neurology,depression,"CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)[C@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:15,&2:9|",Phase 2
LB42708,farnesyltransferase inhibitor,,,,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
LCL-161,XIAP inhibitor,"BIRC2, XIAP",,,"CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1",Phase 2
LCQ908,diacylglycerol O acyltransferase inhibitor,DGAT1,,,"OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|",Phase 3
LCZ696,angiotensin receptor antagonist,,cardiology,"angioedema, hypotension",,Launched
LDC1267,protein tyrosine kinase inhibitor,"AXL, MERTK, TYRO3",,,"CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C, CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C",Preclinical
LDN-209929,haspin kinase inhibitor,GSG2,,,"COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1",Preclinical
LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",,,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
LDN-27219,tissue transglutaminase inhibitor,TGM2,,,"NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1",Preclinical
LDN-57444,ubiquitin C-terminal hydrolase inhibitor,,,,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
LDN193189,bone morphogenic protein inhibitor,"ACVR1, BMPR1A",,,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
LE-135,retinoid receptor agonist,RARB,,,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|",Preclinical
ledipasvir,HCV inhibitor,,infectious disease,hepatitis C,"COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C",Launched
lefamulin,bacterial 50s ribosomal subunit inhibitor,,infectious disease,pneumonia,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C,Launched
leflunomide,"dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor","AHR, DHODH, PTK2B",rheumatology,rheumatoid arthritis,"Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
lemborexant,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1, Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1",Launched
lenacapavir,hiv capsid assembly inhibitor,,infectious disease,human immunodeficiency virus (hiv-1),CC(C)(C#Cc1ccc(c(n1)[C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn3nc(c4[C@H]5C[C@H]5C(F)(F)c34)C(F)(F)F)c6ccc(Cl)c7c(NS(=O)(=O)C)nn(CC(F)(F)F)c67)S(=O)(=O)C,Launched
lenalidomide,anticancer agent,TNF,hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)","Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|, Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|",Launched
leniolisib,PI3K inhibitor,,,,CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F,Phase 2/Phase 3
lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,"COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O",Launched
leonurine,anti-inflammatory agent,,,,COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N,Preclinical
leptomycin b,exportin antagonist,XPO1,Oncology,anticancer antibiotic,CC\C(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O |c:9|,Phase 1
LEQ506,G protein signaling inhibitor,,,,C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C,Phase 1
lercanidipine,calcium channel blocker,CACNA2D1,cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |c:4,9|",Launched
lerisetron,serotonin receptor antagonist,HTR3A,,,"C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1",Phase 3
lersivirine,non-nucleoside reverse transcriptase inhibitor,,,,"CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N, CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N",Phase 2
lesinurad,uric acid diuretic,SLC22A12,rheumatology,gout,"OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12, OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12",Launched
lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1, NTRK2, NTRK3",Oncology,acute myeloid leukemia (aml),"C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13",Phase 2/Phase 3
leteprinim,nerve growth factor agonist,,,,OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1,Phase 2
letermovir,CMV terminase inhibitor,,infectious disease,cytomegalovirus (CMV),"COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|",Launched
letosteine,mucolytic agent,,"pulmonary, infectious disease","bronchitis, pneumonia","CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9,&2:11,r|",Launched
letrazuril,antiinfective drug,,,,"Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|",Phase 1
letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
leucomethylene-blue,"nitric oxide production inhibitor, tau aggregation inhibitor",MAPT,,,CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C,Phase 3
leucovorin,folate receptor ligand,,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|",Launched
leucovorin calcium,folate receptor ligand,,oncology,osteosarcoma,Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1,Launched
leucylleucine-methyl-ester,,,,,COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C,Phase 2
leuprolide,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1",Launched
levalbuterol,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm,"CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1",Launched
levallorphan,opioid receptor antagonist,"CHRNA2, OPRM1",pulmonary,respiratory depression,"Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1",Launched
levamisole,acetylcholine receptor agonist,ALPL,,,"C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|",Withdrawn
levamlodipine,calcium channel blocker,,cardiology,hypertension,"CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5,14|",Launched
levcromakalim,potassium channel activator,KCNJ5,,,"CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N",Phase 3
levetiracetam,calcium channel blocker,"CACNA1B, SCN1A, SV2A",neurology/psychiatry,seizures,"CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O",Launched
levo-phencynonate,acetylcholine receptor antagonist,CHRM1,,,"CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|",Launched
levobetaxolol,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"intraocular pressure, glaucoma","CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1",Launched
levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
levobunolol-(+),adrenergic receptor antagonist,,,,"CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12",Preclinical
levobunolol-(+/-),adrenergic receptor antagonist,,,,"CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|",Preclinical
levobupivacaine,voltage-gated potassium channel blocker,KCNA5,Anesthesia,local anesthetic,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Launched
levocabastine,histamine receptor antagonist,"HRH1, NTSR2",ophthalmology,conjunctivitis,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,Launched
levocarnitine,,"CRAT, CROT",endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
levocarnitine-propionate,carnitine palmitoyltransferase inhibitor,CRAT,"neurology/psychiatry, endocrinology","peripheral neuropathy, carnitine deficiency","CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C, CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C",Launched
levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1",Launched
levodopa,"dopamine precursor, dopamine analog","DDC, DRD1, DRD2, DRD3, DRD4, DRD5, GPR143",neurology/psychiatry,Parkinson's Disease,"N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, COC(=O)C(N)Cc1ccc(O)c(O)c1",Launched
levodropropizine,antitussive,,pulmonary,cough suppressant,"OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1",Launched
levofloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, otolaryngology, pulmonary, urology","pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague","C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
levomenol,,,"neurology/psychiatry, infectious disease","spasms, skin infections",CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|,Launched
levomenthol,,"OPRK1, TRPA1, TRPM8, TRPV3",neurology/psychiatry,pain relief,"CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O",Launched
levomepromazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C","neurology/psychiatry, gastroenterology","psychosis, schizophrenia, bipolar disorder, nausea, insomnia","COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1",Launched
levomequitazine,histamine receptor antagonist,HRH1,,,"C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|",Phase 2
levonordefrin,vasodilator,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2",hematology,hemorrhage,"C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1",Launched
levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist",PGR,endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|",Launched
levopropoxyphene,antitussive,,pulmonary,cough suppressant,"CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5,&2:13|",Launched
levosimendan,calcium sensitizer,"KCNJ11, KCNJ8, PDE3A, TNNC1",cardiology,congestive heart failure,"C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|",Launched
levosulpiride,dopamine receptor antagonist,"CA1, CA12, CA7, DRD2, DRD3","neurology/psychiatry, gastroenterology, urology","schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)","CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O",Launched
levothyroxine,thyroid hormone stimulant,"THRA, THRB",endocrinology,myxedema coma,"N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O",Launched
LFM-A13,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,"CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|",Preclinical
LGD-6972,glucagon receptor antagonist,,,,"Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1, Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1",Phase 2
LGK-974,porcupine inhibitor,PORCN,,,"Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C",Phase 2
lhf-535,antiviral,,endocrinology,fever,CC(C)Oc1ccc(cc1)n2cnc3cc(\C=C/c4ccc(cc4)C(C)(C)O)ccc23,Phase 1
LH846,casein kinase inhibitor,CSNK1D,,,"Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl",Preclinical
liarozole,cytochrome P450 inhibitor,"CYP19A1, CYP26A1",,,"Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|",Phase 2/Phase 3
licarbazepine,voltage-gated sodium channel blocker,SCN5A,,,"NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|",Phase 3
licochalcone a,topoisomerase inhibitor,,,,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
licochalcone-A,topoisomerase inhibitor,PTPN1,,,COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
licofelone,"cyclooxygenase inhibitor, lipoxygenase inhibitor","ALOX5, PLA2G2E, PTGS2",,,"CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1",Phase 3
licogliflozin,sodium/glucose cotransporter inhibitor,,,,CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,Preclinical
licostinel,NMDA receptor antagonist ,,,,[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12,Phase 1
lidamidine,adrenergic receptor agonist,,gastroenterology,diarrhea,"CNC(=N)NC(=O)Nc1c(C)cccc1C, CNC(=N)NC(=O)Nc1c(C)cccc1C, CNC(=N)NC(=O)Nc1c(C)cccc1C",Launched
lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN5A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
lidoflazine,calcium channel blocker,"SCN1A, SCN3A, SLC29A1",cardiology,coronary artery disease (CAD),"Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1",Launched
lifirafenib,RAF inhibitor,,,,FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12,Phase 1/Phase 2
lifitegrast,lymphocyte function-associated antigen negative modulator,,ophthalmology,dry eye syndrome,CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1,Launched
ligandrol,androgen receptor modulator,"AR, SARM1",endocrinology,cachexia,O[C@H]([C@H]1CCCN1c2ccc(C#N)c(c2)C(F)(F)F)C(F)(F)F,Phase 2
ligustilide,tumor necrosis factor production inhibitor,TNF,,,"CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|, CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|",Preclinical
limaprost-alfadex,prostanoid receptor agonist,PTGER1,cardiology,claudication,"CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O",Launched
LIMKi-3,LIM kinase inhibitor,LIMK1,,,"CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F",Preclinical
limonin,HIV protease inhibitor,,,,"CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1",Preclinical
linaclotide,guanylate cyclase activator,GUCY2C,gastroenterology,"irritable bowel syndrome, constipation, irritable bowel syndrome, constipation","[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O, C[C@@H](O)C1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2",Launched
linagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1",Launched
linalool,anticonvulsant,,,,"CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|, CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|",Phase 1
linaprazan,ATP-sensitive potassium channel inhibitor,,,,Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO,Preclinical
lincomycin,bacterial 30S ribosomal subunit inhibitor,,gastroenterology,enteritis,"CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O",Launched
lincomycin hcl,bacterial 30s ribosomal subunit inhibitor,,gastroenterology,enteritis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O,Launched
lincomycin hydrochloride,bacterial 30s ribosomal subunit inhibitor,,gastroenterology,enteritis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,Launched
lincomycin hydrochloride (lincocin),,,,,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O,
lindane,,"GABRB1, GLRA1, GLRA2, GLRA3, GLRB",infectious disease,scabies,"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl",Launched
linezolid,bacterial 50S ribosomal subunit inhibitor,"MAOA, MAOB",infectious disease,"pneumonia, skin infections","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1",Launched
linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",,,"Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1",Phase 3
linoleic-acid,oxidative stress inducer,"FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8",,,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,Phase 3
linopirdine,potassium channel blocker,"KCNQ2, KCNQ3, KCNQ4, KCNQ5",,,"O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1",Phase 3
linsidomine,nitric oxide donor,,urology,erectile dysfunction,"Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1",Launched
linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",,,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|",Phase 3
lintopride,serotonin receptor antagonist,,,,CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|,Preclinical
liothyronine,thyroid hormone stimulant,"THRA, THRB",endocrinology,"hypothyroidism, myxedema coma","N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O",Launched
liothyronine-(isomer),,,,,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,Preclinical
lipoamide,,,,,"NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|",Preclinical
liquiritin,antioxidant,,,,OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O,Preclinical
liraglutide,GLP receptor agonist,GLP1R,endocrinology,"weight-loss aid, diabetes mellitus, weight-loss aid, diabetes mellitus","CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O, CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O",Launched
liranaftate,fungal squalene epoxidase inhibitor,,infectious disease,fungal infection,"COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1, COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1",Launched
lirimilast,phosphodiesterase inhibitor,,,,"CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl",Phase 2
lisadimate,topical sunscreen agent,,dermatology,sunscreen lotion,"Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11,r|",Launched
lisinopril,angiotensin converting enzyme inhibitor,"ACE, ACE2","cardiology, endocrinology","hypertension, congestive heart failure, diabetes mellitus","NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O",Launched
lisofylline,"interleukin receptor antagonist, STAT inhibitor",,,,"C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|, C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|",Phase 2
lisuride,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6",neurology/psychiatry,Parkinson's Disease,"CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|",Launched
lithium-acetoacetate,,FAH,,,CC(=O)CC(O)=O,Preclinical
lithium-citrate,,,neurology/psychiatry,"bipolar disorder, depression","[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O",Launched
lithocholic-acid,"FXR antagonist, vitamin D receptor agonist","GPBAR1, NR1H4, NR1I2, VDR",,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Preclinical
litronesib,kinesin-like spindle protein inhibitor,KIF11,,,"CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|",Phase 2
lixivaptan,vasopressin receptor antagonist,AVPR2,,,"Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1",Phase 3
LM-22A4,tropomyosin receptor kinase inhibitor,NTRK2,,,"OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO",Preclinical
LMI070,survival motor neuron protein modulator,SMN1,,,"CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1",Phase 1/Phase 2
LMK-235,HDAC inhibitor,"HDAC4, HDAC5",,,"Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO",Preclinical
lmp7-in-1,,PSMB8,,,OB(O)[C@H](Cc1coc2ccccc12)NC(=O)[C@@H]1C[C@H]2CC[C@@H]1O2,Preclinical
lmp744 hydrochloride,topoisomerase inhibitor,TOP1,oncology,ovarian cancer,COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCNCCO)c(=O)c2cc1OC.Cl,Phase 1
LM11A-31,neurotrophic agent,NGFR,,,"CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|",Phase 1
lobeline,acetylcholine receptor antagonist,"CHRNA10, CHRNA9, SLC18A2",neurology/psychiatry,smoking cessation,"CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1",Launched
lobeline hydrochloride,acetylcholine receptor antagonist,,neurology/psychiatry,smoking cessation,CN1C(CC(O)c2ccccc2)CCCC1CC(=O)c1ccccc1,Launched
lobendazole,anthelmintic agent,,,,"CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1",Preclinical
lobenzarit,immunosuppressant,,rheumatology,rheumatoid arthritis,"OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O, OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O",Launched
lodenosine,antiretroviral ,,,,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F,Phase 2
lodoxamide,histamine receptor antagonist,,ophthalmology,vernal keratoconjunctivitis (VKC),"OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N",Launched
lofemizole,cyclooxygenase inhibitor,,,,"Cc1[nH]cnc1-c1ccc(Cl)cc1, Cc1[nH]cnc1-c1ccc(Cl)cc1",Phase 3
lofepramine,"norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","HTR1A, SLC6A2, SLC6A4",neurology/psychiatry,depression,"CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1",Launched
lofexidine,adrenergic receptor agonist,,neurology/psychiatry,opioid withdrawal,"C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|",Launched
lomefloxacin,bacterial DNA gyrase inhibitor,,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|",Launched
lomefloxacin hcl,bacterial dna gyrase inhibitor,,infectious disease,"respiratory tract infections, urinary tract infections",CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,Launched
lomeguatrib,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,"Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1",Phase 2
lomerizine,calcium channel blocker,"CACNA1B, SCN5A",neurology/psychiatry,migraine headache,"COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC",Launched
lometrexol,glycinamide ribonucleotide formyltransferase inhibitor,GART,,,Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1,Phase 2
lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,"FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12",Launched
lomustine,DNA synthesis inhibitor,,"hematologic malignancy, oncology","Hodgkin's lymphoma, brain tumors","[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1",Launched
lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",,,"NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1",Phase 3
lonapalene,lipoxygenase inhibitor,ALOX5,dermatology,psoriasis,COc1c(OC)c(OC(=O)C)c2cc(Cl)ccc2c1OC(=O)C,Preclinical
lonidamine,glucokinase inhibitor,GCK,,,"OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12",Launched
loperamide,opioid receptor agonist,"CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC",gastroenterology,diarrhea,"CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1",Launched
lopinavir,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1",Launched
loracarbef,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology, pulmonary","ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections","N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|",Launched
loratadine,histamine receptor antagonist,HRH1,"allergy, neurology/psychiatry","allergic rhinitis, itching","CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12",Launched
loreclezole,benzodiazepine receptor agonist,"GABRB2, GABRB3",,,"Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl",Phase 2
lorediplon,GABA receptor modulator,GABRA1,,,"CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 2
lorglumide,CCK receptor antagonist,"CCKAR, CCKBR",,,"CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|",Phase 1
lorglumide sodium,cck receptor antagonist,,,,CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,Phase 1
lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,oncology,non-small cell lung cancer (NSCLC),"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Launched
lornoxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, neurology/psychiatry","osteoarthritis, sciata","CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|",Launched
losartan,angiotensin receptor antagonist,AGTR1,"cardiology, nephrology","hypertension, diabetic nephropathy, hypertension","CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",Launched
losmapimod,p38 MAPK inhibitor,MAPK14,,,"Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1",Phase 3
lotamilast,phosphodiesterase inhibitor,,,,CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1,Preclinical
loteprednol,"glucocorticoid receptor agonist, phospholipase inhibitor",NR3C1,ophthalmology,conjunctivitis,"CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|",Launched
lotilaner,gaba receptor antagonist,GABRA1,infectious disease,flea control,CC1=C(SC(=C1)C2=NO[C@@](C2)(C3=CC(=C(C(=C3)Cl)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F,Launched
lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|",Launched
loxapine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,schizophrenia,"CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|",Launched
loxistatin-acid,cysteine peptidase inhibitor,CTSB,,,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
loxoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist",PTGS2,neurology/psychiatry,pain relief,"C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|",Launched
LP-533401,tryptophan hydroxylase inhibitor,,,,N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|,Preclinical
LPA2-antagonist-1,lysophosphatidic acid receptor antagonist,LPAR2,,,"C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12",Preclinical
LRRK2-IN-1,leucine rich repeat kinase inhibitor,LRRK2,,,"COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",Preclinical
LSN-2463359,glutamate receptor positive allosteric modulator,GRM5,,,"CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1",Preclinical
LSZ-102,selective estrogen receptor modulator (SERM),,,,"CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1, CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1",Phase 1
LTA,,,,,N=C(Nc1ccccc1)c1cccs1,Phase 2
lta4h-in-1,leukotriene inhibitor,LTA4H,gastroenterology,inflammatory bowel disease,N[C@@H](CC(=O)O)Cn1nnc(n1)c2ccc(Oc3ncc(Cl)cc3F)cc2,Phase 2
LTB4,leukocyte activator,"LTB4R, LTB4R2",,,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,Phase 2
LTX-315,anticancer agent,,,,NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,Phase 2
Lu-AA-47070,adenosine receptor antagonist,ADORA2A,,,"CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O",Phase 2
lubiprostone,chloride channel activator,CLCN2,gastroenterology,"constipation, irritable bowel syndrome","CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O",Launched
lucanthone,endonuclease inhibitor,"APEX1, TOP1, TOP2A",,,CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,Phase 2
lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,"CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12",Phase 2
LUF-5834,adenosine receptor agonist,"ADORA2A, ADORA2B",,,"Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N",Preclinical
lufenuron,chitin inhibitor,,infectious disease,flea control,"F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|",Launched
luliconazole,sterol demethylase inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1",Launched
lumacaftor,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis,"Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O, Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O",Launched
lumateperone,"dopamine receptor modulator, serotonin receptor antagonist","DRD2, HTR2A",,,"CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23",Launched
lumefantrine,antimalarial agent,ATP1A1,infectious disease,malaria,"CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|",Launched
lumiracoxib,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1",Withdrawn
lupanine,"sodium channel blocker, sodium channel blocker, insulin secretagogue, insulin secretagogue",INS,Endocrinology,diabetes mellitus,"[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], [H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3",Preclinical
lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12",Launched
lurbinectedin,DNA binding agent,,,,[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|,Phase 3
lusaperidone,adrenergic receptor antagonist,,,,Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1,Preclinical
lusutrombopag,thrombopoietin receptor agonist,,,,CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC,Launched
lutein,antioxidant,,ophthalmology,"macular degeneration, cataracts, retinitis pigmentosa (RP)","C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|, C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|",Launched
luteolin,glucosidase inhibitor,TOP1,,,"Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1",Phase 2
luzindole,melatonin receptor antagonist,"MTNR1A, MTNR1B",,,"CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",Preclinical
LXH254,RAF inhibitor,,,,Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1,Phase 1
LXR-623,LXR agonist,"AR, NR1H2, NR1H3, NR1I2, NR3C1",,,"Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F",Phase 1
LXS196,PKC inhibitor,,,,CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F,Phase 1
LX1031,tryptophan hydroxylase inhibitor,TPH1,,,"COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F",Phase 2
LX7101,"LIM kinase inhibitor, rho associated kinase inhibitor","LIMK2, ROCK1, ROCK2",,,"CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1",Phase 1/Phase 2
lycopene,free radical scavenger,,,,"CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C",Launched
lylamine,cannabinoid receptor agonist,CNR1,,,"CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1",Preclinical
lymecycline,bacterial 50S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV),"CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7,&2:26|, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O",Launched
lynestrenol,progestogen hormone,,endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|",Launched
lypressin,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,central diabetes insipidus,"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O",Launched
LY2090314,glycogen synthase kinase inhibitor,GSK3B,,,"Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|",Phase 2
LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",,,"C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1",Preclinical
LY2140023,glutamate receptor agonist,GRM3,,,"N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",Phase 3
LY215490,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1",,,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,Phase 1
LY2157299,TGF beta receptor inhibitor,TGFBR1,,,"Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O",Phase 2/Phase 3
LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,,,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
LY2228820,p38 MAPK inhibitor,MAPK14,,,"CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C",Phase 2
LY223982,leukotriene receptor antagonist,LTB4R,,,"COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1",Phase 2
LY225910,CCK receptor antagonist,CCKBR,,,"CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O",Preclinical
LY231617,lipid peroxidase inhibitor,,,,"CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Preclinical
LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",,,,"CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Phase 1
LY2365109,glycine transporter inhibitor,SLC6A9,,,"CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O",Preclinical
LY2452473,androgen receptor modulator,AR,,,CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N,Phase 2
LY2510924,CC chemokine receptor antagonist,,,,[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O,Phase 2
LY255283,leukotriene receptor antagonist,"LTB4R, LTB4R2",,,"CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1",Preclinical
ly2562175,fxr agonist,NR1H4,gastroenterology,non-alcoholic steatohepatitis (nash),Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1,Phase 2
LY2584702,ribosomal protein inhibitor,RPS6KB1,,,"Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F",Phase 1
LY2603618,CHK inhibitor,CHEK1,,,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
LY2606368,CHK inhibitor,CHEK1,,,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1",Phase 2
LY2608204,glucokinase activator,GCK,,,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
LY266097,serotonin receptor antagonist,HTR2B,,,"COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|",Preclinical
LY2784544,JAK inhibitor,"JAK2, JAK3",,,"Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1",Phase 2
LY2795050,opioid receptor antagonist,,,,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1,Preclinical
LY2801653,MET inhibitor,MET,,,"Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1",Phase 2
LY2811376,beta-secretase inhibitor,BACE1,,,"C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|",Phase 1
LY2828360,cannabinoid receptor agonist,,,,"CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl, CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl",Phase 2
LY2857785,CDK inhibitor,CDK9,,,"CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|",Preclinical
LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",,,"C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl",Phase 1
LY288513,CCK receptor antagonist,CCKBR,,,"Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1",Preclinical
ly2886721,beta-secretase inhibitor,,,,NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F,Phase 1/Phase 2
LY2886721,beta-secretase inhibitor,BACE1,,,NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|,Phase 1/Phase 2
ly2922470,g protein-coupled receptor agonist,FFAR1,endocrinology,diabetes mellitus,COc1cccc2CCCN(Cc3ccc(COc4ccc(cc4)[C@H](CC(O)=O)C#CC)s3)c12,Phase 1
LY294002,"DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1",,,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1",Preclinical
ly2940094,nociceptin/orphanin fq (nop) receptor antagonist,OPRL1,neurology/psychiatry,depression,Cc1nn(cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc21)-c1ncccc1CO,Phase 2
LY2979165,glutamate receptor agonist,GRM2,,,"C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",Phase 1
LY3000328,cathepsin inhibitor,CTSS,,,"CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1",Phase 1
LY3009120,RAF inhibitor,"BRAF, RAF1",,,"CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C",Phase 1
LY3023414,"mTOR inhibitor, PI3K inhibitor",MTOR,,,"CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O",Phase 2
LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",,,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
LY310762,serotonin receptor antagonist,HTR1D,,,"CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12",Preclinical
LY311727,phospholipase inhibitor,,,,CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1,Preclinical
LY3200882,TGF beta receptor inhibitor,,,,CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1,Phase 1
LY320135,cannabinoid receptor antagonist,CNR1,,,"COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N",Preclinical
LY3214996,ERK inhibitor,,,,Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1,Phase 1
LY3295668,Aurora kinase inhibitor,,,,C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O,Phase 1/Phase 2
LY334370,serotonin receptor agonist,,,,CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12,Preclinical
LY344864,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7",,,"CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1",Preclinical
LY364947,"p38 MAPK inhibitor, TGF beta receptor inhibitor",TGFBR1,,,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
LY393558,serotonin receptor antagonist,"HTR1B, HTR1D, HTR2A, HTR2B",,,"CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|",Preclinical
LY404187,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|",Preclinical
LY411575,gamma secretase inhibitor,,,,"C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
LY450108,glutamate receptor modulator,,,,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1",Phase 1
LY456236,glutamate receptor antagonist,GRM1,,,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
m-chlorophenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",,,"NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1",Preclinical
m-THP,,,,,Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2,Phase 1
M-14157,ATP-sensitive potassium channel antagonist,KCNQ1,,,CCCCCC(O)CCCC(O)=O,Phase 2
M-25,smoothened receptor antagonist,"DHH, IHH, SMO",,,"CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC",Preclinical
m-3M3FBS,phospholipase activator,"PLCB2, PLCB3, PLCD1, PLCG1, PLCG2",,,"Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F",Preclinical
M-344,HDAC inhibitor,HDAC8,,,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
mabuprofen,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|",Launched
mabuterol,adrenergic receptor agonist,ADRB2,pulmonary,asthma,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|,Launched
macelignan,"anti-inflammatory agent, antioxidant",,,,COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O,Preclinical
macimorelin,ghrelin receptor agonist,GHSR,endocrinology,cachexia,CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N,Launched
macitentan,endothelin receptor antagonist,"EDNRA, EDNRB",endocrinology,contraceptive,"CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",Launched
macitentan-n-butyl-analogue,endothelin receptor antagonist,,,,CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,Preclinical
macozinone,DPRE1 inhibitor,,,,[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F,Preclinical
madecassoside,anti-inflammatory agent,,,,[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|,Preclinical
madrasin,cell splicing inhibitor,,,,"COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1",Preclinical
maduramicin acid,other antibiotic,"PPP2CA, PTEN",infectious disease,coccidiosis,CO[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]2[C@]3(C)CC[C@@H](O3)[C@]4(C)CC[C@]5(C[C@H](O)[C@@H](C)[C@H](O5)[C@@H](C)[C@@H]6O[C@](O)(CC(O)=O)[C@@H](C)[C@H](OC)[C@H]6OC)O4)[C@H]7O[C@](C)(O)[C@H](C)C[C@@H]7C)O[C@@H](C)[C@@H]1OC,Launched
mafenide,carbonic anhydrase inhibitor,"CA12, CA14, CA2, CA4, CA6, CA9",infectious disease,"first-aid antibiotic, skin infections","NCc1ccc(cc1)S(N)(=O)=O, NCc1ccc(cc1)S(N)(=O)=O",Launched
magnolol,PPAR receptor agonist,"GABRA1, PPARG",,,"Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O",Preclinical
malathion,cholinesterase inhibitor,ACHE,infectious disease,lice,"CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|",Launched
malic-acid,,PKD2L1,,,"O[C@@H](CC(O)=O)C(O)=O |&1:1,r|, O[C@@H](CC(O)=O)C(O)=O |&1:1,r|, O[C@@H](CC(O)=O)C(O)=O |&1:1,r|",Launched
malotilate,protein synthesis stimulant,,gastroenterology,hepatic cirrhosis,"CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|, CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|",Launched
maltobionic-acid,matrix metalloprotease inhibitor,,dermatology,cosmetic,"OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O",Launched
mandelic-acid,,,,,"O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|, O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|",Launched
mangafodipir,contrast agent,,radiology,contrast agent,"Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12",Launched
manidipine,calcium channel blocker,"CACNA1C, CACNA1D",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|",Launched
manidipine hydrochloride,calcium channel blocker,,cardiology,hypertension,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,Launched
manitimus,dehydrogenase inhibitor,,,,"FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|",Preclinical
mannitol-D,diuretic,,"neurology/psychiatry, ophthalmology, gastroenterology","intracranial pressure, intraocular pressure, constipation","OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",Launched
mapracorat,glucocorticoid receptor agonist,"CXCL8, MYOC, NR3C1",ophthalmology,cataracts,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4CCOc34)C(F)(F)F)cccc2n1 |a:8|,Phase 3
maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant",SLC6A2,neurology/psychiatry,"depression, dysthymic disorder","CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|, CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|",Launched
maprotiline hcl,"norepinephrine reputake inhibitor, tricyclic antidepressant",,neurology/psychiatry,"depression, dysthymic disorder",CNCCCC12CCC(c3ccccc13)c1ccccc21,Launched
map4343,microtubule stimulant,MAP2,neurology/psychiatry,depression,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC |t:19|,Phase 2
maraviroc,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1, CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1",Launched
marbofloxacin,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,"CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O",Launched
maribavir,"cytomegalovirus inhibitor, protein kinase inhibitor",PYGM,,,"CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O",Phase 3
marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",,,"CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C",Phase 3
maropitant,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting,"COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C",Launched
masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
masoprocol,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK),"C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|",Launched
matrine,opioid receptor agonist,OPRK1,,,O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,Phase 2
mavacamten,myosin inhibitor ,,,,CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O,Phase 3
mavacoxib,cyclooxygenase inhibitor,PTGS2,rheumatology,joint inflammation,C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F,Launched
mavatrep,transient receptor potential channel antagonist,,,,CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1,Preclinical
mavoglurant,glutamate receptor antagonist,GRM5,,,"COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1",Phase 2
maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,Launched
maytansinol-isobutyrate,,,,,"CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|, CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|",Preclinical
mb-07344,thyroid hormone receptor agonist,THRB,endocrinology,hypercholesterolemia,CC(C)c1cc(Cc2c(C)cc(OCP(O)(O)=O)cc2C)ccc1O,Preclinical
MBX-2982,glucose dependent insulinotropic receptor agonist,GPR119,,,"CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1",Phase 2
MC-1,,"AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1",,,"Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O",Phase 3
mcb-3681,other antibiotic,,infectious disease,gram-positive bacterial infections,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1,Phase 2
MCC950,NOD like receptor inhibitor,NLRP3,,,"CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12",Preclinical
McN-5652-(+/-),selective serotonin reuptake inhibitor (SSRI),,,,"CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12, CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12",Preclinical
MCOPPB,nociceptin/orphanin FQ receptor agonist,OPRL1,,,"CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1",Preclinical
mCPP,serotonin receptor agonist,"HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6",,,"Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1",Phase 2
MC1568,HDAC inhibitor,HDAC2,,,"Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1",Preclinical
MD-920,NFkB pathway inhibitor,AADACL2,,,"C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|",Phase 1
mdivi-1,dynamin inhibitor,DNM1,,,"COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O",Preclinical
mdl 72222,serotonin receptor antagonist,,,,CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1,Phase 3
MDL-11939,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|",Phase 2
MDL-27531,glycine receptor agonist,,,,Cn1c(nnc1S(C)(=O)=O)-c1ccccc1,Preclinical
MDL-29951,glutamate receptor antagonist,FBP1,,,"OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O",Preclinical
MDL-72832,serotonin receptor agonist,HTR1A,,,"O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|",Preclinical
MDL-73005EF,serotonin receptor antagonist,HTR1A,,,"O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|",Phase 1
MDMS,DNA inhibitor,,,,CS(=O)(=O)OCOS(C)(=O)=O,Phase 2
mdr-652,trpv agonist,TRPV1,neurology/psychiatry,chronic pain,O=C(NC1=CC=C(CO)C(F)=C1)NCC2=C(C3=CC=CC(Cl)=C3)N=C(C(C)(C)C)S2,Preclinical
ME-0328,PPAR receptor antagonist,PARP3,,,"C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1",Preclinical
mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis","COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1",Launched
mebeverine,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,"CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|, CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|",Launched
mebhydrolin,antihistamine,,allergy,"allergic rhinitis, urticaria","CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1",Launched
mebicar,anxiolytic,,neurology/psychiatry,anxiety,"CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C",Launched
mebrofenin,,,radiology,diagnostic agent,Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br,Launched
mecamylamine,acetylcholine receptor antagonist,"CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4",cardiology,hypertension,"CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C",Launched
mecamylamine hydrochloride,nicotinic receptor antagonist,CHRNA7,Neurology,depression,"CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C |&1:2,&2:4,7,r|",Launched
mecarbinate,,,,,CCOC(=O)c1c(C)n(C)c2ccc(O)cc12,Preclinical
meclinertant,neurotensin receptor antagonist,"NTSR1, NTSR2",,,"COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O",Phase 2/Phase 3
meclizine,constitutive androstane receptor (CAR) agonist,NR1I3,"gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|, Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|",Launched
meclizine hydrochloride,constitutive androstane receptor (car) agonist,,"gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness",Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1,Launched
meclocycline,ribosomal protein inhibitor,,dental,mucositis,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N,Launched
meclocycline-sulfosalicylate,bacterial 50S ribosomal subunit inhibitor,,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|",Launched
meclofenamic-acid,"cyclooxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2","rheumatology, neurology/psychiatry, endocrinology","joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)","Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl, Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl",Launched
meclofenoxate,nootropic agent,,neurology/psychiatry,"senile dementia, Alzheimer's disease","CN(C)CCOC(=O)COc1ccc(Cl)cc1, CN(C)CCOC(=O)COc1ccc(Cl)cc1",Launched
mecysteine,analgesic agent,,pulmonary,chest congestion,"COC(=O)[C@@H](N)CS, COC(=O)[C@@H](N)CS",Launched
mecysteine hydrochloride,analgesic agent,,pulmonary,chest congestion,COC(=O)C(N)CS,Launched
medetomidine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,sedative,"C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|",Launched
medica-16,ATP citrase lyase inhibitor,FFAR1,,,"CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O, CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O",Phase 2
medorinone,,,,,"Cc1nccc2[nH]c(=O)ccc12, Cc1nccc2[nH]c(=O)ccc12",Phase 1
medronic-acid,bone resorption inhibitor,,radiology,skeletal imaging agent,"OP(O)(=O)CP(O)(O)=O, OP(O)(=O)CP(O)(O)=O",Launched
medroxyprogesterone,progesterone receptor agonist,PGR,endocrinology,contraceptive,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|",Launched
medroxyprogesterone acetate,progesterone receptor agonist,,endocrinology,contraceptive,C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12,Launched
medroxyprogesterone-acetate,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|,Launched
medrysone,glucocorticoid receptor agonist,NR3C1,ophthalmology,"conjunctivitis, episcleritis, conjunctivitis, episcleritis","C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12",Launched
mefenamic-acid,cyclooxygenase inhibitor,"KCNQ1, PTGS1, PTGS2, TRPM3",endocrinology,primary dysmenorrhea (PD),"Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C",Launched
mefexamide,psychoactive drug,,,,"CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1",Preclinical
mefloquine,"protein synthesis inhibitor, adenosine receptor antagonist, hemoglobin antagonist",,infectious disease,malaria,"O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F, OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F",Launched
megestrol,progesterone receptor agonist,PGR,oncology,breast cancer,"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|",Launched
megestrol-acetate,progesterone receptor agonist,"NR3C1, PGR","neurology/psychiatry, endocrinology","anorexia, cachexia","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",Launched
meglitinide,potassium channel blocker,CCR2,,,"COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O",Phase 2
meglumine,excipient,,,,"CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",Launched
meglutol,HMGCR inhibitor,HMGCR,,,"CC(O)(CC(O)=O)CC(O)=O, CC(O)(CC(O)=O)CC(O)=O",Launched
meisoindigo,STAT inhibitor,STAT3,,,"CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12",Phase 3
MEK1-2-inhibitor,MEK inhibitor,MAP2K2,,,"Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1",Preclinical
melanotan i,,,,,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,
melanotan-ii,melanocortin receptor agonist,,,,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O,Launched
melatonin,"melatonin receptor agonist, nitric oxide synthase inhibitor","ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB",neurology/psychiatry,sleep cycle support,"COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1",Launched
meldonium,gamma butyrobetaine hydroxylase inhibitor,BBOX1,cardiology,coronary artery disease (CAD),"C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O",Launched
melengestrol-acetate,progesterone receptor agonist,,,,"CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|",Preclinical
melevodopa,"dopamine precursor, dopamine receptor agonist, dopamine precursor, dopamine receptor agonist",DDC,neurology/psychiatry,Parkinson's Disease,"COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)C(N)Cc1ccc(O)c(O)c1",Launched
melflufen (hydrochloride),dna alkylating agent,,hematologic malignancy,multiple myeloma,"CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(cc1)N(CCCl)CCCl.Cl |a:5,17|",Launched
meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis, osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|",Launched
melperone,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,psychosis,"CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1",Launched
melphalan,"DNA alkylating agent, DNA inhibitor",,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
melphalan flufenamide,dna alkylating agent,,hematologic malignancy,multiple myeloma,"CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc2ccc(cc2)N(CCCl)CCCl, CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N",Launched
melphalan-n-oxide,hypoxia inducible factor inhibitor,HIF1A,,,N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O,Phase 1
meluadrine,,,,,"CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|",Preclinical
memantine,glutamate receptor antagonist,,neurology/psychiatry,"Alzheimer's disease, senile dementia",C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2,Launched
memantine hcl,glutamate receptor antagonist,,neurology/psychiatry,"alzheimer's disease, senile dementia",CC12CC3CC(C)(C1)CC(N)(C3)C2,Launched
menadiol sodium sulfate,vitamin k,"F10, F2, F7, F9, GGCX, PROC, PROS1",hematology,hemorrhage,Oc2c1ccccc1c(O)c(c2)C,Withdrawn
menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|",Launched
menadione-bisulfite,vitamin K,"GGCX, VKORC1, VKORC1L1",,,"C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|, C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|",Phase 2
menaquinone-7,osteoclast inhibitor,TNFRSF11B,cardiology,arteriosclerosis,CC(=CCC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC1=C(C)C(=O)c2ccccc2C1=O)\C)\C)\C)\C)\C)\C)C,Phase 2
menatetrenone,bone resorption inhibitor,,orthopedics,osteoporosis,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|",Launched
menbutone,,,gastroenterology,bile stimulation,"COc1ccc(C(=O)CCC(O)=O)c2ccccc12, COc1ccc(C(=O)CCC(O)=O)c2ccccc12",Launched
mepacrine,"cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator",PLA2G1B,infectious disease,giardiasis,"CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|",Launched
meparfylon,,,,,CCC(C)(O)C#C |&1:2|,Preclinical
mepazine,MALT1 inhibitor (JH),MALT1,,,"CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|",Phase 2
mepenzolate,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|",Launched
mephenesin,muscle relaxant,,neurology/psychiatry,muscle relaxant,"Cc1ccccc1OC[C@@H](O)CO |&1:9,r|, Cc1ccccc1OC[C@@H](O)CO |&1:9,r|",Launched
mephentermine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3",cardiology,hypotension,"CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1",Launched
mephenytoin,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,"CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|",Launched
mepiroxol,,,,,"OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1",Preclinical
mepivacaine,"potassium channel blocker, sodium channel blocker",,neurology/psychiatry,local anesthetic,"CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|",Launched
meprednisone,,NR3C1,,,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",Launched
meprylcaine,local anesthetic,,,,"CCCNC(C)(C)COC(=O)c1ccccc1, CCCNC(C)(C)COC(=O)c1ccccc1",Preclinical
meptazinol,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief,"CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|",Launched
mepyramine,histamine receptor antagonist,HRH1,"otolaryngology, obstetrics/gynecology","common cold, menstrual pain","COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1",Launched
mequinol,,TYR,dermatology,skin depigmentation,"COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1",Launched
merbarone,topoisomerase inhibitor,TOP2A,,,"Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1",Phase 2
merbromin,antiseptic,,infectious disease,first-aid antiseptic,"O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12, O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12",Launched
mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12",Launched
mercaptosuccinic-acid,,,,,"OC(=O)C[C@@H](S)C(O)=O |&1:4,r|, OC(=O)C[C@@H](S)C(O)=O |&1:4,r|, OC(=O)C[C@@H](S)C(O)=O |&1:4,r|",Launched
Merck60,HDAC inhibitor,"HDAC1, HDAC2",,,,Preclinical
mericitabine,HCV inhibitor,,,,"CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C",Phase 2
merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,,"COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1",Phase 2
meropenem,bacterial cell wall synthesis inhibitor,,infectious disease,"skin infections, intra-abdominal infections, meningitis","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|",Launched
mertansine,microtubule inhibitor,,,,"[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|",Phase 2
mesalazine,"cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist","ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2",gastroenterology,"ulcerative colitis, inflammatory bowel disease","Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O",Launched
mesna,antioxidant,,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|",Launched
mestinon,cholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,myasthenia gravis,"CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1",Launched
mestranol,estrogen receptor agonist,ESR1,endocrinology,contraceptive,"COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1",Launched
mesulergine,dopamine receptor agonist,"HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7",,,"CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1",Phase 2
meta-cresyl-acetate,,,,,CC(=O)Oc1cccc(C)c1,Preclinical
metacetamol,analgesic agent,,,,CC(=O)Nc1cccc(O)c1,Preclinical
metacresol,,INS,,,"Cc1cccc(O)c1, Cc1cccc(O)c1, Cc1cccc(O)c1",Launched
metaflumizone,sodium channel blocker,SCN8A,infectious disease,flea control,FC(F)(F)OC1=CC=C(NC(=O)NN=C(CC2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C(F)(F)F)C=C1,Withdrawn
metafolin,,,,,"CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12",Launched
metamizole,"cyclooxygenase inhibitor, opioid receptor agonist",PTGS1,,,"CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O",Withdrawn
metaphit,phencyclidine receptor acylator,,,,"S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1, S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1",Preclinical
metaproterenol,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, asthma, bronchitis, emphysema, bronchospasm, asthma, bronchitis, emphysema","CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|",Launched
metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
metarrestin,rna polymerase inhibitor,EEF1A2,oncology,pancreatic cancer,O[C@H]1CC[C@@H](CC1)n1cnc2n(Cc3ccccc3)c(c(-c3ccccc3)c2c1=N)-c1ccccc1 |r|,Phase 1
metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",,,"Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",Phase 1
metaxalone,muscle relaxant,,neurology/psychiatry,muscle pain,"Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|, Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|",Launched
metazosin,adrenergic receptor antagonist,ADRA1A,,,"CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|",Phase 2
metenkephalin,immunostimulant,OPRD1,,,"CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|, CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|",Phase 2
metergoline,"dopamine receptor agonist, serotonin receptor antagonist, dopamine receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","neurology/psychiatry, endocrinology, neurology/psychiatry, endocrinology","seasonal affective disorder, anxiety, hyperprolactinemia, seasonal affective disorder, anxiety, hyperprolactinemia","CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1CC(CNC(=O)OCc2ccccc2)C[C@@H]2C1Cc1cn(C)c3cccc2c13",Launched
metformin,insulin sensitizer,"ACACB, PRKAB1",endocrinology,diabetes mellitus,"CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N",Launched
methacholine,acetylcholine receptor agonist,"CHRM2, CHRM4",pulmonary,bronchial hyperresponsiveness diagnostic,"C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|",Launched
methacycline,protein synthesis inhibitor,,pulmonary,bronchitis,"[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|, [H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|",Preclinical
methacycline hcl,protein synthesis inhibitor,,pulmonary,bronchitis,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,Preclinical
methanesulfonyl-fluoride,acetylcholinesterase inhibitor,ACHE,,,"CS(F)(=O)=O, CS(F)(=O)=O",Phase 2
methantheline,acetylcholine receptor antagonist,"CHRM1, HRH2","gastroenterology, neurology/psychiatry, urology","peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder","CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12, CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12",Launched
methapyrilene,histamine receptor antagonist,HRH1,,,"CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1",Withdrawn
metharbital,GABA receptor modulator,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2",neurology/psychiatry,epilepsy,"CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O",Launched
methazolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"glaucoma, intraocular pressure, glaucoma, intraocular pressure","CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)\N=c1/sc(nn1C)S(N)(=O)=O",Launched
methenamine,bacterial DNA inhibitor,,infectious disease,urinary tract infections,"C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3",Launched
methiazole,anthelmintic agent,,,,"COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1, COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1",Preclinical
methicillin,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
methimazole,antithyroid agent,TPO,endocrinology,hyperthyroidism,"Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S",Launched
methionine,,METAP2,,,"CSCC[C@@H](N)C(O)=O |&1:4,r|",Launched
methiopril,angiotensin converting enzyme inhibitor,ACE,,,"C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|, CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O",Phase 2
methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|",Launched
methoprene-(s),,,,,"COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C, COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C",Preclinical
methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
methotrexate(+/-),,,,,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O,
methoxamine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,"COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N",Launched
methoxsalen,DNA synthesis inhibitor,"CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4",dermatology,psoriasis,"COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12",Launched
methoxyamine,DNA repair enzyme inhibitor,APEX1,,,"CON, CON",Phase 2
methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
methoxyphenamine,adrenergic receptor agonist,,pulmonary,asthma,"CN[C@@H](C)Cc1ccccc1OC |&1:2,r|",Launched
methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
methscopolamine bromide,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (pud),C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1,Launched
methsuximide,T-type calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,"CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|",Launched
methyclothiazide,chloride reabsorption inhibitor,"SLC12A1, SLC12A3",cardiology,"hypertension, edema","CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",Launched
methyl-aminolevulinate,oxidizing agent,"FCGR1A, FECH",dermatology,actinic keratosis (AK),"COC(=O)CCC(=O)CN, COC(=O)CCC(=O)CN",Launched
methyl-nicotinate,,,,,"COC(=O)c1cccnc1, COC(=O)c1cccnc1",Phase 2
methyl-salicylate,,,"endocrinology, neurology/psychiatry","fever, pain relief","COC(=O)c1ccccc1O, COC(=O)c1ccccc1O",Launched
methyl-5-hydroxytryptamine,,,,,"C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|",Preclinical
methylatropine-nitrate,acetylcholine receptor antagonist,CHRM1,,,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|",Preclinical
methylbenactyzium-bromide,cholinergic receptor antagonist,,,,CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,Preclinical
methylbenzethonium-chloride,other antibiotic,,,,"Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C, Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C",Preclinical
methylcobalamin,vitamin B,,,,"[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|",Phase 3
methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
methyldopate,,,cardiology,hypertension,"CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1",Launched
methylene-blue,"guanylyl cyclase inhibitor, nitric oxide production inhibitor",ACHE,hematology,methemoglobinemia,"CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C",Launched
methylergometrine,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C","hematology, neurology/psychiatry","postpartum hemorrhage (PPH), migraine headache","CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|",Launched
methyllycaconitine,acetylcholine receptor antagonist,CHRNA7,,,"CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14",Preclinical
methylnaltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,constipation,[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O,Launched
methylnaltrexone (bromide),opioid receptor antagonist,,gastroenterology,constipation,C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O,Launched
methylparaben,other antifungal,,dermatology,cosmetic,"COC(=O)c1ccc(O)cc1, COC(=O)c1ccc(O)cc1",Launched
methylphenidate hydrochloride,,,,,COC(=O)C(C1CCCCN1)c1ccccc1,
methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",Launched
methylprednisolone sodium succinate,glucocorticoid receptor agonist,,"endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry","hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis",C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12,Launched
methylprednisolone-aceponate,"anti-inflammatory agent, glucocorticoid receptor agonist",NR3C1,"endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology","congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia","CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|",Launched
methylprednisolone-sodium-succinate,glucocorticoid receptor agonist,,"endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry","hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis","[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35,t:31|",Launched
methylthiouracil,,,endocrinology,hyperthyroidism,"Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1",Launched
methysergide,serotonin receptor antagonist,"HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",neurology/psychiatry,headache,"CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|",Launched
meticrane,diuretic,,cardiology,edema,"Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O",Launched
metipranolol,adrenergic receptor antagonist,,,,"CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|",Withdrawn
metirosine,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension,"C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O",Launched
metitepine,"serotonin receptor antagonist, anti-HCVE2","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",Infectious disease,antiviral,"CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1",Preclinical
metixene,acetylcholine receptor antagonist,CHRM5,neurology/psychiatry,Parkinson's Disease,"CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|, CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|",Launched
metixene hydrochloride,acetylcholine receptor antagonist,,neurology/psychiatry,parkinson's disease,CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1,Launched
metoclopramide,"dopamine receptor antagonist, serotonin receptor antagonist","CHRM1, DRD2, HTR3A, HTR3B, HTR4",gastroenterology,"gastroparesis, nausea, vomiting","CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC",Launched
metocurine,acetylcholine receptor antagonist,"CHRM2, CHRNA2",neurology/psychiatry,muscle relaxant,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,Launched
metolazone,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension","C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|",Launched
metomidate,cytochrome p450 inhibitor,"CYP1B1, CYP3A4",radiology,pet imaging,O=C(OC)c1cncn1C(c2ccccc2)C,Launched
metoprine,histamine n-methyltransferase inhibitor,"DHFR, HNMT",oncology,renal cell carcinoma (rcc),CC1=C(C(N)=NC(N)=N1)C2=CC=C(C(Cl)=C2)Cl,Phase 2
metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|",Launched
metoprolol tartrate,adrenergic receptor antagonist,,cardiology,"hypertension, angina pectoris, myocardial infarction",COCCc1ccc(OCC(O)CNC(C)C)cc1,Launched
metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|, COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|",Launched
metrifonate,acetylcholinesterase inhibitor,ACHE,,,"COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|",Phase 3
metrizamide,radiopaque medium,,radiology,contrast agent,"CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|",Launched
metrizoic-acid,radiopaque medium,,radiology,contrast agent,"CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I",Launched
metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
mevastatin,HMGCR inhibitor,HMGCR,,,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|",Preclinical
mexeneone,,,,,"COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1",Preclinical
mexiletine,sodium channel blocker,"PLAU, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|",Launched
mezlocillin,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O",Launched
ME0328,PARP inhibitor,PARP3,,,"C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|",Preclinical
MF-101,estrogen receptor agonist,"CYP19A1, XDH",,,"Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1",Phase 3
MG-132,proteasome inhibitor,PSMB1,,,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
MG-624,acetylcholine receptor antagonist,CHRNA7,,,"CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1",Preclinical
MGCD-265,VEGFR inhibitor,"AXL, MET",,,"Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1, Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1",Preclinical
mhp,sphingosine kinase inhibitor,SPHK1,dermatology,sunburn,OC(C=C1)=CC=C1C[C@@H](C(OC)=O)NC(CCCCC)=O,
MI-14,PI4K inhibitor,PI4KB,,,"CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12",Preclinical
mi-773,,,,,CC(C)(C)C[C@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1,
mianserin,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7",neurology/psychiatry,depression,"CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21",Launched
mianserin hydrochloride,5-ht2a receptor antagonist,HTR2A,Neurology,depression,"CN1CCN2[C@@H](C1)c1ccccc1Cc1ccccc21 |&1:5,r|",Launched
mibampator,glutamate receptor modulator,GRIA1,,,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1",Phase 2
mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",,,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
micafungin,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,"candidemia, peritonitis, esophageal candidiasis, candidemia, peritonitis, esophageal candidiasis","CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O",Launched
micafungin (sodium),,,,,CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)NC1C[C@@H](O)[C@@H](O)NC(=O)C2[C@@H](O)[C@@H](C)CN2C(=O)C(NC(=O)C(NC(=O)C2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O,
miconazole,bacterial cell wall synthesis inhibitor,"TRPM2, TRPV5","infectious disease, neurology/psychiatry","yeast infection, itching","Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|",Launched
miconazole nitrate,bacterial cell wall synthesis inhibitor,,"infectious disease, neurology/psychiatry","yeast infection, itching",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Launched
micronomicin,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections,"CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1, CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1",Launched
midafotel,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1",Phase 3
midecamycin,protein synthesis inhibitor,,infectious disease,"respiratory tract infections, ear infections, skin infections","CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32,34|",Launched
midodrine,adrenergic receptor agonist,,cardiology,hypotension,"COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|",Launched
midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),"CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1",Launched
mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|",Launched
mifobate,PPAR receptor antagonist,PPARG,,,"COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|",Phase 2
migalastat,alpha-galactosidase a inhibitor,GLA,endocrinology,fabry disease,C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O,Launched
miglitol,glucosidase inhibitor,"GAA, GANAB, GANC, MGAM",endocrinology,diabetes mellitus,"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO",Launched
miglustat,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,"CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",Launched
mik665,mcl1 inhibitor,MCL1,hematologic malignancy,multiple myeloma,COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)-c2ccc(F)cc2)C(O)=O)n1,Phase 1
milacemide,monoamine oxidase inhibitor,MAOB,,,"CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O",Phase 3
milademetan,MDM inhibitor,,,,CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O,Phase 1
milnacipran,serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI),"SLC6A2, SLC6A4",rheumatology,fibromyalgia,CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|,Launched
milnacipran (hydrochloride),,,,,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1,
milnacipran hydrochloride,serotonin√¢¬Ä¬ìnorepinephrine reuptake inhibitor (snri),,rheumatology,fibromyalgia,CCN(CC)C(=O)C1(CC1CN)c1ccccc1,Launched
milrinone,phosphodiesterase inhibitor,"PDE2A, PDE3A, PDE3B, PDE5A",cardiology,congestive heart failure,"Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N",Launched
miltefosine,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis,"CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|, CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|",Launched
mimosine,DNA replication inhibitor,"CCL2, SHMT1, SHMT2, TYR",,,"N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O",Preclinical
minaprine,serotonin reuptake inhibitor,"ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4",,,"Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1",Withdrawn
minerval,FAAH inhibitor,,,,"CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|",Phase 1/Phase 2
minocycline,"bacterial 30S ribosomal subunit inhibitor, ribosomal protein inhibitor",,"endocrinology, infectious disease, ophthalmology, urology, neurology/psychiatry","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis, stroke","[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19,&2:12|, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C",Launched
minocycline hydrochloride,"ribosomal protein inhibitor, bacterial 30s ribosomal subunit inhibitor",,"neurology/psychiatry, endocrinology, infectious disease, ophthalmology, urology","stroke, fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis",CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C,Launched
minodronic-acid,bone resorption inhibitor,"FDPS, GGPS1",orthopedics,osteoporosis,"OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O",Launched
minoxidil,"KATP activator, Kir6 channel (KATP) activator, vasodilator","ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1",endocrinology,androgenetic alopecia,"Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1",Launched
miocamycin,other antibiotic,,infectious disease,"urinary tract infections, chlamydia","CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38,40|",Launched
MIRA-1,apoptosis stimulant,,,,CCC(=O)OCN1C(=O)C=CC1=O |c:9|,Preclinical
mirabegron,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3",urology,urinary incontinence,"Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1",Launched
miridesap,amyloid protein inhibitor,,,,OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O,Preclinical
mirin,MRE11A exonuclease inhibitor,MRE11A,,,"NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|",Preclinical
miriplatin,"dna alkylating drug, DNA synthesis inhibitor",,"oncology, Oncology","hepatocellular carcinoma (HCC), hepatic cancer","[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|, [Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|, CCCCCCCCCCCCCC(=O)O[Pt]1(N[C@@H]2CCCC[C@H]2N1)OC(=O)CCCCCCCCCCCCC",Launched
mirodenafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1",Launched
mirogabalin-besylate,calcium channel antagonist,,,,[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|,Preclinical
mirtazapine,"adrenergic receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C",neurology/psychiatry,depression,"CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|",Launched
misonidazole,,,,,"COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|",Phase 3
misoprostol,prostanoid receptor agonist,"PTGER2, PTGER3, PTGER4, PTGIR",gastroenterology,duodenal ulcer disease,"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|",Launched
mitapivat,pyruvate kinase isozyme activator,,,,O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1,Preclinical
mitiglinide,insulin secretagogue,"ABCC8, KCNJ10, PPARG",endocrinology,diabetes mellitus,"OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1, OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1",Launched
mitoflaxone,antitumor agent,VWF,,,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,Phase 2
mitoguazone,polyamine biosynthesis inhibitor,AMD1,oncology,follicular lymphoma,C\C(=N/NC(=N)N)\C=N\NC(=N)N,Phase 2
mitomycin-C,"DNA alkylating agent, DNA synthesis inhibitor",,oncology,"pancreatic cancer, gastric adenocarcinoma","CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10,t:22|",Launched
mitoquinone,antioxidant,,,,"COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|, COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|, COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|",Launched
mitotane,antineoplastic agent,"CYP11A1, CYP11B1, ESR1",oncology,adrenal cortical carcinoma,"ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|",Launched
mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
mivacurium,acetylcholine receptor antagonist,CHRNA2,"critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|",Launched
mivacurium chloride,,,,,"COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55|",Launched
mivebresib,bromodomain inhibitor,,,,"CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12, CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12",Phase 1
mivobulin,microtubule inhibitor,,,,CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|,Phase 2
MIW-815,interferon inducer,,,,[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12,Preclinical
mizolastine,histamine receptor antagonist,HRH1,allergy,"urticaria, allergic rhinitis","CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1, CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1",Launched
mizoribine,"immunosuppressant, inosine monophosphate dehydrogenase inhibitor",IMPDH1,"transplant, rheumatology","organ rejection, nephrotic syndrome","NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|",Launched
MJ-15,cannabinoid receptor antagonist,CNR1,,,"Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1",Preclinical
MK-0354,niacin receptor agonist,"HCAR2, HCAR3",,,"C1Cc2[nH]nc(-c3nn[nH]n3)c2C1, C1Cc2[nH]nc(-c3nn[nH]n3)c2C1",Phase 2
mk-0429,integrin antagonist,ITGAV,nephrology,diabetic nephropathy,COc1ccc(cn1)[C@H](CC(=O)O)N2CCN(CCCc3ccc4CCCNc4n3)C2=O,Phase 1
MK-0557,neuropeptide receptor antagonist,,,,Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|,Phase 3
MK-0608,antiviral,,,,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12,Phase 1
MK-0752,gamma secretase inhibitor,,,,"OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|",Phase 1/Phase 2
MK-0773,androgen receptor modulator,AR,,,"CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|",Phase 2
MK-0812,CC chemokine receptor antagonist,CCR2,,,"CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F",Phase 2
MK-0893,glucagon receptor antagonist,GCGR,,,"COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1",Phase 2
mk-0941,glucokinase activator,GCK,endocrinology,diabetes mellitus,CS(=O)(O)=O.O=C(NC1=NN(C)C=C1)C2=CC(O[C@@H](C)CO)=CC(OC3=CC=C(S(=O)(CC)=O)N=C3)=C2,Phase 2
MK-1064,orexin receptor antagonist,,,,COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC,Phase 1
MK-1775,WEE1 kinase inhibitor,WEE1,,,"CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1",Phase 2
MK-1903,niacin receptor agonist,,,,OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12,Phase 2
MK-2048,HIV integrase inhibitor,,,,"CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O",Preclinical
MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",,,"NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1",Phase 2
MK-2295,TRPV antagonist,TRPV1,,,FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1,Phase 2
MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",,,"CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1",Phase 1/Phase 2
MK-2894,prostaglandin inhibitor,PTGER4,,,Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F,Preclinical
MK-3207,calcitonin antagonist,CALCA,,,"Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31",Phase 2
MK-3697,orexin receptor antagonist,HCRTR2,,,"COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC",Phase 2
MK-4074,acetyl-CoA carboxylase inhibitor,,,,COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O,Phase 1
MK-5046,bombesin receptor agonist,"BRS3, GRPR, NMBR",,,"O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F, O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F",Preclinical
MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|",Phase 1
MK-571,leukotriene receptor antagonist,"ABCC2, CYSLTR1",,,"CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|, CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|",Phase 2
MK-6096,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1, C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1",Phase 2
MK-7246,CRTH receptor antagonist,,,,CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,Preclinical
MK-7622,cholinergic receptor agonist,,,,Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1,Phase 2
MK-8033,c-Met inhibitor,MET,,,"Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1",Phase 1
MK-8245,stearoyl-CoA desaturase inhibitor,SCD,,,"OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br",Phase 2
MK-8617,hypoxia inducible factor prolyl hydroxylase inhibitor,,,,COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1,Preclinical
MK-8745,Aurora kinase inhibitor,AURKA,,,"Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1",Preclinical
MK-886,lipoxygenase inhibitor,,,,CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1,Preclinical
MK-8998,T-type calcium channel blocker,,,,CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1,Phase 2
mkc8866,ire1 inhibitor,ERN1,oncology,prostate cancer,COc1cc2c(C)c(CC(=O)N3CCOCC3)c(=O)oc2c(C=O)c1O,
MKT-077,HSP inhibitor,,,,"CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O, CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O",Phase 1
MK2-IN-1,MAP kinase inhibitor,MAPKAPK2,,,"Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1, Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1",Preclinical
MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",,,"CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12",Phase 2
MLN1117,PI3K inhibitor,PIK3CA,,,"Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1",Phase 2
MLN2480,RAF inhibitor,,,,"C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F",Phase 1/Phase 2
MLN8054,Aurora kinase inhibitor,AURKA,,,"OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|",Phase 1
MLN9708,proteasome inhibitor,,,,"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1",Phase 3
ML10302,serotonin receptor partial agonist,"HTR3A, HTR3B, HTR4",,,"COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1",Preclinical
ML130,NOD1 inhibitor,,,,"Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12",Preclinical
ML133,potassium channel blocker,,,,"COc1ccc(CNCc2cccc3ccccc23)cc1, COc1ccc(CNCc2cccc3ccccc23)cc1",Preclinical
ML141,GTPase inhibitor,CDC42,,,"COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|",Preclinical
ML161,protease-activated receptor inhibitor,,,,"CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1",Preclinical
ML167,"CLK inhibitor, DYRK inhibitor","CLK4, DYRK1B",,,"Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1",Preclinical
ML179,liver receptor homolog inverse agonist,NR5A2,,,"FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1",Preclinical
ML193,G protein-coupled receptor antagonist,GPR55,,,"Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C",Preclinical
ML204,transient receptor potential channel antagonist,"TRPC4, TRPC5",,,"Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1",Preclinical
ML213,potassium channel activator,KCNQ4,,,"Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|",Preclinical
ML218,T-type calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I",,,"CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1",Preclinical
ML228,hypoxia inducible factor activator,HIF1A,,,"C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1",Preclinical
ML277,potassium channel activator,KCNQ1,,,"COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1",Preclinical
ML281,serine/threonine kinase inhibitor,STK33,,,"CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O",Preclinical
ML297,inward rectifier potassium channel activator,KCNJ3,,,"Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1",Preclinical
ML298,phospholipase inhibitor,PLD2,,,"Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1",Preclinical
ML314,neurotensin agonist,NTSR1,,,"COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1, COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1",Preclinical
ML323,ubiquitin specific protease inhibitor,USP1,,,"CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1, CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1",Preclinical
ML324,histone lysine demethylase inhibitor,KDM4A,,,"CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1",Preclinical
ML3403,MAP kinase inhibitor,"CYP3A4, MAPK11, MAPK12, MAPK14",,,"CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|",Preclinical
ML347,ALK tyrosine kinase receptor inhibitor,"ACVR1, ACVRL1, BMPR1A",,,"COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
ML348,lysophospholipase inhibitor,LYPLA1,,,"FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1",Preclinical
ml355,lipoxygenase inhibitor,ALOX12,hematology,thrombosis,COc1cccc(CNc2ccc(cc2)S(=O)(=O)Nc3nc4ccccc4s3)c1O,Phase 1
ML365,potassium channel blocker,"KCNK3, KCNK9",,,"COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1",Preclinical
ML786,RAF inhibitor,"BRAF, RAF1",,,"CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1",Preclinical
ML9,myosin light chain kinase inhibitor,TRPC6,,,"Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1",Preclinical
MM-102,WDR5/MLL interaction inhibitor,,,,"CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1, CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1",Preclinical
MM-11253,retinoid receptor antagonist,RARG,,,"CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O",Preclinical
MM-206,STAT inhibitor,,,,Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12,Preclinical
mmaf (hydrochloride),tubulin polymerisation inhibitor,TPPP,oncology,breast cancer,CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O.Cl,
MMPX,phosphodiesterase inhibitor,,,,"COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1",Preclinical
MMV-390048,PI4K inhibitor,,,,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F,Preclinical
MM77,serotonin receptor antagonist,HTR1A,,,"COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1",Preclinical
MN-64,tankyrase inhibitor,TNKS,,,"CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1",Preclinical
MNITMT,lymphocyte inhibitor,,,,"Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O, Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O",Preclinical
mobocertinib,egfr inhibitor,EGFR,oncology,non-small cell lung cancer (nsclc),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34,Phase 2
mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",,,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
moclobemide,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,"depression, anxiety","Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1",Launched
modaline,,,,,Cc1nccnc1N1CCCCC1,Preclinical
moexipril,angiotensin converting enzyme inhibitor,"ACE, ACE2",cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O",Launched
mofegiline,monoamine oxidase inhibitor,"MAOA, MAOB",,,"NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F",Phase 1
mofezolac,cyclooxygenase inhibitor,PTGS1,"rheumatology, orthopedics","rheumatoid arthritis, osteoporosis",COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,Launched
moguisteine,ATP-sensitive potassium channel inhibitor,,,,"CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|, CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|",Phase 2
molidustat,hypoxia inducible factor inhibitor,EGLN2,,,"O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1",Phase 3
molindone,dopamine receptor antagonist,"DRD2, HRH1, HTR2A",neurology/psychiatry,schizophrenia,"CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|, CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|",Launched
molnupiravir,antiviral,,,,CC(C)C(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=NC2=O)NO,Phase 2/Phase 3
molsidomine,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD),"CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1",Launched
mometasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|",Launched
mometasone-furoate,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|",Launched
monastrol,kinesin inhibitor,KIF11,,,"CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|",Preclinical
monensin,bacterial permeability inducer,,infectious disease,gastrointestinal parasites,CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C,Launched
monepantel,mTOR inhibitor,,,,C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N,Preclinical
monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
monocrotaline,antitumor agent,,,,C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|,Preclinical
monoctanoin,,,gastroenterology,gallstones,"CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|, CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|",Launched
monomethyl-fumarate,,,neurology/psychiatry,multiple sclerosis,COC(=O)\C=C\C(O)=O,Launched
monosodium-alpha-luminol,,,,,"Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O",Launched
monostearin,,,,,"CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|",Preclinical
montelukast,leukotriene receptor antagonist,"ALOX5, CYSLTR1","pulmonary, allergy","asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)","CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1",Launched
moprolol,adrenergic receptor antagonist,,"cardiology, ophthalmology, neurology/psychiatry","hypertension, glaucoma, anxiety","COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|, COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|",Launched
moracizine,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias,"CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1",Withdrawn
morantel,acetylcholine receptor agonist,,infectious disease,tapeworm,"CN1CCCN=C1\C=C\c1sccc1C |c:5|, CN1CCCN=C1\C=C\c1sccc1C |c:5|",Launched
morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",,,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
morinidazole,other antibiotic,CYP51A1,,,"Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|",Launched
morniflumate,anti-inflammatory agent,,neurology/psychiatry,pain relief,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1,Launched
moroxydine,antiviral,,infectious disease,influenza A virus infection,NC(=N)\N=C(/N)N1CCOCC1,Launched
moroxydine hcl,antiviral,,infectious disease,influenza a virus infection,NC(=N)NC(=N)N1CCOCC1,Launched
morphothiadin,antiinfective drug,,,,"CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|",Preclinical
mosapride,serotonin receptor agonist,HTR4,gastroenterology,"hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome","CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|",Launched
mosapride citrate,5-ht4 receptor agonist,5-HT4,Gastroenterology,gastroesophageal reflux disease (gerd),CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|,Launched
motapizone,phosphodiesterase inhibitor,,,,CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|,Preclinical
motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",,,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
motolimod,toll-like receptor agonist,TLR8,,,"CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|",Phase 2
moxalactam,bacterial cell wall synthesis inhibitor,,infectious disease,"gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis","CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|, CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|",Launched
moxalactam (sodium salt),,,,,CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:30|,
moxaverine,phosphodiesterase inhibitor,,neurology/psychiatry,spasms,"CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1, CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1",Launched
moxidectin,chloride channel antagonist,,infectious disease,gastrointestinal parasites,"CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C, [H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,t:6,12,45|",Launched
moxifloxacin,bacterial DNA gyrase inhibitor,TOP2A,"otolaryngology, pulmonary, infectious disease","sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections","COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1",Launched
moxisylyte,adrenergic receptor antagonist,,,,"CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C, CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C",Withdrawn
moxonidine,imidazoline receptor agonist,"ADRA2A, ADRA2B, ADRA2C",cardiology,hypertension,"COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|",Launched
mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,"CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|",Launched
MPEP,glutamate receptor antagonist,"GRM1, GRM4, GRM5",,,"Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1",Preclinical
MPI-0479605,mitotic kinase inhibitor,TTK,,,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
Mps-BAY-2a,monopolar spindle 1 kinase inhibitor,TTK,,,"CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12",Preclinical
Mps1-IN-1,monopolar spindle 1 kinase inhibitor,TTK,,,"COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1",Preclinical
Mps1-IN-5,protein kinase inhibitor,,,,"COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O, COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O",Phase 1
MR-16728,acetylcholine release enhancer,,,,"O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|, O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|",Preclinical
MR-948,thromboxane synthase inhibitor,TBXAS1,,,OCCc1ccc(OCCn2ccnc2)cc1,Phase 1
MRK-016,GABA receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,"Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C",Phase 1
MRK-409,benzodiazepine receptor agonist,,,,"Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F",Phase 1
MRK-560,gamma secretase inhibitor,APP,,,"Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|",Preclinical
MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",,,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
MRS-1334,adenosine receptor antagonist,ADORA3,,,"CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|",Preclinical
MRS-1845,calcium channel blocker,,,,"CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|",Preclinical
MRS-2578,purinergic receptor antagonist,P2RY6,,,"S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1",Preclinical
MRS-3777,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12",Preclinical
mrtx849,ras gtpase inhibitor,KRAS,oncology,gastric adenocarcinoma,CN1CCC[C@H]1COc2nc3CN(CCc3c(n2)N4CCN([C@@H](CC#N)C4)C(=O)C(=C)F)c5cccc6cccc(Cl)c56,Phase 3
MRX-2843,MER tyrosine kinase inhibitor,,,,CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|,Phase 1
MS-424,glutamate transporter modulator,,,,C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|,Phase 2
msc2360844,pi3k inhibitor,PIK3CD,rheumatology,lupus,Fc1cccc2-c3c(CS(=O)(=O)c12)c(nn3-c1ccc(CN2CCOCC2)cc1)C(=O)N1CCOCC1,Phase 1
MSDC-0160,insulin sensitizer,,,,"CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|",Phase 2
MSDC-0602K,mitochondrial pyruvate carrier modulator,,,,COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1,Phase 2
MSX-122,CC chemokine receptor antagonist,CXCR4,,,"C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1",Phase 2
mtep,glutamate metabotropic receptor antagonist,GRM5,Neurology,parkinson's disease,Cc1nc(cs1)C#Cc1cccnc1,Preclinical
MTPG,glutamate receptor antagonist,"GRM2, GRM3",,,"C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|",Preclinical
mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",,,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
mupirocin,isoleucyl-tRNA synthetase inhibitor,,infectious disease,impetigo,"C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O",Launched
muscimol,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3",,,"NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1",Phase 1
MUT056399,FABI inhibitor,,,,"CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F",Phase 1
mw-150,p38 mapk inhibitor,MAPK14,neurology/psychiatry,alzheimer's disease,CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1,Preclinical
MY-5445,"phosphodiesterase inhibitor, platelet aggregation inhibitor",PDE5A,,,"Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1",Preclinical
mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
myricetin,"androgen receptor agonist, cytochrome P450 inhibitor",PIK3CG,,,"Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O",Preclinical
myricitrin,PKC inhibitor,"NOS1, PRKCA",,,C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,Preclinical
myristyl-nicotinate,topical sunscreen agent,,,,"CCCCCCCCCCCCCCOC(=O)c1cccnc1, CCCCCCCCCCCCCCOC(=O)c1cccnc1",Phase 1
M8-B,transient receptor potential channel antagonist,TRPM8,,,"COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1",Preclinical
N-(p-amylcinnamoyl)-anthranilic-acid,phospholipase inhibitor,,,,CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1,Preclinical
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide,,,,,CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,Preclinical
n-(4-carboxyphenyl)pentopyranosylamine,,,,,"O[C@H]1CO[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:1,&2:4,&3:15,&4:17,r|",
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide,sigma receptor ligand,,,,"Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1",Preclinical
N-acetyl-D-glucosamine,,"B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP",,,"CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO, CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO",Phase 2/Phase 3
N-acetyl-tyrosine,,,,,"CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|, CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|, CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|",Launched
N-acetylcarnosine,,,,,CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O,Launched
n-acetylcysteine amide,antioxidant,PSEN2,neurology/psychiatry,parkinson's disease,CC(=O)N[C@@H](CS)C(N)=O,Preclinical
N-acetylglycyl-D-glutamic-acid,glutamate receptor agonist,,,,"CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O",Preclinical
N-acetylmannosamine,,,,,"CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|",Phase 2
N-acetyltryptamine,melatonin receptor agonist,,,,"CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12",Preclinical
N-alpha-methylhistamine-dihydrochloride,histamine receptor agonist,HRH4,,,"CNCCc1cnc[nH]1, CNCCc1cnc[nH]1, CNCCc1cnc[nH]1",Phase 3
N-benzylnaltrindole,opioid receptor antagonist,,,,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|",Preclinical
N-cyclohexyl-2-benzothiazolesulfenamide,,,,,C1CCC(CC1)NSc1nc2ccccc2s1,Preclinical
N-hydroxynicotinamide,,,,,ONC(=O)c1cccnc1,Preclinical
"N-methyl-(-)ephedrine-[1R,2S]",,,,,"C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C",Preclinical
N-methylformamide,,,,,CNC=O,Phase 2
N-methyllidocaine-iodide,antiarrhythmic medication,,,,CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,Preclinical
N-methylpyrrolidone,,,,,CN1CCCC1=O,Phase 1
N-methylquipazine,serotonin receptor agonist,,,,"CN1CCN(CC1)c1ccc2ccccc2n1, CN1CCN(CC1)c1ccc2ccccc2n1",Preclinical
N-MPPP,opioid receptor agonist,,,,"CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1",Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide,,,,,"C1CN(CCO1)Sc1nc2ccccc2s1, C1CN(CCO1)Sc1nc2ccccc2s1",Preclinical
N-salicoylaminophenol,ribonucleotide reductase inhibitor,,,,"Oc1ccc(NC(=O)c2ccccc2O)cc1, Oc1ccc(NC(=O)c2ccccc2O)cc1",Phase 1/Phase 2
NAB-2,ubiquitin ligase transport promoter,NEDD4,,,"Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl",Preclinical
nabumetone,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1",Launched
nadide,free radical scavenger,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",,,"NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|",Launched
nadifloxacin,bacterial DNA gyrase inhibitor,,"dermatology, infectious disease","acne vulgaris (AV), skin infections","C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|",Launched
nadolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",cardiology,"angina pectoris, hypertension","CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|",Launched
NADPH,,"DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C",,,,Preclinical
nafadotride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",,,"CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|",Preclinical
nafamostat,serine protease inhibitor,"ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7",cardiology,anticoagulent,"NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N",Launched
nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
naftidrofuryl,adrenergic receptor antagonist,,cardiology,claudication,"CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|",Launched
naftifine,fungal squalene epoxidase inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
naftopidil,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH),"COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|",Launched
naftopidil dihcl,adrenergic receptor antagonist,,urology,benign prostatic hyperplasia (bph),COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,Launched
nalbuphine,"opioid receptor agonist, opioid receptor antagonist","OPRD1, OPRK1, OPRM1",neurology/psychiatry,pain relief,"O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45",Launched
naldemedine,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",gastroenterology,constipation,CC(C)(c1nc(no1)c2ccccc2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)Cc7c6c(c(cc7)O)O4)CC8CC8)O,Launched
nalfurafine,opioid receptor agonist,"OPRK1, OPRM1",nephrology,uremic pruritus,"CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1, CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1",Launched
nalidixic-acid,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections,"CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12",Launched
nalmefene,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O",Launched
nalmefene hcl,opioid receptor antagonist,,pulmonary,respiratory depression,Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=C)CCC35O,Launched
naloxegol,opioid receptor antagonist,OPRM1,gastroenterology,constipation,"COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45",Launched
naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
naloxone-benzoylhydrazone,opioid receptor antagonist,"OPRK1, OPRM1",,,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1",Preclinical
naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
naltriben,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O,Preclinical
naltrindole,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O",Preclinical
namitecan,topoisomerase inhibitor,TOP1,oncology,soft tissue sarcoma (sts),CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(\C=N\OCCN)c3Cn1c2=O |a:2|,Phase 1
Nampt-IN-1,,,,,CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1,Preclinical
NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",,,"COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1",Preclinical
nanchangmycin,other antibiotic,,,,"CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|",Preclinical
napabucasin,STAT inhibitor,STAT3,,,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
napamezole,"adrenergic receptor antagonist, monoamine reuptake inhibitor",,,,"C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|",Preclinical
naphazoline,adrenergic receptor agonist,"ADRA1A, ADRA2A",ophthalmology,eye irritation,"C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|",Launched
naphthoquine-phosphate,antimalarial agent,,infectious disease,malaria,"CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O",Launched
napirimus,immunosuppressant,,,,Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12,Phase 1
naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
naquotinib,EGFR inhibitor,,,,CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C,Phase 3
narasin,antiprotozoal agent,,infectious disease,coccidiosis,"CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|",Launched
naratriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1",Launched
naringenin,"aromatase inhibitor, TRPV antagonist","CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1",,,"Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1",Phase 1
naringeninic-acid,,"HCAR2, PTGR1",,,"OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1",Phase 1
naringin,cytochrome P450 inhibitor,SLCO1A2,,,"C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O",Preclinical
naringin-dihydrochalcone,cytochrome P450 inhibitor,,,,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,Preclinical
narlaprevir,HCV inhibitor,,,,"CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1",Phase 3
NAS-181,serotonin receptor antagonist,HTR1B,,,C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|,Preclinical
nastorazepide,CCK receptor antagonist,CCKBR,,,"CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1",Phase 2
natamycin,fungal ergosterol inhibitor,,"ophthalmology, infectious disease","conjunctivitis, fungal keratosis, blepharitis","C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|",Launched
nateglinide,insulin secretagogue,"ABCC8, KCNJ10, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O",Launched
NAV-26,voltage-gated sodium channel blocker,SCN9A,,,"FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|",Preclinical
navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",,,"CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1",Phase 2
navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",,,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|",Phase 2
navoximod,"indoleamine 2,3-dioxygenase inhibitor",IDO1,oncology,melanoma,O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3,Phase 1
naxagolide,dopamine receptor agonist,,,,CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21,Phase 3
NB-001,antiviral,,,,Nc1ncnc2n(CCNCCCCCO)cnc12,Preclinical
NBI-27914,corticotropin releasing factor receptor antagonist,CRHR1,,,"CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl",Preclinical
NBI-74330-(+/-),CC chemokine receptor antagonist,CXCR3,,,"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|",Preclinical
NBI-98782,vesicular monoamine transporter inhibitor,,,,COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC,Preclinical
NBQX,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B",,,"NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O",Preclinical
NCS-382,GABA receptor antagonist,"GABBR1, GABBR2, SLC52A2",,,"O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|, O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|",Preclinical
ncs-382,gaba receptor antagonist,,Neurology,epilepsy,OC1c2ccccc2CCC\C1=C/C(O)=O,Preclinical
NCX-1015,interleukin sythesis stimulator,,,,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|",Preclinical
NDD-094,,,,,Cc1nccn1Cc1ccccn1,Preclinical
NDT-9513727,complement antagonist,C5AR1,,,"CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1",Preclinical
NE-100,sigma receptor antagonist,SIGMAR1,,,"CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1",Phase 2
nebivolol,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,"O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|",Launched
nebivolol hydrochloride,adrenergic receptor antagonist,,cardiology,hypertension,"O[C@@H](CNC[C@@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,&2:5,&3:7,&4:18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1",
nebracetam,acetylcholine receptor agonist,CHRM1,,,"NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|, NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|",Phase 3
NECA,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",Launched
necrostatin-1,RIPK inhibitor,RIPK1,,,"CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|",Preclinical
necrostatin-2,"necroptosis inhibitor, RIPK inhibitor",RIPK2,,,"CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O",Preclinical
nedaplatin,DNA inhibitor,,oncology,"non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer, non-small cell lung cancer (nsclc), small cell lung cancer, esophageal cancer","N[Pt++]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|",Launched
nedocromil,histamine receptor antagonist,"CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR","neurology/psychiatry, ophthalmology","itching, conjunctivitis","CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O",Launched
nefazodone,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4",,,"CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1",Withdrawn
nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,,,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
nefopam,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,"CN1CCOC(c2ccccc2)c2ccccc2C1, CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|, CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|",Launched
nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
nelfinavir,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),"Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C",Launched
nelociguat,guanylate cyclase stimulant,,,,COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Preclinical
nelotanserin,serotonin receptor inverse agonist,,,,COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C,Phase 2
nemazoline,"adrenergic receptor agonist, adrenergic receptor antagonist",,,,Nc1c(Cl)cc(C=C2NCCN2)cc1Cl,Phase 2
nemiralisib,,,,,CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1,Phase 2
nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|",Launched
nemorexant,orexin receptor antagonist,,,,COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1,Preclinical
nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",,,"CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O",Phase 2
neo-gilurytmal,,,cardiology,cardiac arrythmia,"CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|, CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|, CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|",Launched
neohesperidin,,,,,[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,Preclinical
neohesperidin-dihydrochalcone,,,,,"COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O",Preclinical
neomycin,bacterial 30S ribosomal subunit inhibitor,CXCR4,"infectious disease, gastroenterology","first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections","NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
neostigmine,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,"CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C",Launched
nepafenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",ophthalmology,eye inflammation,"NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N, NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N",Launched
nepicastat,dopamine beta hydroxylase inhibitor,DBH,,,"NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1",Phase 2
nepinalone,antitussive,SIGMAR1,pulmonary,cough suppressant,CC1(CCN2CCCCC2)C(=O)CCc3ccccc13,Preclinical
neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",oncology,breast cancer,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",Launched
nerbacadol,cyclooxygenase inhibitor,,,,Cc1oncc1C(=O)N1CCCCC1,Phase 3
neridronic-acid,bone resorption inhibitor,FDPS,endocrinology,"brittle bone disease, Paget's disease","NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
nesbuvir,RNA polymerase inhibitor,,,,"CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1",Phase 2
netarsudil,rho associated kinase inhibitor,ROCK2,ophthalmology,ocular hypertension,Cc1ccc(C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3)c(C)c1,Launched
neticonazole,other antifungal,,infectious disease,fungal infection,CCCCCOc1ccccc1\C(=C/SC)\n2ccnc2,Preclinical
netilmicin,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections,[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|,Launched
netilmicin (sulfate),,,,,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O,
netilmicin sulfate,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O,Launched
netupitant,"neurokinin receptor antagonist, tachykinin antagonist",TACR1,gastroenterology,"nausea, vomiting","CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1",Launched
neurodazine,neurogenesis of non-pluripotent C2C12 myoblast inducer,,,,"COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1",Preclinical
neuropathiazol,neural stem cell inducer,"BMP2, LIF",,,"CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1",Preclinical
Neu2000,ionotropic glutamate receptor antagonist,,,,OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O,Phase 2
nevanimibe,,,,,CC(C)c1cccc(C(C)C)c1NC(=O)NCC2(CCCC2)c3ccc(cc3)N(C)C,Phase 2
nevanimibe hydrochloride,acat inhibitor,ACAT1,endocrinology,congenital adrenal hyperplasia,CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(CCCC1)c1ccc(cc1)N(C)C.Cl,Phase 2
nevirapine,non-nucleoside reverse transcriptase inhibitor,"CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5",infectious disease,human immunodeficiency virus (HIV-1),"Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12",Launched
nexturastat-A,HDAC inhibitor,"HDAC1, HDAC6",,,"CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1",Preclinical
NFKB-activation-inhibitor-II,NFkB pathway inhibitor,RELA,,,"Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1",Preclinical
NG-nitro-arginine,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,"N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O",Phase 1
NGB-2904,dopamine receptor antagonist,DRD3,,,"Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl",Preclinical
NGD-94-1,dopamine receptor antagonist,DRD4,,,"C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1",Phase 1
NGD-98-2,corticotropin releasing factor receptor antagonist,CRHR1,,,"CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC",Preclinical
NGP555,gamma secretase modulator,,,,CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C,Phase 1
NHI-2,lactate dehydrogenase inhibitor,LDHA,,,"COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F",Preclinical
NH125,eukaryotic translation elongation factor 2 inhibitor,,,,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
NI-57,bromodomain inhibitor,"BRD1, BRPF1, BRPF3",,,"COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N",Preclinical
niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
nialamide,monoamine oxidase inhibitor,"COMT, MAOA, MAOB",,,"O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1",Withdrawn
nibentan,potassium channel blocker,,,,"CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|, CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|",Phase 2
nicainoprol,angiotensin converting enzyme inhibitor,,,,"CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|",Preclinical
nicaraven,free radical scavenger,,,,"C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|, C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|",Phase 3
nicardipine,calcium channel blocker,ADORA3,cardiology,"chronic stable angina, hypertension","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|",Launched
nicardipine hydrochloride,potassium channel blocker,"KCND2, KCND3",Cardiology,angina pectoris,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|",Launched
nicergoline,adrenergic receptor antagonist,ADRA1A,"rheumatology, neurology/psychiatry, cardiology, hematology","Raynaud's disease, migraine headache, atherosclerosis, thrombosis","CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13",Launched
niceritrol,NAD precursor,,endocrinology,hyperlipidemia,"O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1, O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1",Launched
niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
nicodicosapent,sterol regulatory element binding protein (SREBP) inhibitor,,,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1,Preclinical
nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
nicotinamide,protein synthesis stimulant,"BST1, LDHA, PARP1, SIRT5",dermatology,acne vulgaris (AV),"NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1",Launched
nicotinamide riboside,sirt activator,SIRT1,cardiology,cardiomyopathy,NC(=O)c1ccc[n+](c1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Phase 3
nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCC[C@H]1c1cccnc1, CN1CCC[C@H]1c1cccnc1",Launched
nicotine bitartrate,nicotinic receptor agonist,NACHR,Smoking,smoking cessation,CN1CCCC1c1cccnc1,Launched
nicotinyl-alcohol-tartrate,,,"cardiology, neurology/psychiatry","vascular spasm, vertigo","OCc1cccnc1, OCc1cccnc1",Launched
NIDA-41020,cannabinoid receptor antagonist,CNR1,,,"COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
nidufexor,fxr agonist,NR1H4,gastroenterology,non-alcoholic steatohepatitis (nash),Cn1nc(C(=O)N(Cc2ccccc2)Cc3ccc(cc3)C(=O)O)c4COc5ccc(Cl)cc5c14,Phase 2
nifedipine,calcium channel blocker,"CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3",cardiology,"vasospastic angina, chronic stable angina","COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|",Launched
nifekalant,potassium channel blocker,,cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O, Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O",Launched
nifenalol,adrenergic receptor antagonist,"ADRB1, ADRB2",,,"CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|",Launched
nifenazone,analgesic agent,,neurology/psychiatry,pain relief,"Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C",Launched
niflumic-acid,cyclooxygenase inhibitor,"ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9","rheumatology, neurology/psychiatry","joint pain, muscle pain","OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F",Launched
nifuroxazide,bacterial DNA inhibitor,,gastroenterology,"colitis, diarrhea","Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O",Launched
nifursol,bacterial DNA inhibitor,,,,"Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O",Launched
nifurtimox,DNA inhibitor,,infectious disease,"Chagas disease, African trypanosomiasis, chagas disease, african trypanosomiasis","C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1,r|, CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O",Launched
niguldipine-(R)-(-),,,,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r,c:4,9|",Preclinical
niguldipine-(S)-(+),adrenergic receptor antagonist,ADRA1A,,,"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",Preclinical
nikethamide,immunostimulant,,,,"CCN(CC)C(=O)c1cccnc1, CCN(CC)C(=O)c1cccnc1",Withdrawn
nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),"Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F, Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F",Launched
nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
nilvadipine,calcium channel blocker,"CACNA1C, CACNA1D",cardiology,"hypertension, cerebral artery occlusion","COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|",Launched
nimesulide,cyclooxygenase inhibitor,"LTF, PLA2G2E, PTGS1, PTGS2","rheumatology, obstetrics/gynecology","osteoarthritis, menstrual pain","CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O",Launched
nimodipine,calcium channel blocker,"CFTR, NR3C2",hematology,hemorrhage,"COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|",Launched
nimorazole,bacterial DNA inhibitor,,oncology,head and neck squamous cell carcinoma (HNSCC),"[O-][N+](=O)c1cncn1CCN1CCOCC1, [O-][N+](=O)c1cncn1CCN1CCOCC1",Launched
nimustine,"DNA alkylating agent, dna damage inducer",,oncology,brain tumors,"Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1",Phase 2
NIM811,mitochondrial permeability transition inhibitor,,,,"[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C, [H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",Phase 2
ningetinib-tosylate,protein tyrosine kinase inhibitor,,,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C,Preclinical
nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1",Launched
niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
niridazole,phosphofructokinase inhibitor,,infectious disease,schistosomiasis,"[O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O",Launched
nisin,bacterial cell wall synthesis inhibitor,,,,,Phase 1
nisoldipine,calcium channel blocker,"A1BG, CACNA1C, CACNA1D, CACNA1F, CACNA1S",cardiology,hypertension,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |c:4,9|",Launched
nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",,,"CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|",Phase 1
nisoxetine hydrochloride,norepinephrine reuptake inhibitor,,,,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
nitarsone,,,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
nitazoxanide,pyruvate ferredoxin oxidoreductase inhibitor,,gastroenterology,diarrhea,"CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O",Launched
nitecapone,catechol O methyltransferase inhibitor,COMT,,,CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O,Phase 2
nitenpyram,,,infectious disease,flea control,CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O,Launched
nithiamide,bacterial DNA inhibitor,,,,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,,metabolism,tyrosinemia,"OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F",Launched
nitrendipine,calcium channel blocker,"CACNA1D, CACNA2D1, KCNN4",cardiology,hypertension,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|",Launched
nitrocaramiphen,cholinergic receptor antagonist,CHRM1,,,"CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O",Preclinical
nitroflurbiprofen,cyclooxygenase inhibitor,,,,"C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|",Preclinical
nitrofurantoin,DNA inhibitor,,infectious disease,"urinary tract infections, pyelonephritis","[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1",Launched
nitrofurazone,bacterial DNA inhibitor,,infectious disease,first-aid antibiotic,"NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O",Launched
nitromide,,,infectious disease,coccidiosis,"NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O",Launched
nitroscanate,anthelmintic agent,,infectious disease,hookworm,C1=CC(=CC=C1N=C=S)OC2=CC=C(C=C2)[N+](=O)[O-],Launched
nitrosodimethylurea,DNA synthesis inhibitor,,,,CNC(=O)N(C)[NH2+][O-],Preclinical
nitroxoline,cathepsin inhibitor,METAP2,infectious disease,urinary tract infections,"Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12",Launched
nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
nizofenone,ion channel antagonist,,neurology/psychiatry,stroke,"CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O, CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O",Launched
NK-252,"nuclear factor erythroid derived, like (NRF2) activator",NFE2L2,,,"O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1",Preclinical
nkp-1339,hsp inhibitor,,,,Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1,Phase 1
NKP-1339,HSP inhibitor,,,,"Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",Phase 1
NKY-80,adenylyl cyclase inhibitor,ADCY5,,,"Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|",Preclinical
NLG919,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,"O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|",Phase 1
NMDA,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O",Preclinical
NMS-E973,HSP inhibitor,,,,"CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O",Preclinical
NMS-P715,protein kinase inhibitor,,,,CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21,Preclinical
NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",,,"CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1",Phase 2
NMS-873,ATPase inhibitor,VCP,,,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
NM107,RNA polymerase inhibitor,,,,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,Phase 2
nm107,rna polymerase inhibitor,,,,CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O,Phase 2
NN-DNJ,glucosidase inhibitor,GBA,,,CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Preclinical
NNC-05-2090,"GABA uptake inhibitor, GAT inhibitor",SLC6A12,,,"COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1",Preclinical
NNC-55-0396,T-type calcium channel blocker,"CATSPER1, CATSPER2, CATSPER3, CATSPER4",,,"CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1",Preclinical
NNC-63-0532,opioid receptor agonist,OPRL1,,,"COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O",Preclinical
NNC-711,GABA uptake inhibitor,"SIGMAR1, SLC6A1",,,"OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|",Preclinical
NO-ASA,cyclooxygenase inhibitor,PTGS2,,,"CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1",Phase 2
nobiletin,MEK inhibitor,MAP2K1,,,"COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",Preclinical
nocodazole,tubulin polymerization inhibitor,HPGDS,,,"COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1",Preclinical
nolatrexed,thymidylate synthase inhibitor,TYMS,,,Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1,Phase 3
nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|",Launched
nomifensine,"dopamine reuptake inhibitor, noradrenaline uptake inhibitor","DRD2, SLC6A2, SLC6A3",Antidepressant,depression,"CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3,r|",Launched
nonivamide,TRPV agonist,TRPV1,"rheumatology, neurology/psychiatry","rheumatoid arthritis, muscle pain","CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1",Launched
nonoxinol 9,,,null,contraceptive,CCCCCCCCCc1ccc(OCCO)cc1,Launched
nonoxynol-9,membrane integrity inhibitor,,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
nor-binaltorphimine,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",,,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O",Preclinical
norcyclobenzaprine,"adrenergic receptor agonist, serotonin receptor antagonist",,,,"CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|",Preclinical
norelgestromin,,PGR,endocrinology,contraceptive,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|,Launched
norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|",Launched
norethindrone acetate,progesterone receptor agonist,,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
norethindrone-acetate,progesterone receptor agonist,PGR,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|,Launched
norethisterone-enanthate,contraceptive agent,,endocrinology,contraceptive,"CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|",Launched
noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|",Launched
norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
norfluoxetine,selective serotonin reuptake inhibitor (SSRI),HTR2B,,,"NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|, NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|",Phase 1
norgestimate,progesterone receptor agonist,"ESR1, PGR",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|",Launched
norgestrel,progesterone receptor agonist,"AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|",Launched
nornicotine,acetylcholine receptor agonist,,,,C1CN[C@H](C1)c1cccnc1 |r|,Preclinical
nortriptyline,tricyclic antidepressant,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4",neurology/psychiatry,depression,"CNCCC=C1c2ccccc2CCc2ccccc12, CNCCC=C1c2ccccc2CCc2ccccc12",Launched
norvancomycin,,,,,[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O,Preclinical
noscapine,"bradykinin receptor antagonist, tubulin polymerization inhibitor",SIGMAR1,pulmonary,cough suppressant,"COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12",Launched
noscapine hydrochloride,"bradykinin receptor antagonist, tubulin polymerization inhibitor",,pulmonary,cough suppressant,COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12,Launched
NOV-002,,GSR,,,"N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O",Phase 3
novobiocin,bacterial DNA gyrase inhibitor,,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
np-g2-044,,PDCD1,oncology,breast cancer,Cc1occc1C(=O)Nc2nn(Cc3ccc(cc3)C(F)(F)F)c4ccccc24,Phase 1
NPC-01,steroid,,,,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",Phase 3
NPC-15199,ICAM1 antagonist,PPARG,,,"CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",Phase 2
NPPB,chloride channel blocker,"ANO1, CLCN2, CLCN7, TRPA1",,,"OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O",Preclinical
NPS-2143,calcium receptor antagonist,CASR,,,"CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N",Preclinical
NPS-2407,glutamate receptor antagonist,,,,CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1,Preclinical
NPY-5RA972,neuropeptide receptor antagonist,NPY5R,,,"CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12",Preclinical
NQDI-1,caspase inhibitor,CASP3,,,"CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23, CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23",Preclinical
nrc-2694,anticancer agent,EGFR,oncology,non-small cell lung cancer (nsclc),COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1,Phase 1
NS-018,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",,,"C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1",Phase 1/Phase 2
NS-11021,calcium-activated potassium channel activator,KCNMA1,,,"FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",Preclinical
NS-11394,GABA receptor agonist,,,,CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N,Preclinical
NS-1643,voltage-gated potassium channel activator,"KCNH2, KCNH6, KCNMA1",,,"Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F",Preclinical
NS-19504,calcium-activated potassium channel activator,KCNMA1,,,"Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1",Preclinical
NS-309,calcium-activated potassium channel activator,"KCNN1, KCNN2, KCNN3, KCNN4",,,O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl,Preclinical
NS-3623,voltage-gated potassium channel activator,KCNH2,,,"FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1",Preclinical
NS-3861,acetylcholine receptor agonist,"CHRNA3, CHRNB4",,,"CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|",Preclinical
NS-5806,voltage-gated potassium channel activator,KCND3,,,"FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",Preclinical
NS-8,potassium channel agonist,KCNMA1,,,Cc1c([nH]c(N)c1C#N)-c1ccccc1F,Phase 2
NS-8593,calcium-activated potassium channel modulator,"KCNN1, KCNN2, KCNN3",,,"C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1",Preclinical
NS-9283,acetylcholine receptor allosteric modulator,CHRNA4,,,"N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1",Preclinical
NSC-23766,Ras GTPase inhibitor,,,,"CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|",Preclinical
NSC-319726,p53 activator,,,,"C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1",Preclinical
NSC-3852,HDAC inhibitor,HDAC1,,,"Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12",Preclinical
NSC-405020,matrix metalloprotease inhibitor,MMP1,,,"CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|",Preclinical
NSC-4644,"ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor",PYGM,,,"CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12",Phase 2
NSC-5844,CC chemokine receptor agonist,CCR1,,,Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1,Preclinical
NSC-625987,CDK inhibitor,"CDK2, CDK4",,,COc1ccc(OC)c2c1[nH]c1ccccc1c2=S,Preclinical
NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",,,"Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1",Preclinical
NSC-636819,histone demethylase inhibitor,"KDM4A, KDM4B",,,[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O,Preclinical
NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",,,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|",Preclinical
NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,,,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
NSC-95397,CDC inhibitor,"CDC25A, CDC25B",,,"OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|, OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|",Preclinical
NSC-9965,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",,,"CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|",Preclinical
NSI-189,neurotrophic agent,,,,"CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1, CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1",Phase 2
NSP-805,phosphodiesterase inhibitor,,,,"CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|",Preclinical
NTNCB,neuropeptide receptor antagonist,NPY5R,,,"[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|",Preclinical
NTRC-824,neurotensin receptor antagonist,NTSR2,,,"CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O",Preclinical
nTZDpa,PPAR receptor agonist,PPARG,,,"OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1",Preclinical
NT157,IGF-1 inhibitor,IGF1R,,,"Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O",Preclinical
NU-1025,PARP inhibitor,PARP1,,,"Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1",Preclinical
NU-2058,cyclin D inhibitor,"CCNA2, CDK2",,,"Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1, Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1",Preclinical
NU-6027,CDK inhibitor,"CCNA2, CDK2",,,"Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1",Preclinical
NU-7026,"DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",PRKDC,,,"O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1",Preclinical
NU-7441,DNA dependent protein kinase inhibitor,PRKDC,,,"O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1",Preclinical
nuclomedone,immunosuppressant,,,,"Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r,t:9|",Phase 3
nutlin-3,MDM inhibitor,"MDM2, TP53",,,"COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|",Preclinical
nuvenzepine,acetylcholine receptor antagonist,,,,CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12,Preclinical
NVP-ADW742,insulin growth factor receptor inhibitor,IGF1R,,,"Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|",Preclinical
NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",,,"Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|",Preclinical
NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",,,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",,,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 3
NVP-BGJ398,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",,,"CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1",Phase 3
NVP-BHG712,ephrin inhibitor,EPHB4,,,"Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F",Preclinical
NVP-BSK805,JAK inhibitor,JAK2,,,"Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1",Preclinical
NVP-BVU972,MET inhibitor,MET,,,"Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1",Preclinical
NVP-DPP728,dipeptidyl peptidase inhibitor,DPP4,,,"O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N",Phase 2
NVP-HSP990,HSP inhibitor,"HSP90AA1, HSP90AB1",,,"COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1",Phase 1
NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,,,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",,,"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",Preclinical
NVP-TNKS656,tankyrase inhibitor,TNKS2,,,"COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1, COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1",Preclinical
NVP-231,ceramidase inhibitor,CERK,,,"O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1",Preclinical
NVS-PAK1-1,p21 activated kinase inhibitor,PAK1,,,"CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|, CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|",Preclinical
NXY-059,free radical scavenger,,,,"CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O",Phase 3
nystatin,fungal ergosterol inhibitor,,infectious disease,"esophageal candidiasis, skin infections, yeast infection, esophageal candidiasis, skin infections, yeast infection","C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1OC(OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)C(C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O",Launched
nystatin (fungicidin),fungal ergosterol inhibitor,,infectious disease,"esophageal candidiasis, skin infections, yeast infection","C[C@@H]1O[C@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@H](O)[C@H](N)[C@H]1O, C[C@@H]1O[C@H](O[C@@H]2C[C@@H]3O[C@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@H](O)[C@H](N)[C@H]1O",Launched
N20C,glutamate receptor antagonist,,,,"NC(=O)CNCCC(c1ccccc1)c1ccccc1, NC(=O)CNCCC(c1ccccc1)c1ccccc1",Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12",Preclinical
N6-methyladenosine,,,,,"CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Preclinical
N6022,alcohol dehydrogenase inhibitor,ADH5,,,"Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O",Phase 1/Phase 2
O-acetyl-L-serine,,PTGS1,,,CC(=O)OC[C@H](N)C(O)=O,Preclinical
o-mercapto-benzoic-acid,,,,,OC(=O)c1ccccc1S,Preclinical
O-1918,cannabinoid receptor antagonist,,,,"COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|",Preclinical
o-3M3FBS,phospholipase activator,,,,"Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F",Preclinical
O-304,AMPK activator,,,,Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1,Preclinical
OAC1,Oct activator,,,,"O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1",Preclinical
OAC2,Oct activator,POU5F1,,,"O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1",Preclinical
obatoclax,BCL inhibitor,BCL2,,,"COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|",Phase 3
obeticholic-acid,FXR agonist,NR1H4,gastroenterology,primary biliary cholangitis,"CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|",Launched
obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning","O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1, O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1",Launched
ocaperidone,serotonin receptor antagonist,,,,Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O,Preclinical
ochromycinone,STAT inhibitor,STAT3,,,C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21,Phase 1
ocinaplon,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA5",,,"O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1, O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1",Phase 3
oclacitinib,jak inhibitor,JAK2,dermatology,dermatitis,CNS(=O)(=O)C[C@@H]1CC[C@H](CC1)N(C)c2[nH]cnc3nccc23,Launched
OCO-1112,cholesterol inhibitor,,,,"CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O",Phase 2
octadecan-1-ol,,,,,CCCCCCCCCCCCCCCCCCO,Preclinical
octamethyltrisiloxane,,,,,C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,Preclinical
octenidine,membrane integrity inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1",Launched
octinoxate,,,dermatology,sunscreen lotion,"CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1, CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|",Launched
octisalate,,,dermatology,sunscreen lotion,"CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|, CCCC[C@@H](CC)COC(=O)c1ccccc1O",Launched
octocrylene,,,dermatology,sunscreen lotion,"CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1, CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|",Launched
octodrine,antitumor agent,,,,"CC(C)CCC[C@@H](C)N |&1:6,r|, CC(C)CCC[C@@H](C)N |&1:6,r|",Preclinical
octopamine,"trace amine associated receptor agonist, neurotransmitter","ADRA2A, ADRA2B, ADRA2C, F10, TAAR1",,,"NC[C@@H](O)c1ccc(O)cc1 |&1:2,r|, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
octreotide,somatostatin receptor agonist,"SSTR2, SSTR3, SSTR5","gastroenterology, endocrinology, oncology","diarrhea, acromegaly, carcinoid tumors","C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|",Launched
OC000459,CRTH receptor antagonist,PTGDR2,,,"Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O",Phase 2
odanacatib,cathepsin inhibitor,CTSK,,,"CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N",Phase 3
odm-203,fgfr inhibitor,"FGFR1, FLT1",oncology,breast cancer,Cn1cc(cn1)c2ccc3c(c2)ncn3c4cc(NS(=O)(=O)C5CC5)cc(c4)c6ccc(F)cc6F,Phase 1
ODQ,guanylyl cyclase inhibitor,"GUCY1A2, GUCY1A3, GUCY1B3",,,"O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12",Preclinical
OF-1,bromodomain inhibitor,BRD1,,,"COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C",Preclinical
ofloxacin,bacterial DNA gyrase inhibitor,,"infectious disease, otolaryngology, gastroenterology, endocrinology","respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections","C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|",Launched
ofloxacin (floxin),bacterial dna gyrase inhibitor,,"infectious disease, otolaryngology, gastroenterology, endocrinology","respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections",CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,Launched
OG-L002,histone lysine demethylase inhibitor,KDM1A,,,"N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1",Preclinical
ogerin,G protein-coupled receptor modulator,,,,Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO,Preclinical
oglemilast,phosphodiesterase inhibitor,,,,"CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1",Phase 2
oglufanide,VEGF antagonist,,,,N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O,Phase 2
OICR-9429,WDR5/MLL interaction inhibitor,WDR5,,,"CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1",Preclinical
olanexidine,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections,CCCCCCCCN=C(N)NC(=NCC1=CC(=C(C=C1)Cl)Cl)N,Launched
olanzapine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder","CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|",Launched
olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
OLDA,TRPV agonist,GPR119,,,"CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1",Preclinical
oleamide,cannabinoid receptor agonist,"HTR7, PLA2G2A",,,"CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O",Preclinical
oleandrin,Na/K-ATPase inhibitor,,,,"CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|",Phase 1
oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,,,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|",Preclinical
oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",,,"CCCCCCCC\C=C/CCCCCCCC(=O)NCCO, CCCCCCCC\C=C/CCCCCCCC(=O)NCCO",Preclinical
olesoxime,apoptosis stimulant,,,,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|",Phase 2/Phase 3
oleuropein,"estrogen receptor agonist, antioxidant",GPER1,null,fungal infection,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)\C(=C\C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |t:4|, COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|",Preclinical
oligomycin-A,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,,,"[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|",Preclinical
olinciguat,guanylyl cyclase activator,"GUCY1A1, GUCY1A2",hematology,anemia,FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NC[C@](C(N)=O)(O)C(F)(F)F)=N4)=N2,Phase 2
olmesartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O",Launched
olmesartan-medoxomil,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O",Launched
olmutinib,"Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor","BTK, EGFR",oncology,non-small cell lung cancer (NSCLC),"CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1",Launched
olodanrigan,angiotensin antagonist,,,,COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1,Phase 2
olomoucine,CDK inhibitor,"CDK1, CDK2, CDK5, MAPK1",,,"Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12",Preclinical
olopatadine,histamine receptor antagonist,"HRH1, S100A1, S100A12, S100A13, S100A2, S100B",ophthalmology,conjunctivitis,"CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12",Launched
olprinone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,"Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N",Launched
olsalazine,cyclooxygenase inhibitor,"IFNG, TPMT",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O",Launched
oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,,,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
olumacostat-glasaretil,acetyl-CoA carboxylase inhibitor,,,,CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC,Phase 3
olutasidenib,isocitrate dehydrogenase inhibitor,IDH1,oncology,glioma,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,Phase 1/Phase 2
olvanil,TRPV agonist,"CNR1, GPR119, TRPV1",,,"CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1",Preclinical
omaciclovir,dna polymerase inhibitor,,infectious disease,virus herpes simplex (hsv),Nc1nc(=O)c2ncn(C[C@H](CO)CCO)c2[nH]1,Preclinical
omadacycline,bacterial 30S ribosomal subunit inhibitor,,infectious disease,pneumonia,"[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26,&2:19|, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C",Launched
omadacycline (mesylate),bacterial 30s ribosomal subunit inhibitor,,infectious disease,pneumonia,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C,Launched
omapatrilat,metalloproteinase inhibitor,"ACE, MME",,,[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O,Preclinical
omarigliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F",Launched
ombitasvir,HCV inhibitor,,infectious disease,hepatitis C,"COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1",Launched
ombrabulin,tubulin polymerization inhibitor,,,,COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,Phase 3
OMDM-2,FAAH inhibitor,GPR119,,,"CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1",Preclinical
omecamtiv-mecarbil,cardiac myosin activator,MYBPC3,,,"COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1",Phase 3
omega-(4-iodophenyl)pentadecanoic-acid,,,,,OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1,Preclinical
omega-3-acid-esters,cholesterol inhibitor,,,,"CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC",Launched
omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|",Launched
omeprazole-magnesium,proton pump inhibitor,"ATP4A, ATP4B",gastroenterology,"gastroesophageal reflux disease (GERD), heartburn",COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,Launched
omeprazole-sulfide,ATPase inhibitor,,,,"COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1, COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1",Phase 1
omidenepag,prostanoid receptor agonist,PTGER2,ophthalmology,intraocular pressure,CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4,Launched
omtriptolide,ERK1 and ERK2 phosphorylation inhibitor,,,,[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|,Preclinical
ON-01500,apoptosis stimulant,,,,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1",Preclinical
oncrasin-1,apoptosis stimulant,,,,"Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1",Preclinical
ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,,,"Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|",Phase 2
onc206,dopamine receptor antagonist,DRD2,oncology,glioblastoma,"Fc1ccc(CN2C3=NCCN3C3=C(CN(Cc4ccccc4)CC3)C2=O)c(F)c1 |t:7,13|",Phase 1
ondansetron,"serotonin receptor antagonist, 5-ht3 receptor antagonist","HTR3A, HTR3B, HTR3C, HTR3D, HTR3E","Alcoholism, gastroenterology","abstinence from alcohol, nausea, vomiting","Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C",Launched
ondansetron (zofran),"serotonin receptor antagonist, 5-ht3 receptor antagonist",,"Alcoholism, gastroenterology","abstinence from alcohol, nausea, vomiting",Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C,Launched
ONO-AE3-208,prostanoid receptor antagonist,PTGER4,,,"C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|",Preclinical
ono-4059,bruton's tyrosine kinase (btk) inhibitor,,,,Nc1ncnc2n(C3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12,Phase 1
ONO-4059,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,"CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O",Phase 1
ONO-4817,matrix metalloprotease inhibitor,MMP8,,,"CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1",Phase 1
ONO-8130,prostanoid receptor antagonist,PTGER1,,,"CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1",Preclinical
ONX-0914,proteasome inhibitor,,,,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1,Preclinical
ON123300,CDK inhibitor,"CDK4, NUAK1, PDGFRB",,,"CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1",Preclinical
OP-0595,beta lactamase inhibitor,,,,NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O,Preclinical
opaganib,angiogenesis inhibitor,"DEGS1, DEGS2, SPHK2",Cardiology,atherosclerosis,Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2,Phase 2/Phase 3
OPC-21268,vasopressin receptor antagonist,"AVPR1A, AVPR2, OXTR",,,"CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12",Phase 1
opicapone,catechol O methyltransferase inhibitor,COMT,,,"Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O",Phase 3
opipramol,sigma receptor agonist,,neurology/psychiatry,generalized anxiety disorder (GAD),"OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|",Launched
oprozomib,proteasome inhibitor,,,,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,Phase 1/Phase 2
oprozomib (onx 0912),proteasome inhibitor,,,,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
or-1896,phosphodiesterase inhibitor,"PDE3A, SMPD1",cardiology,congestive heart failure,C[C@@H]1CC(=O)NN=C1c1ccc(NC(C)=O)cc1 |c:6|,Phase 1
OR-486,catechol O methyltransferase inhibitor,COMT,,,"Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O",Preclinical
orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",,,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
orbifloxacin,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Launched
orelabrutinib,,,,,NC(=O)c1ccc(nc1c2ccc(Oc3ccccc3)cc2)C4CCN(CC4)C(=O)C=C,Phase 3
ORE1001,angiotensin converting enzyme inhibitor,ACE2,,,"CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O",Phase 1/Phase 2
ORG-12962,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",,,"FC(F)(F)c1ccc(nc1Cl)N1CCNCC1, FC(F)(F)c1ccc(nc1Cl)N1CCNCC1",Phase 2
ORG-25543,glycine transporter inhibitor,"GLRB, SLC6A5",,,"COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C",Preclinical
ORG-26576,glutamate receptor modulator,,,,O=C1N2CCC[C@H]2COc2ncccc12,Phase 2
ORG-27569,cannabinoid receptor modulator,CNR1,,,"CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1",Preclinical
ORG-9768,adrenergic receptor antagonist,ADRA2A,,,"CC1(CN)Cc2ccccc2C1, CC1(CN)Cc2ccccc2C1",Phase 1
oridonin,BCL inhibitor,BCL2,,,[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O,Preclinical
oridonin (isodonol),bcl inhibitor,,,,O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C,Preclinical
oritavancin,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections,[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O,Launched
oritavancin (diphosphate),,,,,CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2,
orlistat,lipase inhibitor,"CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP",endocrinology,weight-loss aid,"CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O",Launched
ormeloxifene,selective estrogen receptor modulator (SERM),,endocrinology,contraceptive,COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1,Launched
ormetoprim,folic acid antagonist,,infectious disease,coccidiosis,COC1=CC(C)=C(CC2=C(N)N=C(N)N=C2)C=C1OC,Launched
ornidazole,antiprotozoal agent,,infectious disease,protozoan infection,"Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|",Launched
ornipressin,vasoconstrictor,,,,[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O,Preclinical
ornithine,NFkB pathway modulator,GPRC6A,,,"Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|",Launched
orotic-acid,,DHODH,,,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
orphanin-fq,opioid receptor agonist,"OPRL1, OPRM1",,,"CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O",Phase 1
orphenadrine,acetylcholine receptor antagonist,,neurology/psychiatry,muscle pain,"CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|",Launched
orteronel,"androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor",CYP17A1,,,"CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12",Phase 3
ORY-1001,histone lysine demethylase inhibitor,KDM1A,,,"NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1",Phase 1/Phase 2
oseltamivir-carboxylate,neuraminidase inhibitor,,infectious disease,influenza A virus infection,"CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|, CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|",Launched
oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|",Launched
osemozotan,serotonin receptor agonist,HTR1A,,,C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1,Phase 2/Phase 3
OSI-027,mTOR inhibitor,MTOR,,,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|",Phase 1
OSI-420,EGFR inhibitor,EGFR,,,"COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO",Preclinical
OSI-930,"KIT inhibitor, VEGFR inhibitor","FLT1, KDR, KIT",,,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
osilodrostat,cytochrome P450 inhibitor,,,,Fc1cc(ccc1[C@H]1CCc2cncn12)C#N,Launched
osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12",Launched
ospemifene,selective estrogen receptor modulator (SERM),"ESR1, ESR2","obstetrics/gynecology, endocrinology","vaginal atrophy, dyspareunia, menopause","OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1",Launched
ostarine,androgen receptor modulator,AR,,,"C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Phase 3
osthol,calcium channel blocker,,,,"COc1ccc2ccc(=O)oc2c1CC=C(C)C, COc1ccc2ccc(=O)oc2c1CC=C(C)C",Preclinical
OT-R-antagonist-1,oxytocin receptor antagonist,"AVPR1A, OXTR",,,CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1,Preclinical
otamixaban,coagulation factor inhibitor,F10,,,"COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1",Phase 3
otenzepad,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,"CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|",Phase 3
oteseconazole,other antifungal,,infectious disease,vulvovaginal candidiasis,O[C@@](Cn1cnnn1)(c2ccc(F)cc2F)C(F)(F)c3ccc(cn3)c4ccc(OCC(F)(F)F)cc4,Phase 3
otilonium,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome,"CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC",Launched
OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,,,"CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|",Phase 1/Phase 2
OTS514,TOPK inhibitor,,,,"C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12",Preclinical
OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",,,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|",Phase 1/Phase 2
ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|",Launched
OXA-06,rho associated kinase inhibitor,"ROCK1, ROCK2",,,"Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12",Preclinical
oxaceprol,anti-inflammatory agent,,,,CC(=O)N1C[C@H](O)C[C@H]1C(O)=O,Preclinical
oxacillin,bacterial cell wall synthesis inhibitor,,infectious disease,staphylococcal infections,"Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1",Launched
oxacyclohexadecan-2-one,protein kinase inhibitor,,,,O=C1CCCCCCCCCCCCCCO1,Preclinical
oxaliplatin,DNA inhibitor,,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
oxaloacetate,glutamate release inhibitor,,,,"OC(=O)C=C(O)C(O)=O, OC(=O)C=C(O)C(O)=O",Phase 2/Phase 3
oxamniquine,dna inhibitor,,infectious disease,schistosomiasis,[O-][N+](=O)c1c(cc2c(c1)NC(CC2)CNC(C)C)CO,Withdrawn
oxantel,anthelmintic agent,,infectious disease,gastrointestinal parasites,"CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|, CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|",Launched
oxaprozin,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1",Launched
oxatomide,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
oxelaidin,antitussive,,pulmonary,cough suppressant,"CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1",Launched
oxethazaine,local anesthetic,,neurology/psychiatry,local anesthetic,"CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1",Launched
OXF-BD-02,bromodomain inhibitor,BRD4,,,"Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|",Preclinical
oxfendazole,anthelmintic agent,,infectious disease,"lungworms, tapeworm, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|, COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|, COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|",Launched
oxfenicine,carnitine palmitoyltransferase inhibitor,"CPT1A, CPT1B",,,"N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1",Phase 1
oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
oxiconazole,bacterial cell wall synthesis inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1",Launched
oxidopamine,neurotoxin,,,,"NCCc1cc(O)c(O)cc1O, NCCc1cc(O)c(O)cc1O",Preclinical
oxiniacic-acid,,,,,"OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1",Preclinical
oxiperomide,dopamine receptor antagonist,,,,O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
oxiracetam,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia,"NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O",Launched
oxolamine,antitussive,,pulmonary,cough suppressant,"CCN(CC)CCc1nc(no1)-c1ccccc1, CCN(CC)CCc1nc(no1)-c1ccccc1",Launched
oxolinic-acid,bacterial DNA gyrase inhibitor,,,,"CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12",Preclinical
oxonic-acid,uricase inhibitor,,,,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
oxotremorine-M,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O",Preclinical
oxotremorine-sesquifumarate,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1",Preclinical
oxprenolol,adrenergic receptor antagonist,ADRB1,cardiology,"angina pectoris, hypertension, cardiac arrythmia","CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|",Launched
oxybenzone,lipase inhibitor,LIPE,dermatology,sunscreen lotion,"COc1ccc(C(=O)c2ccccc2)c(O)c1, COc1ccc(C(=O)c2ccccc2)c(O)c1",Launched
oxybuprocaine,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic,"CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC",Launched
oxybutynin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",urology,urinary incontinence,"CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|",Launched
oxybutynin chloride,acetylcholine receptor antagonist,,urology,urinary incontinence,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
oxyclozanide,,,infectious disease,fascioliasis,"Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl",Launched
oxyfedrine,adrenergic receptor agonist,,cardiology,angina pectoris,"COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1, COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1",Launched
oxymatrine,,,,,"[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H], [O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23",Launched
oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|",Launched
oxymetholone,,,,,CC1(O)CCC2C3CCC4CC(=O)C(CC4(C)C3CCC12C)C=O,
oxyphenbutazone,cyclooxygenase inhibitor,,,,"CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|, CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|",Withdrawn
oxyphencyclimine,cholinergic receptor antagonist,,gastroenterology,peptic ulcer disease (PUD),"CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|, CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|, CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|",Launched
oxyphenonium,cholinergic receptor antagonist,"CHRM1, CHRM3",gastroenterology,peptic ulcer disease (PUD),CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
oxypurinol,xanthine oxidase inhibitor,XDH,,,"O=c1nc2[nH][nH]cc2c(=O)[nH]1, O=c1nc2[nH][nH]cc2c(=O)[nH]1",Phase 2/Phase 3
oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,"Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12",Launched
oxytetracycline,bacterial 30S ribosomal subunit inhibitor,30S-RIBOSOMAL SUBUNIT,"infectious disease, urology, Infectious disease, Infectious disease, infectious disease, urology","chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease, first-aid antibiotic, first-aid antibiotic, chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, lyme disease","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3[C@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(N)=O)C1=O |&1:27,&2:8|",Launched
oxytetracycline dihydrate,,,,,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,
oxytocin,oxytocin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",obstetrics/gynecology,labor induction,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O",Launched
ozagrel,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke,"OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1",Launched
ozanimod,sphingosine 1-phosphate receptor agonist,S1PR1,,,"CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO",Phase 3
ozenoxacin,antiinfective drug,,,,CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1,Phase 3
ozolinone,diuretic,,,,"CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|",Phase 3
O4I1,Oct inducer,POU5F1,,,"COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1",Preclinical
O6-benzylguanine,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,"Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1",Phase 3
p-dimethylinamyl-benzoate,,,,,"CCCCCOC(=O)c1ccc(cc1)N(C)C, CCCCCOC(=O)c1ccc(cc1)N(C)C",Preclinical
PA-452,retinoid receptor antagonist,RXRA,,,"CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C",Preclinical
PAC-1,caspase activator,CASP3,,,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|",Launched
PACOCF3,phospholipase inhibitor,PLA2G4A,,,"CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F",Preclinical
pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",,,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|",Phase 3
padimate o,,,dermatology,sunscreen lotion,O=C(OCC(CC)CCCC)c1ccc(N(C)C)cc1,Launched
padsevonil,antiepileptic,,,,COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F,Phase 3
paeoniflorin,anticonvulsant,,,,"C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",Preclinical
paeonol,anti-inflammatory agent,,,,"COc1ccc(C(C)=O)c(O)c1, COc1ccc(C(C)=O)c(O)c1",Preclinical
pafuramidine,DNA synthesis inhibitor,,,,"CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC, CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC",Phase 3
pagoclone,GABA receptor agonist,,,,"CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|",Phase 2/Phase 3
palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
palifosfamide,DNA alkylating agent,,,,"OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl",Phase 3
paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, HTR2A",neurology/psychiatry,schizophrenia,"Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|",Launched
paliperidone palmitate,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(=C(C)N=C12)CCN3CCC(CC3)c4noc5cc(F)ccc45,Launched
palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,,,"COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC",Preclinical
palmitoleic-acid,,,,,"CCCCCC\C=C/CCCCCCCC(O)=O, CCCCCC\C=C/CCCCCCCC(O)=O",Preclinical
palmitoylcarnitine,protein kinase inhibitor,,,,"CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|",Preclinical
palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",,,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,,,"COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|",Phase 1
palonosetron,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting","O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2, O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2",Launched
palosuran,urotensin receptor antagonist,UTS2R,,,"Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1, Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1",Phase 2
palovarotene,retinoid receptor agonist,RARG,,,"CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12",Phase 3
pamabrom,diuretic,,gastroenterology,bloating,"CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O, CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O",Launched
pamapimod,p38 mapk inhibitor,"MAPK10, MAPK11, MAPK14, MAPK8, MAPK9",rheumatology,rheumatoid arthritis,O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C,Phase 2
pamicogrel,cyclooxygenase inhibitor,PTGS2,hematology,thrombosis,O=C(OCC)CN1C(C2=NC(C3=CC=C(OC)C=C3)=C(C4=CC=C(OC)C=C4)S2)=CC=C1,Preclinical
pamidronate,bone resorption inhibitor,FDPS,"endocrinology, oncology, hematologic malignancy","hypercalcemia, Paget's disease, breast cancer, multiple myeloma","NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O",Launched
pamiparib,PARP inhibitor,,,,C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34,Phase 3
pamufetinib,,,,,CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC,Phase 1
pancuronium,acetylcholine receptor antagonist,"CHRM2, CHRM3, CHRNA1, CHRNA2","critical care, neurology/psychiatry","endotracheal intubation, muscle relaxant","CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1",Launched
panipenem,antibacterial ,,,,C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|,Preclinical
panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
pantethine,coenzyme A precursor,,,,"CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO",Launched
panthenol (dl),,,gastroenterology,paralytic ileus,"CC(C)(CO)[C@@H](O)C(=O)NCCCO |&1:5,r|",Launched
pantoprazole,ATPase inhibitor,ATP4A,gastroenterology,"gastroesophageal reflux disease (gerd), erosive esophagitis (ee), zollinger-ellison syndrome, gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome","COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|",Launched
pantoprazole (sodium),h+/k+-atpase inhibitor,A1BG,Infectious disease,tuberculosis,COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |r|,Launched
pantothenic-acid,coenzyme A precursor,,,,"CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O",Launched
PAOPA,dopamine receptor modulator,DRD2,,,"NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O",Preclinical
papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC",Launched
paquinimod,S100A9 inhibitor,,,,CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1,Phase 2
para-toluenesulfonamide,,"CA12, CA2, CA6, CA9",,,"Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O",Phase 3
paracetamol,cyclooxygenase inhibitor,"FAAH, PTGS1, PTGS2, TRPV1","neurology/psychiatry, endocrinology","pain relief, fever","CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1",Launched
parachlorophenol,antiinfective drug,,infectious disease,first-aid antiseptic,"Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1",Launched
paramethadione,anticonvulsant,CACNA1G,neurology/psychiatry,seizures,"CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|, CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|",Launched
paraxanthine,adenosine receptor antagonist,,,,"Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12",Phase 1
parbendazole,tubulin polymerization inhibitor,TUBB,,,"CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1",Preclinical
parcetasal,anti-inflammatory agent,,,,"CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|",Preclinical
pardoprunox,"dopamine receptor agonist, serotonin receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",,,"CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12",Phase 3
parecoxib,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief,"CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1",Launched
parethoxycaine,local anesthetic,,,,CCOc1ccc(cc1)C(=O)OCCN(CC)CC,Preclinical
pargyline,monoamine oxidase inhibitor,"MAOA, MAOB",cardiology,hypertension,"CN(CC#C)Cc1ccccc1, CN(CC#C)Cc1ccccc1",Launched
paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism","C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1",Launched
paritaprevir,HCV inhibitor,,infectious disease,hepatitis C,"Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|, Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|, Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|",Launched
paromomycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,amebiasis,"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4",neurology/psychiatry,"depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder","Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1",Launched
paroxypropione,gonadotropin inhibitor,,,,"CCC(=O)c1ccc(O)cc1, CCC(=O)c1ccc(O)cc1",Launched
parsaclisib,PI3K inhibitor,,,,CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12,Phase 2
parthenolide,NFkB pathway inhibitor,,,,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",Phase 1
parthenolide-(-),NFkB pathway inhibitor,HDAC1,,,"C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|, C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|",Preclinical
parthenolide-(alternate-stereo),NFkB pathway inhibitor,"IKBKB, RELA",,,"C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",Preclinical
pasireotide,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5",endocrinology,"Cushing's syndrome, acromegaly","NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1, NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1",Launched
PAT-1251,lysyl oxidase inhibitor,,,,NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F,Phase 1
pavinetant,neurokinin receptor antagonist,,,,CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,Phase 2
pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
pazufloxacin,topoisomerase inhibitor,,infectious disease,"pneumonia, peritonitis, bacterial septicemia","C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1, C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1",Launched
PBI-4050,free fatty acid receptor agonist,,,,CCCCCc1cccc(CC(O)=O)c1,Phase 2/Phase 3
PBT-1033,chelating agent,,,,CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,Preclinical
PCA-4248,platelet activating factor receptor antagonist,PTAFR,,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|",Phase 1
PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",,,"CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO",Phase 3
PCI-27483,ERK1 and ERK2 phosphorylation inhibitor,,,,NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O,Phase 2
PCI-29732,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,"Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1",Preclinical
PCI-34051,HDAC inhibitor,"HDAC1, HDAC10, HDAC6, HDAC8",,,"COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1",Preclinical
PCO-400,potassium channel activator,KCNJ8,,,"CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|",Phase 1
pco371,,PTH1R,endocrinology,hypoparathyroidism,Cc1cc(cc(C)c1CCS(=O)(=O)N1CCC2(CC1)NC(=NC2=O)c1ccc(OC(F)(F)F)cc1)N1C(=O)NC(=O)C1(C)C |c:22|,Phase 1
PD-0325901,MEK inhibitor,MAP2K1,,,"OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F",Phase 2
PD-102807,acetylcholine receptor antagonist,CHRM4,,,"CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|",Preclinical
PD-118057,potassium channel activator,KCNH2,,,"OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1",Preclinical
PD-123319,angiotensin antagonist,AGTR2,,,"CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C",Phase 1
PD-128907,dopamine receptor agonist,"DRD2, DRD3",,,"CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21",Preclinical
PD-153035,EGFR inhibitor,"EGFR, KDR",,,"COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC",Phase 1
PD-156707,endothelin receptor antagonist,"EDNRA, EDNRB",,,COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1,Preclinical
PD-158780,EGFR inhibitor,EGFR,,,"CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1",Preclinical
PD-160170,neuropeptide receptor antagonist,NPY1R,,,"CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O",Preclinical
PD-161570,FGFR inhibitor,FGFR1,,,"CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl",Preclinical
PD-166285,SRC inhibitor,"EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1",,,"CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1",Preclinical
PD-166793,"collagenase inhibitor, metalloproteinase inhibitor","MMP13, MMP2, MMP3",,,"CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O",Preclinical
PD-168077,dopamine receptor agonist,DRD2,,,Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N,Preclinical
PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",,,"Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1",Preclinical
PD-168568,dopamine receptor antagonist,"DRD2, DRD4",,,"Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|",Preclinical
PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",,,"CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1",Preclinical
PD-173212,calcium channel blocker,CACNA1B,,,"CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C",Preclinical
PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",,,"Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F",Phase 2
PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",,,"Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1",Preclinical
PD-318088,MEK inhibitor,,,,"OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|",Preclinical
PD-407824,PKC inhibitor,WEE1,,,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
PD-81723,adenosine receptor agonist,ADORA1,,,"Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C",Preclinical
PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,"COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1",Preclinical
PDD-00017273,PARG inhibitor,,,,"Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1, Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1",Preclinical
PDE10-IN-1,phosphodiesterase inhibitor,PDE10A,,,Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1,Preclinical
PDP-EA,FAAH activator,FAAH,,,"CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1",Preclinical
PD1-PDL-inhibitor-1,programmed death ligand inhibitor,CD274,,,"COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O",Preclinical
peficitinib,JAK inhibitor,"JAK1, JAK2, JAK3",rheumatology,rheumatoid arthritis,"NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|, NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2, NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|",Launched
pefloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","gastrointestinal infections, urethritis, gonorrhea, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1",Launched
pelanserin,serotonin receptor antagonist,HTR2A,,,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,Phase 2
pelitinib,EGFR inhibitor,EGFR,,,"CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",Phase 2
pelrinone,phosphodiesterase inhibitor,,,,Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1,Phase 2
pemafibrate,PPAR receptor agonist,,,,CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O,Phase 3
pemetrexed,"dihydrofolate reductase inhibitor, thymidylate synthase inhibitor","ATIC, DHFR, GART, TYMS",oncology,"non-small cell lung cancer (NSCLC), mesothelioma","Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1",Launched
pemigatinib,fgfr inhibitor,"FGFR1, FGFR2, FGFR3",oncology,colorectal cancer,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,Launched
pemirolast,mediator release inhibitor,HRH1,pulmonary,asthma,"Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O",Launched
pempidine,ganglionic blocker,,cardiology,hypertension,"CN1C(C)(C)CCCC1(C)C, CN1C(C)(C)CCCC1(C)C, CN1C(C)(C)CCCC1(C)C",Launched
penbutolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B",cardiology,hypertension,"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1",Launched
penciclovir,DNA directed DNA polymerase inhibitor,,dental,cold sore,"Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1",Launched
penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
penicillamine-(D),chelating agent,,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
penicillamine-(racemic),,,,,"CC(C)(S)[C@@H](N)C(O)=O |&1:4|, CC(C)(S)[C@@H](N)C(O)=O |&1:4|",Launched
penicillin-v-potassium,bacterial cell wall synthesis inhibitor,,infectious disease,"pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever","CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O",Launched
pentacosanoic-acid,,,,,"CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O",Preclinical
pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
pentetic-acid,chelating agent,,,,"OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O",Phase 2
pentolinium,cholinergic receptor antagonist,"CHRNA10, CHRNA3, CHRNA4, CHRNB4",cardiology,hypertension,"C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1",Launched
pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor, adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
pentoxifylline,phosphodiesterase inhibitor,"ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF",cardiology,claudication,"CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O",Launched
pentylenetetrazol,GABA receptor antagonist,,,,"C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1",Withdrawn
peposertib,DNA dependent protein kinase inhibitor,,,,COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1,Phase 1/Phase 2
pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",,,"CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O",Preclinical
peramivir,neuraminidase inhibitor,,infectious disease,influenza A virus infection,"CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O",Launched
perchlozone,,,infectious disease,tuberculosis,"NC(=S)NN=Cc1ccncc1, NC(=S)N\N=C\c1ccncc1",Launched
peretinoin,retinoid receptor agonist,RXRA,,,"CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O",Phase 3
perfluamine,,,,,"FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F, FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F",Launched
perflubron,contrast agent,,radiology,contrast agent,"FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br",Launched
perfluorodecalin,,,dermatology,cosmetic,FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F,Launched
perfluorohexyloctane,,,,,CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,Launched
pergolide,dopamine receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,"CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",Withdrawn
perhexiline,carnitine palmitoyltransferase inhibitor,CPT1A,cardiology,angina pectoris,"C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|",Launched
perhexiline maleate,potassium channel blocker,"A1BG, KCNH2, SCN5A",Cardiology,angina pectoris,"C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14,r|",Launched
periciazine,adrenergic receptor antagonist,"ADRA1B, ADRA2A, AR, DRD1",neurology/psychiatry,psychosis,OC1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(C=C24)C#N)CC1,Launched
perifosine,AKT inhibitor,AKT1,,,"CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|",Phase 3
perillyl-alcohol,"apoptosis stimulant, farnesyltransferase inhibitor",FNTA,,,"CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|",Phase 2
perindopril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction, coronary artery disease (CAD)","CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC",Launched
perindoprilat,angiotensin converting enzyme inhibitor,ACE,,,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O,Phase 2
permethrin,,,infectious disease,lice,"CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|",Launched
perospirone,"dopamine receptor antagonist, serotonin receptor antagonist","DRD2, DRD3, DRD4",neurology/psychiatry,"schizophrenia, bipolar disorder","O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12",Launched
perphenazine,dopamine receptor antagonist,"CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7","neurology/psychiatry, gastroenterology","schizophrenia, nausea, vomiting","OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1",Launched
peruvoside,cardiac glycoside,,,,"CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|, CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|",Phase 1
perzinfotel,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B",,,"OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O",Phase 2
pesampator,,,neurology/psychiatry,schizophrenia,CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC1=CC=C(C=C1)C1=CC=C(S1)C#N,Phase 2
PETCM,caspase activator,CASP3,,,"O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|, O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|",Preclinical
petesicatib,cathepsin inhibitor,"CTSS, CTSV",rheumatology,sjogren's syndrome,O=C(N1[C@@H](C[C@@H](S(=O)(C2=C(C=C(C3=CN(C)N=C3)C=C2)C(F)(F)F)=O)C1)C(NC4(CC4)C#N)=O)C5(CC5)C(F)(F)F,Phase 2
pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",,,"NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12",Phase 3
pexacerfont,crf receptor antagonist,"CRHR1, PLXNA2",neurology/psychiatry,generalized anxiety disorder (gad),CC[C@@H](C)Nc1nc(C)nc2c(c(C)nn12)-c1ccc(OC)nc1C |a:2|,Phase 2/Phase 3
pexidartinib,tyrosine kinase inhibitor,"CSF1R, FLT3, KIT",,,"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1",Launched
pexmetinib,"MAP kinase inhibitor, TIE tyrosine kinase inhibitor","MAPK14, TEK",,,"Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C",Phase 1
pf 03716556,h+/k+-atpase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (gerd),CN(CCO)C(=O)c1cc(N[C@@H]2CCOc3cccc(C)c23)c2nc(C)cn2c1,Preclinical
pf 04531083,voltage-gated sodium channel modulator,SCN10A,neurology/psychiatry,chronic pain,ClC1=CC=C(OC)C=C1C2=C(N=C(NC(C3=CC=NN3C)=O)C=C2)N,Phase 2
pf-00446687,melanocortin receptor agonist,MC4R,neurology/psychiatry,hypoactive sexual desire disorder,O=C([C@H]1[C@H](C2=C(C=C(F)C=C2)F)CN(C(C)(C)C)C1)N3C[C@H]([C@](O)(C4=CC=CC=C4)[C@@H](C)C3)C,Phase 2
PF-02413873,progesterone receptor antagonist,,,,Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1,Phase 1
PF-02545920,phosphodiesterase inhibitor,PDE10A,,,"Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1",Phase 2
PF-03049423,phosphodiesterase inhibitor,PDE5A,,,"CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1, CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1",Phase 2
PF-03084014,gamma secretase inhibitor,,,,"CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C",Phase 3
pf-03463275,glycine transporter inhibitor,SLC6A9,neurology/psychiatry,schizophrenia,O=C(C(N=C1)=CN1C)N(CC(C=C2)=CC(Cl)=C2F)C[C@@H]3[C@](C4)([H])[C@@]3([H])CN4C,Phase 2
PF-03758309,p21 activated kinase inhibitor,PAK4,,,"CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1",Phase 1
PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",,,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
PF-03882845,mineralocorticoid receptor antagonist,,,,"OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|",Phase 1
PF-04136309,CC chemokine receptor antagonist,,,,"O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1",Phase 2
PF-04217903,c-Met inhibitor,MET,,,"OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1",Phase 1
PF-04418948,prostaglandin inhibitor,PTGER2,,,"COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1",Phase 1
PF-04447943,phosphodiesterase inhibitor,PDE9A,,,"C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1",Phase 2
PF-04457845,FAAH inhibitor,FAAH,,,"FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1",Phase 2
PF-04620110,diacylglycerol O acyltransferase inhibitor,DGAT1,,,"Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|",Phase 1
PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",,,"COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|",Phase 2
PF-04885614,voltage-gated sodium channel blocker,SCN10A,,,"CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1",Preclinical
PF-04937319,glucokinase activator,GCK,,,"CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1, CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1",Phase 2
pf-04971729,sodium/glucose cotransporter inhibitor,,endocrinology,diabetes mellitus,CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,Launched
PF-04995274,serotonin receptor agonist,,,,OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1,Phase 1
PF-05089771,sodium channel blocker,,,,Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1,Preclinical
PF-05175157,acetyl-CoA carboxylase inhibitor,,,,[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2,Phase 2
PF-05180999,phosphodiesterase inhibitor,,,,Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1,Phase 1
PF-05190457,growth hormone secretagogue receptor inverse agonist,GHSR,,,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,Phase 2
PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",,,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
PF-06260414,androgen receptor modulator,,,,C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N,Phase 1
PF-06273340,tyrosine kinase receptor inhibitor,,,,CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12,Phase 1
PF-06282999,myeloperoxidase inhibitor,,,,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O,Phase 1
PF-06305591,sodium channel blocker,,,,C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O,Phase 1
pf-06380101,tubulin inhibitor,TUBB,oncology,breast cancer,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)N)C(C)C,Preclinical
PF-06409577,protein kinase activator,,,,OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1,Phase 1
PF-06412562,dopamine receptor partial agonist,,,,Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C,Phase 1
PF-06447475,serine/threonine kinase inhibitor,LRRK2,,,"N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12",Preclinical
PF-06459988,receptor tyrosine protein kinase inhibitor,,,,CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C,Phase 2
PF-06463922,ALK tyrosine kinase receptor inhibitor,"ALK, FES, ROS1",oncology,non-small cell lung cancer (NSCLC),"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|",Launched
PF-06650833,kinase inhibitor,,,,CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F,Phase 1
PF-06651600,JAK inhibitor,,,,C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12,Phase 2/Phase 3
PF-06747775,EGFR inhibitor,,,,COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C,Phase 2
PF-06751979,beta secretase inhibitor,,,,C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|,Phase 1
PF-06840003,"indoleamine 2,3-dioxygenase inhibitor",,,,"Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|",Phase 1
PF-06873600,CDK inhibitor,,,,C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O,Phase 2
PF-06928215,cyclic GMP-AMP synthase inhibitor,,,,OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1,Preclinical
pf-06952229,antineoplastic agent,TGFBR1,oncology,breast cancer,CC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F,Phase 1
PF-3274167,oxytocin receptor antagonist,"AVPR1A, OXTR",,,"COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1, COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1",Phase 2
PF-3845,FAAH inhibitor,FAAH,,,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
PF-4191834,lipoxygenase inhibitor,,,,Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1,Preclinical
PF-429242,SREBP inhibitor,MBTPS1,,,"CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1",Preclinical
PF-431396,focal adhesion kinase inhibitor,"PTK2, PTK2B",,,"CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Preclinical
PF-4708671,ribosomal protein inhibitor,RPS6KB1,,,"CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1",Preclinical
PF-477736,CHK inhibitor,"CHEK1, CHEK2",,,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
PF-4800567,casein kinase inhibitor,"CSNK1D, CSNK1E",,,"Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1",Preclinical
PF-4981517,cytochrome P450 inhibitor,CYP3A4,,,"Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12",Preclinical
PF-514273,cannabinoid receptor antagonist,,,,CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O,Preclinical
PF-5274857,smoothened receptor antagonist,SMO,,,"Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O",Preclinical
PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",,,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",,,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
PF-670462,casein kinase inhibitor,"CSNK1D, CSNK1E",,,"Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1",Preclinical
PF-750,FAAH inhibitor,FAAH,,,"O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1",Preclinical
PF-8380,autotaxin inhibitor,ENPP2,,,"Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1",Preclinical
PF-915275,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,,,"Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1",Phase 1
PFI-1,bromodomain inhibitor,BRD4,,,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
PFI-3,bromodomain inhibitor,"PBRM1, SMARCA4",,,"Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1",Preclinical
PFI-4,bromodomain inhibitor,BRPF1,,,"COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1",Preclinical
PFK-015,phosphofructokinase inhibitor,PFKFB3,,,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
PFK-158,phosphofructokinase inhibitor,PFKFB3,,,"FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1",Phase 1
PG-9,acetylcholine receptor agonist,,,,"C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|",Preclinical
pg-9 maleate,cholinergic receptor modulator,,,,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,Preclinical
PGL5001,JNK inhibitor,"MAPK10, MAPK8, MAPK9",,,"N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|",Phase 2
PH-797804,p38 MAPK inhibitor,"MAPK11, MAPK14",,,"CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O",Phase 2
PHA-543613,nicotinic receptor agonist,,,,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1,Preclinical
PHA-568487,nicotinic receptor agonist,CHRNA7,,,"O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1",Preclinical
PHA-665752,c-Met inhibitor,MET,,,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1",Preclinical
PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",,,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",,,"CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",,,"CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21",Phase 2
PHCCC,glutamate receptor agonist,"GRM1, GRM4",,,"O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|",Preclinical
phenacaine,local anesthetic,,neurology/psychiatry,local anesthetic,"CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1, CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1",Launched
phenacemide,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, seizures","NC(=O)NC(=O)Cc1ccccc1, NC(=O)NC(=O)Cc1ccccc1",Launched
phenacetin,cyclooxygenase inhibitor,PTGS1,,,"CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1",Withdrawn
phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
phenazopyridine,local anesthetic,SCN1A,infectious disease,urinary tract infections,"Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1",Launched
phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
phenethicillin,bacterial cell wall synthesis inhibitor,,,,"C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|, C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|",Launched
phenethyl-isothiocyanate,anticancer agent,CYP2E1,,,S=C=NCCc1ccccc1,Phase 2
phenformin,AMPK activator,"KCNJ8, PRKAA1",,,"NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1",Withdrawn
phenindamine,histamine receptor antagonist,HRH1,"allergy, otolaryngology","allergic rhinitis, common cold","CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|, CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|",Launched
phenindione,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),"O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1",Launched
pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|",Launched
phenol,,"CA1, CA12, CA14, CA2, CA4, CA9",otolaryngology,pharyngitis,Oc1ccccc1,Preclinical
phenolphthalein,indicator dye,UGT1A9,,,"Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1",Withdrawn
phenolsulfonphthalein,,,,,"Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1",Launched
phenothiazine,dopamine receptor antagonist,,,,"N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12",Preclinical
phenothrin,,,infectious disease,lice,"CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|",Launched
phenoxybenzamine,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","cardiology, endocrinology","hypertension, pheochromocytoma","CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1",Launched
phenprobamate,muscle relaxant,,neurology/psychiatry,"anxiety, muscle relaxant","NC(=O)OCCCc1ccccc1, NC(=O)OCCCc1ccccc1",Launched
phenprocoumon,vitamin K antagonist,VKORC1,hematology,"thrombosis, pulmonary embolism (PE)","CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|, CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|",Launched
phenserine,"acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor","ACHE, BCHE",,,"CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21",Phase 3
phensuximide,succinimide antiepileptic,,neurology/psychiatry,seizures,"CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|",Launched
phentolamine,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","endocrinology, cardiology","pheochromocytoma, hypertension","Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|",Launched
phenyl-aminosalicylate,,,infectious disease,tuberculosis,"Nc1ccc(C(=O)Oc2ccccc2)c(O)c1, Nc1ccc(C(=O)Oc2ccccc2)c(O)c1",Launched
phenyl-salicylate,antiseptic,,urology,interstitial cystitis (IC),"Oc1ccccc1C(=O)Oc1ccccc1, Oc1ccccc1C(=O)Oc1ccccc1",Launched
phenylacetylglutamine,"DNA methylase inhibitor, protein synthesis inhibitor",,,,"NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O, NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O",Phase 2
phenylbenzimidazole-sulfonic-acid,,,dermatology,sunscreen lotion,"OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1, OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1, OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1",Launched
phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",,,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
phenylbutyrate,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders,"OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1",Launched
phenylephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D","otolaryngology, gastroenterology, cardiology","nasal congestion, hemorrhoids, hypotension","CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1",Launched
phenylethyl-alcohol,,,,,"OCCc1ccccc1, OCCc1ccccc1",Preclinical
phenylmercuric-acetate,other antifungal,,,,"CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1",Preclinical
phenylmethylsulfonyl-fluoride,serine protease inhibitor,,,,"FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1",Preclinical
phenylpiracetam,noradrenaline uptake inhibitor,,neurology/psychiatry,"anxiety, fatigue, depression","NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6,r|",Launched
phenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1",Launched
PhiKan-083,p53 stabilizing agent,TP53,,,"CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12",Preclinical
phloretin,sodium/glucose cotransporter inhibitor,"AQP9, CLCN3, SLC23A1",,,"Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1",Launched
phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",,,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Preclinical
phloroglucin,,,neurology/psychiatry,spasms,"Oc1cc(O)cc(O)c1, Oc1cc(O)cc(O)c1",Launched
phortress,aryl hydrocarbon receptor ligand,AHR,,,"Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1",Phase 1
phosphatidylcholine,,,"infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology, infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology","hepatitis b, hepatitis c, eczema, gallbladder disease, cholesterol, premenstrual syndrome, hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome","CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, null",Launched
PHP-501,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2",,,"On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1",Preclinical
PHT-427,"AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1",,,"CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1",Preclinical
phthalylsulfacetamide,,,,,"CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1",Preclinical
phthalylsulfathiazole,dihydropteroate synthetase inhibitor,,"infectious disease, gastroenterology","dysentry, colitis","OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",Launched
PHTPP,estrogen receptor antagonist,ESR2,,,"Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1",Preclinical
physostigmine,"acetylcholinesterase inhibitor, cholinesterase inhibitor","ACHE, BCHE","cardiology, neurology/psychiatry, ophthalmology, gastroenterology","hypotension, Alzheimer's disease, glaucoma, gastroparesis","CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1",Launched
phytonadione,,"BGLAP, GGCX",hematology,"vitamin K deficiency, anticoagulation reversal","CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|",Launched
phytosphingosine,,,,,"CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO",Phase 1
PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
PI-828,PI3K inhibitor,,,,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
pibenzimol,DNA inhibitor,,,,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
piboserod,serotonin receptor antagonist,"HTR2B, HTR4",,,"CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1",Phase 2
pibrentasvir,antiviral,NS5A,infectious disease,hepatitis c,C[C@H]([C@@H](C(=O)N1CCC[C@H]1c2[nH]c3cc(c(cc3n2)[C@H]4CC[C@@H](N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)[nH]c(n9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)F)NC(=O)OC)OC,Launched
picartamide,H+/K+-ATPase inhibitor,ATP4A,,,"CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|",Phase 2
piceatannol,SYK inhibitor,"ATP5A1, ATP5B, ATP5C1, IRF3",,,"Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1",Preclinical
piclamilast,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",,,"COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl",Phase 2
picolamine,,,,,"NCc1cccnc1, NCc1cccnc1",Preclinical
picolinic-acid,chelating agent,,,,"OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
piconol,,,,,"OCc1ccccn1, OCc1ccccn1",Preclinical
picotamide,"thromboxane receptor antagonist, thromboxane synthase inhibitor",TBXA2R,hematology,thrombosis,"COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1",Launched
picrotin,GABA receptor antagonist,"GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB",Pulmonology,respiratory distress syndrome (rds),"CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|",Phase 2
picrotoxin,,,,,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,Preclinical
picrotoxinin,GABA receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B",,,"CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C",Preclinical
pidolic-acid,,"ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA",dermatology,xerosis cutis,"OC(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CCC(=O)N1",Launched
pidotimod,"interferon receptor agonist, interleukin receptor agonist",,infectious disease,immune adjuvant,"OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1",Launched
pifithrin-alpha,TP53 inhibitor,TP53,,,"Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N",Preclinical
pifithrin-cyclic,TP53 inhibitor,TP53,,,"Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1",Preclinical
pifithrin-mu,HSP inhibitor,"HSPA1A, TP53",,,"NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1",Preclinical
PIK-293,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O",Preclinical
PIK-294,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",,,"Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O",Preclinical
PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",,,"CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",Preclinical
PIK-93,PI3K inhibitor,"PI4KB, PIK3C3, PIK3CG",,,"CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO",Preclinical
pikamilone,,,,,"OC(=O)CCCNC(=O)c1cccnc1, OC(=O)CCCNC(=O)c1cccnc1",Phase 1
piketoprofen,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,"C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|",Launched
pilaralisib,PI3K inhibitor,,,,"COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1",Phase 2
pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
pilsicainide,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,"Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2",Launched
PIM-1-Inhibitor-2,Pim kinase inhibitor,PIM1,,,"Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1",Preclinical
PIM-447,Pim kinase inhibitor,,,,C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F,Phase 1
pimavanserin,serotonin receptor inverse agonist,"DRD2, HTR2A",neurology/psychiatry,Parkinson's Disease,"CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1, CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1",Launched
pimecrolimus,calcineurin inhibitor,,dermatology,eczema,"CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|, CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|",Launched
pimethixene,antihistamine,,"neurology/psychiatry, allergy","attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis","CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12, CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12",Launched
pimitespib,hsp90 inhibitor,HSP90AB1,oncology,gastrointestinal stromal tumors (gist),CCc1cc(ccc1n2nc(C(C)C)c3c(ccnc23)n4cnc(c4)c5cnn(C)c5)C(=O)N,Phase 1
pimobendan,"calcium sensitizer, phosphodiesterase inhibitor, calcium sensitizer, phosphodiesterase inhibitor",PDE3A,cardiology,congestive heart failure,"COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C",Launched
pimodivir,antiviral,,,,OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12,Phase 3
pimonidazole,,,,,"O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|",Phase 3
pimozide,dopamine receptor antagonist,"CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2",neurology/psychiatry,Tourette's disorder,"Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1",Launched
pinacidil,"ATP channel activator, potassium channel activator","ABCC8, ABCC9",cardiology,hypertension,"C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|",Launched
pinanediol,,,,,CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2,Preclinical
pinaverium,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome,"COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|",Launched
pinaverium bromide,t-type calcium channel blocker,,gastroenterology,irritable bowel syndrome,COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC,Launched
pincainide,antiarrhythmic,,,,Cc1cccc(C)c1NC(=O)CN1CCCCCC1,Phase 1
pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|",Launched
pindolol-(-),"adrenergic receptor antagonist, serotonin receptor antagonist",HTR1A,,,"CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12",Phase 2
pinitol,gamma secretase inhibitor,,,,COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O,Phase 2
pinocembrin,cytochrome P450 inhibitor,CYP1B1,,,"Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1",Phase 2
pioglitazone,"insulin sensitizer, PPAR receptor agonist","PPARG, TRPM3",endocrinology,diabetes mellitus,"CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|, CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|",Launched
pioglitazone hydrochloride,"insulin sensitizer, ppar receptor agonist",,endocrinology,diabetes mellitus,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,Launched
pipamperone,dopamine receptor antagonist,"DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A",neurology/psychiatry,schizophrenia,"NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1",Launched
pipecuronium,neuromuscular blocker,"CHRM2, CHRM3, CHRNA2",neurology/psychiatry,anesthetic,,Launched
pipemidic-acid,topoisomerase inhibitor,,infectious disease,gram-negative bacterial infections,"CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1",Launched
pipenzolate,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms,"CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|",Launched
pipequaline,benzodiazepine receptor agonist,"ALB, GABRA1",neurology/psychiatry,drowsiness,C(Cc1cc(nc2ccccc12)-c1ccccc1)C1CCNCC1,Preclinical
piperacetazine,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia,"CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1",Launched
piperacillin,bacterial cell wall synthesis inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia","CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O",Launched
piperacillin sodium,bacterial cell wall synthesis inhibitor,,infectious disease,"intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia",CCN1CCN(C(=O)NC(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O,Launched
piperaquine-phosphate,antimalarial agent,,infectious disease,malaria,"Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1, Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1, Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1",Launched
piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,"C1CNCCN1, C1CNCCN1, C1CNCCN1",Launched
piperazinedione,DNA synthesis inhibitor,,,,"O=C1CNC(=O)CN1, O=C1CNC(=O)CN1",Phase 2
piperidolate,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms,"CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|, CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|",Launched
piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",,,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
piperonyl-butoxide,cytochrome P450 inhibitor,,infectious disease,lice,"CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC",Launched
pipobroman,DNA alkylating agent,,hematology,"polycythemia vera, thrombocythemia","BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr",Launched
pipofezine,selective serotonin reuptake inhibitor (SSRI),,,,CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1,Preclinical
pipotiazine,dopamine receptor antagonist,"DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
pipotiazine-palmitate,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,Launched
piracetam,acetylcholine receptor agonist,"GRIA1, GRIA2, GRIA3, GRIA4",neurology/psychiatry,senile dementia,"NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O",Launched
pirarubicin,topoisomerase inhibitor,TOP2A,oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
pirbuterol,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,bronchospasm,Oc1ccc(nc1CO)C(O)CNC(C)(C)C,Withdrawn
pirenoxine,AGE inhibitor,,ophthalmology,cataracts,OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1,Launched
pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",,,"Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1",Preclinical
pirenzepine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",gastroenterology,peptic ulcer disease (PUD),"CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1",Launched
piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema","NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O",Launched
pirfenidone,TGF beta receptor inhibitor,"FURIN, TNF",pulmonary,idiopathic pulmonary fibrosis (IPF),"Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1",Launched
piribedil,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B",neurology/psychiatry,"Parkinson's Disease, dizziness","C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1",Launched
piricapiron,"dopamine receptor antagonist, serotonin receptor antagonist, dopamine receptor antagonist, serotonin receptor antagonist",HTR2A,,,"CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|",Phase 2
pirinixic-acid,PPAR receptor agonist,PPARA,,,"Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C",Preclinical
pirlindole,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|,Launched
pirlindole mesylate,monoamine oxidase inhibitor,,neurology/psychiatry,depression,Cc1ccc2n3CCNC4CCCc(c34)c2c1,Launched
pirmenol,acetylcholine receptor inhibitor,,,,"C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|",Preclinical
piroctone-olamine,,,infectious disease,fungal infection,C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|,Launched
pirodavir,,,,,"CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1",Phase 2
piromidic-acid,bacterial DNA gyrase inhibitor,,,,"CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1",Phase 2
piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis, osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|",Launched
piroximone,phosphodiesterase inhibitor,PDE3A,,,"CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1, CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1",Phase 2
pirozadil,hypolipidemic,,,,COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1,Preclinical
pirquinozol,histamine release inhibitor,,,,OCc1cc2c3ccccc3[nH]c(=O)n2n1,Phase 1
PIT,purinergic receptor antagonist,P2RY1,,,"[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|",Preclinical
pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
pitolisant,histamine receptor antagonist,HRH3,,,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Launched
pivagabine,corticotropin releasing factor receptor antagonist,"CRHR1, CRHR2",neurology/psychiatry,depression,"CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O",Launched
pivampicillin,bacterial cell wall synthesis inhibitor,,"pulmonary, infectious disease","bronchitis, pneumonia, gynecologic infections",CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O,Launched
pivanex,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC8",,,"CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C",Phase 2
pivmecillinam,bacterial cell wall synthesis inhibitor,,infectious disease,"urinary tract infections, gram-negative bacterial infections","CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O",Launched
pixantrone,topoisomerase inhibitor,TOP2A,hematologic malignancy,non-Hodgkin lymphoma (NHL),"NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12",Launched
pizotifen,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C",neurology/psychiatry,migraine headache,"CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12",Launched
PI3K-IN-2,PI3K inhibitor,,,,"Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 2
PI3Kd-IN-2,PI3K inhibitor,,,,COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1,Preclinical
PI4KIII-beta-inhibitor-1,PI4K inhibitor,PI4K2B,,,"COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C, COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C",Preclinical
PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",,,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
PK-THPP,potassium channel blocker,KCNK9,,,"CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1",Preclinical
PK-11195,benzodiazepine receptor antagonist,TSPO,,,"CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|",Phase 1
PK-44,dipeptidyl peptidase inhibitor,DPP4,,,"N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12",Preclinical
PKI-166,EGFR inhibitor,EGFR,,,"C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1",Phase 1
PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,,,"O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|",Phase 1
pleconaril,,,,,"Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1",Phase 3
plerixafor,CC chemokine receptor antagonist,"ACKR3, CCR4, CXCR4",hematologic malignancy,"non-Hodgkin lymphoma (NHL), multiple myeloma","C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1",Launched
plicamycin,alcohol dehydrogenase inhibitor,,"oncology, endocrinology","testicular carcinoma, Paget's disease, hypercalcemia","CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O, CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O",Launched
plinabulin,tubulin polymerization inhibitor,,,,"CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
plovamer-acetate,,"TAT, TH, YARS, YARS2",,,"N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|",Phase 2
plumbagin,anticancer agent,,,,CC1=CC(=O)c2c(O)cccc2C1=O |t:1|,Preclinical
plurisin-1,stearoyl-CoA desaturase inhibitor,SCD,,,"O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1",Preclinical
PLX4720,RAF inhibitor,"BRAF, KDR",,,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F",Preclinical
PLX51107,bromodomain inhibitor,,,,C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C,Phase 1
PLX647,receptor tyrosine protein kinase inhibitor,"CSF1R, KIT",,,"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1",Preclinical
PLX8394,serine/threonine kinase inhibitor,BRAF,,,"F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F",Phase 1/Phase 2
PMPA,glutamate receptor antagonist,FOLH1,,,"OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|",Preclinical
PNU-120596,acetylcholine receptor agonist,CHRNA7,,,"COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl",Preclinical
PNU-142633,serotonin receptor agonist,HTR1D,,,"CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1, CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1",Phase 2
PNU-177864,dopamine receptor antagonist,DRD3,,,"CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1",Preclinical
PNU-22394,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C, MAOA, MAOB",,,"Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12",Phase 2
PNU-282987,cholinergic receptor agonist,CHRNA7,,,"Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2",Preclinical
PNU-37883,ATP-sensitive potassium channel antagonist,,,,C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1,Preclinical
PNU-74654,beta-catenin inhibitor,"CTNNB1, TCF4",,,"Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1",Preclinical
PNU-89843,benzodiazepine receptor agonist,GABBR1,,,Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1,Preclinical
pocapavir,Enterovirus capsid inhibitor,,,,COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1,Preclinical
podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,"COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12",Launched
polaprezinc,chelating agent,,,,O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1,Preclinical
polidocanol,local anesthetic,,dermatology,varicose veins,"CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO, CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO",Launched
polydatin,ICAM1 expression inhibitor,ICAM1,,,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
polyinosine,immunostimulant,"HPRT1, IMPDH2, PYGM",,,"O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|",Preclinical
polymyxin b nonapeptide (tfa),bacterial permeability inducer,,infectious disease,gram-negative bacterial infections,FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@H](CCNC1=O)NC([C@H](CCN)NC([C@@H](N)[C@H](O)C)=O)=O)=O)CCN)=O)CC2=CC=CC=C2.FC(F)(F)C(O)=O,
polymyxin-B-sulfate,bacterial permeability inducer,,ophthalmology,eye infection,"CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|, CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|",Launched
polythiazide,sodium/chloride cotransporter inhibitor,SLC12A3,"cardiology, gastroenterology, rheumatology, nephrology","edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension","CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",Launched
pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",,hematologic malignancy,multiple myeloma,"Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|",Launched
ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
ponazuril,,,infectious disease,encephalomyelitis,CN1C(=O)NC(=O)N(C1=O)C2=CC=C(OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F)C(C)=C2,Launched
ponesimod,sphingosine 1-phosphate receptor agonist,S1PR1,,,"CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C",Phase 3
posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
potassium-canrenoate,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|",Launched
potassium-iodide,,,pulmonary,"asthma, bronchitis, emphysema","[K].I, [K].I",Launched
potassium-p-aminobenzoate,,,"rheumatology, urology","scleroderma, dermatomyositis, Peyronie's disease","Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O",Launched
pozanicline,acetylcholine receptor antagonist,"CHRNA4, CHRNB2",,,"Cc1ncccc1OC[C@@H]1CCCN1, Cc1ncccc1OC[C@@H]1CCCN1",Phase 2
poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",,,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
PP-1,SRC inhibitor,"HCK, RET",,,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",,,"Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1",Preclinical
PP-2,SRC inhibitor,"ABL1, LCK, RIPK2, SRC",,,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
PPT,estrogen receptor agonist,ESR1,,,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
PPY-A,Abl kinase inhibitor,"ABL1, BCR",,,"COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C",Preclinical
PP242,mTOR inhibitor,"MTOR, PASK",,,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
PQ-401,IGF-1 inhibitor,IGF1R,,,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
PR-619,DUB inhibitor,,,,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
practolol,adrenergic receptor antagonist,ADRB1,,,"CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|",Withdrawn
pradefovir,cytochrome P450 activator,,,,Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12,Phase 2
prajmalium bitartrate,voltage-gated sodium channel blocker,,Cardiology,cardiac arrythmia,[H][C@@]12N(C)c3ccccc3[C@]11C[C@H]3[C@@H]([C@H]1O)[C@@]1([H])C[C@]2([H])[N@+]3(CCC)[C@H](O)[C@H]1CC,Launched
pralatrexate,dihydrofolate reductase inhibitor,DHFR,hematologic malignancy,peripheral T-cell lymphoma (PTCL),"Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|",Launched
pralidoxime,acetylcholinesterase inhibitor,"ACHE, BCHE",critical care,organophosphate poisoning,"C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O",Launched
pralidoxime-chloride,acetylcholinesterase inhibitor,"ACHE, BCHE",pulmonary,respiratory depression,"C[n+]1ccccc1CN=O, C[n+]1ccccc1CN=O",Launched
pralmorelin,growth hormone releasing peptide ligand agonist,,,,C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,Launched
pramipexole,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,Parkinson's Disease,"CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1",Launched
pramiracetam,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia,"CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C, CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C",Launched
pramoxine,topical anesthetic,,dermatology,corticosteroid-responsive dermatoses,"CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1",Launched
pranidipine,calcium channel blocker,CACNA1C,,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|",Phase 2
pranlukast,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF",pulmonary,"bronchospasm, asthma","O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1",Launched
pranoprofen,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief,"C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|",Launched
prasterone-acetate,,,,,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|,Preclinical
prasugrel,purinergic receptor antagonist,P2RY12,cardiology,"myocardial infarction, acute coronary syndrome (ACS)","CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|",Launched
pravadoline,cyclooxygenase inhibitor,"CNR1, CNR2",,,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12,Preclinical
pravastatin,HMGCR inhibitor,"HMGCR, SLCO1B1","endocrinology, cardiology","hypercholesterolemia, myocardial infarction, hyperlipidemia","CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|",Launched
pravastatin sodium,hmgcr inhibitor,,"endocrinology, cardiology","hypercholesterolemia, myocardial infarction, hyperlipidemia",CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12,Launched
praziquantel,anthelmintic agent,,infectious disease,"gastrointestinal parasites, cystic hydatid disease, schistosomiasis","O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|, O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|, O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|",Launched
prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
PRE-084,sigma receptor agonist,SIGMAR1,,,"O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1",Preclinical
preclamol,dopamine receptor agonist,DRD2,,,"CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1",Phase 2
prednicarbate,"glucocorticoid receptor agonist, phospholipase activator","NR3C1, PLA2G1B","Dermatology, dermatology, ophthalmology, neurology/psychiatry","dermatitis, eczema, contact dermatitis, itching","CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:17,t:13|",Launched
prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",Launched
prednisolone acetate,glucocorticoid receptor agonist,,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis",CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C,Launched
prednisolone sodium phosphate,glucocorticoid receptor agonist,,"allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis",C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O,Launched
prednisolone tebutate,glucocorticoid receptor agonist,NR3C1,General surgery,hemorrhoids,"[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:34,t:30|",Withdrawn
prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|",Launched
prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,,,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",Preclinical
prednisolone-sodium-phosphate,glucocorticoid receptor agonist,NR3C1,"allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology","allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis","[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|",Launched
prednisolone-tebutate,anti-inflammatory agent,,,,"CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|, CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|",Launched
prednisone,glucocorticoid receptor agonist,"HSD11B1, NR3C1","endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry","congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis","C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|",Launched
pregnenolone,glutamate receptor modulator,SULT2B1,rheumatology,rheumatoid arthritis,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|",Launched
pregnenolone-succinate,GABA receptor negative allosteric modulator,CYP17A1,,,"CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|, CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|",Preclinical
preladenant,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1",Phase 3
prenylamine,calcium channel blocker,,,,"C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|",Withdrawn
presatovir,RSV fusion inhibitor,,,,"Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O",Phase 2
pretomanid,nitric oxide donor,FASN,,,"[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1",Launched
pridinol,muscle relaxant,,neurology/psychiatry,muscle relaxant,"OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1",Launched
pridopidine,dopamine receptor antagonist,,,,CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O,Phase 2
prilocaine,local anesthetic,SCN5A,neurology/psychiatry,anesthetic,"CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|, CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|",Launched
prilocaine hydrochloride,local anesthetic,,neurology/psychiatry,anesthetic,CCCNC(C)C(=O)Nc1ccccc1C,Launched
primaquine,"antimalarial agent, DNA inhibitor",,infectious disease,malaria,COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|,Launched
primaquine phosphate,"antimalarial agent, dna inhibitor",,infectious disease,malaria,COc1cc(NC(C)CCCN)c2ncccc2c1,Launched
PRIMA1,TP53 inhibitor,ACHE,,,"OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O",Preclinical
primidone,GABA receptor antagonist,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1",Launched
prinaberel,estrogen receptor agonist,"ESR2, NCOA1",,,"Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1, Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1",Phase 2
prinomastat,matrix metalloprotease inhibitor,,,,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1,Phase 3
priralfinamide,sodium channel blocker,CACNA1B,,,"C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O",Phase 3
prisotinol,,,,,"CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|",Phase 2
pristinamycin,other antibiotic,,infectious disease,staphylococcal infections,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)c1ncccc1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)CCN1C(=O)[C@H](Cc1ccc(cc1)N(C)C)N(C)C2=O)c1ccccc1,Launched
pritelivir,helicase primase inhibitor,,,,"CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O, CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O",Phase 2
PRLX-93936,voltage-dependent anion selective channel protein inhibitor,,,,CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O,Phase 1/Phase 2
PRN1008,Bruton's tyrosine kinase (BTK) inhibitor,,,,CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1,Preclinical
PRN1371,protein tyrosine kinase inhibitor,,,,CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1,Phase 1
proacipimox,cholesterol inhibitor,,,,"COCc1c[n+]([O-])c(C)cn1, COCc1c[n+]([O-])c(C)cn1",Phase 1
proadifen,nitric oxide synthase inhibitor,NOS1,,,"CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1",Preclinical
probenecid,uricosuric blocker,"PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1","nephrology, rheumatology","hyperuricemia, gout","CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O",Launched
probucol,atherogenesis inhibitor,"ABCA1, ABCB11, CES1",cardiology,coronary artery disease (CAD),"CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",Launched
procainamide,sodium channel blocker,"DNMT1, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1",Launched
procaine,HMGCR inhibitor,"CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3",neurology/psychiatry,anesthetic,"CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1",Launched
procarbazine,monoamine oxidase inhibitor,,hematologic malignancy,Hodgkin's lymphoma,"CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C",Launched
procaterol,adrenergic receptor agonist,ADRB2,pulmonary,asthma,"CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12",Launched
prochlorperazine,dopamine receptor antagonist,"DRD1, DRD2, DRD3, DRD4",gastroenterology,"nausea, vomiting","CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1",Launched
procodazole,immunostimulant,,,,"OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1",Preclinical
procyanidin-B-2,,,,,"O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1",Phase 2
procyclidine,"antispasmodic, acetylcholine receptor antagonist",CHRM1,neurology/psychiatry,"parkinsonism, Parkinson's Disease, akathisia, dystonia","OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3, COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|",Withdrawn
procyclidine (hydrochloride),,,,,OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1 |&1:1|,
procysteine,glutathione synthase stimulant,,,,"OC(=O)[C@@H]1CSC(=O)N1, OC(=O)[C@@H]1CSC(=O)N1",Phase 3
profenamine,"butyrylcholinesterase inhibitor, cholinergic receptor antagonist",CHRM1,neurology/psychiatry,Parkinson's Disease,"CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|, CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|",Launched
proflavine-hemisulfate,topical anesthetic,F2,,,"Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1",Phase 2
progesterone,progesterone receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5","obstetrics/gynecology, endocrinology","infertility, amenorrhea","CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|",Launched
proglumetacin,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|",Launched
proglumide,CCK receptor antagonist,"CCKAR, CCKBR",,,"CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|, CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1",Withdrawn
proguanil,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,"CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1",Launched
prolylleucylglycinamide,melanocyte-stimulating hormone release inhibitor,,,,"CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|",Phase 2
promazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12",Launched
promestriene,estrogen receptor agonist,ESR1,endocrinology,androgenetic alopecia,CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC,Launched
promethazine,histamine receptor antagonist,HRH1,"neurology/psychiatry, allergy","sedative, allergic rhinitis","C[C@@H](CN1c2ccccc2Sc2ccccc12)N(C)C |&1:1,r|, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C",Launched
pronethalol,adrenergic receptor antagonist,,,,"CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|",Withdrawn
pronethalol hydrochloride,adrenergic receptor antagonist,,,,CC(C)NCC(O)c1ccc2ccccc2c1,Withdrawn
propacetamol,cyclooxygenase inhibitor,PTGS2,"endocrinology, neurology/psychiatry","fever, pain relief","CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1, CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1",Launched
propafenone,antiarrhythmic,"ADRB1, ADRB2, KCNA5, KCNH2",cardiology,"atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias","CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|",Launched
propafenone hydrochloride,antiarrhythmic,,cardiology,"atrial fibrillation (af), ventricular tachycardia (vt), ventricular arrhythmias",CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,Launched
propagermanium,"CCR agonist, interferon receptor agonist",CCR2,infectious disease,hepatitis B,OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O,Launched
propantheline,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,peptic ulcer disease (PUD),"CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C",Launched
propatylnitrate,,,cardiology,angina pectoris,"CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O, CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O",Launched
propentofylline,"adenosine reuptake inhibitor, phosphodiesterase inhibitor",PDE1A,neurology/psychiatry,stroke,"CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12, CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12",Launched
propidium-iodide,,ACHE,,,"CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",Preclinical
propiolactone,,,infectious disease,antiseptic,"O=C1CCO1, O=C1CCO1",Launched
propiverine,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Launched
propofol,benzodiazepine receptor agonist,"FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A",neurology/psychiatry,anesthetic,"CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O",Launched
propoxur,,,infectious disease,flea control,"CNC(=O)Oc1ccccc1OC(C)C, CNC(=O)Oc1ccccc1OC(C)C",Launched
propoxycaine,local anesthetic,,neurology/psychiatry,anesthetic,"CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC",Launched
propranolol,adrenergic receptor antagonist,"ADRB1, ADRB2","cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
propranolol hydrochloride,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",Cardiology,angina pectoris,"CC(C)NC[C@@H](O)COc1cccc2ccccc12 |&1:5,r|",Launched
propranolol-(R),adrenergic receptor antagonist,"ADRB2, ADRB3",,,"CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12",Preclinical
propranolol-(S),adrenergic receptor antagonist,"ADRB1, HTR1A, HTR5A, SLC10A1",,,"CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12",Preclinical
propyl-benzoate,,,,,"CCCOC(=O)c1ccccc1, CCCOC(=O)c1ccccc1",Launched
propylene-glycol,,,,,"C[C@@H](O)CO |&1:1,r|",Launched
propylhexedrine,adrenergic receptor agonist,,"otolaryngology, endocrinology, allergy","nasal congestion, fever, allergic rhinitis","CN[C@@H](C)CC1CCCCC1 |&1:2,r|",Launched
propylparaben,,,,,"CCCOC(=O)c1ccc(O)cc1, CCCOC(=O)c1ccc(O)cc1",Launched
propylthiouracil,thyroid peroxidase inhibitor,"DIO1, TPO",endocrinology,"hyperthyroidism, Grave's disease, goiter","CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1",Launched
propyphenazone,anti-inflammatory agent,,,,CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O,Preclinical
proquazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1, CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1",Launched
proscillaridin a,,,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
proscillaridin-A,,,cardiology,"congestive heart failure, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|",Launched
protionamide,,,infectious disease,tuberculosis,"CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S",Launched
protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,"NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1, NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1",Launched
protokylol,adrenergic receptor agonist,ADRB2,infectious disease,respiratory tract infections,O1c2ccc(cc2OC1)CC(NCC(O)c3ccc(O)c(O)c3)C,Withdrawn
protoporphyrin-IX,heme oxygenase inhibitor,HMOX1,,,"Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C",Preclinical
protriptyline,tricyclic antidepressant,"SLC6A2, SLC6A4",neurology/psychiatry,depression,"CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|",Launched
proxodolol,adrenergic receptor antagonist,,,,"Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|, Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|",Launched
proxyfan,histamine receptor modulator,HRH3,,,"C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1",Preclinical
proxymetacaine,sodium channel blocker,"SCN10A, SCN5A",neurology/psychiatry,anesthetic,"CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC",Launched
Proxyphylline,,,pulmonary,asthma,"C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|, C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|",Launched
PRT062070,"JAK inhibitor, SYK inhibitor",SYK,,,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 2/Phase 3
PRT062607,SYK inhibitor,"FGR, MAP3K9, SYK",,,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
PRT4165,polycomb repressive complex inhibitor,PRC1,,,"O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12",Preclinical
prucalopride,serotonin receptor agonist,HTR4,gastroenterology,constipation,"COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12",Launched
prulifloxacin,bacterial DNA gyrase inhibitor,,"infectious disease, pulmonary, gastroenterology","urinary tract infections, bronchitis, diarrhea","C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|",Launched
pruvanserin,serotonin receptor antagonist,"HTR2A, HTR2C",,,"Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1",Phase 2
PRX-07034,serotonin receptor antagonist,,,,"COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|",Phase 1
PRX-08066,serotonin receptor antagonist,HTR2B,,,"Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N",Phase 2
PSB-06126,NTPDase inhibitor,ENTPD3,,,"Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O",Preclinical
PSB-11,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA3",,,"CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|",Preclinical
PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",,,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
PSB-36,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|",Preclinical
PSB-603,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1",Preclinical
PSI-6130,RNA polymerase inhibitor,,,,"C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O, C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O",Phase 1
PSI-697,P selectin inhibitor,,,,OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12,Phase 1
PSI-7976,HCV inhibitor,,,,"CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1",Preclinical
PSN-375963,glucose dependent insulinotropic receptor agonist,GPR119,,,"CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1",Preclinical
PSNCBAM-1,cannabinoid receptor modulator,CNR1,,,"Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1",Preclinical
psoralen,,"MAOA, MAOB",dermatology,"psoriasis, eczema, vitiligo","O=c1ccc2cc3ccoc3cc2o1, O=c1ccc2cc3ccoc3cc2o1",Launched
PS178990,androgen receptor modulator,AR,,,"Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N",Phase 1
PT-2385,hypoxia inducible factor inhibitor,EPAS1,,,"CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12",Phase 1
PTC-028,BMI-1 inhibitor,,,,Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1,Preclinical
PTC-209,BMI-1 inhibitor,,,,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
ptc596,polycomb protein inhibitor,BMI1,oncology,glioma,Cc1nc2ccc(F)cc2n1c3nc(N)c(F)c(Nc4ccc(cc4)C(F)(F)F)n3,Phase 1
pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist, cyclooxygenase inhibitor, ppar receptor agonist",PTGS2,,,"COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1, COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1",Phase 2/Phase 3
pti-428,cftr channel potentiator,CFTR,pulmonary,cystic fibrosis,C[C@@H](O)c1oc(nn1)[C@@H]2C[C@H](C2)NC(=O)c3onc(c3)c4ccccc4,Phase 2
pt2399,hif modulator,EPAS1,oncology,renal cell carcinoma (rcc),O[C@H]1c2c(CC1(F)F)c(Oc3cc(F)cc(c3)C#N)ccc2S(=O)(=O)C(F)F,Preclinical
PU-H71,HSP inhibitor,HSP90AA1,,,"CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12",Phase 1
puerarin,serotonin receptor antagonist,,,,"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O",Phase 2
pulrodemstat,histone lysine demethylase inhibitor,"KDM1A, MBD2",hematologic malignancy,acute myeloid leukemia (aml),COc1ccc(cc1F)-c1c(nc(N2CCC(N)CC2)n(C)c1=O)-c1ccc(C#N)c(F)c1.OS(=O)(=O)c1ccccc1,Phase 2
pumosetrag,serotonin receptor agonist,"HTR3A, HTR4",,,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,Phase 2
purmorphamine,smoothened receptor agonist,SMO,,,"C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12",Preclinical
puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",,,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
puromycin dihydrochloride,ribosomal protein inhibitor,,,,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
purvalanol-A,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC",,,"CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
purvalanol-B,tyrosine kinase inhibitor,"CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2",,,"CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
putrescine,tissue transglutaminase inhibitor,"AMD1, KCNJ4, ODC1",,,NCCCCN,Phase 2
PX-12,thioredoxin inhibitor,"CNR1, TXN",,,"CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|, CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|",Phase 2
PX-478,hypoxia inducible factor inhibitor,,,,"N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|",Phase 1
PYM50028,neurotrophic agent,,,,"C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1",Phase 2
PYR-41,ubiquitin activating enzyme inhibitor,,,,"CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O",Preclinical
pyrantel,"acetylcholine receptor agonist, nicotinic receptor agonist",,infectious disease,gastrointestinal roundworms,OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O,Launched
pyrantel-pamoate,neuromuscular blocker,,infectious disease,"hookworm, tapeworm","CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|",Launched
pyrazinamide,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis,"NC(=O)c1cnccn1, NC(=O)c1cnccn1, NC(=O)c1cnccn1",Launched
pyrazinoylguanidine,diuretic,,,,"NC(=N)NC(=O)c1cnccn1, NC(=N)NC(=O)c1cnccn1",Phase 1
pyrazolanthrone,JNK inhibitor,"MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK",,,"O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23",Preclinical
pyrazoloacridine,"rna synthesis inhibitor, topoisomerase inhibitor","TOP1, TOP2A",oncology,melanoma,"COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2Nc3c(ccc4c3c(nn4CCCN(C)C)c2c1)[N+](=O)[O-]",Phase 2
pyrethrins,,,infectious disease,flea control,"CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|, CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2)C1(C)C",Launched
pyridoxal,,PDXK,neurology/psychiatry,epilepsy,Cc1ncc(CO)c(C=O)c1O,Launched
pyridoxal-isonicotinoyl-hydrazone,apoptosis stimulant,,,,"Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O, Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O",Phase 2
pyridoxamine,AGE inhibitor,,,,Cc1ncc(CO)c(CN)c1O,Phase 3
pyridoxine,vitamin B,"DDC, PDXK",metabolism,vitamin B6 deficiency,"Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O",Launched
pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
pyrintegrin,integrin signaling activator,,,,"Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1, Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1",Preclinical
pyriproxyfen,,,,,O(c1ncccc1)C(COc3ccc(Oc2ccccc2)cc3)C,Launched
pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,"dandruff, cosmetic","O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
pyrithyldione,psychoactive drug,,,,"CCC1(CC)C(=O)NC=CC1=O |c:8|, CCC1(CC)C(=O)NC=CC1=O |c:8|",Withdrawn
pyritinol,,,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia","Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O, Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O",Launched
pyronaridine,antimalarial agent,,,,"COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1",Phase 3
pyrotinib,kinase inhibitor,,,,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C,Phase 3
pyroxamide,HDAC inhibitor,HDAC1,,,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
pyrrolidine-dithiocarbamate,NFkB pathway inhibitor,"HSD11B1, RELA",,,"SC(=S)N1CCCC1, SC(=S)N1CCCC1",Preclinical
pyrvinium-pamoate,androgen receptor antagonist,AR,infectious disease,pinworm,"CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1",Launched
PZ-2891,pantothenate kinase activator,,,,CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1,Preclinical
"p1,p4-di(adenosine-5')tetraphosphate ammonium",adenosine kinase inhibitor,,,,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O,Phase 1
P22077,ubiquitin specific protease inhibitor,USP7,,,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",,,"CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
P5091,ubiquitin specific protease inhibitor,USP7,,,"CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O",Preclinical
P7C3,NAMPT inhibitor,NAMPT,,,"O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|",Preclinical
Q-203,ATP synthase inhibitor,,,,"CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1",Phase 2
quazinone,phosphodiesterase inhibitor,"PDE3A, PDE3B",,,"CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|",Phase 2
quercetin,polar auxin transport inhibitor,"ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1","neurology/psychiatry, allergy","fatigue, allergic rhinitis, drowsiness","Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O",Launched
quetiapine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2",neurology/psychiatry,"schizophrenia, bipolar disorder","OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|",Launched
quiflapon,leukotriene synthesis inhibitor,"ALOX5, ALOX5AP",,,"CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12, CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12",Phase 2
quinagolide,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia,"CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC, CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC",Launched
quinapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure, angioedema","CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O",Launched
quinaprilat,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, angioedema","C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O",Launched
quinelorane,dopamine receptor agonist,"DRD2, DRD3",,,"CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12",Phase 3
quinestrol,estrogen receptor agonist,"ESR1, ESR2",endocrinology,menopause,"C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
quinethazone,thiazide diuretic,,cardiology,hypertension,"CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|",Launched
quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias","COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1",Launched
quinine,hemozoin biocrystallization inhibitor,"GP9, KCNB2, KCNN4, SLC29A4",infectious disease,malaria,"COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1",Launched
quinine-ethyl-carbonate,,,infectious disease,malaria,CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12,Launched
quinolinic-acid,glutamate receptor agonist,,,,OC(=O)c1cccnc1C(O)=O,Preclinical
quinpirol-(-),dopamine receptor agonist,"DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C",,,"CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12",Phase 2
quinupristin,bacterial 50s ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Launched
quipazine,serotonin receptor agonist,"HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4",,,"C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1",Preclinical
quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",,,"CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1",Phase 3
QX-222,sodium channel blocker,,,,Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,Preclinical
QX-314,sodium channel blocker,"MAPK14, TGFBR1",,,"CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C",Preclinical
R-121919,CRF receptor antagonist,,,,CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C,Preclinical
R-1479,HCV inhibitor,,,,"Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1",Phase 1
R-1485,serotonin receptor antagonist,HTR6,,,"Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1",Phase 1
R-1487,p38 MAPK inhibitor,,,,Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O,Phase 1
R-268712,serine/threonine kinase inhibitor,TGFBR1,,,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1",Preclinical
R-428,AXL kinase inhibitor,AXL,,,"Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1",Phase 2
R-59022,"diacylglycerol kinase inhibitor, protein kinase inhibitor",DGKA,,,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1",Preclinical
R-96544,serotonin receptor antagonist,HTR2A,,,"COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1",Preclinical
rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|",Launched
rac-BHFF,GABA receptor positive allosteric modulator,GABBR1,,,"CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|",Preclinical
racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|",Launched
racepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A",Immunology,anaphylactic shock,CNCC(O)c1ccc(O)c(O)c1,Launched
raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",,,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
ractopamine,adrenergic receptor agonist,,endocrinology,weight-gain aid,"C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1,&2:13,r|",Launched
ractopamine hcl,adrenergic receptor agonist,,endocrinology,weight-gain aid,CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1,Launched
radafaxine,dopamine-norepinephrine reuptake inhibitor,SLC6A3,,,"C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1, C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1",Phase 2
radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",,,,"CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1",Phase 2
radiprodil,acetylcholine receptor antagonist,,,,Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1,Phase 2
radotinib,Bcr-Abl kinase inhibitor,,,,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F,Phase 3
RAD140,androgen receptor modulator,,,,[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N,Phase 1
RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,,,"Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12",Phase 2
RAF709,RAF inhibitor,,,,Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1,Preclinical
ralinepag,IP1 prostacyclin receptor agonist,,,,OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|,Phase 3
raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
raltegravir,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C",Launched
raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma","OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1",Launched
ramelteon,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,insomnia,"CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12",Launched
ramifenazone,cyclooxygenase inhibitor,,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
ramipril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O",Launched
ramosetron,serotonin receptor antagonist,HTR3A,gastroenterology,"nausea, vomiting, irritable bowel syndrome","Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12, Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12",Launched
ranirestat,aldose reductase inhibitor,AKR1B1,,,"Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O",Phase 3
ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1, CN\C(=C/[N+](=O)[O-])\NCCSCc1oc(CN(C)C)cc1",Launched
ranitidine (zantac),histamine receptor antagonist,,gastroenterology,heartburn,CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O,Launched
ranolazine,sodium channel blocker,"SCN10A, SCN9A",cardiology,chronic stable angina,"COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|",Launched
rapacuronium bromide,acetylcholine receptor antagonist,CHRM2,neurology/psychiatry,general anaesthetic,[Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC,Withdrawn
rapastinel,glutamate receptor agonist,,,,"C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O",Phase 2
rasagiline,monoamine oxidase inhibitor,"BCL2, MAOB",neurology/psychiatry,Parkinson's Disease,"C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12",Launched
rauwolscine,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B",,,"COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12",Preclinical
ravoxertinib,ERK1 and ERK2 phosphorylation inhibitor,"MAPK1, MAPK3",,,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1",Phase 1
ravuconazole,sterol demethylase inhibitor,,,,"C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",Phase 2
RBC8,Ral GTPase inhibitor,"RALA, RALB",,,"COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|",Preclinical
rebamipide,free radical scavenger,FPR1,gastroenterology,"peptic ulcer disease (PUD), gastritis","OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|",Launched
rebastinib,"Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BCR, FGR, FLT3, HCK, LYN, SRC",,,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1",Phase 1/Phase 2
reboxetine,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression,"CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|",Launched
reboxetine mesylate,adrenergic receptor antagonist,,neurology/psychiatry,depression,CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1,Launched
Rec-15/2615,adrenergic receptor antagonist,ADRA1A,,,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C",Phase 2
recilisib,free radical scavenger,,,,OC(=O)c1ccc(\C=C\S(=O)(=O)Cc2ccc(Cl)cc2)cc1,Phase 1
refametinib,MEK inhibitor,"MAP2K1, MAP2K2",,,"COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1",Phase 2
regadenoson,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",radiology,myocardial perfusion imaging (MPI),"CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1, CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1",Launched
regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1",Launched
relcovaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2, OXTR",,,"COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl",Phase 2
relebactam,beta lactamase inhibitor,,,,"OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O, OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O",Launched
relugolix,gonadotropin releasing factor hormone receptor antagonist,,,,CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C,Phase 3
remacemide,glutamate receptor antagonist,GRIN1,,,"C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|",Phase 3
remdesivir,rna polymerase inhibitor,,,,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,Launched
remetinostat,HDAC inhibitor,,,,COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1,Phase 2
remimazolam,benzodiazepine receptor agonist,GABBR1,,,"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|, COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|",Phase 3
remodelin,transferase inhibitor,NAT10,,,"N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1",Preclinical
remogliflozin etabonate,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc3ccc(OC(C)C)cc3)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",,,"CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC",Withdrawn
rentiapril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,OC(=O)[C@@H]1CS[C@@H](N1C(=O)CCS)c2ccccc2O,Preclinical
repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
reparixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",,,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O",Phase 3
repotrectinib,receptor tyrosine protein kinase inhibitor,,,,C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23,Phase 1/Phase 2
repsox,TGF beta receptor inhibitor,TGFBR1,,,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
resatorvid,toll-like receptor inhibitor,TLR4,,,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|",Phase 3
reserpine,vesicular monoamine transporter inhibitor,"SLC18A1, SLC18A2",cardiology,hypertension,"CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1",Launched
resibufogenin,Na/K-ATPase inhibitor,,,,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1",Phase 2
resiquimod,toll-like receptor agonist,"TLR7, TLR8",,,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
resmetirom,thyroid hormone receptor agonist,,,,CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O,Phase 3
resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",,,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1",Phase 2
resorcinol,phosphodiesterase inhibitor,"CA12, CA14, CA2, PTGS1",dermatology,"acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis","Oc1cccc(O)c1, Oc1cccc(O)c1, Oc1cccc(O)c1",Launched
resorcinol-monoacetate,antiseptic,,,,"CC(=O)Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1",Launched
resveratrol,"cytochrome P450 inhibitor, SIRT activator","CSNK2A1, NQO2, PTGS1, PTGS2",,,"Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1",Launched
retagliptin,dipeptidyl peptidase inhibitor,,,,COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F,Phase 1
retapamulin,protein synthesis inhibitor,,infectious disease,impetigo,"C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C, C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C",Launched
retaspimycin,HSP inhibitor,HSP90AA1,,,"CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|",Phase 3
retinaldehyde,,,dermatology,cosmetic,"C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|",Launched
retinol,retinoid receptor ligand,"ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG",dermatology,"cosmetic, acne vulgaris (AV), keratosis","C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|, C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|",Launched
retinyl-acetate,,,,,"CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|, CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|",Launched
retinyl-palmitate,,,,,"CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|, CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|",Launched
REV-5901,"leukotriene receptor antagonist, lipoxygenase inhibitor",ALOX5,,,"CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|",Phase 2
revaprazan,potassium-competitive acid antagonist,ATP4A,gastroenterology,gastritis,"C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|",Launched
revefenacin,cholinergic receptor antagonist,,,,CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1,Launched
reversan,MRP inhibitor,ABCC1,,,"O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1",Preclinical
reversine,Aurora kinase inhibitor,"AURKB, INCENP, MAP2K1",,,"C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12",Preclinical
reynoutrin,antioxidant,,,,"O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O, O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O",Preclinical
rezafungin,,,,,CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@H](NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)cc7)[C@@H](C)O)OCC[N+](C)(C)C,Phase 3
rezafungin (acetate),other antifungal,,infectious disease,candidemia,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@]([H])(NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O)OCC[N+](C)(C)C)NC(=O)c1ccc(cc1)-c1ccc(cc1)-c1ccc(OCCCCC)cc1)[C@@H](C)O.CC(=O)O,Phase 3
rg-7112,mdm inhibitor,,,,CCOc1cc(ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C,Phase 1
RGB-286638,CDK inhibitor,"CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9",,,"COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1",Phase 1
RGFP966,HDAC inhibitor,HDAC3,,,"Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1",Preclinical
RGX-104,LXR agonist,,,,"C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F, C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F",Phase 1
RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",,,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
RG1530,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2",,,"COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|",Phase 1
RG2833,HDAC inhibitor,"HDAC1, HDAC3",,,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
RG4733,gamma secretase inhibitor,PSEN1,,,"CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O",Phase 2
RG7112,MDM inhibitor,MDM2,,,CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|,Phase 1
RG7800,RNA splicing modifier,,,,CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1,Preclinical
RG7834,antiviral,,,,COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC,Preclinical
RHC-80267,triacylglycerol lipase inhibitor,"DAGLA, DAGLB",,,"O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1",Preclinical
rhein,,HSP90AA1,,,"OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",Phase 1
rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,,,"COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1",Preclinical
rhodamine-123,,,,,"COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12",Phase 1
RI-1,,RAD51,,,"ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|, ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|",Preclinical
riamilovir,antiviral,,infectious disease,influenza a virus infection,CSc1nc2[nH]nc([N+]([O-])=O)c(=O)n2n1.O.O.[NaH],Phase 2/Phase 3
ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
ribitol,,,,,"OC[C@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)[C@H](O)CO",Preclinical
ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
riboflavin,vitamin B,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
riboflavin 5-phosphate sodium,,,,,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)COP(O)(O)=O)c2cc1C,Launched
riboflavin-tetrabutyrate,antioxidant,,,,CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC,Preclinical
riboflavin-5-phosphate-sodium,,"BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1",,,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C",Launched
ribostamycin,bacterial 30S ribosomal subunit inhibitor,P4HB,infectious disease,human immunodeficiency virus (HIV-1),"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
ribostamycin-sulfate,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|",Launched
ricinoleic-acid,prostanoid receptor agonist,PTGER3,,,CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O,Launched
ridinilazole,antibacterial,,,,c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1,Phase 3
rifabutin,protein synthesis inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36,t:3,15,30,38|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21",Launched
rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis, tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
rifamycin,DNA directed RNA polymerase inhibitor,"SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1",infectious disease,"tuberculosis, leprosy","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|",Launched
rifamycin sv na,rna synthesis inhibitor,,,,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C,Phase 3
rifamycin-sv,RNA synthesis inhibitor,,,,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|",Phase 3
rifapentine,RNA polymerase inhibitor,"CYP2C8, CYP2C9, CYP3A4",infectious disease,tuberculosis,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|",Launched
rifaximin,RNA synthesis inhibitor,,gastroenterology,"diarrhea, irritable bowel syndrome, hepatic encephalopathy (he), diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)","CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|",Launched
rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,,,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
rilapladib,phospholipase inhibitor,,,,COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12,Phase 2
rilmenidine,"adrenergic receptor agonist, imidazoline receptor agonist",ADRA2A,cardiology,hypertension,"C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|",Launched
rilpivirine,non-nucleoside reverse transcriptase inhibitor,"NR1I2, SCN10A",infectious disease,human immunodeficiency virus (HIV-1),"Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1",Launched
riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
rimacalib,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,rheumatology,rheumatoid arthritis,N=C(N1CCOCC1)NC2=CC([C@H](C3=CC=C(C4=CC=CC=C4)C(F)=C3)C)=NO2,Phase 2
rimantadine,"antiviral, RNA synthesis inhibitor",,infectious disease,influenza A virus infection,"C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|",Launched
rimantadine hydrochloride,"antiviral, rna synthesis inhibitor",,infectious disease,influenza a virus infection,CC(N)C12CC3CC(CC(C3)C1)C2,Launched
rimcazole,sigma receptor antagonist,SIGMAR1,,,"C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1",Phase 1
rimegepant,calcitonin antagonist,CALCA,,,"N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F",Launched
rimeporide,sodium/hydrogen exchanger inhibitor,,,,Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O,Phase 1
rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,"CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|",Launched
rimonabant,cannabinoid receptor antagonist,"CNR1, GPR55",,,"Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Withdrawn
riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,"COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12",Launched
riodipine,calcium channel blocker,,,,"COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|",Phase 2
riodoxol,other antibiotic,,,,"Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I",Launched
ripasudil,rho associated kinase inhibitor,"ROCK1, ROCK2",ophthalmology,"glaucoma, ocular hypertension","C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12",Launched
ripazepam,benzodiazepine receptor agonist,GABRA1,,,"CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|, CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|",Phase 2
ripretinib,receptor tyrosine protein kinase inhibitor,,,,"CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O, CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O",Phase 3
risdiplam,RNA splicing inhibitor,,,,Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1,Phase 2/Phase 3
risedronate,osteoclast inhibitor,FDPS,"orthopedics, endocrinology","osteoporosis, Paget's disease","OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O",Launched
rislenemdaz,ionotropic glutamate receptor antagonist,,,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,Preclinical
risperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7",neurology/psychiatry,"schizophrenia, bipolar disorder, irritability","Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
RITA,MDM inhibitor,MDM2,,,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
ritanserin,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,"Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1",Phase 3
ritodrine,adrenergic receptor agonist,,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|",Withdrawn
ritodrine hydrochloride,adrenergic receptor agonist,,obstetrics/gynecology,premature labor,CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1,Withdrawn
ritonavir,HIV protease inhibitor,"CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),"CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1",Launched
rivanicline,acetylcholine receptor agonist,"CHRNA4, CHRNB2, CXCL8",,,"CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1",Phase 2
rivaroxaban,coagulation factor inhibitor,F10,"neurology/psychiatry, hematology, cardiology","stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)","Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O",Launched
rivastigmine,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,"Alzheimer's disease, Parkinson's Disease, senile dementia","CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C",Launched
rizatriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12",Launched
RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",,,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
RLX,,,,,"O=c1n2CCCCCc2nc2ccccc12, O=c1n2CCCCCc2nc2ccccc12",Preclinical
RMC-4550,SHIP2 phosphatase inhibitor,,,,"C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N, C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N",Preclinical
RN-1,histone demethylase inhibitor,KDM1A,,,"CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1",Preclinical
RN-1734,TRPV antagonist,TRPV4,,,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
RN-1747,TRPV agonist,TRPV4,,,"[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1",Preclinical
Ro-04-5595,glutamate receptor antagonist,GRIN2B,,,"COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|",Preclinical
Ro-08-2750,NGF binding inhibitor,"NGF, NGFR",,,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O",Preclinical
Ro-10-5824,dopamine receptor agonist,DRD4,,,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|",Preclinical
Ro-106-9920,NFkB pathway inhibitor,,,,"O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|",Preclinical
Ro-1138452,prostanoid receptor antagonist,PTGIR,,,"CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|",Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2",,,"CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]",Preclinical
Ro-19-4605,GABA benzodiazepine site receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,"CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C",Preclinical
Ro-20-1724,phosphodiesterase inhibitor,"PDE3A, PDE4A, PDE4B, PDE4C, PDE4D",,,"CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|",Preclinical
Ro-25-6981,"glutamate receptor antagonist, monamine transporter modulator",GRIN2B,,,"C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1",Preclinical
Ro-28-1675,glucokinase activator,GCK,,,CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1,Preclinical
Ro-3,purinergic receptor antagonist,P2RX3,,,"COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C",Preclinical
Ro-3306,CDK inhibitor,CDK1,,,"O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|",Preclinical
Ro-48-6791,GABA receptor modulator,,,,CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21,Preclinical
Ro-48-8071,oxidosqualene cyclase inhibitor,LSS,,,"CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C",Preclinical
Ro-4987655,MEK inhibitor,MAP2K1,,,"OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F",Phase 1
Ro-5028442,vasopressin receptor antagonist,,,,CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12,Phase 1
Ro-5126766,"MEK inhibitor, RAF inhibitor","BRAF, MAP2K1, MAP2K2, RAF1",,,"CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F",Phase 1
Ro-5263397,trace amine associated receptor agonist,,,,Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|,Preclinical
Ro-60-0175,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",,,"C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12",Preclinical
Ro-61-8048,kynurenine 3-monooxygenase inhibitor,KMO,,,"COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O",Preclinical
Ro-67-7476,glutamate receptor positive allosteric modulator,GRM1,,,"Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1",Preclinical
Ro-90-7501,beta amyloid protein neurotoxicity inhibitor,APP,,,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
Ro-9187,HCV inhibitor,,,,"Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1",Preclinical
robalzotan,serotonin receptor antagonist,HTR1A,,,"NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1",Phase 2
robenidine,other antibiotic,,infectious disease,coccidiosis,C1=CC(=CC=C1C=NNC(=NN=CC2=CC=C(C=C2)Cl)N)Cl,Launched
roblitinib,FGFR inhibitor,,,,COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N,Preclinical
rociletinib,EGFR inhibitor,EGFR,,,"COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O",Phase 3
rocuronium,acetylcholine receptor antagonist,"CHRM2, CHRNA2, HTR3A",neurology/psychiatry,anesthetic,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1",Launched
rofecoxib,cyclooxygenase inhibitor,"ELN, PTGS2",,,"CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|",Withdrawn
roflumilast,phosphodiesterase inhibitor,"PDE4A, PDE4B, PDE4C, PDE4D",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis","FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl",Launched
rogaratinib,FGFR inhibitor,,,,COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1,Phase 2/Phase 3
rolapitant,neurokinin receptor antagonist,,,,[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,Phase 3
rolipram,phosphodiesterase inhibitor,,,,"COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|",Phase 3
rolitetracycline,bacterial 30S ribosomal subunit inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|",Launched
roluperidone,,,,,Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1,Phase 2
rolziracetam,,,,,O=C1CCC2CCC(=O)N12,Phase 2
romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|",Launched
romifidine,adrenergic receptor agonist,ADRA1A,neurology/psychiatry,sedative,C1CN=C(N1)NC2=C(C=CC=C2Br)F,Launched
ronidazole,antiprotozoal agent,,infectious disease,"histomoniasis, dysentry","Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O",Launched
ropinirole,dopamine receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome","CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12",Launched
ropivacaine,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic,"CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C",Launched
roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",,,,"CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1",Phase 3
rosamicin,protein synthesis inhibitor,,,,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|,Phase 2
roscovitine,CDK inhibitor,"CDK2, CDK9",,,"CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1",Phase 2
rose-bengal,"contrast agent, immunostimulant",,radiology,diagnostic agent,"OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12",Launched
rose-bengal-lactone,coloring agent,,ophthalmology,staining agent,"Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I, Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I",Launched
rosiglitazone,"insulin sensitizer, PPAR receptor agonist, insulin sensitizer, ppar receptor agonist","FFAR1, PPARG, TRPC5, TRPM3",Insulin sensitizer,diabetes mellitus,"CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1",Withdrawn
rosiglitazone maleate,,,,,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,Launched
rosiptor,SHIP1 phosphatase activator,,,,[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO,Phase 2
rosmarinic-acid,GABA transaminase inhibitor,"MCL1, TYR",,,"OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1",Launched
rosoxacin,topoisomerase inhibitor,,infectious disease,urinary tract infections,"CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1, CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1",Launched
rostafuroxine,ATPase inhibitor,ATP1A1,,,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1",Phase 2
rosuvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis","CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O",Launched
rotigotine,dopamine receptor agonist,"ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A",neurology/psychiatry,"Parkinson's Disease, restless leg syndrome","CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1",Launched
rotundine,serotonin receptor agonist,"DRD1, DRD2, DRD3, HTR1A",neurology/psychiatry,"anxiety, sedative","COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC, COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC",Launched
rovazolac,LXR agonist,,,,CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F,Preclinical
roxarsone,antiprotozoal agent,,endocrinology,weight-gain aid,"Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O",Launched
roxatidine-acetate,histamine receptor antagonist,HRH2,gastroenterology,"Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis","CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1",Launched
roxithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"respiratory tract infections, urinary tract infections, skin infections","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
RP-001,sphingosine 1-phosphate receptor agonist,S1PR1,,,"CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|",Preclinical
rp-54745,interleukin inhibitor,IL6,rheumatology,rheumatoid arthritis,"C[C@@H]1N(CCc2ccccc12)c1ssc(=O)c1Cl |&1:1,r|",
RP67580,,,,,COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1,Preclinical
RQ-00203078,transient receptor potential channel antagonist,TRPM8,,,"OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F",Preclinical
RRx-001,glucose 6-phosphate dehydrogenase inhibitor,G6PD,,,"[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O",Phase 3
RS-0481,immunostimulant,,,,,Phase 2
RS-100329,adrenergic receptor antagonist,"ADRA1A, ADRA1D",,,"Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O",Preclinical
RS-102221,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O",Preclinical
RS-102895,CCR antagonist,CCR2,,,"FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1",Preclinical
RS-127445,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12",Phase 1
RS-16566,serotonin receptor antagonist,,,,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2,Preclinical
RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",,,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
RS-23597-190,serotonin receptor antagonist,HTR4,,,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,Preclinical
RS-39604,serotonin receptor antagonist,HTR4,,,"COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1",Preclinical
RS-45041-190,imidazoline receptor agonist,,,,"Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|",Preclinical
RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",,,"Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1",Preclinical
RS-56812,serotonin receptor partial agonist,HTR3A,,,Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12,Preclinical
RS-67333,serotonin receptor partial agonist,HTR4,,,"CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1",Preclinical
RS-67506,serotonin receptor partial agonist,HTR4,,,"COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1",Preclinical
RS-79948,adrenergic receptor antagonist,ADRA2A,,,"CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12",Preclinical
RSV604,RSV replication inhibitor,,,,"Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|, Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|",Phase 2
rs0481,immunostimulant,,,,C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1,Phase 2
RTA-408,nitric oxide production inhibitor,NFE2L2,,,"CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|",Phase 2
RU-SKI-43,hedgehog pathway inhibitor,HHAT,,,"CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|",Preclinical
RU-24969,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6",,,"COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|",Phase 1
RU-28318,cytochrome P450 inhibitor,NR3C2,,,"CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|",Phase 2
RU-42173,adrenergic receptor agonist,ADRB2,,,"CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O, CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O",Phase 2
RU-58841,androgen receptor antagonist,AR,,,"CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F",Phase 2
rubitecan,topoisomerase inhibitor,TOP1,,,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O",Phase 3
ruboxistaurin,PKC inhibitor,,,,CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|,Phase 3
rucaparib,PARP inhibitor,"PARP1, PARP2",,,"CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23",Phase 3
rucinol,tyrosinase inhibitor,TYR,,,"CCCCc1ccc(O)cc1O, CCCCc1ccc(O)cc1O",Phase 1
rufinamide,voltage-gated sodium channel blocker,"GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)c1cn(Cc2c(F)cccc2F)nn1, NC(=O)c1cn(Cc2c(F)cccc2F)nn1",Launched
rufloxacin,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,"CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O",Launched
rupatadine,"histamine receptor antagonist, platelet activating factor receptor antagonist","HRH1, PTAFR",allergy,"allergic rhinitis, urticaria","Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1, Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1",Launched
rupintrivir,antiviral,,otolaryngology,common cold,CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c2cc(C)on2)C(C)C)Cc3ccc(F)cc3,Phase 2/Phase 3
rutaecarpine,cyclooxygenase inhibitor,PTGS2,,,"O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12",Preclinical
rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera","N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12",Launched
ruxolitinib-(S),JAK inhibitor,"JAK1, JAK2",,,"N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12",Preclinical
RV1729,PI3K inhibitor,,,,COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12,Phase 1
RWJ-21757,toll-like receptor agonist,TLR7,,,"Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",Phase 2
RWJ-50271,integrin inhibitor,ICAM1,,,"Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO",Preclinical
RWJ-67657,MAP kinase inhibitor,"MAPK14, PTGS2",,,"OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1",Phase 1
RX-3117,"CDK inhibitor, DNA synthesis inhibitor","CDK2, DNMT1",,,"Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|",Phase 1/Phase 2
RX-821002,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",,,"CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|",Preclinical
ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",,,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|",Preclinical
R112,SYK inhibitor,SYK,,,"Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1",Phase 1
R306465,HDAC inhibitor,,,,"ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1",Phase 1
R406,SYK inhibitor,"RET, SYK",,,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",,,"COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N",Phase 1
S-isopropylisothiourea,nitric oxide synthase inhibitor,NOS3,,,"CC(C)SC(N)=N, CC(C)SC(N)=N",Preclinical
S-methylcysteine,,"CTSD, MGMT",,,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
S-nitrosoglutathione,nitric oxide stimulant,PTPN1,,,,Phase 1
S-sulfo-L-cysteine,glutamate receptor agonist,,,,N[C@@H](CSS(O)(=O)=O)C(O)=O,Preclinical
S-trityl-L-cysteine,mitotic kinesin inhibitor,,,,"N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O",Preclinical
S-07662,CAR antagonist,NR1I3,,,"Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1",Preclinical
S-111,PARP inhibitor,PARP1,,,"CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",Phase 2
S-14506,serotonin receptor agonist,HTR1A,,,"COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1",Preclinical
S-17092,prolyl endopeptidase inhibitor,,,,O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1,Preclinical
S-3304,matrix metalloprotease inhibitor,,,,Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O,Phase 1/Phase 2
S-38093,histamine receptor antagonist,,,,NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|,Preclinical
SA-47,FAAH inhibitor,FAAH,,,"CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1",Preclinical
saccharin,DNA polymerase inhibitor,"CA1, CA12, CA2, CA9",,,"O=C1NS(=O)(=O)c2ccccc12, O=C1NS(=O)(=O)c2ccccc12",Launched
saclofen,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",,,"NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",Preclinical
sacubitril,neprilysin inhibitor,MME,cardiology,congestive heart failure,"CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O",Launched
sacubitril valsartan cocrystal,neprilysin inhibitor,"AGTR1, MME",Cardiovascular,hypertension,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,Launched
sacubitrilat,neprilysin inhibitor,,,,[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O,Preclinical
safflower-yellow,anti-inflammatory agent,,,,"OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|",Preclinical
safinamide,"dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",MAOB,neurology/psychiatry,Parkinson's Disease,"C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O",Launched
safingol,PKC inhibitor,TRPM3,,,"CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO",Phase 1
safranal,benzodiazepine receptor agonist,GABBR1,,,"CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|",Phase 2
SAG,smoothened receptor agonist,"SMO, TRPC6",,,"CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|",Preclinical
salazodine,,,null,ulcerative colitis,"COc1ccc(NS(=O)(=O)c2ccc(cc2)\N=N\c2ccc(O)c(c2)C(O)=O)nn1, COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1",Phase 2
salicin,anti-inflammatory agent,,,,"OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O",Phase 1
salicyl-alcohol,,,,,"OCc1ccccc1O, OCc1ccccc1O, OCc1ccccc1O",Preclinical
salicylamide,analgesic agent,,"neurology/psychiatry, endocrinology","pain relief, fever","NC(=O)c1ccccc1O, NC(=O)c1ccccc1O",Launched
salicylanilide,other antibiotic,,,,"Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1",Preclinical
salicylic-acid,"cyclooxygenase inhibitor, prostanoid receptor antagonist","AKR1C1, ASIC3, PTGS1, PTGS2","dermatology, endocrinology, neurology/psychiatry","acne vulgaris (AV), fever, pain relief","OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O",Launched
salidroside,beta amyloid protein neurotoxicity inhibitor,APP,,,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
salinomycin,,,infectious disease,coccidiosis,"CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
"salinomycin, sodium",,,infectious disease,coccidiosis,CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O,Launched
salirasib,mTOR inhibitor,TRPA1,,,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O",Phase 2
salmeterol,adrenergic receptor agonist,ADRB2,pulmonary,"asthma, chronic obstructive pulmonary disease (COPD), bronchospasm","OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|",Launched
salsolinol-1-carboxylic-acid,,,,,"C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|, C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|",Preclinical
salubrinal,eukaryotic translation initiation factor inhibitor,EIF2S1,,,"ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|",Preclinical
salvianolic-acid-A,matrix metalloprotease inhibitor,,,,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1,Phase 1
salvianolic-acid-B,"EGFR inhibitor, metalloproteinase inhibitor",MMP9,,,"OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1",Phase 2
salvinorin-A,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",,,"COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1",Phase 1
sal003,eukaryotic translation initiation factor inhibitor,EIF2A,,,"Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|",Preclinical
SAM-315,serotonin receptor antagonist,,,,O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12,Preclinical
sameridine,opioid receptor modulator,,,,CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1,Preclinical
sanazole,,,,,COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O,Phase 1
sancycline,antitumor agent,,,,"[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|",Preclinical
sangivamycin,DNA inhibitor,,,,"NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12",Phase 1
sanguinarium-chloride,apoptosis stimulant,CASP3,,,"C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12",Phase 1
SANT-1,smoothened receptor antagonist,"SHH, SMO",,,"Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1",Preclinical
SANT-2,smoothened receptor antagonist,"SHH, SMO",,,"CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1",Preclinical
sapacitabine,DNA synthesis inhibitor,,,,CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,Phase 3
sapropterin,phenylalanine 4-hydroxylase stimulant,"NOS3, PAH, TH, TPH1",metabolism,hyperphenylalaninemia (HPA),"C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1",Launched
saquinavir,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),"CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1",Launched
saquinavir mesylate,hiv protease inhibitor,,infectious disease,human immunodeficiency virus (hiv-1),CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Launched
SAR-245409,PI3K inhibitor,"MTOR, PIK3CG",,,"COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1, COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1",Phase 1/Phase 2
sar-260301,pi3k inhibitor,"PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD",oncology,melanoma,O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1,Phase 1
saracatinib,SRC inhibitor,"ABL1, LCK, SRC, YES1",,,"CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1",Phase 2/Phase 3
sarafloxacin,bacterial DNA gyrase inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
saralasin,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC,Withdrawn
sarcosine,glycine transporter inhibitor,SLC6A9,,,CNCC(O)=O,Phase 2
sardomozide,S-adenosylmethionine decarboxylase inhibitor,,,,NC(=N)N\N=C1/CCc2c1cccc2C(N)=N,Preclinical
sarecycline,bacterial 50s ribosomal subunit inhibitor,,dermatology,acne vulgaris (av),CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC,Launched
saredutant,neurokinin receptor antagonist,TACR2,neurology/psychiatry,depression,CC(NC1(C2=CC=CC=C2)CCN(CC[C@@H](C3=CC(Cl)=C(Cl)C=C3)CN(C)C(C4=CC=CC=C4)=O)CC1)=O,Phase 3
sari-59-801,,,,,"CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|, CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|",Phase 1
saroglitazar,PPAR receptor agonist,"PPARA, PPARG","endocrinology, cardiology, gastroenterology","diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)","CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O",Launched
sarolaner,gaba gated chloride channel blocker,GABRD,infectious disease,flea control,CS(=O)(=O)CC(=O)N1CC2(C1)C3=C(CO2)C=C(C=C3)C4=NO[C@@](C4)(C5=CC(=C(C(=C5)Cl)F)Cl)C(F)(F)F,Launched
sarpogrelate,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C","endocrinology, cardiology, rheumatology","diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease","COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|",Launched
sar125844,c-met inhibitor,MET,oncology,gastric adenocarcinoma,Fc1ccc(cc1)c2ccc3nnc(Sc4ccc5nc(NC(=O)NCCN6CCOCC6)sc5c4)n3n2,Phase 2
SAR131675,VEGFR inhibitor,FLT4,,,"CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC",Preclinical
SAR405,PI3K inhibitor,PIK3C3,,,"C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F",Preclinical
SAR405838,MDM inhibitor,MDM2,,,"CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1",Phase 1
SAR407899,rho associated kinase inhibitor,ROCK1,,,"O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12",Phase 2
sasapyrine,NFkB pathway inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O",Launched
satraplatin,DNA alkylating agent,,,,"CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O",Phase 3
savolitinib,c-Met inhibitor,MET,,,"C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1",Phase 3
saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2,Launched
SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",,,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
SB-202190,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",,,"Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1",Preclinical
SB-203186,serotonin receptor antagonist,HTR4,,,"O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12",Preclinical
SB-203580,p38 MAPK inhibitor,"AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF",,,"C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|",Preclinical
SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",,,"CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|",Preclinical
SB-206553,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1",Preclinical
SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",,,"COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C",Preclinical
SB-216763,glycogen synthase kinase inhibitor,"CCNA2, CDK2, GSK3A, GSK3B",,,"Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|",Preclinical
SB-218078,CHK inhibitor,CHEK1,,,,Preclinical
sb-218078,chk inhibitor,CHEK1,,,[H][C@]12CC[C@]([H])(O1)n1c3ccccc3c3c4C(=O)NC(=O)c4c4c5ccccc5n2c4c13 |r|,Preclinical
SB-218795,tachykinin antagonist,TACR3,,,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
SB-221284,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F",Preclinical
SB-222200,tachykinin antagonist,TACR3,,,"CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
SB-225002,CC chemokine receptor antagonist,CXCR2,,,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1",Phase 1
SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",,,"COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|",Preclinical
SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",,,"COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1",Phase 1
SB-243213,serotonin receptor inverse agonist,"HTR2A, HTR2B, HTR2C, HTR6",,,"Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F",Phase 1
SB-258585,serotonin receptor antagonist,HTR6,,,"COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1",Preclinical
SB-268262,calcitonin antagonist,CALCA,,,"CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|",Preclinical
SB-269970,serotonin receptor antagonist,HTR7,,,"CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1",Preclinical
SB-271046,serotonin receptor antagonist,HTR6,,,"COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1",Phase 1
SB-297006,CC chemokine receptor antagonist,CCR3,,,"CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1",Preclinical
SB-328437,CCR antagonist,,,,"COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12",Preclinical
SB-334867,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1",Preclinical
SB-366791,TRPV antagonist,TRPV1,,,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
SB-399885,serotonin receptor antagonist,HTR6,,,"COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC",Preclinical
SB-408124,orexin receptor antagonist,"HCRTR1, HCRTR2",,,"CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1",Preclinical
SB-415286,glycogen synthase kinase inhibitor,"GSK3A, GSK3B, RPS6KB1",,,"Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|",Preclinical
sb-431542,activin receptor inhibitor,"A1BG, ACVR1B, ACVR1C, TGFBR1",Oncology,brain tumors,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1,Preclinical
SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",,,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1",Preclinical
SB-452533,TRPV antagonist,TRPV1,,,"CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1",Preclinical
SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,,,"Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C",Preclinical
SB-525334,TGF beta receptor inhibitor,TGFBR1,,,"Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
SB-590885,RAF inhibitor,BRAF,,,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1",Preclinical
SB-612111,nociceptin/orphanin FQ receptor antagonist,OPRL1,,,"Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12",Preclinical
SB-649868,orexin receptor antagonist,,,,Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1,Phase 2
SB-657510,urotensin receptor antagonist,UTS2R,,,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
SB-683698,integrin antagonist,"ITGA4, ITGAV, ITGB1, ITGB7",,,"COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1",Phase 1
SB-705498,TRPV antagonist,TRPV1,,,"FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br",Phase 2
SB-706375,urotensin receptor antagonist,UTS2R,,,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F",Preclinical
SB-742457,serotonin receptor antagonist,HTR6,,,"O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1",Phase 3
SB-743921,kinesin-like spindle protein inhibitor,KIF11,,,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
SB-747651A,kinase inhibitor,"AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1",,,"CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N",Preclinical
SB-756050,G protein-coupled receptor agonist,GPBAR1,,,"COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1",Phase 1
SB-772077B,rho associated kinase inhibitor,"ROCK1, ROCK2",,,"CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N",Preclinical
SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9",,,"CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC",Phase 3
SBE-13,PLK inhibitor,PLK1,,,"COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC",Preclinical
SBHA,HDAC inhibitor,"HDAC1, HDAC3",,,"ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO",Preclinical
SBI-115,G protein-coupled receptor antagonist,,,,CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1,Preclinical
SC-10,protein kinase activator,PRKCA,,,"CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",Preclinical
SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,,,"COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|",Phase 2
SC-144,P glycoprotein inhibitor,,,,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
SC-19220,prostanoid receptor antagonist,PTGER1,,,"CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12",Preclinical
SC-236,cyclooxygenase inhibitor,PTGS2,,,"NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",Preclinical
SC-51089,prostanoid receptor antagonist,PTGER1,,,"Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1",Preclinical
SC-560,cyclooxygenase inhibitor,PTGS1,,,"COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",Preclinical
SC-9,protein tyrosine kinase activator,PRKCA,,,"Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1",Preclinical
scabertopin,anticancer agent,,,,"[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|",Preclinical
SCH-202676,G protein-coupled receptor modulator,"CHRM1, CHRM2, DRD1, DRD2",,,"CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1",Preclinical
SCH-221510,nociceptin/orphanin FQ receptor agonist,OPRL1,,,"Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|",Preclinical
SCH-23390,dopamine receptor antagonist,"DRD1, DRD5, HTR2C, KCNJ4, KCNJ6",,,"CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1",Preclinical
SCH-28080,ATPase inhibitor,ATP4A,,,"Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N",Phase 1
SCH-51344,MTH1 inhibitor,NUDT1,,,"COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1",Preclinical
SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
SCH-900776,CHK inhibitor,"CDK2, CHEK1",,,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
schisandrin-B,antioxidant,ATR,,,COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|,Preclinical
schisandrol-B,lipid peroxidase inhibitor,,,,"COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC",Phase 3
sclareol,,,,,"CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|, CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|",Preclinical
sclareolide,other antifungal,,,,"C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2",Launched
SCMC-Lys,mucolytic agent,GSTP1,pulmonary,chronic obstructive pulmonary disease (COPD),"N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O",Launched
scopine,,,,,"CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21",Launched
scopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI","neurology/psychiatry, gastroenterology","motion sickness, vomiting, nausea","CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
scopolamine hydrobromide,acetylcholine receptor antagonist,,"neurology/psychiatry, gastroenterology","motion sickness, vomiting, nausea",CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)c1ccccc1,Launched
scopolamine-N-oxide,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|",Preclinical
SCP-1,analgesic agent,,,,"Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1, Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1",Phase 1
scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
SCS,,,,,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
SD-0006,p38 MAPK inhibitor,,,,OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1,Phase 2
SD-169,p38 MAPK inhibitor,MAPK14,,,NC(=O)c1ccc2[nH]ccc2c1,Preclinical
SD-208,TGF beta receptor inhibitor,TGFBR1,,,"Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1",Preclinical
SD-2590,matrix metalloprotease inhibitor,"MMP1, MMP13, MMP2",,,"COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1",Preclinical
SDM25N,opioid receptor antagonist,OPRD1,,,"CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|",Preclinical
sdz-mks 492,phosphodiesterase inhibitor,PDE3A,pulmonary,asthma,COCCn1c(N[C@@H](CO)c2ccc(OC)c(OC)c2)nc2n(C)c(=O)n(C)c(=O)c12 |a:7|,
SDZ-NKT-343,tachykinin antagonist,TACR1,,,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O",Phase 1
SDZ-SER-082,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",,,"CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34",Preclinical
SDZ-WAG-994,adenosine receptor agonist,ADORA1,,,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
SDZ-205-557,serotonin receptor antagonist,"HTR3A, HTR3B",,,"CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC",Preclinical
SDZ-21009,"adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A, HTR1B",,,"CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|",Preclinical
SDZ-220-040,glutamate receptor antagonist,GRIN1,,,"N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O",Preclinical
SDZ-220-581,glutamate receptor antagonist,GRIN1,,,"N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O",Preclinical
Se-methylselenocysteine,,,,,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
secalciferol,vitamin D receptor agonist,VDR,critical care,bone fracture,"C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
seclazone,anti-inflammatory agent,,,,"Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|",Phase 1
seclidemstat,histone demethylase inhibitor,,,,CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O,Phase 1
secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",,infectious disease,protozoan infection,"C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|",Launched
secoisolariciresinol-(-),,,,,"COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O",Phase 2
secoisolariciresinol-diglucoside,antioxidant,,,,"COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O",Phase 2
securinine,"GABA receptor antagonist, TP53 activator",GABRA1,,,"O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|",Preclinical
segesterone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,O=C4\C=C2/[C@@H]([C@H]1CC[C@@]3([C@](OC(=O)C)(C(=C)\C[C@H]3[C@@H]1CC2)C(=O)C)C)CC4,Launched
segesterone-acetate,progesterone receptor agonist,PGR,,,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|,Launched
seladelpar,PPAR receptor agonist,,,,CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1,Phase 3
selamectin,nematocide,,infectious disease,flea control,"CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O, [H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4,t:6,25,56|",Launched
selegiline,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,Parkinson's Disease,C[C@H](Cc1ccccc1)N(C)CC#C,Launched
selegiline hydrochloride,monoamine oxidase inhibitor,,neurology/psychiatry,parkinson's disease,CC(Cc1ccccc1)N(C)CC#C,Launched
selenomethionine,,,,,"C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O",Launched
seletalisib,PI3K inhibitor,,,,[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F,Preclinical
selexipag,"IP1 prostacyclin receptor agonist, platelet aggregation inhibitor",PTGIR,pulmonary,pulmonary arterial hypertension (PAH),"CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1",Launched
selfotel,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1",Phase 3
selinexor,exportin antagonist,XPO1,hematologic malignancy,multiple myeloma,"FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1",Launched
selitrectinib,protein tyrosine kinase inhibitor,,,,[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1,Phase 1/Phase 2
selonsertib,MAP kinase activator,,,,CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1,Phase 2
selpercatinib,ret tyrosine kinase inhibitor,RET,oncology,medullary thyroid cancer (mtc),"COc1ccc(CN2[C@H]3C[C@@H]2CN(C3)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cn1 |&1:8,10,r|",Launched
seltorexant,orexin receptor antagonist,HCRTR2,neurology/psychiatry,depression,Cc1cc(C)nc(n1)N2CC3CN(CC3C2)C(=O)c4c(F)cccc4n5nccn5,Phase 3
selumetinib,MEK inhibitor,MAP2K1,,,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
sel120-34a (monohydrochloride),cdk inhibitor,"CDK19, CDK8",hematologic malignancy,acute myeloid leukemia (aml),Cc1c(Br)c(Br)c2CCCn3c(nc1c23)N1CCNCC1.Cl,Phase 1
semagacestat,gamma secretase inhibitor,PSEN1,,,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O,Phase 3
semagacestat (ly450139),gamma secretase inhibitor,,,,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O,Phase 3
semapimod,"cytokine production inhibitor, p38 MAPK inhibitor",MAPK14,,,"CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N",Phase 2
semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",,,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
semustine,DNA alkylating agent,,,,"CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]",Phase 3
SEN-1269,beta amyloid inhibitor,APP,,,"CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1",Preclinical
senaparib,parp inhibitor,PARP1,oncology,breast cancer,Fc1ccc(CN2C(=O)NC(=O)c3c(F)cccc23)cc1C(=O)N4CCN(CC4)c5ncccn5,Phase 1
senicapoc,intermediate conductance potassium channel blocker,KCNN4,,,"NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1",Phase 3
sennoside a,antiviral,,Infectious disease,human immunodeficiency virus (hiv-1),OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,Preclinical
sennoside-A,glycoside agonist,,gastroenterology,constipation,"OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|, OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|",Launched
sennoside-protonated,,,,,"OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|, OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|",Preclinical
seocalcitol,vitamin D receptor agonist,VDR,,,"CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Phase 3
SEP-227900,D-amino acid oxidase Inhibitor,DAO,,,"OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1",Phase 1
sep-363856,trace amine associated receptor agonist,"HTR1A, TAAR1",neurology/psychiatry,schizophrenia,CNC[C@@H]1OCCc2ccsc12,Phase 2
seratrodast,prostanoid receptor antagonist,TBXA2R,pulmonary,asthma,"CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|",Launched
serdemetan,MDM inhibitor,MDM2,,,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
serotonin,growth factor receptor activator,"DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1",neurology/psychiatry,"anxiety, depression, sleeplessness","NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12",Launched
sertaconazole,sterol demethylase inhibitor,,infectious disease,tinea pedis,"Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|",Launched
sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",,,"Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12",Withdrawn
sertraline,selective serotonin reuptake inhibitor (SSRI),"SLC6A3, SLC6A4","neurology/psychiatry, obstetrics/gynecology","depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder","CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12",Launched
sesamin,NFkB pathway inhibitor,,,,"C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1",Preclinical
setipiprant,prostaglandin inhibitor,PTGDR2,,,"OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12, OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12",Phase 3
setiptiline,adrenergic receptor antagonist,"HRH1, HTR2A, HTR2C",neurology/psychiatry,depression,"CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|, CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|",Launched
setmelanotide,melanocortin receptor agonist,,,,"[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O, [H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O",Phase 3
sevelamer hcl,,,,,"NCC=C.ClCC1CO1, null",
sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
SEW-2871,lysophospholipid receptor agonist,S1PR1,,,"FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F",Preclinical
SF-11,neuropeptide receptor antagonist,"MCOLN3, NPY2R",,,"CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1",Preclinical
SGC-CBP30,bromodomain inhibitor,"CREBBP, EP300",,,"COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl",Preclinical
SGC-0946,histone lysine methyltransferase inhibitor,,,,"CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12",Preclinical
SGC-707,protein arginine N-methyltransferase inhibitor,PRMT3,,,"O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1",Preclinical
SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",,,"Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1",Preclinical
SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",,,"CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1",Phase 1
SGS-742,GABA receptor antagonist,"GABBR1, GABBR2",,,CCCCP(O)(=O)CCCN,Preclinical
SGX523,hepatocyte growth factor receptor inhibitor,MET,,,"Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1",Phase 1
SHA-68,neuropeptide receptor antagonist,NPSR1,,,"Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|",Preclinical
shikimic-acid,,,,,"O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|, O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|",Preclinical
SHP099,protein tyrosine kinase inhibitor,PTPN11,,,"CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl",Preclinical
SIB-1553A,acetylcholine receptor agonist,CHRNB4,,,CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|,Phase 2
SIB-1757,glutamate receptor antagonist,GRM5,,,"C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|",Preclinical
SIB-1893,glutamate receptor antagonist,"GRM4, GRM5",,,"Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1",Preclinical
sibofimloc,,,gastroenterology,crohn's disease,CC(=O)N1CCC2(CC1)c3cc(ccc3c4ccc(cc24)C#C[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C#C[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O,Phase 2
SID-7969543,steroidogenic factor antagonist,NR5A1,,,"CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|",Preclinical
sigma-2 receptor antagonist 1,sigma receptor antagonist,"PGRMC1, TMEM97",neurology/psychiatry,alzheimer's disease,CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3ccc(cc3C2)S(=O)(=O)C)ccc1O,Phase 2
siguazodan,phosphodiesterase inhibitor,"PDE3A, PDE3B",Cardiology,heart failure therapy,"CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |&1:19,t:14|",Phase 1
sildenafil,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3",urology,erectile dysfunction,"CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1",Launched
silibinin,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis,"COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O",Launched
silodosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),"C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F",Launched
silver-sulfadiazine,PABA antagonist,,critical care,sepsis,"Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1",Launched
silymarin,,,,,"COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|",Launched
simeprevir,HCV inhibitor,"CYP1A2, CYP3A4",infectious disease,hepatitis C,"COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C",Launched
simurosertib,kinase inhibitor,,,,"Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|",Preclinical
simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|",Launched
sincalide,cholecystokinin agonist,,,,CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,Preclinical
sinefungin,"DNA methyltransferase inhibitor, RNA synthesis inhibitor",CARM1,,,"N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",Preclinical
sinomenine,angiogenesis inhibitor,,,,"COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|, COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|",Preclinical
sipatrigine,voltage-gated sodium channel blocker,"CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A",,,"CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl",Phase 2
siponimod,sphingosine 1-phosphate receptor modulator,S1PR1,neurology/psychiatry,multiple sclerosis,"CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F",Launched
siramesine,sigma receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",,,"Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12",Phase 2
siremadlin,MDM inhibitor,,,,COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1,Preclinical
sirolimus,mTOR inhibitor,"FKBP1A, MTOR","transplant, pulmonary, transplant, pulmonary","organ rejection, lymphangioleiomyomatosis, organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O",Launched
SirReal-2,SIRT inhibitor,SIRT2,,,"Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1",Preclinical
sirtinol,SIRT inhibitor,"SIRT1, SIRT2",,,"C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|",Preclinical
sisomicin,protein synthesis inhibitor,,ophthalmology,"conjunctivitis, punctate keratitis","CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|",Launched
sisomicin-sulfate,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,"CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2,5,7,8,11,13,15,22,24,28,&1:3,c:19|",Launched
SIS3,serine/threonine kinase inhibitor,"SMAD3, TGFBR1",,,"COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12",Preclinical
sitafloxacin,bacterial DNA gyrase inhibitor,,infectious disease,buruli ulcer,"N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F",Launched
sitagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F",Launched
sitaxentan,endothelin receptor antagonist,"EDNRA, EDNRB",,,"Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl",Withdrawn
sitosterol,,,,,"CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",Preclinical
sitravatinib,receptor tyrosine protein kinase inhibitor,,,,COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1,Phase 3
sivelestat,elastase inhibitor,"CELA1, ELANE",pulmonary,acute lung injury,"CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O",Launched
SJ-172550,MDM inhibitor,MDM4,,,"CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|",Preclinical
SJ-733,ATPase inhibitor,,,,Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N,Phase 1
SJG-136,DNA intercalating agent,,,,"COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|",Phase 2
SK&F-10047-(+),sigma receptor agonist,SIGMAR1,,,"C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C, C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C",Phase 1
SKA-31,potassium channel activator,KCNN4,,,"Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1",Preclinical
skepinone-L,p38 MAPK inhibitor,MAPK14,,,"OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1",Preclinical
SKF-38393,dopamine receptor agonist,"CALY, DRD1, DRD5",,,"Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|",Preclinical
SKF-77434,dopamine receptor agonist,DRD1,,,"Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|",Preclinical
SKF-81297,dopamine receptor agonist,"DRD1, DRD5",,,"Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1",Preclinical
SKF-83566,dopamine receptor antagonist,"DRD1, DRD5",,,"CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|",Preclinical
SKF-86002,p38 MAPK inhibitor,"ALOX5, MAPK14",,,"Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1",Preclinical
SKF-89976A,GABA uptake inhibitor,SLC6A1,,,"OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|",Preclinical
SKF-91488,histamine N-methyltransferase inhibitor,HNMT,,,"CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N",Preclinical
SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",,,"COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|",Preclinical
SKI-II,sphingosine kinase inhibitor,SPHK1,,,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
SKLB-1028,"Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor",,,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12,Preclinical
SKLB1002,VEGFR inhibitor,KDR,,,"COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC",Preclinical
SLV-319-(+/-),cannabinoid receptor antagonist,"CNR1, DRD2, HTR1A",,,"C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|",Phase 2
SLV-320,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|",Phase 2
SM-108,,,,,"NC(=O)C1N=CNC1=O |c:4|, NC(=O)C1N=CNC1=O |c:4|",Phase 2
SM-164,XIAP inhibitor,"BIRC2, BIRC3, XIAP",,,"CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1",Preclinical
SM-21,sigma receptor antagonist,PGRMC1,,,"CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|",Preclinical
sm-21 maleate,cholinergic receptor antagonist,,,,CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C,Preclinical
SMER-28,autophagy inducer,SNCA,,,"Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1",Preclinical
SMI-4a,Pim kinase inhibitor,PIM1,,,FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1,Preclinical
smn-c3,cell splicing inhibitor,SMN2,,,CCN1CCC(CC1)c1cc(C)c2nc(cc(=O)n2c1)-c1cc2c(C)nc(C)cn2n1,Preclinical
SN-2,transient receptor potential channel agonist,MCOLN3,,,"Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|",Preclinical
SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
SN-6,sodium/calcium exchange inhibitor,,,,"CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|",Preclinical
SNAP,nitric oxide donor,PTPN1,,,"CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|",Phase 2
SNAP-5089,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D",,,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|",Preclinical
SNAP-94847,,"ADRA1A, DRD2",,,"CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1",Preclinical
SNC-80,,OPRD1,,,"CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1",Preclinical
sndx-5613,,"KMT2A, MEN1",hematologic malignancy,acute myeloid leukemia (aml),CCN(C(C)C)C(=O)c1cc(F)ccc1Oc2cncnc2N3CC4(CCN(C[C@@H]5CC[C@H](CC5)NS(=O)(=O)CC)CC4)C3,Phase 1
SNG-1153,selective estrogen receptor modulator (SERM),ESR1,,,"CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F",Preclinical
snog,,,,,N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O,
SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",,,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
SNX-2112,HSP inhibitor,,,,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|",Phase 1
SNX-5422,HSP inhibitor,"HSP90AA1, HSP90AB1",,,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|",Phase 1/Phase 2
sobetirome,thyroid hormone receptor agonist,"THRA, THRB",,,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1/Phase 2
soblidotin,microtubule inhibitor,,,,[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1,Phase 2
sobrepin,mucolytic agent,,pulmonary,chest congestion,CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|,Launched
sobuzoxane,topoisomerase inhibitor,,hematologic malignancy,peripheral T-cell lymphoma (PTCL),CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O,Launched
sodium gluconate,,,,,[Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O,Launched
sodium monensin,bacterial permeability inducer,,infectious disease,gastrointestinal parasites,CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C,Launched
sodium nitroprusside,nitric oxide donor,,cardiology,"hypertension, congestive heart failure",[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N,Launched
sodium oxybate,,,,,OCCCC(O)=O,
sodium stibogluconate,tyrosine phosphatase inhibitor,,infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
sodium-ascorbate,,,,,"OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|, OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|, OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|",Launched
sodium-butyrate,HDAC inhibitor,"BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8",,,"CCCC(O)=O, CCCC(O)=O, CCCC(O)=O",Phase 2
sodium-danshensu,,,,,"O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|",Preclinical
sodium-dodecyl-sulfate,,ALB,,,"[Na].CCCCCCCCCCCCOS(O)(=O)=O, [Na].CCCCCCCCCCCCOS(O)(=O)=O",Launched
sodium-gluconate,,,,,"OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O",Launched
sodium-gualenate,antacid,,"gastroenterology, otolaryngology","peptic ulcer disease (PUD), pharyngitis","CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O, CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O",Launched
sodium-monofluorophosphate,,PYGM,dental,cavities,"OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O",Launched
sodium-nitrite,nitric oxide donor,,critical care,"poison antidote, cyanide poisoning","[O-][NH2+][O-], [O-][NH2+][O-]",Launched
sodium-nitroprusside,nitric oxide donor,,cardiology,"hypertension, congestive heart failure","[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N, [O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N",Launched
sodium-orthovanadate,,,,,"O[V](O)(O)=O, O[V](O)(O)=O",Preclinical
sodium-picosulfate,,,gastroenterology,constipation,"OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1, OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1",Launched
sodium-stibogluconate,tyrosine phosphatase inhibitor,PTPN6,infectious disease,leishmaniasis,[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO,Launched
sodium-tanshinone-II-A-sulfonate,potassium channel activator,,,,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
sodium-tetradecyl-sulfate,,PROC,dermatology,varicose veins,"CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCCCCCCCCCCCCOS(O)(=O)=O, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|",Launched
sofalcone,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD),"CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1",Launched
sofosbuvir,HCV inhibitor,,infectious disease,"hepatitis C, hepatitis C","CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1",Launched
sofosbuvir-impurity-m,antiviral,,,,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1,Preclinical
sograzepide,gastrin inhibitor,,,,CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|,Phase 2
solamargine,"apoptosis stimulant, apoptosis inhibitor",,,,"C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CN1 |t:8|",Launched
solasonine,hedgehog pathway inhibitor,"CYCS, MAPK14, MAPK8",dermatology,actinic keratosis (ak),C[C@@H]1CC[C@@]2(NC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O,Launched
solcitinib,JAK inhibitor,JAK1,,,"CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12",Phase 1
solifenacin succinate,acetylcholine receptor antagonist,,urology,"urinary incontinence, urinary frequency",O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,Launched
solifenacin-succinate,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency",[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1,Launched
solithromycin,protein synthesis inhibitor,,,,"CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC",Phase 3
solriamfetol,dopamine reuptake inhibitor,,neurology/psychiatry,narcolepsy,"N[C@@H](COC(N)=O)Cc1ccccc1, N[C@@H](COC(N)=O)Cc1ccccc1",Launched
somantadine,antiviral,,,,CC(C)(N)CC12CC3CC(CC(C3)C1)C2,Phase 1
somatostatin,somatostatin receptor agonist,"OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5",hematology,hemorrhage,"C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O",Launched
sonepiprazole,dopamine receptor antagonist,,,,NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1,Phase 2
sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1",Launched
sophocarpine,,,,,"O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|",Phase 3
sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
soraprazan,proton pump inhibitor,,,,COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1,Preclinical
sorbic-acid,,,,,C\C=C\C=C\C(O)=O,Launched
sorbinil,aldose reductase inhibitor,AKR1B1,,,"Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|",Phase 3
sorbitan-monostearate,,,,,"CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|, CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|",Preclinical
sorbitol,mucolytic agent,,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO",Launched
sorivudine,dna polymerase inhibitor,DPYD,infectious disease,virus herpes simplex (hsv),OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=C(\C=C\Br)C(=O)NC2=O,Phase 3
sotagliflozin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2",,,"CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1",Phase 3
sotalol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3, KCNH2","cardiology, Cardiology","atrial fibrillation (AF), ventricular arrhythmias, angina pectoris","CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:5,r|",Launched
sotorasib,ras gtpase inhibitor,KRAS,oncology,non-small cell lung cancer (nsclc),CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F,Launched
sotrastaurin,PKC inhibitor,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ",,,"CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|",Phase 2
SP-100030,NFkB pathway inhibitor,"JUN, NFKB1",,,"FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F",Preclinical
SP-141,ubiquitin ligase inhibitor,MDM2,,,"COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12",Preclinical
SP-420,,,,,"COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|",Phase 1
spaglumic-acid,glutamate receptor antagonist,GRM3,allergy,"allergic conjunctivitis, allergic rhinitis","CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,,,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
sparfosate,aspartate carbamoyltransferase inhibitor,"CA2, CA4",,,OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|,Phase 3
sparsentan,angiotensin receptor antagonist,,,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|,Phase 3
sparteine-(+),,,,,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Launched
sparteine-(-),,,,,"C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1, C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1",Launched
sparteine-sulfate,,,,,C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1,Launched
spautin-1,deubiquitinase inhibitor,"USP10, USP13",,,"Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1",Preclinical
spectinomycin,bacterial 30S ribosomal subunit inhibitor,,pulmonary,"airsacculitis, chronic respiratory disease","CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O",Launched
spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",,,"NCCCCNCCCN, NCCCCNCCCN",Preclinical
spermine,,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",,,NCCCNCCCCNCCCN,Preclinical
sphingosylphosphorylcholine,gene expression stimulant,GPR12,,,"CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|",Preclinical
spinosad,acetylcholine receptor agonist,CHRNA7,infectious disease,lice,CC[C@H]1CCC[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@@H](C)C(=O)C3=C[C@H]4[C@@H]5C[C@@H](C[C@H]5C=C[C@H]4[C@@H]3CC(=O)O1)O[C@@H]6O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]6OC,Launched
spiperone,dopamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7",neurology/psychiatry,schizophrenia,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1",Launched
spiradoline,opioid receptor agonist,OPRK1,,,"CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",Phase 2
spiramycin,bacterial 50S ribosomal subunit inhibitor,,infectious disease,"toxoplasmosis, soft tissue infection, toxoplasmosis, soft tissue infection","CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12,14|",Launched
spirapril,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3,Withdrawn
spirobromin,,,,,BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2,Phase 1
spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|",Launched
spiroxatrine,serotonin receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B",,,"O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|",Preclinical
spizofurone,,,,,CC(=O)c1ccc2OC3(CC3)C(=O)c2c1,Withdrawn
splitomycin,SIRT inhibitor,SIRT1,,,"O=C1CCc2c(O1)ccc1ccccc21, O=C1CCc2c(O1)ccc1ccccc21",Preclinical
SPP301,endothelin receptor antagonist,EDNRA,,,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1",Phase 3
SPP86,receptor tyrosine protein kinase inhibitor,RET,,,"CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12",Preclinical
spr741 (acetate),other antibiotic,,infectious disease,gram-negative bacterial infections,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(C)=O)[C@@H](C)O)[C@@H](C)O.CC(=O)O,
SQ-109,bacterial cell wall synthesis inhibitor,FDFT1,,,"CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|",Phase 3
SQ-22536,adenylyl cyclase inhibitor,ADCY1,,,"Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|",Preclinical
squalamine,antiviral,,,,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C,Phase 3
squaric-acid-dibutyl-ester,oxidative stress inducer,,,,CCCCOc1c(OCCCC)c(=O)c1=O,Preclinical
sq109,bacterial cell wall synthesis inhibitor,,Infectious disease,tuberculosis,CC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3,Phase 2/Phase 3
sr 146131,cck receptor agonist,CCKAR,oncology,neuroblastoma,O=C(O)CN1C(C(NC2=NC(C3=CC(OC)=C(Cl)C=C3OC)=C(CCC4CCCCC4)S2)=O)=CC5=C1C(C)=CC(C)=C5,Preclinical
sr 202,ppar receptor antagonist,,,,COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,Phase 2
SR-1078,retinoid receptor agonist,"RORA, RORC",,,"OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F",Preclinical
SR-11302,,,,,"C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|, C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|",Preclinical
SR-140333,neurokinin receptor antagonist,TACR1,,,"CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1",Phase 2
SR-1664,PPAR receptor ligand,PPARG,,,"C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O",Preclinical
SR-2211,retinoid receptor inverse agonist,RORC,,,"OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F",Preclinical
SR-2640,leukotriene receptor antagonist,CYSLTR1,,,"OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1",Phase 2
SR-27897,CCK receptor antagonist,CCKAR,,,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
sr-31747,immunosuppressant,SIGMAR1,oncology,prostate cancer,CCN(C/C=C\C1=CC=C(C2CCCCC2)C(Cl)=C1)C3CCCCC3.Cl,Preclinical
SR-3306,JNK inhibitor,"MAPK10, MAPK8, MAPK9",,,"Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1",Preclinical
SR-33805,calcium channel blocker,,,,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
SR-3576,JNK inhibitor,MAPK10,,,"COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC",Preclinical
SR-3677,rho associated kinase inhibitor,ROCK2,,,"CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|",Preclinical
SR-57227A,serotonin receptor agonist,HTR3A,,,"NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1",Phase 2
SR-59230A,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,"CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12",Preclinical
SR-95639A,acetylcholine receptor agonist,CHRM1,,,"C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1, C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1",Preclinical
SRC-kinase-inhibitor-I,SRC inhibitor,"CSK, LCK, RIPK2",,,"COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC",Preclinical
SRPIN340,serine arginine protein kinase inhibitor,"SRPK1, SRPK2",,,"FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1",Preclinical
SRT1720,SIRT activator,SIRT1,,,"O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1",Preclinical
SRT2104,SIRT activator,SIRT1,,,"Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1",Phase 2
SRT3190,CC chemokine receptor antagonist,,,,"C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO",Preclinical
SSR128129E,,,,,"COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12, COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12",Preclinical
SSR180711,acetylcholine receptor agonist,CHRNA7,,,Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|,Phase 2
SSR240612,bradykinin receptor antagonist,,,,COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1,Preclinical
sstr5 antagonist 1,,SSTR5,endocrinology,diabetes mellitus,CCOc1cc(CN2CC3(C2)CC(=NO3)N2CCC(CC2)C(O)=O)cc(OCC)c1-c1ccc(F)cc1 |c:13|,
ST-1535,adenosine receptor antagonist,,,,CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1,Preclinical
ST-1859,antiamyloidogenic agent,,,,"Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12",Phase 1
ST-2825,myeloid differentiation primary response inhibitor,MYD88,,,"NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12, NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12",Preclinical
ST-91,adrenergic receptor agonist,,,,"CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|",Preclinical
STA-5326,interleukin synthesis inhibitor,IL12A,,,"Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1",Phase 2
stanozolol,androgen receptor agonist,AR,Oncology,breast cancer,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5n[nH]cc5C[C@]4(C)[C@H]3CC[C@]12C,Launched
statil,aldose reductase inhibitor,,,,OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12,Preclinical
stattic,,,,,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|,Preclinical
STAT3-inhibitor-VI,STAT inhibitor,STAT3,,,"Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1",Preclinical
stavudine,"DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,human immunodeficiency virus (HIV-1),"Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|",Launched
stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,,,"CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12",Preclinical
stepronin,mucolytic agent,,,,"C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|",Launched
stetaderm,,,,,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|",Launched
STF-083010,serine/threonine kinase inhibitor,ERN1,,,"Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1",Preclinical
STF-118804,NAMPT inhibitor,NAMPT,,,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
STF-31,NAMPT inhibitor,"NAMPT, SLC2A1",,,"CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1",Preclinical
STF-62247,autophagy inducer,,,,"Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1",Preclinical
stigmasterol,,,,,"CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",Preclinical
stiripentol,GABA uptake inhibitor,GABRA3,neurology/psychiatry,epilepsy,"CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|, CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|",Launched
stobadine,adrenergic receptor antagonist,ADRA1A,,,"CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1, CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1",Phase 2
streptomycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,tuberculosis,"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O",Launched
streptomycin sulfate [5mm; 10% aq dmso + 5mm ethanolamine],bacterial 30s ribosomal subunit inhibitor,,infectious disease,tuberculosis,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O,Launched
streptozocin,dna alkylating drug,,Oncology,pancreatic cancer,CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,
streptozotocin,DNA alkylating agent,,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
strontium-ranelate,"bone formation stimulant, bone resorption inhibitor",CASR,"orthopedics, rheumatology","osteoporosis, osteoarthritis","OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N",Launched
strophanthidin acetate,atpase inhibitor,,,,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
strychnine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB",,,"O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61, O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|",Preclinical
subasumstat,,SAE1,hematologic malignancy,myeloproliferative neoplasms,Cc1sc(cc1[C@@H]2NCCc3ccc(Cl)cc23)C(=O)c4cncnc4N[C@H]5C[C@H](O)[C@@H](COS(=O)(=O)N)C5,Phase 1
substance-P,neurokinin receptor antagonist,"TACR1, TACR2, TACR3",,,"CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",Phase 1
succinic-acid,,"ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE",,,"OC(=O)CCC(O)=O, OC(=O)CCC(O)=O",Launched
succinobucol,antioxidant,VCAM1,,,CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C,Phase 2/Phase 3
succinylcholine-chloride,,"CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10",neurology/psychiatry,muscle relaxant,"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C",Launched
succinylsulfathiazole,dihydrofolate reductase inhibitor,DHFR,,,"OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",Phase 2
sucralfate,antacid,,gastroenterology,duodenal ulcer disease,"O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O, O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O",Launched
sucralose,,,,,"OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl",Launched
sucrose,,"ACTA1, ATOX1, C22orf28, LYZ",,,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,Launched
sucrose-octaacetate,,,,,CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,Preclinical
sudan-IV,,,,,Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1,Preclinical
sufugolix,gonadotropin releasing factor hormone receptor antagonist,,,,CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1,Preclinical
sugammadex,neuromuscular blockade reversal agent,,,,O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O,Launched
sulbactam,beta lactamase inhibitor,,infectious disease,"skin infections, intra-abdominal infections, gynecologic infections, skin infections, intra-abdominal infections, gynecologic infections","CC1(C)C(N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O",Launched
sulbactam-pivoxil,beta lactamase inhibitor,,infectious disease,skin infections,"CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11,&2:13,r|",Launched
sulbentine,other antifungal,,,,"S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1, S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1",Preclinical
sulbutiamine,acetylcholine receptor antagonist,,neurology/psychiatry,asthenia,CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O,Launched
sulconazole,sterol demethylase inhibitor,,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|",Launched
sulfabenzamide,bacterial antifolate,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1",Launched
sulfacarbamide,,,,,"NC(=O)NS(=O)(=O)c1ccc(N)cc1, NC(=O)NS(=O)(=O)c1ccc(N)cc1",Withdrawn
sulfacetamide,PABA antagonist,,ophthalmology,conjunctivitis,"CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1",Launched
sulfachlorpyridazine,bacterial antifolate,,infectious disease,urinary tract infections,"Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1",Launched
sulfadiazine,bacterial antifolate,,"infectious disease, ophthalmology","malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid","Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1",Launched
sulfadoxine,dihydropteroate synthase inhibitor,,infectious disease,malaria,"COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC",Launched
sulfafurazole,bacterial antifolate,,infectious disease,urinary tract infections,"Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C",Launched
sulfaguanidine,bacterial antifolate,,infectious disease,urinary tract infections,"NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1",Launched
sulfamerazine,bacterial antifolate,,infectious disease,"coccidiosis, cholera","Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
sulfameter,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections,"COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1",Launched
sulfamethazine,PABA antagonist,,gastroenterology,enteritis,"Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
sulfamethizole,bacterial antifolate,,infectious disease,urinary tract infections,"Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1",Launched
sulfamethoxazole,PABA antagonist,,"infectious disease, gastroenterology","pneumonia, enteritis, urinary tract infections","Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1",Launched
sulfamethoxypyridazine,bacterial antifolate,,,,"COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1",Withdrawn
sulfametopyrazine,PABA antagonist,,infectious disease,"malaria, urinary tract infections, respiratory tract infections","COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1",Launched
sulfamonomethoxine,bacterial antifolate,,infectious disease,urinary tract infections,"COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1",Launched
sulfamoxole,PABA antagonist,,infectious disease,urinary tract infections,"Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C",Launched
sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
sulfanilate-zinc,,,,,Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1,Preclinical
sulfanitran,,,infectious disease,coccidiosis,"CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O, CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O",Launched
sulfaphenazole,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections,"Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1",Launched
sulfapyridine,PABA antagonist,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
sulfaquinoxaline,vitamin K antagonist,,infectious disease,coccidiosis,"Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1, Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1, Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1",Launched
sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
sulfathiazole,dihydropteroate synthase inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",Launched
sulfatinib,tyrosine kinase inhibitor,,,,CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1,Phase 1
sulfinpyrazone,uricosuric blocker,"ABCC1, FPR1, SLC22A12",rheumatology,gout,"O=C1C(CC[S@@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |r|, O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|",Launched
sulfisomidin,antibacterial,,,,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1,Preclinical
sulfisoxazole-acetyl,folic acid antagonist,,"infectious disease, otolaryngology","meningitis, urinary tract infections, otitis, trachoma","CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1, CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1",Launched
sulforaphane,"anticancer agent, aryl hydrocarbon receptor antagonist",NFE2L2,,,"C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|",Phase 2
"sulfuric acid compound with (2r,3r,4r,5r)-2-((1s,2s,3r,4s,6r)-4,6-diamino-3-((2r,3r,6s)-3-amino-6-((r)-1-(met hylamino)ethyl)tetrahydro-2h-pyran-2-yloxy)-2-h",,,,,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O.CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,
sulindac,cyclooxygenase inhibitor,AKR1B1,rheumatology,"osteoarthritis, rheumatoid arthritis, ankylosing spondylitis","CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|",Launched
sulisobenzone,,,dermatology,sunscreen lotion,"COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1",Launched
sulmazole,adenosine receptor antagonist,,,,"COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|",Phase 1
sulmetozine,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD),"COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1",Launched
suloctidil,adrenergic receptor antagonist,,,,"CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|",Withdrawn
sulopenem,antibacterial,,,,"C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|",Phase 3
sulphadimethoxine,dihydropteroate synthetase inhibitor,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1",Launched
sulpiride,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia,"CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|",Launched
sultamicillin,antibacterial ,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections",CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C,Launched
sultiame,carbonic anhydrase inhibitor,CA2,,,NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O,Phase 3
sultopride,dopamine receptor antagonist,,,,"CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|",Preclinical
sumanirole,dopamine receptor agonist,DRD2,,,"CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23, CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23",Phase 3
sumatriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7",neurology/psychiatry,migraine headache,"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1",Launched
SUN-B-8155,calcitonin agonist,CALCR,,,"C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O",Preclinical
SUN-11602,fibroblast growth factor mimetic,FGFR1,,,"CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C",Preclinical
sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
suplatast,"histamine release inhibitor, immunoglobulin inhibitor",,rheumatology,Kimura's disease,"CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|",Launched
suprofen,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|",Withdrawn
suramin,DNA synthesis inhibitor,"F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5",infectious disease,"African trypanosomiasis, onchocerciasis","Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O",Launched
suritozole,GABA receptor inverse agonist,GABBR1,,,"Cn1nc(-c2cccc(F)c2)n(C)c1=S, Cn1nc(-c2cccc(F)c2)n(C)c1=S",Phase 2
sutezolid,protein synthesis inhibitor,,,,"CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1",Phase 2
suxibuzone,cyclooxygenase inhibitor,,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
SU11274,"hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor",MET,,,"CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1",Preclinical
su14813,"pdgfr tyrosine kinase receptor inhibitor, vegfr inhibitor",,,,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
SU16f,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,,,"Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O",Preclinical
SU3327,JNK inhibitor,MAPK8,,,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
SU4312,"PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor","KDR, PDGFRB",,,"CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1",Preclinical
SU9516,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5",,,"COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1",Preclinical
swainsonine,alpha mannosidase inhibitor,MAN2A1,,,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,Phase 2
SX-011,MAP kinase inhibitor,MAPK14,,,"CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1",Preclinical
sx-682,antitumor agent,"CXCL11, CXCR1, CXCR2",hematologic malignancy,myeloproliferative neoplasms,OB(O)c1ccc(OC(F)(F)F)cc1CSc1ncc(cn1)C(=O)Nc1ccc(F)cc1,Phase 1/Phase 2
SY-640,,,,,CN(Cc1ccc2OCOc2c1)C(C)=O,Phase 2
SYM-2081,kainate receptor antagonist,"GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2",,,"C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O",Preclinical
SYM-2206,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,"CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|",Preclinical
symclosene,,,,,"Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O, Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O",Preclinical
synephrine,adrenergic receptor agonist,ADRA1A,otolaryngology,sinusitis,"CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|",Launched
synephrine (oxedrine),adrenergic receptor agonist,,otolaryngology,sinusitis,CNCC(O)c1ccc(O)cc1,Launched
S1P1-agonist-III,sphingosine kinase inhibitor,S1PR1,,,"COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F",Preclinical
S15535,serotonin receptor agonist,,,,C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12,Preclinical
S18986,glutamate receptor modulator,"GRIA1, GRIA2, GRIA3, GRIA4",,,"O=S1(=O)N[C@H]2CCCN2c2ccccc12, O=S1(=O)N[C@H]2CCCN2c2ccccc12",Phase 2
S26948,PPAR receptor agonist,PPARG,,,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
S4,carbonic anhydrase inhibitor,"CA12, CA9",,,"Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1",Preclinical
S49076,tyrosine kinase inhibitor,,,,O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1,Preclinical
s55746,bcl inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (cll),Oc1ccc(cc1)N(C(=O)c1cc(-c2cc3OCOc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2CCCCc12)c1ccccc1,Phase 1
S63845,MCL1 inhibitor,,,,"CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1, CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1",Preclinical
T-0070907,PPAR receptor antagonist,PPARG,,,"[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1",Preclinical
T-0156,phosphodiesterase inhibitor,PDE5A,,,"COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1",Preclinical
t-025,clk inhibitor,,,,CNc1nc(NCc2ncccn2)c2c(c[nH]c2n1)-c1ccc2ncccc2c1,Preclinical
T-025,CLK inhibitor,,,,,Preclinical
T-0901317,LXR agonist,"NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB",,,"OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F",Preclinical
T-1095,sodium/glucose cotransporter inhibitor,,,,COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O,Preclinical
t-1101 (tosylate),hec1 inhibitor,"NDC80, NEK2",oncology,prostate cancer,COCCOc1cnc(Sc2cc(C)c(-c3csc(NC(=O)c4ccncc4)n3)c(C)c2)cn1.Cc1ccc(cc1)S(=O)(=O)O,Phase 1
T-5224,AP inhibitor,JUN,,,"OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O",Phase 2
T-5601640,LIM kinase inhibitor,LIMK2,,,"Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F",Preclinical
T-62,adenosine receptor modulator,ADORA2A,,,"Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1",Phase 2
T-807,PET radiotracer,,,,Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21,Phase 2
TA-01,"casein kinase inhibitor, MAP kinase inhibitor","CSNK1D, CSNK1E, MAPK14",,,"Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F",Preclinical
tabimorelin,growth hormone secretagogue receptor agonist,GHSR,,,"CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N",Phase 2
tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips","CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
tacedinaline,HDAC inhibitor,HDAC1,,,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
tacrine,acetylcholinesterase inhibitor,"ACHE, BCHE",neurology/psychiatry,Alzheimer's disease,"Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12",Launched
tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|",Launched
tadalafil,phosphodiesterase inhibitor,"PDE11A, PDE5A",urology,erectile dysfunction,"CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O",Launched
tafamidis-meglumine,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP),"OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1, OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1",Launched
tafenoquine,antimalarial agent,,infectious disease,malaria,"COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|, COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|",Launched
tafluprost,prostaglandin inhibitor,PTGFR,ophthalmology,"glaucoma, ocular hypertension",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1,Launched
tagatose,phosphorylase inhibitor,PYGL,,,"OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Launched
TAK-063,phosphodiesterase inhibitor,PDE10A,,,"COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1, COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1",Phase 2
tak-071,mitotic inhibitor,"FOS, SNCA",neurology/psychiatry,parkinson's disease,Cc1c(Cc2ccc(cc2)n3cccn3)cc4C(=O)N(Cc4c1F)[C@H]5COCC[C@@H]5O,Phase 2
TAK-220,CC chemokine receptor antagonist,CCR5,,,"CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1",Phase 1
TAK-243,ubiquitin activating enzyme inhibitor,,,,NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O,Phase 1
TAK-285,EGFR inhibitor,ERBB2,,,"CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12",Phase 1
TAK-593,VEGFR inhibitor,PDGFRA,,,"Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1",Phase 1
TAK-632,RAF inhibitor,BRAF,,,"Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F",Preclinical
TAK-659,spleen associated tyrosine kinase inhibitor,,,,"Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12, Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12",Phase 2
TAK-715,p38 MAPK inhibitor,MAPK14,,,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
TAK-733,MEK inhibitor,MAP2K1,,,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
TAK-779,CC chemokine receptor antagonist,,,,Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|,Preclinical
TAK-875,insulin secretagogue,FFAR1,,,"Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1",Phase 3
TAK-901,Aurora kinase inhibitor,AURKB,,,"CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12",Phase 1
TAK-960,PLK inhibitor,PLK1,,,"COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1",Phase 1
talabostat,"dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor",DPP4,,,"CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O",Phase 3
taladegib,smoothened receptor antagonist,"DHH, IHH, SMO",,,"CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F",Phase 2
talampanel,glutamate receptor antagonist,"GRIA1, GRIA2, GRIA3, GRIA4",,,"C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|",Phase 2
talaporfin,photosensitizing agent,,oncology,glioma,"CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C, CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C.[NaH].[NaH].[NaH].[NaH]",Launched
talarozole,cytochrome P450 inhibitor,CYP26A1,,,"CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|",Phase 2
talazoparib,PARP inhibitor,PARP2,oncology,breast cancer,"Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1",Launched
talc,,,,,O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O,
taletrectinib,proto-oncogene tyrosine protein kinase inhibitor,ROS1,oncology,non-small cell lung cancer (nsclc),C[C@@H](N)COc1ccc(cc1)-c1cnc2ccc(N[C@H](C)c3cccc(F)c3)nn12.OC(=O)CCCCC(=O)O,Phase 2
talinolol,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,"CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|",Launched
talipexole,"adrenergic receptor agonist, dopamine receptor agonist","ADRA2A, DRD2, HTR3A",infectious disease,genitial herpes,"Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1",Launched
talmapimod,p38 MAPK inhibitor,"IL1B, MAPK11, MAPK14, MT-CO2, TNF",,,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
talnetant,tachykinin antagonist,"TACR2, TACR3",,,"CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1",Phase 2
talniflumate,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief,"FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|",Launched
talopram,adrenergic inhibitor,SLC6A2,,,"CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|",Phase 2
talsaclidine,acetylcholine receptor agonist,,,,C#CCO[C@H]1CN2CCC1CC2,Phase 2/Phase 3
taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,"CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O, CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O",Launched
taltobulin,tubulin polymerization inhibitor,,,,"CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1",Phase 1
TAME,,,,,"COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1, COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1",Preclinical
tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),"CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12",Launched
taminadenant,adenosine receptor antagonist,,,,Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1,Phase 1/Phase 2
tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1",Launched
tamsulosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D",urology,benign prostatic hyperplasia (BPH),"CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O",Launched
tanaproget,progesterone receptor agonist,PGR,,,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
tandospirone,serotonin receptor agonist,HTR1A,neurology/psychiatry,"generalized anxiety disorder (GAD), dysthymic disorder","O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1",Launched
tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",,,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
tanespimycin,HSP inhibitor,HSP90AA1,,,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|",Phase 3
tangeritin,cell cycle inhibitor,,,,"COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",Preclinical
tannic acid,parg inhibitor,,gastroenterology,constipation,Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,Launched
tannic-acid,PARG inhibitor,ANO1,gastroenterology,constipation,Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,Launched
tanshinone-I,AP inhibitor,IFNG,,,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
tanshinone-IIA,"anti-inflammatory agent, interleukin inhibitor","IL1B, NR1I2, TNF",,,"Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21",Phase 2/Phase 3
tapentadol hydrochloride,,,,,CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1,
tapinarof,aryl hydrocarbon receptor agonist,,,,CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O,Phase 3
taprenepag,prostaglandin receptor agonist,PTGER2,,,"OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1, OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1",Phase 2
tarafenacin,acetylcholine receptor antagonist,CHRM3,,,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2,Phase 2
tarafenacin (d-tartrate),acetylcholine receptor antagonist,,,,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2,Phase 2
taranabant,cannabinoid receptor inverse agonist,CNR1,,,"C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N",Phase 3
targinine,nitric oxide synthase inhibitor,NOS3,,,"CNC(=N)NCCC[C@H](N)C(O)=O, CNC(=N)NCCC[C@H](N)C(O)=O",Phase 3
tariquidar,P glycoprotein inhibitor,ABCB1,,,"COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC",Phase 3
tartaric-acid,antioxidant,,,,"O[C@H]([C@@H](O)C(O)=O)C(O)=O, O[C@H]([C@@H](O)C(O)=O)C(O)=O",Launched
TAS-103,topoisomerase inhibitor,TOP1,,,"CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12",Phase 1
tas-115 mesylate,protein tyrosine kinase inhibitor,"HGF, PDGFRA, TNK1",oncology,osteosarcoma,CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC.CS(=O)(=O)O,Phase 1
taselisib,PI3K inhibitor,PIK3CA,,,"CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O",Phase 3
tasimelteon,melatonin receptor agonist,"MTNR1A, MTNR1B",neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12,Launched
tasisulam,apoptosis stimulant,,,,"Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1",Phase 3
tasquinimod,"angiogenesis inhibitor, S100A9 inhibitor",HDAC4,,,"COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12",Phase 3
tasuldine,mucolytic agent,,,,"C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1",Phase 3
tas4464,nedd activating enzyme inhibitor,NAE1,hematologic malignancy,multiple myeloma,NC1=NC=NC2=C1C(C#CC3=C(F)C=CC=C3OCC)=CN2[C@@H]4O[C@H](CNS(=O)(N)=O)[C@@H](O)[C@H]4O,Phase 1
taurine,antioxidant,,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
taurocholate,G protein-coupled receptor agonist,"CEL, FABP6, SLCO1C1",,,"C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",Phase 1
tauroglycocholate,membrane permeability enhancer,,,,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O,Preclinical
taurolidine,apoptosis stimulant,,infectious disease,catheter-related bloodstream infection,"O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1, O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1",Launched
tavaborole,leucyl-tRNA synthetase inhibitor,,infectious disease,onychomycosis,"OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12",Launched
tavapadon,dopamine agonist,"DRD1, DRD5",neurology/psychiatry,parkinson's disease,CN1C(=O)NC(=O)C(=C1c2ccc(Oc3ncccc3C(F)(F)F)cc2C)C,Phase 2
tavilermide,tyrosine kinase partial agonist,,,,NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O,Phase 3
taxifolin,opioid receptor antagonist,ADIPOR2,,,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1",Phase 2
tazarotene,retinoid receptor agonist,"RARA, RARB, RARG, RXRB",dermatology,"cosmetic, sunscreen lotion","CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1",Launched
tazemetostat,histone lysine methyltransferase inhibitor,EZH2,,,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Launched
tazobactam,beta lactamase inhibitor,,infectious disease,pneumonia,"C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O |a:1,&1:8,&2:10|, C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O",Launched
TBA-354,,,,,"[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1",Phase 1
tbaj-587,atp synthase inhibitor,,infectious disease,tuberculosis,COc1cc(cc(OC)n1)[C@](O)(CCN(C)C)[C@H](c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC,Phase 1
TBOA-(DL),excitatory amino acid transporter inhibitor,"SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7",,,"N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O",Preclinical
TC-A-2317,Aurora kinase inhibitor,AURKA,,,"C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|",Preclinical
TC-ASK-10,MAP kinase inhibitor,"MAP3K5, MAP3K6",,,"CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1",Preclinical
TC-E-5002,histone demethylase inhibitor,"KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8",,,"ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1",Preclinical
TC-E-5006,gamma secretase modulator,APP,,,"C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|",Preclinical
TC-F-2,FAAH inhibitor,FAAH,,,"CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O",Preclinical
TC-FPR-43,formyl peptide receptor agonist,FPR2,,,"CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C",Preclinical
TC-G-1000,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",,,"Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|",Preclinical
TC-G-1004,adenosine receptor antagonist,ADORA2A,,,"COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C",Preclinical
TC-G-1005,G protein-coupled receptor agonist,GPBAR1,,,"Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1",Preclinical
TC-G-1008,G protein-coupled receptor agonist,GPR39,,,"CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1",Preclinical
TC-H-106,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC8",,,"Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1",Preclinical
TC-I-15,integrin inhibitor,"ITGA2, ITGB1",,,"CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1",Preclinical
TC-I-2000,transient receptor potential channel antagonist,TRPM8,,,"Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|",Preclinical
TC-I-2014,transient receptor potential channel antagonist,TRPM8,,,"FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|",Preclinical
TC-LPA5-4,lysophosphatidic acid receptor antagonist,LPAR5,,,"COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O",Preclinical
TC-Mps1-12,monopolar spindle 1 kinase inhibitor,TTK,,,"CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N",Preclinical
TC-N-1752,sodium channel blocker,SCN9A,,,"CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C",Preclinical
TC-NTR1-17,neurotensin agonist,NTSR1,,,"COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O",Preclinical
TC-O-9311,G protein-coupled receptor agonist,GPR139,,,"COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12",Preclinical
TC-OT-39,"oxytocin receptor agonist, vasopressin receptor agonist","AVPR1A, OXT",,,"CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12",Preclinical
TC-S-7003,SRC inhibitor,LCK,,,"CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1",Preclinical
TC-S-7004,DYRK inhibitor,"DYRK1A, DYRK1B",,,"COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1",Preclinical
TC-S-7005,PLK inhibitor,PLK2,,,"C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1",Preclinical
TC-S-7006,MAP kinase inhibitor,MAP3K8,,,"Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl",Preclinical
TC-S-7009,hypoxia inducible factor inhibitor,EPAS1,,,"[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12",Preclinical
TC-SP-14,sphingosine 1-phosphate receptor agonist,S1PR1,,,"OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1",Preclinical
TCID,,,,,"Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl",Preclinical
TCN201,glutamate receptor antagonist,GRIN2A,,,"Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1",Preclinical
TCN238,glutamate receptor positive allosteric modulator,GRM4,,,"Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1",Preclinical
TCS-HDAC6-20b,HDAC inhibitor,HDAC6,,,"CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2",Preclinical
TCS-OX2-29,orexin receptor antagonist,HCRTR2,,,"COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C",Preclinical
TCS-PIM-1-1,Pim kinase inhibitor,PIM1,,,"Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1",Preclinical
TCS-2002,glycogen synthase kinase inhibitor,GSK3B,,,"Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|",Preclinical
TCS-21311,JAK inhibitor,JAK3,,,"CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|",Preclinical
TCS-2210,neural stem cell inducer,,,,"ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1, ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1",Preclinical
TCS-2314,integrin inhibitor,"ITGA4, ITGB1",,,"Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1",Preclinical
TCS-3035,G protein-coupled receptor agonist,GPR35,,,"OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1",Preclinical
TCS-359,FLT3 inhibitor,FLT3,,,"COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O",Preclinical
TCS-5861528,transient receptor potential channel antagonist,TRPA1,,,"CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|",Preclinical
TCV-309,platelet activating factor receptor antagonist,,,,CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1,Preclinical
TC1,beta-secretase inhibitor,BACE1,,,"O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|",Preclinical
TC2559,acetylcholine receptor agonist,CHRNA4,,,"CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1",Preclinical
TD139,anti-inflammatory agent,,,,OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1,Phase 2
tebanicline (dihydrochloride),acetylcholine receptor agonist,"CHRNA4, CHRNB2",neurology/psychiatry,chronic pain,[H]Cl.ClC(C=C1)=NC=C1OC[C@@H]2NCC2.[H]Cl,Preclinical
tebipenem,bacterial cell wall synthesis inhibitor,CNR1,"infectious disease, otolaryngology","pneumonia, otitis","C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|, O=C(C(N1C2=O)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@]1([H])[C@@]2([H])[C@H](O)C)O",Launched
tebipenem pivoxil,bacterial cell wall synthesis inhibitor,,"infectious disease, otolaryngology","pneumonia, otitis",C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C,Launched
tecadenoson,adenosine receptor agonist,ADORA1,,,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12,Phase 2
tecalcet,calcium-sensing receptor agonist,CASR,,,"COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl",Phase 2
tecarfarin,vitamin k antagonist,VKORC1,hematology,thrombosis,CC(OC(=O)c1ccc(CC2=C(O)c3ccccc3OC2=O)cc1)(C(F)(F)F)C(F)(F)F,Phase 3
tecastemizole,histamine receptor antagonist,KCNH2,,,"Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1",Phase 3
tecovirimat,orthopoxvirus egress inhibitor,,infectious disease,smallpox,"FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|, FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|",Launched
tedizolid,bacterial 50S ribosomal subunit inhibitor,,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O",Launched
tedizolid-phosphate,protein synthesis inhibitor,,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
tefinostat,hdac inhibitor,HDAC1,oncology,hepatocellular carcinoma (hcc),ONC(=O)CCCCCCC(=O)Nc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1,Phase 1/Phase 2
tegafur,,,,,FC=1C(=O)NC(=O)N(C=1)[C@@H]2OCCC2,Launched
tegaserod,serotonin receptor partial agonist,"HTR2A, HTR2B, HTR2C, HTR4",,,"CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12",Withdrawn
teglicar,carnitine palmitoyltransferase inhibitor,CPT1A,endocrinology,diabetes mellitus,CCCCCCCCCCCCCCNC(=O)N[C@H](CC(O)=O)C[N+](C)(C)C |a:18|,Phase 2
tegobuvir,"HCV inhibitor, protease inhibitor",,,,"Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1, Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1",Phase 3
teicoplanin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl, CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl",Launched
teicoplanin-A2-1,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,"CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|, CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|",Launched
teicoplanin-A2-3,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl,Launched
teijin-compound-1,CC chemokine receptor antagonist,CCR2,,,"FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1",Preclinical
telaprevir,HCV inhibitor,"CTSA, PGR",infectious disease,hepatitis C,"CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1",Launched
telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,,,"CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1",Phase 2
telavancin,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections,null,Launched
telbivudine,DNA polymerase inhibitor,,infectious disease,hepatitis B,"Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O",Launched
telcagepant,calcitonin antagonist,"CALCRL, RAMP1",,,"Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F",Phase 3
telenzepine,acetylcholine receptor antagonist,CHRM1,,,"CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1",Phase 3
telithromycin,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor, bacterial 30s ribosomal subunit inhibitor, bacterial 50s ribosomal subunit inhibitor","CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7",infectious disease,pneumonia,"CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC",Launched
telmesteine,mucolytic agent,,pulmonary,cough suppressant,"CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|, CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|",Launched
telmisartan,angiotensin receptor antagonist,"AGTR1, PPARG",cardiology,hypertension,"CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C",Launched
telotristat,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F",Launched
telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
telratolimod,toll-like receptor agonist,,,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12,Preclinical
temanogrel,serotonin receptor antagonist,,,,COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C,Preclinical
temefos,cholinesterase inhibitor,,,,"COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1, COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1",Launched
temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)","CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1",Launched
temoporfin,radical formation stimulant,,oncology,head and neck squamous cell carcinoma (HNSCC),"Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2",Launched
temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
tempol,free radical scavenger,,,,"CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O",Phase 2
temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|",Launched
TEN-010,bromodomain inhibitor,,,,"CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|, CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|",Preclinical
tenalisib,PI3K inhibitor,,,,CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,Phase 2
tenapanor,sodium/hydrogen exchanger inhibitor,,,,CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1,Launched
tenatoprazole,ATPase inhibitor,IDO1,,,"COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|",Phase 2
teneligliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1",Launched
tenidap,cyclooxygenase inhibitor,"KCNJ4, PTGS1",,,"NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|, NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12",Phase 3
tenilsetam,AGE inhibitor,,,,"O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|, O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|",Phase 3
teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
tenofovir,"HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor",,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B","C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O",Launched
tenofovir alafenamide,hiv gag inhibitor,GAG-POL,Infectious disease,human immunodeficiency virus (hiv-1),CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1,Launched
tenofovir-alafenamide,nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis B,"CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6,&2:9,&3:13,r|",Launched
tenofovir-disoproxil,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,"human immunodeficiency virus (HIV-1), hepatitis B","CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C",Launched
tenovin-1,"SIRT inhibitor, TP53 activator",SIRT1,,,"CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",,,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
tenoxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2","rheumatology, orthopedics","rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis","CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|",Launched
tenylidone,,,,,"O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1, O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1",Preclinical
tepilamide fumarate,"nuclear factor erythroid derived, like (nrf2) activator","GSTP1, HCAR2, NFE2L2",neurology/psychiatry,multiple sclerosis,CCN(CC)C(=O)COC(=O)\C=C\C(=O)OC,Launched
tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
TEPP-46,pyruvate kinase isozyme activator,PKM,,,"Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|",Preclinical
teprenone,mucus protecting agent,,dermatology,cosmetic,"CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O",Launched
terameprocol,lipoxygenase inhibitor,"BIRC5, CDK1",,,COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,Phase 1/Phase 2
terazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D","urology, cardiology","benign prostatic hyperplasia (BPH), hypertension","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|",Launched
terazosin hydrochloride,adrenergic receptor antagonist,,"urology, cardiology","benign prostatic hyperplasia (bph), hypertension",COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1,Launched
terbinafine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12",Launched
terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|",Launched
terciprazine,,,,,"O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|, O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|",Phase 1
terconazole,sterol demethylase inhibitor,,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
terfenadine,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",,,"CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|",Withdrawn
terguride,"dopamine receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",neurology/psychiatry,Parkinson's Disease,"CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|",Launched
teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|",Launched
terlipressin,vasopressin receptor agonist,AVPR1A,cardiology,hypotension,"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O",Launched
terodiline,cholinergic receptor antagonist,,,,"C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|, C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|",Withdrawn
teroxirone,DNA inhibitor,,,,"O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|",Phase 1
terpene,,,,,"CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|",Preclinical
terpinen-4-ol,anti-inflammatory agent,"BCL2, BIRC5, XIAP",oncology,melanoma,"CC(C)[C@@]1(O)CCC(C)=CC1 |&1:3,r,c:8|",Launched
terreic-acid-(-),Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,,Preclinical
terutroban,prostanoid receptor antagonist,TBXA2R,,,"Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1",Phase 3
tesaglitazar,"insulin sensitizer, PPAR receptor agonist","PPARA, PPARG",,,"CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O",Phase 3
testosterone propionate,,,,,CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,
tetomilast,phosphodiesterase inhibitor,PDE4D,,,CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O,Phase 2
tetrabenazine,vesicular monoamine transporter inhibitor,"SLC18A1, SLC18A2","infectious disease, neurology/psychiatry","cholera, Huntington's disease","COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC",Launched
tetracaine,membrane integrity inhibitor,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,anesthetic,"CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C",Launched
tetracycline,bacterial 30S ribosomal subunit inhibitor,,"infectious disease, dermatology","respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis","[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24,&2:5|",Launched
tetracycline hcl,bacterial 30s ribosomal subunit inhibitor,,"infectious disease, dermatology","respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (av), plague, psittacosis",CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,Launched
tetradecylthioacetic-acid,lipid peroxidase inhibitor,,,,"CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O",Phase 2
tetraethylenepentamine,superoxide dismutase inhibitor,"SOD1, SOD2",,,"NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN",Phase 2/Phase 3
tetrahydrofolic-acid,,FOLR2,,,"Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|",Launched
tetrahydropapaverine,,,,,"COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|, COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|",Preclinical
tetrahydrouridine,cytidine deaminase inhibitor,CDA,,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|",Phase 2
tetrahydrozoline,adrenergic receptor agonist,,ophthalmology,eye irritation,"C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|",Launched
tetramethylthiuram-monosulfide,,,,,CN(C)C(=S)SC(=S)N(C)C,Preclinical
tetramisole,immunostimulant,"ALPPL2, CHRNA3",infectious disease,gastrointestinal parasites,"C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|",Launched
tetrandrine,calcium channel blocker,SLC6A3,,,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|",Preclinical
tetrindole,monoamine oxidase inhibitor,MAOA,,,"C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1",Phase 3
tetroquinone,,,,,"OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O",Preclinical
tezacaftor,CFTR channel agonist,,pulmonary,cystic fibrosis,"CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO, CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO",Launched
TFC-007,prostaglandin inhibitor,HPGDS,,,"O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1",Preclinical
TG-003,CLK inhibitor,"CLK1, CLK4, DYRK1A, DYRK1B",,,"CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O",Preclinical
TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",,,"CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|",Phase 1/Phase 2
TG-100572,"SRC inhibitor, VEGFR inhibitor","KDR, SRC",,,"Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl",Preclinical
TG-100713,PI3K inhibitor,,,,"Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1",Preclinical
TG-100801,"SRC inhibitor, VEGFR inhibitor","CSK, FGFR1, FLT1, FLT4, KDR, SRC",,,"Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl",Phase 2
TG-101209,JAK inhibitor,"JAK2, JAK3",,,"CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1",Preclinical
TGR-1202,PI3K inhibitor,,,,"CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12, CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12",Phase 3
TGX-221,PI3K inhibitor,"PIK3CB, PIK3CD",,,"C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|",Preclinical
TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",,,"Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1",Phase 1/Phase 2
TH-302,DNA alkylating agent,,,,"Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O",Phase 3
TH-588,MTH1 inhibitor,NUDT1,,,"Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl",Preclinical
thaliblastine,DNA inhibitor,,,,COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC,Phase 2
thalidomide,tumor necrosis factor production inhibitor,TNF,oncology,myeloma,"O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|",Launched
theaflavin,antiviral,,,,O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O,Preclinical
theobromine,phosphodiesterase inhibitor,"ADORA1, ADORA2A, PDE4B",,,"Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12",Launched
thiamet-g,GLCNAC phosphotransferase inhibitor,MGEA5,,,"CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|",Preclinical
thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
thiamine-pyrophosphate,,,hematology,anemia,Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|,Launched
thiamphenicol,bacterial 50S ribosomal subunit inhibitor,,infectious disease,pelvic inflammatory disease,"CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl",Launched
thiamylal,glutamate receptor antagonist,GABRA1,neurology/psychiatry,sedative,"CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|",Launched
thiazovivin,rho associated kinase inhibitor,,,,"O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1",Preclinical
thiethylperazine,dopamine receptor antagonist,"DRD1, DRD2, DRD4",gastroenterology,nausea,"CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1",Launched
thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,"COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC",Launched
thioctic-acid,reducing agent,"ACHE, PTGS2",nephrology,diabetic nephropathy,"OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|",Launched
thiodiglycol,,,,,"OCCSCCO, OCCSCCO",Preclinical
thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
thiomersal,other antibiotic,OXCT1,infectious disease,preservative,"CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O",Launched
thiopental,GABA receptor antagonist,FAAH,neurology/psychiatry,anesthetic,"CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|, CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|",Launched
thioperamide,histamine receptor antagonist,"HRH3, HRH4",,,"S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|",Preclinical
thiophanate,,,,,"COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC",Preclinical
thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,"CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1",Launched
thioridazine,dopamine receptor antagonist,"CHRNA7, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, MALT1",Neurology,psychosis,"CSc1ccc2Sc3ccccc3N(CC[C@H]3CCCCN3C)c2c1 |&1:16,r|, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1",Launched
thiorphan,membrane metalloendopeptidase inhibitor,MME,,,"OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|",Phase 1
thiostrepton,"foxm1 inhibitor, protein synthesis inhibitor, FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O",Launched
thiotepa,cytochrome P450 inhibitor,"CYP2B6, CYP3A4",oncology,"breast cancer, ovarian cancer, bladder cancer","S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1",Launched
thiothixene,dopamine receptor antagonist,"DRD1, DRD2, HRH1, HTR2A",neurology/psychiatry,schizophrenia,"CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1",Launched
thiram,,JAK2,ophthalmology,contact dermatitis,"CN(C)C(=S)SSC(=S)N(C)C, CN(C)C(=S)SSC(=S)N(C)C, CN(C)C(=S)SSC(=S)N(C)C",Launched
THK5351,PET radiotracer ,,,,CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1,Phase 2
thonzonium,ATPase inhibitor,,infectious disease,ear infections,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
thonzylamine,antihistamine,,neurology/psychiatry,itching,"COc1ccc(CN(CCN(C)C)c2ncccn2)cc1, COc1ccc(CN(CCN(C)C)c2ncccn2)cc1",Launched
threo-2-methylisocitrate-(DL),isocitrate lyase substrate,,,,"[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|, [NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|",Preclinical
thymalfasin,immune response modulator,,infectious disease,"hepatitis B, hepatitis C","CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O",Launched
thymol,GABA receptor positive allosteric modulator,TRPA1,infectious disease,"ringworm, antiseptic","CC(C)c1ccc(C)cc1O, CC(C)c1ccc(C)cc1O",Launched
thymol-iodide,,,,,CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C,Preclinical
thymopentin,immune response stimulator,,,,CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O,Launched
THZ1,CDK inhibitor,CDK7,,,"CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",Preclinical
THZ1-R,CDK inhibitor,CDK7,,,"CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",Preclinical
THZ2,CDK inhibitor,CDK7,,,"CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",Preclinical
tiabendazole,angiogenesis inhibitor,,infectious disease,"gastrointestinal roundworms, hookworm","c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1",Launched
tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
tiamulin,bacterial 50s ribosomal subunit inhibitor,,infectious disease,dysentry,CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CC[C@H]([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C,Launched
tianeptine,selective serotonin reuptake enhancer (SSRE),"OPRD1, OPRK1, OPRM1","neurology/psychiatry, pulmonary, gastroenterology","depression, asthma, irritable bowel syndrome","CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|",Launched
tianeptine (sodium salt),,,,,CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O,
tiapride,dopamine receptor antagonist,"DRD2, DRD3",neurology/psychiatry,"dyskinesia, abstinence from alcohol, psychosis","CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O",Launched
tiaprofenic-acid,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis,"C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|",Launched
tiaramide,anti-inflammatory agent,,pulmonary,asthma,OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O,Launched
tibolone,"androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist","AR, ESR1, PGR, STS","Oncology, obstetrics/gynecology","breast cancer, endometriosis","C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12 |t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|",Launched
ticagrelor,purinergic receptor antagonist,P2RY12,cardiology,"acute coronary syndrome (acs), myocardial infarction, acute coronary syndrome (ACS), myocardial infarction","CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1",Launched
ticarcillin,lactamase inhibitor,,infectious disease,gram-negative bacterial infections,"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O",Launched
ticlopidine,purinergic receptor antagonist,P2RY12,"hematology, neurology/psychiatry","thrombosis, stroke","Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1",Launched
TIC10,"AKT inhibitor, TRAIL modulator","AKT1, MAPK1",,,"Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|",Phase 2
tideglusib,glycogen synthase kinase inhibitor,GSK3B,,,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
tienilic-acid,"cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor","CYP2C9, SLC12A1",,,"OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl",Withdrawn
tie2-kinase-inhibitor,TIE tyrosine kinase inhibitor,"KDR, MAPK14",,,"COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|",Preclinical
tifenazoxide,ATP-sensitive potassium channel agonist,"ABCC8, KCNJ11",,,"CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|",Phase 1
tigecycline,"bacterial 30S ribosomal subunit inhibitor, bacterial 30s ribosomal subunit inhibitor, bacterial dna inhibitor, bacterial dna inhibitor",,"infectious disease, infectious disease, Infectious disease, Infectious disease","skin infections, pneumonia, intra-abdominal infections, skin infections, pneumonia, intra-abdominal infections, gram-negative bacterial infections, gram-negative bacterial infections","[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28,&2:21|, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
tildipirosin,bacterial 50s ribosomal subunit inhibitor,,infectious disease,respiratory tract infections,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN3CCCCC3)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CN4CCCCC4,Launched
tilmicosin,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43,46|",Launched
tilorone,interferon inducer,,"infectious disease, gastroenterology, neurology/psychiatry","influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C","CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1",Launched
tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,"OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O",Launched
timofibrate,"cholesterol inhibitor, lipase clearing factor inhibitor",LPL,,,"CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|",Phase 2
timolol,adrenergic receptor antagonist,"ADRB1, ADRB2",ophthalmology,"ocular hypertension, glaucoma","CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1",Launched
timolol maleate,adrenergic receptor antagonist,,ophthalmology,"ocular hypertension, glaucoma",CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,Launched
timonacic,antioxidant,,,,"OC(=O)[C@H]1CSCN1 |&1:3|, OC(=O)C1CSCN1",Launched
tinazoline,adrenergic receptor agonist,,,,C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|,Launched
tinidazole,antiprotozoal agent,,"infectious disease, obstetrics/gynecology","giardiasis, amebiasis, bacterial vaginosis, trichomoniasis","CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O",Launched
tinoridine,anti-inflammatory agent,,neurology/psychiatry,pain relief,CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12,Launched
tioconazole,sterol demethylase inhibitor,,infectious disease,yeast infection,"Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl, Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|",Launched
tioguanine,purine antagonist,,hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)","Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",Launched
tiopronin,"chelating agent, reducing agent",,urology,kidney stones,"C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|",Launched
tiotidine,histamine receptor antagonist,HRH2,,,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N",Phase 2
tiotropium,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1",Launched
tioxolone,carbonic anhydrase inhibitor,CA2,,,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
tipelukast,leukotriene receptor antagonist,,,,CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O,Phase 2
tipepidine,g protein signaling inhibitor,KCNJ3,neurology/psychiatry,attention-deficit/hyperactivity disorder (adhd),CN1CCCC(=C(c2cccs2)c3cccs3)C1,Phase 2
tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",,,"Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1",Phase 3
tipiracil,thymidine phosphorylase inhibitor,,oncology,colorectal cancer,"Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O",Launched
tiplaxtinin,plasminogen activator inhibitor,SERPINE1,,,"OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1",Phase 1
tipranavir,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|",Launched
tiprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,"CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|",Phase 2
tiquizium,acetylcholine receptor antagonist,,neurology/psychiatry,spasms,"C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1, C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1",Launched
tirabrutinib,bruton's tyrosine kinase (btk) inhibitor,BTK,hematologic malignancy,small lymphocytic lymphoma (sll),CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,Launched
tiracizine,sodium channel blocker,SCN5A,,,"CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1",Withdrawn
tirapazamine,DNA inhibitor,,,,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
tirasemtiv,troponin activator,,,,"CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C, CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C",Phase 2
tiratricol,thyroid hormone stimulant,"THRA, THRB",endocrinology,Refetoff syndrome,"OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1",Launched
tirbanibulin,protein tyrosine kinase inhibitor,"SRC, TUBB",dermatology,actinic keratosis (ak),C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4,Launched
tirofiban,"platelet aggregation inhibitor, structural glycoprotein antagonist","ITGA2B, ITGB3",cardiology,"myocardial infarction, refactory angina","CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O",Launched
titanocene-dichloride,apoptosis stimulant,,,,"Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|, Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|",Phase 2
tivantinib,tyrosine kinase inhibitor,MET,,,"O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23",Phase 3
tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",oncology,renal cell carcinoma (RCC),"COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC",Launched
tizanidine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, NISCH",neurology/psychiatry,spasms,"Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|",Launched
tk216,binding of rna helicase a to the transcription factor ews-fli1 inhibitor,"EWSR1, FLI1",oncology,ewing's sarcoma,OC1(CC(=O)c2ccc(cc2)C3CC3)C(=O)Nc4c(Cl)ccc(Cl)c14,Phase 1
TMC-353121,RSV fusion inhibitor,,,,"Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1, Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1",Phase 2
TMC647055,RNA polymerase inhibitor,,,,"COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|, COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|",Phase 2
TMN-355,cyclophilin inhibitor,PPIA,,,"Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12",Preclinical
TMPH,,,,,"CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1",Preclinical
TMS,,,,,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
tno155,tyrosine phosphatase inhibitor,PTPN11,oncology,colorectal cancer,"C[C@@H]1OCC2(CCN(CC2)c2cnc(Sc3ccnc(N)c3Cl)c(N)n2)[C@@H]1N |a:1,26|",Phase 1/Phase 2
TNP-470,methionine aminopeptidase inhibitor,METAP2,,,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl",Phase 2
tobramycin,bacterial 30S ribosomal subunit inhibitor,,infectious disease,"bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections","NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O",Launched
tocainide,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,"C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|, C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|",Launched
tocainide hydrochloride,sodium channel blocker,,cardiology,cardiac arrythmia,CC(N)C(=O)Nc1c(C)cccc1C,Launched
toceranib,protein tyrosine kinase inhibitor,"FLT1, FLT3, KDR, PDGFRA, PDGFRB",oncology,cutaneous mast cell tumors,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1",Launched
tocofersolan,antioxidant,,cardiology,cerebral cholesterosis,"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1, CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1",Launched
todralazine,antihypertensive agent,,cardiology,hypertension,"CCOC(=O)NNc1nncc2ccccc12, CCOC(=O)NNc1nncc2ccccc12",Launched
tofacitinib,JAK inhibitor,"JAK1, JAK2, JAK3",rheumatology,rheumatoid arthritis,"C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N",Launched
tofisopam,"cytochrome P450 inhibitor, phosphodiesterase inhibitor",CYP3A4,neurology/psychiatry,"anxiety, abstinence from alcohol","CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|, CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|",Launched
tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,diabetes mellitus,"CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
tolamolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",,,"Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|",Phase 3
tolazamide,ATP channel blocker,"ABCC8, KCNJ1, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1",Launched
tolazoline,adrenergic receptor antagonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2",neurology/psychiatry,reverse sedative,"C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|",Launched
tolbutamide,ATP channel blocker,"ABCC8, KCNJ1, KCNJ11, KCNJ8",endocrinology,diabetes mellitus,"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1",Launched
tolcapone,catechol O methyltransferase inhibitor,COMT,,,"Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O",Withdrawn
tolebrutinib,bruton's tyrosine kinase (btk) inhibitor,BTK,neurology/psychiatry,multiple sclerosis,Nc1nccc2n([C@@H]3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12,Phase 3
tolfenamic-acid,"cyclooxygenase inhibitor, prostanoid receptor antagonist",,neurology/psychiatry,migraine headache,"Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O",Launched
tolimidone,SRC activator,"LYN, SRC",,,"Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1",Phase 2
tolmetin,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"rheumatoid arthritis, osteoarthritis","Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C",Launched
tolnaftate,fungal squalene epoxidase inhibitor,,infectious disease,"tinea pedis, tinea corporis","CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1",Launched
tolonidine,adrenergic receptor antagonist,ADRA2A,,,"Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|, Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|",Launched
tolonium,,,hematology,methemoglobinemia,"Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C, Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C",Launched
toloxatone,monoamine oxidase inhibitor,"MAOA, MAOB",neurology/psychiatry,depression,"Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|",Launched
tolperisone,voltage-gated sodium channel blocker,"CYP2C19, CYP2D6","neurology/psychiatry, infectious disease, rheumatology, cardiology","muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease","C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|",Launched
tolrestat,aldose reductase inhibitor,"AKR1A1, AKR1B1, AKR1B10",,,"COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O",Withdrawn
tolterodine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,"urinary incontinence, urinary frequency","CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C",Launched
toltrazuril,antiprotozoal agent,,infectious disease,coccidiosis,"Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O",Launched
tolvaptan,vasopressin receptor antagonist,"AVPR1A, AVPR2","endocrinology, cardiology, gastroenterology","hyponatremia, congestive heart failure, hepatic cirrhosis","Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|",Launched
tomeglovir,antiviral,,,,CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1,Preclinical
tomelukast,leukotriene receptor antagonist,CYSLTR1,,,"CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O, CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O",Phase 3
tomivosertib,MAPK-interacting kinase inhibitor,,,,Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,Phase 2
tonabersat,"gap junction modulator, nitric oxide production inhibitor",,,,"CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1, CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1",Phase 2
topilutamide,androgen receptor antagonist,,,,"C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|",Preclinical
topiramate,"carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist","CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, migraine headache","CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1",Launched
topiroxostat,xanthine oxidase inhibitor,XDH,"rheumatology, nephrology","gout, hyperuricemia","N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1",Launched
topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,,,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
torcitabine,DNA polymerase inhibitor,"DCK, TK2",,,"Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Phase 2
toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1",Launched
torin-1,mTOR inhibitor,MTOR,,,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
torin-2,mTOR inhibitor,MTOR,,,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",,,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
tosufloxacin,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections,"N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|, NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|",Launched
toyocamycin,serine/threonine kinase inhibitor,ERN1,,,"Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Phase 1
tozadenant,adenosine receptor antagonist,ADORA2A,,,"COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12",Phase 3
tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",,,"CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
TP-003,GABA receptor inverse agonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,"CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N",Preclinical
TP-0903,AXL kinase inhibitor,AXL,,,"CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl",Phase 1/Phase 2
TP-3654,"1,4,5-trisphosphate inhibitor",,,,"CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|, CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|",Phase 1
TPCA-1,IKK inhibitor,IKBKB,,,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
TPPS4,,,,,OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2,Phase 1
tpps4,,,,,OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1n2,Phase 1
trabectedin,antitumor agent,,,,[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|,Phase 3
trabodenoson,adenosine receptor agonist,,,,O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,Phase 3
tracazolate,GABA receptor modulator,GABRA1,,,"CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12",Phase 2
tradipitant,neurokinin receptor antagonist,,,,FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F,Phase 3
TRAM-34,potassium channel antagonist,KCNN4,,,"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1",Preclinical
TRAM-39,calcium-activated potassium channel activator,KCNN4,,,"Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1",Preclinical
tramadol hydrochloride,,,,,COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C,
trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
tramiprosate,beta amyloid protein neurotoxicity inhibitor,APP,,,"NCCCS(O)(=O)=O, NCCCS(O)(=O)=O",Phase 3
trandolapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, myocardial infarction, hypertension, myocardial infarction","CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O",Launched
tranexamic-acid,"antifibrinolytic, plasminogen activator inhibitor",PLG,hematology,hemophilia,"NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|",Launched
tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
"trans-10,cis-12-conjugated-linoleic-acid",,,,,"CCCCC\C=C/C=C/CCCCCCCCC(O)=O, CCCCC\C=C/C=C/CCCCCCCCC(O)=O",Launched
trans-2-undecenoic-acid,,,,,CCCCCCCC\C=C\C(O)=O,Preclinical
"trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",,,,,"OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1, OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1",Preclinical
trans-4-hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,,,,"OC\C=C\C(O)=O, OC\C=C\C(O)=O",Preclinical
trans-4-methoxycinnamic-acid,,,,,"COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1",Preclinical
transcrocetinate,glutamate receptor antagonist,,,,C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O,Preclinical
tranylcypromine,monoamine oxidase inhibitor,"KDM1A, MAOA, MAOB",neurology/psychiatry,depression,"N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|",Launched
tranylcypromine (2-pcpa) hcl,,,,,N[C@H]1C[C@@H]1c1ccccc1,
tranylcypromine hydrochloride,monoamine oxidase inhibitor,,neurology/psychiatry,depression,N[C@@H]1C[C@H]1c1ccccc1,Launched
tranylcypromine sulfate,monoamine oxidase inhibitor,,neurology/psychiatry,depression,NC1C[C@H]1c1ccccc1,Launched
trap-101,"nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist",OPRL1,,,"CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|",Preclinical
trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),"CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12",Launched
travoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma","CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F",Launched
traxoprodil,glutamate receptor antagonist,GRIN2B,,,"C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1, C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1",Phase 2
trazodone,"adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4",neurology/psychiatry,depression,"Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1",Launched
trebenzomine,,,,,"C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|",Phase 2
trelagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O",Launched
tremorine,acetylcholine receptor agonist,,,,"C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1",Preclinical
treosulfan,DNA synthesis inhibitor,,oncology,ovarian cancer,"CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O",Launched
trepibutone,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",gastroenterology,irritable bowel syndrome,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,Launched
treprostinil,prostanoid receptor agonist,"P2RY12, PPARD, PTGIR",pulmonary,pulmonary arterial hypertension (PAH),CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O,Launched
trequinsin,phosphodiesterase inhibitor,PDE5A,,,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
tretazicar,DNA replication inhibitor,NQO2,,,"NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O",Phase 2
tretinoin,"retinoid receptor agonist, retinoid receptor ligand","ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG",hematologic malignancy,acute promyelocytic leukemia (APL),"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|",Launched
triacetin,,,,,"CC(=O)OCC(COC(C)=O)OC(C)=O, CC(=O)OCC(COC(C)=O)OC(C)=O",Launched
triamcinolone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|",Launched
triamcinolone acetonide,"glucocorticoid receptor agonist, immunosuppressant",,dermatology,corticosteroid-responsive dermatoses,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant","NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",Launched
triamcinolone-hexacetonide,anti-inflammatory agent,,,,"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13,t:9|",Launched
triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1",Launched
triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",,,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
tribenoside,"anti-inflammatory agent, capillary stabilizing agent",,,,"CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|, CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|",Launched
tribomsalan,,,,,"Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1",Preclinical
tribromoethanol,analgesic agent,,,,"OCC(Br)(Br)Br, OCC(Br)(Br)Br",Preclinical
tributyrin,HDAC inhibitor,,,,"CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC, CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC",Phase 1
tricaine,sodium channel blocker,SCN1A,neurology/psychiatry,anesthetic,CCOC(=O)C1=CC=CC(N)=C1,Withdrawn
tricaprylin,,,dermatology,cosmetic,"CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC, CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC",Launched
trichlormethiazide,chloride channel blocker,"PTGS1, PTGS2, SLC12A1",cardiology,"hypertension, edema","NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|",Launched
trichloroacetic-acid,,,dermatology,warts,"OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl",Launched
trichloroethylene,,,,,"ClC=C(Cl)Cl, ClC=C(Cl)Cl",Preclinical
trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",,,"C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Phase 1
triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",,,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
triciribine-phosphate,AKT inhibitor,,,,Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23,Phase 1/Phase 2
triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
triclocarban,other antibiotic,,infectious disease,first-aid antiseptic,"Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1",Launched
triclosan,antibacterial agent,DNMT1,infectious disease,first-aid antiseptic,"Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl",Launched
tridihexethyl,acetylcholine receptor antagonist,,"gastroenterology, ophthalmology","peptic ulcer disease (PUD), nystagmus",CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|,Launched
trientine,chelating agent,CA14,metabolism,Wilson's disease,"NCCNCCNCCN, NCCNCCNCCN",Launched
trifarotene,retinoid receptor agonist,"RARA, RARB, RARG",dermatology,acne vulgaris (av),CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4,Launched
trifloxystrobin,mitochondrial electron transport inhibitor,,,,CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F,Preclinical
trifluoperazine,dopamine receptor antagonist,"ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1",neurology/psychiatry,schizophrenia,"CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1",Launched
triflupromazine,dopamine receptor antagonist,"CHRM1, CHRM2, DRD1, DRD2, HTR2B","neurology/psychiatry, gastroenterology","psychosis, nausea, vomiting","CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F",Launched
trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
triflusal,"cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor","NFKB1, NOS2, PDE10A, PTGS1","neurology/psychiatry, cardiology","stroke, myocardial infarction, atrial fibrillation (AF)","CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F",Launched
trigonelline,,,,,"C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O",Phase 1
triheptanoin,anticonvulsant,,cardiology,cardiomyopathy,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,Launched
trihexyphenidyl,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,parkinsonism,O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|,Launched
trihexyphenidyl hydrochloride,acetylcholine receptor antagonist,,neurology/psychiatry,parkinsonism,OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|,Launched
trilaciclib,CDK inhibitor,,,,CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1,Phase 2
trilostane,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,,endocrinology,Cushing's syndrome,"C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|",Launched
TRIM,,,,,FC(F)(F)c1ccccc1-n1ccnc1,Preclinical
trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|,Launched
trimebutine maleate,opioid receptor agonist,,gastroenterology,irritable bowel syndrome,CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1,Launched
trimetaphan camsilate,acetylcholine receptor antagonist,CHRNA10,cardiology,hypertension,CC1(C)C2CCC1(CS([O-])(=O)=O)C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1,Withdrawn
trimetazidine,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris,"COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC",Launched
trimethadione,oxazolidine antiepileptic,"CACNA1G, CACNA1H, CACNA1I",neurology/psychiatry,seizures,"CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O",Launched
trimethobenzamide,histamine receptor antagonist,DRD2,gastroenterology,"vomiting, nausea, gastroenteritis","COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1",Launched
trimethoprim,dihydrofolate reductase inhibitor,"DHFR, TYMS","infectious disease, gastroenterology","urinary tract infections, ear infections, diarrhea","COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC",Launched
trimethoquinol,adrenergic receptor antagonist,"ADRB2, ADRB3",pulmonary,asthma,COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|,Launched
trimethylolpropane-triacrylate,,,,,CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C,Preclinical
trimetozine,sedative,,neurology/psychiatry,sedative,"COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1",Launched
trimetrexate,dihydrofolate reductase inhibitor,DHFR,,,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,Phase 3
trimipramine,"norepinephrine reputake inhibitor, tricyclic antidepressant","SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|,Launched
trimipramine maleate,"norepinephrine reputake inhibitor, tricyclic antidepressant",,neurology/psychiatry,depression,CC(CN(C)C)CN1c2ccccc2CCc2ccccc12,Launched
trioxsalen,DNA synthesis inhibitor,,dermatology,"vitiligo, eczema","Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1, Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1",Launched
tripelennamine,histamine receptor antagonist,HRH1,"pulmonary, allergy","asthma, allergic rhinitis, urticaria","CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1",Launched
triprolidine,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,"Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1",Launched
triptan,serotonin receptor agonist,"HTR1B, HTR1D",,,CC(C)C(C)(C)C,Phase 1
triptolide,RNA polymerase inhibitor,RELA,,,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|",Phase 3
triptorelin,gonadotropin releasing factor hormone receptor agonist,GNRHR,"oncology, endocrinology, obstetrics/gynecology","prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria","CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O",Launched
tro 19622,,,,,CC(C)CCCC(C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=NO,
troclosene,,,,,"Cln1c(=O)[nH]c(=O)n(Cl)c1=O, Cln1c(=O)[nH]c(=O)n(Cl)c1=O",Launched
trodusquemine,tyrosine phosphatase inhibitor,,,,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C,Phase 1
trofinetide,"anti-inflammatory agent, cytokine production inhibitor","ATF3, IFNG, IL6, TNF",,,"NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O, C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:1,13|",Phase 3
trofosfamide,DNA alkylating agent,,oncology,medulloblastoma,"ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7,r|",Launched
troglitazone,"insulin sensitizer, PPAR receptor agonist","CYP2C8, PPARG, TRPM3",,,"Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|",Withdrawn
troleandomycin,"ribosomal protein inhibitor, protein synthesis inhibitor",,"infectious disease, pulmonary, otolaryngology, infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, tonsillitis, sinusitis, pneumonia, bronchitis, tonsillitis, sinusitis","CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O, CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O, CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O",Launched
trolox,antioxidant,,,,"Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|",Launched
tromaril,prostanoid receptor antagonist,,ophthalmology,eye inflammation,"OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1",Launched
trometamol,,"AMD1, CANT1, DCN, NEIL1, VEGFA",,,"NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
"tropanyl-3,5-dimethylbenzoate",serotonin receptor antagonist,"HTR3A, HTR3B",,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|",Preclinical
tropesin,cyclooxygenase inhibitor,"PTGS1, PTGS2",,,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|",Launched
tropicamide,acetylcholine receptor antagonist,"CHRM3, CHRM4",ophthalmology,"mydriasis diagnostic, cycloplegia diagnostic","CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|",Launched
tropifexor,FXR agonist,,,,OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|,Phase 2
tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
trospium,acetylcholine receptor antagonist,CHRM1,urology,"urinary incontinence, urinary frequency","[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|",Launched
trospium chloride,acetylcholine receptor antagonist,,urology,"urinary incontinence, urinary frequency",OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1,Launched
trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,,,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
troventol,,,,,"CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|",Phase 1
trovirdine,non-nucleoside reverse transcriptase inhibitor,,,,"Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1",Phase 1
troxerutin,antioxidant,,,,"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
troxipide,glucosamine synthetase stimulant,,gastroenterology,gastroesophageal reflux disease (GERD),"COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|",Launched
TRV130,opioid receptor agonist,OPRM1,,,"COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1, COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1",Phase 3
tryptanthrin,cyclooxygenase inhibitor,IDO1,,,"O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O",Preclinical
tryptophan,serotonin receptor partial agonist,"CASR, IDO1, SLC36A1, WARS, WARS2","neurology/psychiatry, gastroenterology","anxiety, bloating, constipation, fatigue, sleeplessness","N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O",Launched
TS-011,delayed vasospasm antagonist,,,,[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1,Preclinical
TTNPB,retinoid receptor agonist,"RARA, RARB, RARG",,,"C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C",Phase 1
TTP-22,casein kinase inhibitor,CSNK2A1,,,"Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12",Preclinical
TU-2100,,,,,"CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC, CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC",Phase 2
tuaminoheptane,,,otolaryngology,nasal congestion,"CCCCC[C@@H](C)N |&1:5|, CCCCC[C@@H](C)N |&1:5|",Launched
tubastatin-A,HDAC inhibitor,HDAC6,,,"CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO",Preclinical
tubocurarine,acetylcholine receptor antagonist,"ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN",neurology/psychiatry,anesthetic,"COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4",Launched
tucatinib,EGFR inhibitor,ERBB2,,,"Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|",Phase 3
tucidinostat,HDAC inhibitor,,,,Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Phase 3
tuftsin,macrophage activator,,,,C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,Preclinical
TUG-770,free fatty acid receptor agonist,FFAR1,,,OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N,Preclinical
TUG-891,free fatty acid receptor agonist,FFAR4,,,"Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1",Preclinical
tulathromycin,bacterial 50s ribosomal subunit inhibitor,,pulmonary,bovine respiratory disease (brd),CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(NC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O,Launched
tulobuterol,adrenergic receptor agonist,ADRB2,pulmonary,asthma,CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|,Launched
tulobuterol hydrochloride,adrenergic receptor agonist,,pulmonary,asthma,CC(C)(C)NCC(O)c1ccccc1Cl,Launched
tulrampator,antidepressant ,,,,"Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1, Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1",Phase 2
TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",,,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",,,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
TXA127,angiotensin receptor agonist,,,,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O",Phase 2
TY-52156,sphingosine 1-phosphate receptor antagonist,S1PR3,,,"CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1",Preclinical
tylosin,protein synthesis inhibitor,,"infectious disease, gastroenterology","gram-positive bacterial infections, colitis","CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|",Launched
tyloxapol,,,,,"null, C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, null",
tylvalosin,bacterial 50s ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections,CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC,Launched
tymazoline,,,allergy,allergic rhinitis,CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|,Launched
tyroserleutide,antitumor agent,PIK3CA,oncology,hepatocellular carcinoma (hcc),CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,Phase 3
tyrphostin-AG-1296,FLT3 inhibitor,FLT3,,,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",,,"COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC",Preclinical
tyrphostin-AG-18,"EGFR inhibitor, tyrosine kinase inhibitor",EGFR,,,"Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O",Preclinical
tyrphostin-AG-494,EGFR inhibitor,EGFR,,,"Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O",Preclinical
tyrphostin-AG-825,protein tyrosine kinase inhibitor,ERBB2,,,"COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O",Preclinical
tyrphostin-AG-835,protein tyrosine kinase inhibitor,EGFR,,,"C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1",Preclinical
tyrphostin-AG-879,tyrosine kinase inhibitor,"ERBB2, KDR, NTRK1",,,"CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C",Preclinical
tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,,,"NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N",Preclinical
tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",,,,"CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C",Preclinical
U-0124,MEK inhibitor,,,,"CSC(=N)C(C#N)C(C#N)C(=N)SC, CSC(=N)C(C#N)C(C#N)C(=N)SC",Preclinical
U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",,,"Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N",Preclinical
U-0521,catechol O methyltransferase inhibitor,COMT,,,CC(C)C(=O)c1ccc(O)c(O)c1,Preclinical
U-104,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA9",,,"NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1",Phase 1/Phase 2
U-18666A,oxidosqualene cyclase inhibitor,,,,"CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|",Preclinical
U-50488-(-),opioid receptor agonist,OPRK1,,,"CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",Preclinical
U-54494A,opioid receptor agonist,OPRK1,,,"CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1",Preclinical
U-75799E,growth hormone releasing factor agonist,GHSR,,,"C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",Phase 1
U-99194,dopamine receptor antagonist,DRD3,,,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,Preclinical
UAMC-00039,dipeptidyl peptidase inhibitor,"DPP4, DPP7",,,"N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1",Preclinical
UB-165,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNB2",,,"Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|",Preclinical
ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
UBP-296,glutamate receptor antagonist,GRIK1,,,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|",Preclinical
UBP-302,glutamate receptor antagonist,GRIK1,,,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O",Preclinical
UBP-310,glutamate receptor antagonist,"GRIK1, GRIK5",,,"Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O",Preclinical
ubrogepant,calcitonin antagonist,CALCRL,neurology/psychiatry,migraine headache,C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6ccccc6,Launched
UC-112,XIAP inhibitor,XIAP,,,"Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12",Preclinical
UCL-2077,slow afterhyperpolarization channel blocker,,,,"C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1",Preclinical
udenafil,phosphodiesterase inhibitor,,urology,erectile dysfunction,"CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30,r|",Launched
UF-010,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC8",,,"CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1",Preclinical
ufenamate,cyclooxygenase inhibitor,"PTGS1, PTGS2",dermatology,"eczema, dermatitis","CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Launched
UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",,,"CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C",Preclinical
UK-356618,metalloproteinase inhibitor,"MMP13, MMP14, MMP2, MMP3, MMP9",,,"C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1",Preclinical
UK-383367,procollagen C-endopeptidase inhibitor,BMP1,,,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
UK-5099,monocarboxylate transporter inhibitor,SLC16A1,,,"OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N",Preclinical
uki-1,urokinase inhibitor,,,,CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C,Preclinical
ulifloxacin,,,infectious disease,"gram-negative bacterial infections, gram-positive bacterial infections","C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|",Launched
ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|",Launched
umbralisib,casein kinase inhibitor,"ABL1, CSNK1E, PIK3CD",hematologic malignancy,non-hodgkin lymphoma (nhl),CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F,Launched
umeclidinium,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",pulmonary,"chronic obstructive pulmonary disease (COPD), bronchitis, emphysema","OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2",Launched
unbs-5162,CC chemokine receptor antagonist,,,,"CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23",Phase 1
UNC0224,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1",Preclinical
UNC0321,histone lysine methyltransferase inhibitor,EHMT2,,,"COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1",Preclinical
UNC0631,histone lysine methyltransferase inhibitor,EHMT2,,,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
UNC0638,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1",Preclinical
UNC0642,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,"COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1",Preclinical
UNC0646,histone lysine methyltransferase inhibitor,EHMT2,,,"COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
UNC0737,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",,,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,Preclinical
UNC1215,L3MBTL antagonist,L3MBTL3,,,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1",Preclinical
UNC1999,histone lysine methyltransferase inhibitor,EZH2,,,"CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C",Preclinical
UNC2025,"FLT3 inhibitor, MER tyrosine kinase inhibitor","FLT3, MERTK",,,"CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|, CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|",Preclinical
UNC2250,MER tyrosine kinase inhibitor,MERTK,,,"CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|",Preclinical
UNC2327,protein arginine N-methyltransferase inhibitor,PRMT3,,,"O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1",Preclinical
UNC3230,phosphatidyl-inositol activator,PIP5K1C,,,"NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1",Preclinical
UNC669,L3MBTL antagonist,L3MBTL1,,,"Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1",Preclinical
UNC926,MBT inhibitor,L3MBTL1,,,"Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1",Preclinical
undecylenic-acid,other antifungal,,infectious disease,"tinea pedis, tinea corporis","OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C",Launched
upadacitinib,JAK inhibitor,,,,CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F,Launched
upamostat,serine protease inhibitor,,,,CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C,Phase 2
UPF-1069,PARP inhibitor,PARP2,,,"O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1",Preclinical
uprifosbuvir,antiviral,,,,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1,Preclinical
uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",,,"Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1",Phase 2
uracil,,"DPYD, UCKL1",,,"O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1",Launched
uracil-mustard,DNA synthesis inhibitor,,hematologic malignancy,non-Hodgkin lymphoma (NHL),"ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O",Launched
urapidil,adrenergic receptor antagonist,HTR1A,cardiology,hypertension,"COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1",Launched
URB597,FAAH inhibitor,"FAAH, FAAH2, TRPA1",,,"NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1",Phase 1
urea,hydroxy radical formation stimulant,"ARG1, CA2, CTNNB1",dermatology,"psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis","NC(N)=O, NC(N)=O, NC(N)=O",Launched
urethane,local anesthetic,,,,"CCOC(N)=O, CCOC(N)=O",Preclinical
uric-acid,,PYGL,,,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
uridine,dopamine receptor agonist,"LSM6, TYMP",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
uridine-triacetate,,,nephrology,orotic aciduria,"CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O, CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O",Launched
uridine-5'-triphosphate,purinergic receptor activator,"P2RY11, P2RY2, P2RY4, P2RY6, UCK2",,,"O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|",Launched
URMC-099,mixed lineage kinase inhibitor,"CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2",,,"CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1",Preclinical
urolithin-A,antioxidant,,,,Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21,Phase 3
ursodeoxycholyltaurine,cholesterol inhibitor,,,,"C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Phase 3
ursodiol,"nuclear factor erythroid derived, like (NRF2) activator","AKR1C2, NR1H4",gastroenterology,gallstones,"C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",Launched
ursolic-acid,"ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor","HSD11B1, PLA2G1B, PTPN1, PYGM",,,"C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",Phase 2/Phase 3
usl311,cc chemokine receptor antagonist,CXCR4,oncology,glioblastoma,CC(C)N1CCC(CC1)N1CCCN(CC1)c1cccc(n1)C(=O)Nc1ccncc1,Phase 1/Phase 2
usniacin-(+),MAP kinase activator,PTPN1,,,"CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|",Preclinical
V-51,adrenergic receptor antagonist,,,,"COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC, COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC",Phase 1
vabicaserin hydrochloride,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C",neurology/psychiatry,schizophrenia,[H][C@@]12C3=CC=CC4=C3N(CCNC4)C[C@]1([H])CCC2.Cl,Phase 2
vaborbactam,beta lactamase inhibitor,,,,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1,Launched
vadadustat,hypoxia inducible factor prolyl hydroxylase inhibitor,,,,OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1,Phase 3
val-tyr,angiotensin converting enzyme inhibitor,,,,CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O,Preclinical
valaciclovir,DNA polymerase inhibitor,,infectious disease,"shingles, virus herpes simplex (HSV)","CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O",Launched
valbenazine,vesicular monoamine transporter inhibitor,,neurology/psychiatry,dyskinesia,[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21,Launched
valdecoxib,cyclooxygenase inhibitor,"CA12, PTGS2",,,"Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1",Withdrawn
valethamate,acetylcholine receptor antagonist,"CHRM1, CHRM4, CHRM5",obstetrics/gynecology,labor induction,"CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|",Launched
valganciclovir,DNA synthesis inhibitor,,infectious disease,cytomegalovirus (CMV),"CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|, CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|",Launched
valganciclovir hydrochloride,dna synthesis inhibitor,,infectious disease,cytomegalovirus (cmv),CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O,Launched
valnemulin,bacterial 50S ribosomal subunit inhibitor,,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3,Launched
valnemulin hcl,bacterial 50s ribosomal subunit inhibitor,,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
valnivudine,antiviral,,infectious disease,varicella-zoster virus (vzv),O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@]4([H])O[C@@H]([C@H](C4)O)COC([C@@H](N)C(C)C)=O,Phase 3
valnoctamide,"arachidonic acid acylation inhibitor, benzodiazepine receptor agonist",,neurology/psychiatry,sleeplessness,"CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2,&2:4,r|",Launched
valproic-acid,"benzodiazepine receptor agonist, HDAC inhibitor","ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"epilepsy, seizures, seizures","CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O",Launched
valpromide,epoxide hydolase inhibitor,,neurology/psychiatry,epilepsy,"CCCC(CCC)C(N)=O, CCCC(CCC)C(N)=O",Launched
valrocemide,,,,,"CCCC(CCC)C(=O)NCC(N)=O, CCCC(CCC)C(=O)NCC(N)=O",Phase 2
valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,"CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1",Launched
valsartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure, congestive heart failure","CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O",Launched
valspodar,P glycoprotein inhibitor,ABCB1,,,"C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C",Phase 3
vamorolone,glucocorticoid receptor agonist,"DMD, NFKB1, NR3C1",genetics,duchenne muscular dystrophy (dmd),"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:15,26,t:22|",Phase 2
vancomycin,bacterial cell wall synthesis inhibitor,,infectious disease,endocarditis,"CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2",Launched
vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),"COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1",Launched
vanillin,,"ABAT, ALDH5A1",,,"COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O",Preclinical
vanillylacetone,,,,,"COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O",Preclinical
vaniprevir,serine protease inhibitor,,,,"CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1",Phase 3
vanitiolide,,,,,"COc1cc(ccc1O)C(=S)N1CCOCC1, COc1cc(ccc1O)C(=S)N1CCOCC1",Preclinical
vanoxerine,dopamine reuptake inhibitor,SLC6A3,,,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
vapendavir,antiviral,,,,CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12,Phase 2
vardenafil,phosphodiesterase inhibitor,"PDE5A, PDE6G, PDE6H",urology,erectile dysfunction,"CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1",Launched
varenicline,acetylcholine receptor agonist,"CHRNA3, CHRNA4, CHRNA6, CHRNA7",neurology/psychiatry,smoking cessation,"C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|",Launched
varenicline tartrate,acetylcholine receptor agonist,,neurology/psychiatry,smoking cessation,C1C2CNCC1c1cc3nccnc3cc21,Launched
varespladib,secretory phospholipase inhibitor,PLA2G2A,,,"CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1, CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1",Phase 3
vasopressin,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR",gastroenterology,abdominal distension,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,Launched
vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",,,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
vatinoxan,adrenergic receptor antagonist,,,,[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12,Preclinical
VBY-825,cathepsin inhibitor,"CTSB, CTSL, CTSS",,,"CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1",Preclinical
VCH-916,HCV inhibitor,,,,"CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|",Phase 1
VE-821,ATR kinase inhibitor,ATR,,,"CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1",Preclinical
VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",,,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
vecabrutinib,Bruton's tyrosine kinase (BTK) inhibitor,,,,NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F,Phase 1/Phase 2
vecuronium,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1",Launched
vedaprofen,anti-inflammatory agent,PTGS2,"neurology/psychiatry, endocrinology","pain relief, fever","C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|",Launched
vedotin,antimitotic agent,"TNFRSF10B, TPPP",hematologic malignancy,acute lymphoblastic leukemia (all),[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1,Phase 2
velaresol,,,,,OC(=O)CCCCOc1cccc(O)c1C=O,Preclinical
veledimex,cytochrome P450 inhibitor,,,,CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C,Phase 2
veliflapon,leukotriene synthesis inhibitor,ALOX5AP,,,"OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1, OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1",Phase 3
veliparib,PARP inhibitor,"PARP1, PARP2",,,C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1,Phase 3
velneperit,neuropeptide receptor antagonist,NPY5R,,,"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|",Phase 2
velpatasvir,antiviral,,infectious disease,hepatitis C,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1,Launched
vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|",Launched
venlafaxine,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin‚Äìnorepinephrine reuptake inhibitor (SNRI)","SLC6A2, SLC6A4",neurology/psychiatry,"depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder","COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|",Launched
VER-155008,HSP inhibitor,HSPA1A,,,"Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12",Preclinical
VER-49009,HSP inhibitor,HSP90AA1,,,"CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O",Preclinical
veralipride,dopamine receptor antagonist,,,,"COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|",Preclinical
verapamil,calcium channel blocker,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4",cardiology,hypertension,"COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|",Launched
verbascoside,"NFkB pathway inhibitor, PKC inhibitor",,,,"C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",Phase 2/Phase 3
vercirnon,CC chemokine receptor antagonist,CCR9,,,"CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1",Phase 3
verdinexor,exportin antagonist,,,,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1,Preclinical
verdiperstat,myeloperoxidase inhibitor,,,,CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S,Phase 3
vericiguat,guanylate cyclase stimulant,,,,COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12,Phase 3
verinurad,urate transporter inhibitor,SLC22A12,,,"CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O, CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O",Phase 2
vernakalant,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF),"COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC",Launched
verteporfin,photosensitizing agent,,ophthalmology,macular degeneration,"COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|",Launched
verubecestat,beta secretase inhibitor,,,,CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|,Phase 3
verubulin,tubulin polymerization inhibitor,TUBB,,,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
verucerfont,corticotropin releasing factor receptor antagonist,,,,CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1,Phase 2
vesamicol,acetylcholinesterase inhibitor,SLC18A3,,,"O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1",Preclinical
vesnarinone,phosphodiesterase inhibitor,"KCNH2, PDE3A",cardiology,congestive heart failure,"COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1",Launched
VGX-1027,tumor necrosis factor receptor antagonist,TLR4,,,"OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|",Phase 1
vicagrel,platelet aggregation inhibitor,P2RY12,cardiology,coronary artery disease (cad),COC(=O)[C@@H](N1CCc2sc(OC(=O)C)cc2C1)c3ccccc3Cl,Phase 2
vicriviroc,CC chemokine receptor antagonist,CCR5,,,"COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F",Phase 3
vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
vigabatrin,GABA aminotransferase inhibitor,"ABAT, SLC32A1",neurology/psychiatry,"seizures, spasms","N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|",Launched
vilanterol,adrenergic receptor agonist,ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD),OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl,Launched
vilanterol trifenatate,adrenergic receptor agonist,ADRB2,Lung diseases,chronic obstructive pulmonary disease (copd),OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl,Phase 3
vilazodone,serotonin reuptake inhibitor,"DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4",neurology/psychiatry,depression,"NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1",Launched
vildagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N,Launched
vildagliptin (laf-237),dipeptidyl peptidase inhibitor,,endocrinology,diabetes mellitus,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,Launched
viloxazine,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression,"CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|",Launched
vimirogant,ror antagonist,RORC,neurology/psychiatry,multiple sclerosis,CCS(=O)(=O)c1ccc(CNC(=O)c2cnc3[C@H](C(C)C)N(C[C@@H]4CC[C@H](CC4)C(F)(F)F)Cc3c2)nc1,Preclinical
vimseltinib,csf1r inhibitor,CSF1R,,,CC(C)Nc1ncc(-c2ccc(Oc3ccnc(c3)-c3cnn(C)c3)c(C)n2)c(=O)n1C,Launched
vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|",Launched
vinblastine (sulfate),,,,,CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|,
vinburnine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",neurology/psychiatry,stroke,"CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41, CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41",Launched
vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC, CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC",Withdrawn
vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|",Launched
vincristine (sulfate),,,,,CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|,
vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma","CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|",Launched
vinflunine,microtubule inhibitor,,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|",Launched
vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|",Launched
vinpocetine,"phosphodiesterase inhibitor, sodium channel blocker","PDE1A, PDE1C",neurology/psychiatry,"stroke, senile dementia","CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|",Launched
viomycin,protein synthesis inhibitor,,infectious disease,tuberculosis,"NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4,10,15,23,29,42,&1:40,&2:35,w:35.35,t:45|",Launched
vipadenant,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N",Phase 1
vipivotide tetraxetan,glutamate carboxypeptidase inhibitor,FOLH1,oncology,prostate cancer,O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O,Phase 3
vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),"CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1",Launched
visomitin,antioxidant,,,,"CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|, CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|",Preclinical
vitamin-B12,,,hematology,megaloblastic anemia,"C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16,20,24,t:22,26,29|",Launched
vitamin-b12,,,hematology,megaloblastic anemia,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12,Launched
vitamin-E,"LDL oxidation inhibitor, PKC inhibitor","ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4",,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1,Launched
vixotrigine,sodium channel blocker,,,,NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1,Phase 2
VLX1570,deubiquitinase inhibitor,,,,[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F,Phase 1/Phase 2
VLX600,"antitumor agent, ubiquitin C-terminal hydrolase inhibitor","TP53, USP14",,,"CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1",Phase 1
VL285,PROTAC,,,,CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C,Preclinical
voclosporin,calcineurin inhibitor,,,,"[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C, [H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",Phase 3
voglibose,glucosidase inhibitor,MGAM,endocrinology,"diabetes mellitus, hyperglycemia","OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O",Launched
volasertib,PLK inhibitor,PLK1,,,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
volinanserin,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C, KCNH2",,,"COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC",Phase 3
vonoprazan,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD),"CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1",Launched
vorapaxar,thrombin inhibitor,F2R,cardiology,"myocardial infarction, peripheral artery disease (PAD)","CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1",Launched
vorasidenib,isocitrate dehydrogenase inhibitor,,,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F,Preclinical
voreloxin,topoisomerase inhibitor,TOP2A,,,"CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1",Phase 3
voriconazole,cytochrome P450 inhibitor,"CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1",infectious disease,"esophageal candidiasis, aspergillosis, skin infections","C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",Launched
vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
vortioxetine,"serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4",neurology/psychiatry,depression,"Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1",Launched
voruciclib,CDK9 inhibitor,,,,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F,Phase 1
voxelotor,hemoglobin modulator,,,,"CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O, CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O, CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O",Launched
voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",,,"CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O",Phase 2
VP-20629,beta amyloid antagonist,"PLA2G2E, SLC36A1",,,"OC(=O)CCc1c[nH]c2ccccc12, OC(=O)CCc1c[nH]c2ccccc12",Phase 1
VS-4718,focal adhesion kinase inhibitor,,,,"CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F",Phase 1
VT-464,cytochrome P450 inhibitor,CYP17A1,,,"CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1",Phase 2
VTP-27999,renin inhibitor,REN,,,"CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1",Phase 1
VUF10166,serotonin receptor antagonist,"HTR3A, HTR3B",,,"CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl",Preclinical
VUF10460,histamine receptor agonist,HRH4,,,"CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1",Preclinical
VUF11207,CC chemokine receptor agonist,ACKR3,,,"COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|",Preclinical
VU0155069,phospholipase inhibitor,PLD1,,,"C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1",Preclinical
VU0238429,acetylcholine receptor allosteric modulator,CHRM5,,,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
VU0240551,potassium/chloride cotransporter inhibitor,SLC12A5,,,Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1,Preclinical
VU0357121,glutamate receptor positive allosteric modulator,GRM5,,,"CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F",Preclinical
VU0360172,glutamate receptor positive allosteric modulator,GRM5,,,"Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1",Preclinical
VU0361737,glutamate receptor positive allosteric modulator,GRM4,,,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
VU0364439,glutamate receptor positive allosteric modulator,GRM4,,,"Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl",Preclinical
VU0364739,phospholipase inhibitor,PLD2,,,"Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1",Preclinical
VU0364770,glutamate receptor positive allosteric modulator,GRM4,,,"Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1",Preclinical
VU0422288,glutamate receptor positive allosteric modulator,GRM3,,,"Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1",Preclinical
VU10010,acetylcholine receptor allosteric modulator,CHRM4,,,"Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1",Preclinical
VU152100,acetylcholine receptor allosteric modulator,CHRM4,,,"COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1",Preclinical
VU1545,glutamate receptor positive allosteric modulator,GRM5,,,"[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1",Preclinical
VU29,glutamate receptor potentiator,GRM5,,,"[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1",Preclinical
VU591,potassium channel blocker,KCNJ1,,,"[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1",Preclinical
VX-11e,MAP kinase inhibitor,MAPK1,,,"Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1",Preclinical
VX-222,HCV inhibitor,,,,"C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|, C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|",Phase 2
VX-702,p38 MAPK inhibitor,"IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF",,,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
VX-745,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",,,"Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1",Phase 2
VX-765,caspase inhibitor,CASP1,,,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
vx-765,caspase inhibitor,,,,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
vx-984,dna repair enzyme inhibitor,,oncology,breast cancer,[2H]c1nc(C)nc([2H])c1-c1cc(NC[C@@H](C)c2cccc3c(ccnc23)C(=O)NC)ncn1,Phase 1
W-54011,anaphylatoxin chemotactic receptor antagonist,C5AR1,,,"COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|",Preclinical
walrycin-B,transcriptional regulatory protein WalR,,,,"Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F",Preclinical
warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology, hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction, deep vein thrombosis (dvt), pulmonary embolism (pe), atrial fibrillation (af), myocardial infarction","CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O",Launched
WAY-100635,serotonin receptor antagonist,HTR1A,,,"COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1",Phase 1
WAY-161503,serotonin receptor agonist,HTR2C,,,"Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|",Preclinical
WAY-170523,metalloproteinase inhibitor,MMP13,,,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
way-181187,serotonin receptor agonist,HTR2A,neurology/psychiatry,depression,NCCc1cn(c2ccccc12)S(=O)(=O)c1c(Cl)nc2sccn12,Preclinical
WAY-200070,estrogen receptor agonist,"ERBB2, ERBB3, ERBB4, ESR2",,,"Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1",Preclinical
WAY-207024,gonadotropin releasing factor hormone receptor antagonist,"GNRHR, HRH2, TACR2",,,"CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1",Preclinical
WAY-208466,serotonin receptor agonist,"DRD2, HTR2A, HTR2C, HTR6, HTR7",,,"CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1",Preclinical
WAY-213613,glutamate inhibitor,SLC1A2,,,"N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O",Preclinical
WAY-255348,progesterone receptor antagonist,,,,Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N,Preclinical
WAY-316606,secreted frizzled related protein inhibitor,SFRP1,,,"FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1",Preclinical
WAY-362450,FXR agonist,NR1H4,,,"CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|",Phase 1
WAY-600,mTOR inhibitor,MTOR,,,"C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1",Preclinical
WAY-629,serotonin receptor agonist,HTR2C,,,"C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13",Preclinical
WB-4101,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A",,,"COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|",Preclinical
WDR5-0103,histone lysine methyltransferase inhibitor,WDR5,,,"COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1",Preclinical
WEHI-345-analog,SRC inhibitor,,,,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C",Preclinical
WH-4-023,SRC inhibitor,"LCK, SRC",,,"COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1",Preclinical
WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",,,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
WIKI4,"tankyrase inhibitor, WNT pathway inhibitor",TNKS2,,,"COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1",Preclinical
WIN-18446,aldehyde dehydrogenase inhibitor,ALDH1A2,,,ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl,Preclinical
WIN-64338,bradykinin receptor antagonist,BDKRB2,,,"CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1",Preclinical
wiskostatin,"actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor",WASL,,,"CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|",Preclinical
wnt-c59,porcupine inhibitor,PORCN,,,"Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1",Preclinical
wortmannin,PI3K inhibitor,"PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC",,,"COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|",Preclinical
WP1066,STAT inhibitor,STAT3,,,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",,,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
WP921,,,,,OC(=O)Cn1nnnc1-c1ccsc1,Preclinical
WR99210,dihydrofolate reductase inhibitor,TYMS,infectious disease,malaria,"CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|",Preclinical
WWL-113,carboxylesterase inhibitor,CES3,,,"CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1",Preclinical
WWL-123,monoacylglycerol lipase inhibitor,ABHD6,,,"CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O",Preclinical
WY-16922,histamine release inhibitor,,,,CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O,Phase 1
WYE-125132,mTOR inhibitor,MTOR,,,"CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|",Preclinical
WYE-354,mTOR inhibitor,MTOR,,,"COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1",Preclinical
WYE-687,mTOR inhibitor,MTOR,,,"COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1",Preclinical
WZ-3146,EGFR inhibitor,EGFR,,,"CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1",Preclinical
WZ-4002,EGFR inhibitor,"EGFR, ERBB2",,,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
WZ4003,AMPK inhibitor,"NUAK1, NUAK2",,,"CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1",Preclinical
WZ8040,EGFR inhibitor,EGFR,,,"CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1",Preclinical
WZ811,CC chemokine receptor antagonist,CXCR4,,,"C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1",Preclinical
xaliproden,serotonin receptor agonist,HTR1A,,,"FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|",Phase 3
xamoterol,adrenergic receptor agonist,ADRB1,,,"OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1",Phase 3
xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",,,"CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|",Phase 3
xanthone,antimalarial agent,,,,"O=c1c2ccccc2oc2ccccc12, O=c1c2ccccc2oc2ccccc12",Preclinical
XAV-939,tankyrase inhibitor,"TNKS, TNKS2",,,"FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1",Preclinical
XBD173,benzodiazepine receptor ligand,TSPO,,,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
XD-14,bromodomain inhibitor,"BRD2, BRD3, BRD4, BRDT",,,"CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1",Preclinical
XE-991,potassium channel blocker,"KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5",,,"O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12",Preclinical
xenalipin,,,,,"OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F, OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F",Phase 2
xibenolol,adrenergic receptor antagonist,,,,"Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|",Phase 3
xiliertinib,egfr inhibitor,"EGFR, ERBB4",oncology,esophageal cancer,O=C(N1C[C@]2([H])N(C)CC[C@]2([H])C1)NC3=CC4=C(NC5=CC=CC(C#C)=C5)N=CN=C4C=C3OC,Phase 1
xilobam,,,,,"CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C, CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C",Phase 1
xipamide,carbonic anhydrase inhibitor,SLC12A3,cardiology,"edema, hypertension","Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O",Launched
XL019,JAK inhibitor,"JAK1, JAK2, JAK3",,,"O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1",Phase 1
XL041,LXR agonist,,,,CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O,Preclinical
XL147,PI3K inhibitor,"PIK3CA, PIK3CD, PIK3CG",,,"Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1",Phase 2
XL228,"Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor","IGF1R, SRC",,,"CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1",Phase 1
XL388,mTOR inhibitor,MTOR,,,"Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O",Preclinical
XL647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",,,"COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1",Phase 3
XL888,HSP inhibitor,,,,[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|,Phase 1
XMD17-109,MAP kinase inhibitor,MAPK7,,,"CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",Preclinical
XMD8-92,MAP kinase inhibitor,"DCLK2, MAPK7, PLK4, TNK1",,,"CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1",Preclinical
xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|",Launched
xylometazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","otolaryngology, allergy","nasal congestion, allergic rhinitis","Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|",Launched
xylose,,,,,"OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O",Launched
Y-11,focal adhesion kinase inhibitor,PTK2,,,"OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2",Preclinical
Y-134,estrogen receptor antagonist,"ESR1, ESR2",,,"CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1",Preclinical
Y-26763,potassium channel activator,KCNJ8,,,"CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",Phase 1
Y-27152,potassium channel activator,KCNJ8,,,"CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",Phase 1
Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",,,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
Y-29794,prolyl endopeptidase inhibitor,PREP,,,"CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1",Preclinical
Y-320,interleukin inhibitor,IL17A,,,"Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N",Preclinical
Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",,,"C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12",Phase 2
YC-1,guanylyl cyclase activator,"GUCY1A2, GUCY1A3, GUCY1B3, HIF1A",,,"OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12",Preclinical
YIL-781,ghrelin receptor antagonist,GHSR,,,"CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1",Preclinical
YK-4-279,apoptosis inhibitor,"EWSR1, FLI1",,,"COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|",Preclinical
YL0919,selective serotonin reuptake inhibitor (SSRI),,,,OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1,Preclinical
YM-022,CCK receptor antagonist,CCKBR,,,"Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|, Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|",Phase 2
YM-155,survivin inhibitor,BIRC5,,,"COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O",Phase 2
YM-201636,PI3K inhibitor,,,,"Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
YM-244769,sodium/calcium exchange inhibitor,,,,"Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1, Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1",Preclinical
YM-298198,glutamate receptor antagonist,GRM1,,,"CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C",Preclinical
YM-298198-desmethyl,glutamate receptor antagonist,GRM1,,,"Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1",Preclinical
YM-511,aromatase inhibitor,CYP19A1,,,"Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1, Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1",Phase 2
YM-58483,calcium channel blocker,"TRPC3, TRPC5, TRPM4",,,"Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F",Preclinical
YM-750,ACAT inhibitor,SOAT1,,,"Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1",Phase 1
YM-90709,IL5 inhibitor,"CSF2RB, IL5RA",,,"COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC",Preclinical
YM-976,phosphodiesterase inhibitor,PDE4A,,,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
YO-01027,gamma secretase inhibitor,,,,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
yoda-1,piezo channel activator,PIEZO1,,,"Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1",Preclinical
yohimbine,adrenergic receptor antagonist,"ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8",cardiology,"cardiac arrythmia, bradycardia","COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12",Launched
YS-035,calcium channel blocker,,,,"COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC",Preclinical
YS-201,calcium receptor antagonist,,,,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|",Preclinical
YZ9,phosphofructokinase inhibitor,"MIF, PFKFB3",,,"CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O",Preclinical
Y16,rho associated kinase inhibitor,RHOA,,,"Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1",Preclinical
zacopride,serotonin receptor antagonist,"HTR3A, HTR3B, HTR4, HTR5A",,,"COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|",Phase 2
zafirlukast,leukotriene receptor antagonist,"CYSLTR1, CYSLTR2",pulmonary,asthma,"COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C",Launched
zalcitabine,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1),"Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1",Launched
zaldaride,calmodulin antagonist,CALM1,,,"C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|",Phase 3
zaltidine,histamine receptor antagonist,HRH2,,,"Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1",Phase 3
zaltoprofen,cyclooxygenase inhibitor,,"endocrinology, neurology/psychiatry","fever, pain relief","C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|",Launched
ZAMI-633,urease inhibitor,,,,CCC(=O)NO,Phase 3
zamicastat,dopamine beta hydroxylase inhibitor,DBH,pulmonary,pulmonary arterial hypertension (pah),Fc1cc(F)c2OC[C@@H](Cc2c1)n1c(CCNCc2ccccc2)c[nH]c1=S,Phase 2
zamifenacin,acetylcholine receptor antagonist,CHRM3,,,"C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1",Phase 3
zanamivir,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection,"CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|",Launched
zandelisib,pi3k inhibitor,PIK3CD,oncology,non-hodgkin lymphoma (nhl),CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1,Phase 2
zanubrutinib,Bruton's tyrosine kinase (BTK) inhibitor,,,,NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1,Launched
ZAPA,,,,,"NC(=N)S\C=C/C(O)=O, NC(=N)S\C=C/C(O)=O",Preclinical
zaprinast,phosphodiesterase inhibitor,"GPR35, PDE1A, PDE4D, PDE5A, PDE9A",,,"CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1",Phase 2
zardaverine,phosphodiesterase inhibitor,PDE4D,,,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
zatebradine,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",,,"COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC",Phase 3
zaurategrast ethyl ester,integrin antagonist,"ITGA4, ITGB7",neurology/psychiatry,multiple sclerosis,O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O,Phase 2
ZCL-278,CDC inhibitor,CDC42,,,"Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1",Preclinical
ZD-0947,potassium channel activator,,,,"FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|",Preclinical
ZD-2079,adrenergic receptor agonist,ADRB3,,,"O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
zd-4190,antitumor agent,"EGFR, KDR",oncology,gastric adenocarcinoma,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,Phase 1
ZD-7114,adrenergic receptor agonist,ADRB3,,,"COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1",Phase 1
ZD-7155,angiotensin receptor antagonist,AGTR1,,,"CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1",Preclinical
ZD-7288,HCN channel blocker,"HCN1, HCN2, HCN3, HCN4",,,"CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1",Phase 2
zeatin,,,,,"C\C(CO)=C/CNc1ncnc2nc[nH]c12, C\C(CO)=C/CNc1ncnc2nc[nH]c12",Phase 1
zebularine,DNA methyltransferase inhibitor,"CDA, DNMT1",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O",Preclinical
zeranol,estrogen receptor agonist,"ACTA2, ESR1, NR1I2, SHBG",,,C[C@H]1CCC[C@H](O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1,Launched
zibotentan,endothelin receptor antagonist,EDNRA,,,"COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1",Phase 3
zidebactam,beta lactamase inhibitor,,infectious disease,gram-negative bacterial infections,"OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=O |a:6,9,18|",Phase 1
zidovudine,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,"human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)","Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O",Launched
zileuton,"leukotriene synthesis inhibitor, lipoxygenase inhibitor",ALOX5,pulmonary,asthma,"C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|",Launched
zilpaterol,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid,CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O,Launched
zimelidine,selective serotonin reuptake inhibitor (SSRI),"MAOA, MAOB, SLC6A4",,,"CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1",Withdrawn
zinc-undecylenate,other antifungal,,infectious disease,tinea pedis,"C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C, C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C",Launched
zindotrine,phosphodiesterase inhibitor,,,,Cc1cc(nn2cnnc12)N1CCCCC1,Phase 2
ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
ziritaxestat,autotaxin inhibitor,,,,CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1,Phase 3
ZK-164015,estrogen receptor antagonist,"ESR1, ESR2",,,"CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1",Preclinical
ZK-200775,kainate receptor antagonist,,,,"OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F",Phase 2
ZK-811752,CC chemokine receptor antagonist,CCR1,,,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",,,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",,,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
ZLN005,,,,,"CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1",Preclinical
ZLN024,AMPK activator,"PRKAA1, PRKAB1, PRKAG1",,,"Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1",Preclinical
ZM-226600,Kir6 channel (KATP) activator,,,,"C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|, C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|",Preclinical
ZM-241385,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1",Preclinical
ZM-306416,"Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",,,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
ZM-323881,VEGFR inhibitor,KDR,,,"Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O",Preclinical
ZM-336372,RAF inhibitor,"BRAF, LCK, MAPK14, RAF1",,,"CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1",Preclinical
ZM-39923,JAK inhibitor,"JAK1, JAK3",,,"CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1",Preclinical
ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",,,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
zofenopril-calcium,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,"C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1",Launched
zolantidine,histamine receptor antagonist,,,,"C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1, C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1",Preclinical
zoledronic-acid,bone resorption inhibitor,"FDPS, GGPS1",endocrinology,Paget's disease,"OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O",Launched
zoliflodacin,antibacterial ,,,,[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O,Phase 3
zolimidine,mucus protecting agent,,gastroenterology,"peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)",CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1,Launched
zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
zomepirac,prostaglandin synthesis inhibitor,PTGDR2,,,"Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1",Withdrawn
zometapine,,,,,Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|,Phase 2
zoniporide,sodium/hydrogen exchanger inhibitor,SLC9A1,,,"NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12",Phase 3
zonisamide,"sodium channel blocker, T-type calcium channel blocker","CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,"seizures, epilepsy","NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12",Launched
zopolrestat,,"AKR1B1, AKR1B10",,,"OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12, OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12",Phase 2
zosuquidar,P glycoprotein inhibitor,"ABCB1, ABCB4",,,"O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F",Phase 3
zotarolimus,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|",Launched
zotatifin,eukaryotic translation initiation factor inhibitor,EIF4A1,,,COc1cc2O[C@]3([C@@H]([C@@H](CN(C)C)[C@@H](O)[C@@]3(O)c2c(OC)n1)c4ccccc4)c5ccc(cc5)C#N,Phase 1
zotepine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4",neurology/psychiatry,schizophrenia,"CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|",Launched
zoxazolamine,myorelaxant,,,,"Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1",Phase 2
ZSET1446,nicotinic receptor agonist,,,,"O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|",Preclinical
ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",,,"FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1",Phase 1/Phase 2
zuclopenthixol,dopamine receptor antagonist,"ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A",neurology/psychiatry,"schizophrenia, bipolar disorder","OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1",Launched
zuranolone,GABA receptor agonist,,,,[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H],Phase 3
Z160,N-type calcium channel blocker,CACNA2D1,,,"O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Phase 2
"1,12-Besm",polyamine biosynthesis inhibitor,,,,CCNCCCNCCCCNCCCNCC,Phase 2
"1,2,3,4,5,6-hexabromocyclohexane",JAK inhibitor,JAK2,,,"BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br",Preclinical
"1,3-dipropyl-8-phenylxanthine",adenosine receptor antagonist,,,,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1",Preclinical
"1,4-butanediol","benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist","MAN1B1, PLA2G2A, PLA2G2E",,,OCCCCO,Phase 1
"1,5-dicaffeoylquinic-acid",,,,,"O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O, O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O",Phase 1
"1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",,,,,Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2,Preclinical
"1-(1,2-diphenylethyl)piperidine-(+/-)",glutamate receptor antagonist,,,,"C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|, C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|",Preclinical
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol,,,,,"CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|",Preclinical
"1-(4-(((2s,4r)-2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine",sterol demethylase inhibitor,,infectious disease,vulvovaginal candidiasis,CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1,Launched
1-acetyl-4-methylpiperazine,acetylcholine receptor agonist,,,,"CN1CCN(CC1)C(C)=O, CN1CCN(CC1)C(C)=O",Preclinical
1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",,,"Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1",Preclinical
1-deoxymannojirimycin,alpha mannosidase inhibitor,MAN2A1,,,"OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O",Preclinical
1-EBIO,potassium channel activator,"KCNN1, KCNN2, KCNN3, KCNN4",,,"CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O",Preclinical
1-ethyl-2-pyrrolidone,transdermal absorption-enhancing compound,,,,CCN1CCCC1=O,Preclinical
1-hexadecanal,sphingosine 1-phosphate receptor substrate,"DBI, RHO",,,"CCCCCCCCCCCCCCCC=O, CCCCCCCCCCCCCCCC=O",Preclinical
1-hexadecanol,,,dermatology,cosmetic,"CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO",Launched
1-naphthyl-PP1,SRC inhibitor,SRC,,,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
1-octacosanol,,,,,"CCCCCCCCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCCCCCCCO",Phase 2
1-octanol,,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1",,,"CCCCCCCCO, CCCCCCCCO, CCCCCCCCO",Phase 2
1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",,,"NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1",Preclinical
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime,,,,,"CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|",Preclinical
"1h,1'h-2,2'-bibenzo[d]imidazole",dna inhibitor,,,,c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1,Phase 2
"1S,2R-phenylpropanolamine",adrenergic receptor agonist,,,,C[C@@H](N)[C@@H](O)c1ccccc1,Withdrawn
10-deacetylbaccatin,antitumor agent,,,,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|",Preclinical
10-DEBC,AKT inhibitor,PIM1,,,"CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12",Preclinical
10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,,,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
10058-F4,c-Myc inhibitor,,,,"CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1",Preclinical
12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",,,"CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|",Phase 2
1400W,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,"CC(=N)NCc1cccc(CN)c1, CC(=N)NCc1cccc(CN)c1",Preclinical
"16,16-dimethylprostaglandin-e2",prostanoid receptor agonist,HPGD,,,"CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",Phase 2
"17,21-dihydroxypregn-4-ene-3,20-dione",glucocorticoid receptor agonist,,"gastroenterology, rheumatology, dermatology","ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema",C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,"AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR",obstetrics/gynecology,spontaneous preterm birth,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|,Launched
17-PA,glucocorticoid receptor agonist,,,,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|",Preclinical
2'-C-methylguanosine,HCV inhibitor,,,,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O,Preclinical
2'-MeCCPA,adenosine receptor agonist,ADORA1,,,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
"2,3-cis/exo-camphanediol",,,,,CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O,Phase 1
"2,3-cis/exo-pinanediol",,,,,CC1(C)C2CC1[C@](C)(O)[C@H](O)C2,Phase 1
"2,3-DCPE",BCL-XL downregulator,BCL2L1,,,"OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl",Preclinical
"2,4-dihydroxypyrimidine-5-carboxylic acid",,,,,O=C(N1)NC=C(C(O)=O)C1=O,Preclinical
"2,4-dinitrochlorobenzene",thioredoxin inhibitor,TXN,,,[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O,Phase 2
"2,4-dinitrophenol",ATP synthase inhibitor,APP,,,Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O,Preclinical
"2,5-furandimethanol",hemoglobin modulator,HBB,,,OCc1ccc(CO)o1,Phase 2
"2,6-dimethylpiperidine",,,,,"C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|, C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|",Preclinical
"2-(((((((2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-n,n,n-trimethylethan-1-aminium",,,,,C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O,
2-((2-ethoxyphenoxy)(phenyl)methyl)morpholine methanesulfonate,,,,,CCOc1ccccc1OC(C1CNCCO1)c1ccccc1,
"2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",,,,,ClC=C1Nc2sc3CCCCc3c2C(=O)N1,Preclinical
2-(1-adamantylamino)benzoic-acid,,,,,OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2,Preclinical
2-(3-mercaptopropyl)pentanedioic-acid,glutamate carboxypeptidase inhibitor,FOLH1,,,"OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|",Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole,serotonin receptor agonist,HTR4,,,"C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1",Preclinical
2-amino-2-(4-hydroxyphenyl)acetic acid,,,,,"N[C@@H](C(O)=O)c1ccc(O)cc1 |&1:1,r|",
2-amino-4-(methylselanyl)butanoic acid,,,,,"C[Se]CC[C@@H](N)C(O)=O |&1:4,r|",
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,"CA12, CA14, CA2, CA6, CA9",,,Nc1ccccc1S(N)(=O)=O,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor","TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6",,,"NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1",Preclinical
2-BFI,imidazoline receptor ligand,"ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB",,,C1CN=C(N1)c1cc2ccccc2o1 |c:2|,Preclinical
2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",,,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
2-chloroadenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B",,,"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Preclinical
2-chloropyrazine,,,,,"Clc1cnccn1, Clc1cnccn1",Preclinical
2-CMDO,dopamine receptor antagonist,"DRD2, DRD4",,,"CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|",Preclinical
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose,,,"oncology, endocrinology","pancreatic cancer, hypoglycemia","CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|",Preclinical
2-deoxyglucose,glycolysis inhibitor,"SLC2A1, SLC2A2, SLC2A3, SLC2A4",,,"OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O",Phase 2
2-ethoxybenzoic-acid,analgesic agent,,,,"CCOc1ccccc1C(O)=O, CCOc1ccccc1C(O)=O",Phase 1
"2-ethyl-1,3-hexanediol",,,,,"CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|",Preclinical
2-fluoro-2-deoxy-D-galactose,,LCT,,,"OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|, OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|",Phase 1
2-fluorofucose,,,,,C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|,Phase 1
"2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione",,,,,"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|",Preclinical
2-hydroxyethyl-salicylate,,,neurology/psychiatry,pain relief,OCCOC(=O)c1ccccc1O,Launched
2-hydroxyflutamide,androgen receptor antagonist,AR,,,"CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Phase 2
2-hydroxysaclofen,GABA receptor antagonist,"GABBR1, GABBR2",,,"NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",Preclinical
2-iminobiotin,nitric oxide synthase inhibitor,"NOS1, NOS2",,,"NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|",Phase 2
2-iodohippuric-acid,,,,,"OC(=O)CNC(=O)c1ccccc1I, OC(=O)CNC(=O)c1ccccc1I",Preclinical
2-iodomelatonin,melatonin receptor agonist,"MTNR1A, MTNR1B, NQO2",,,"COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1",Preclinical
2-isopropyl-5-methylcyclohexanol,,,,,CC(C)C1CCC(C)CC1O,
2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",,,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,"HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6",,,"Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN",Preclinical
2-methyl-5-nitrophenol,,,,,"Cc1ccc(cc1O)[N+]([O-])=O, Cc1ccc(cc1O)[N+]([O-])=O",Preclinical
2-methylimidazole,cholesterol inhibitor,,,,Cc1ncc[nH]1,Preclinical
2-octyldodecan-1-ol,,,,,"CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|",Preclinical
2-oleoylglycerol,glucose dependent insulinotropic receptor ligand,GPR119,,,"CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO",Phase 1
2-oxoglutaric-acid,,OXGR1,,,"OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O",Preclinical
2-oxopropanoate,pyruvate dehydrogenase kinase inhibitor,ABAT,,,OC(=C)C(O)=O,Preclinical
2-phenylmelatonin,melatonin receptor agonist,"MTNR1A, MTNR1B",,,"COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1",Preclinical
2-PMDQ,adrenergic receptor antagonist,ADRA1A,,,"O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|",Preclinical
2-pyridylethylamine,histamine receptor agonist,HRH1,,,"NCCc1ccccn1, NCCc1ccccn1, NCCc1ccccn1",Preclinical
2-TEDC,lipoxygenase inhibitor,ALOX12,,,"Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O",Preclinical
2-thiouracil,,,,,"O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1",Preclinical
20-HETE,ion channel antagonist,,,,OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,Preclinical
20-hydroxyecdysone,ecdysone receptor modulator,,,,CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|,Phase 2
3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,,,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
"3,3'-dichlorobenzaldazine",glutamate receptor modulator,GRM5,,,"Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1",Preclinical
"3,3'-diindolylmethane","CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor","AR, HIF1A, IFNG, PI3",,,"C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12",Phase 3
"3,4-DCPG-(+/-)",glutamate receptor agonist,GRM8,,,"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|",Preclinical
"3,4-DCPG-(R)",glutamate receptor antagonist,,,,"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",Preclinical
"3,4-DCPG-(S)",glutamate receptor agonist,GRM8,,,"N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",Preclinical
"3,4-methylenedioxy-beta-nitrostyrene","SRC inhibitor, SYK inhibitor","SRC, SYK",,,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
"3,5-DHPG-(S)",glutamate receptor agonist,GRM1,,,"N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1",Preclinical
3-(4-methylbenzylidene)camphor,endocrine disruptor,,dermatology,sunscreen lotion,"Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|, Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|",Launched
3-alpha-bis(4-fluorophenyl)methoxytropane hydrochloride,dopamine reuptake inhibitor,,,,CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,Preclinical
3-alpha-bis-(4-fluorophenyl)-methoxytropane,dopamine uptake inhibitor,"CHRM1, SLC6A2, SLC6A3, SLC6A4",,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|",Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one,,"HSD17B11, IGHG2, SULT2A1",,,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|",Preclinical
3-amino-benzamide,PARP inhibitor,PARP1,,,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
3-anilinopropan-1-ol,,,,,"OCCCNc1ccccc1, OCCCNc1ccccc1",Preclinical
3-AQC,serotonin receptor agonist,HTR3A,,,"C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N",Preclinical
3-benzoyl-n-(1-phenylethyl)thiazolidine-4-carboxamide,,,,,"C[C@@H](NC(=O)[C@H]1CSCN1C(=O)c1ccccc1)c1ccccc1 |&1:1,&2:5,r|",
3-bromo-7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,"[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12",Preclinical
3-bromocamphor,,,,,"[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1,3,6|, CC1(C)C2CCC1(C)C(=O)C2Br",Launched
3-bromopyruvate,hexokinase inhibitor,HK2,,,"OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr",Preclinical
3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",,,"N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",Preclinical
3-carboxy-4-hydroxyphenylglycine-(S),glutamate receptor antagonist,"GRM1, GRM5",,,"N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",Preclinical
3-CPMT,dopamine reuptake inhibitor,,,,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|",Preclinical
3-cpmt,dopamine reuptake inhibitor,,,,CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1,Preclinical
3-deazaadenosine,adenosylhomocysteinase inhibitor,AHCY,,,"Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|, Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|",Phase 2
3-deazaadenosine (hydrochloride),adenosylhomocysteinase inhibitor,AHCY,Immunology,rheumatoid arthritis,Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Phase 2
3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,,,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|",Preclinical
3-deazauridine,cytidine deaminase inhibitor,,,,"OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|",Preclinical
"3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl 3,4,6-trideoxy-3-(dimethylamino)hexopyranoside",,,,,"CC[C@H]1OC(=O)C[C@@H](O)[C@@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H]([C@@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@@]2(C)O[C@@H]2[C@@H]1C |&1:2,&2:7,&3:9,&4:11,&5:13,&6:15,&7:18,&8:19,&9:24,&11:35,&12:38,&13:39,r,t:34|",
3-hydroxy-3-phenylpentanamide,GABA receptor modulator,,,,"CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|, CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|",Phase 1
3-indolebutyric-acid,,"B2M, HLA-A, TRAC, TRBC1",,,"OC(=O)CCCc1c[nH]c2ccccc12, OC(=O)CCCc1c[nH]c2ccccc12",Preclinical
3-MATIDA,glutamate receptor antagonist,GRM1,,,"Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|",Preclinical
3-methyl-GABA,GABA aminotransferase activator,ABAT,,,"C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|",Preclinical
3-methyladenine,PI3K inhibitor,PI3,,,"Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12",Preclinical
3-MPPI,adrenergic receptor ligand,ADRA1A,,,"COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1",Preclinical
3PO,phosphofructokinase inhibitor,PFKFB3,,,"O=C(\C=C\c1cccnc1)c1ccncc1, O=C(\C=C\c1cccnc1)c1ccncc1",Preclinical
"4,4'-DDT",,,,,Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl,Preclinical
"4,4-pentamethylenepiperidine",M2 channel blocker,,,,"C1CCC2(CC1)CCNCC2, C1CCC2(CC1)CCNCC2",Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,"AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1",,,"Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br",Preclinical
"4,6-diamino-3-hydroxy-2-(pentofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxyhexopyranoside",,,,,NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O,
4-(aminomethyl)benzoic-acid,hemostatic agent,,,,NCc1ccc(cc1)C(O)=O,Preclinical
4-(3-phosphonopropyl)-2-piperazinecarboxylic acid,,,,,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1 |&1:3,r|",
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,,,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
"4-acetyl-1,1-dimethylpiperazinium",acetylcholine receptor agonist,,,,"CC(=O)N1CC[N+](C)(C)CC1, CC(=O)N1CC[N+](C)(C)CC1",Preclinical
4-aminohippuric-acid,,SLC22A6,nephrology,renal diagnostic agent,"Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O",Launched
4-carboxy-3-hydroxyphenylglycine-(RS),"glutamate receptor agonist, glutamate receptor antagonist",GRM1,,,"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|",Preclinical
4-carboxy-3-hydroxyphenylglycine-(S),"glutamate receptor agonist, glutamate receptor antagonist","GRM1, GRM2",,,"N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1",Preclinical
4-chlorophenylguanidine,urokinase inhibitor,PLAUR,,,"NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1",Preclinical
4-CMTB,free fatty acid receptor agonist,FFAR2,,,"CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|",Preclinical
4-cpa,pesticide,DPP9,,,OC(=O)COc1ccc(Cl)cc1,Preclinical
4-DAMP,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",,,"C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1",Preclinical
4-galactosyllactose,,,,,"OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|",Preclinical
4-HQN,PARP inhibitor,PARP1,,,"O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12",Preclinical
4-hydroxy-phenazone,,,,,"Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C",Preclinical
4-IBP,sigma receptor agonist,SIGMAR1,,,Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1,Preclinical
4-iodo-L-phenylalanine,,DPP4,,,"N[C@H](Cc1ccc(I)cc1)C(O)=O, N[C@H](Cc1ccc(I)cc1)C(O)=O",Preclinical
4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,,,Ic1cc(ncn1)-c1ccccc1,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",,,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
4-methylhistamine,histamine receptor agonist,HRH4,,,Cc1nc[nH]c1CCN,Preclinical
4-mu-8C,IRE1 inhibitor,ERN1,,,"Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12",Preclinical
4-P-PDOT,melatonin receptor antagonist,"MTNR1A, MTNR1B",,,"CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|",Preclinical
4-phenolsulfonic-acid,,,,,Oc1ccc(cc1)S(O)(=O)=O,Preclinical
"4-phenyl-1,2,3,4-tetrahydroisoquinoline",dopamine release inhibitor,,,,"C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|, C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|",Preclinical
4-PPBP,sigma receptor ligand,SIGMAR1,,,"C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1",Preclinical
4-propylbenzoic-acid,,,,,CCCc1ccc(cc1)C(O)=O,Preclinical
4-pyrimidinecarbonitrile,,,,,N#Cc1ccncn1,Preclinical
4-tert-butylphenol,,,,,"CC(C)(C)c1ccc(O)cc1, CC(C)(C)c1ccc(O)cc1",Preclinical
4BP-TQS,nicotinic receptor agonist,CHRNA7,,,"NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|",Preclinical
4EGI-1,protein synthesis inhibitor,EIF4E,,,OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1,Preclinical
4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",,,"OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|",Preclinical
4SC-202,HDAC inhibitor,HDAC1,,,"Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1",Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-),adenosine receptor agonist,ADORA1,,,"O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|",Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,"GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",,,"OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1",Preclinical
"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one",,,,,CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1,Preclinical
5-[({[1-(2-chloroethyl)-2-oxohydrazino]carbonyl}amino)methyl]-2-methyl-4-pyrimidinamine hydrochloride,,,,,Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1,
"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",,TLR7,,,Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,Preclinical
5-aminolevulinic-acid,oxidizing agent,ALAD,"oncology, dermatology","glioma, actinic keratosis (AK)","NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O",Launched
5-BDBD,purinergic receptor antagonist,P2RX4,,,"Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|",Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7",,,"NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O",Preclinical
5-fluoro-3-pyridyl-methanol,,,,,OCc1cncc(F)c1,Preclinical
5-fluoropyrimidine,kinase inhibitor,,,,Fc1cncnc1,Phase 3
5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
5-FP,thymidylate synthase inhibitor,TYMS,,,"Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1",Phase 1
5-HMF,,,,,"OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1",Phase 2
5-hydroxydecanoic-acid,,,,,CCCCC[C@@H](O)CCCC(O)=O |&1:5|,Preclinical
5-hydroxyectoine,,,,,"CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|",Preclinical
5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,,,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
5-hydroxytryptophan,neurotransmitter,"SLC36A1, SLC36A2",neurology/psychiatry,insomnia,"N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|",Launched
5-iodo-A-85380,acetylcholine receptor agonist,,,,"Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1",Phase 2
5-methylfurmethiodide,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4",,,"Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1",Preclinical
5-methylhydantoin-(D),,,,,"C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O",Preclinical
5-methylhydantoin-(L),,,,,C[C@@H]1NC(=O)NC1=O,Preclinical
5-octanoylsalicylic-acid,protein kinase activator,,,,CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O,Preclinical
"6,7-dehydro-17-acetoxy-progesterone",steroidal progestin,,,,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|",Preclinical
6-aminochrysene,transferase inhibitor,,,,Nc1cc2c3ccccc3ccc2c2ccccc12,Phase 2
6-aminopenicillanic-acid,,,,,"CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O",Preclinical
6-benzylaminopurine,purinergic receptor activator,,,,"C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1",Preclinical
6-chloromelatonin,melatonin receptor agonist,"MTNR1A, MTNR1B",,,"COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl",Preclinical
6-diazo-5-oxo-l-nor-leucine,glutaminase inhibitor,"GGT1, GLS",hematologic malignancy,burkitt's lymphoma,N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)O,Phase 2
6-diazo-5-oxo-L-norleucine,"glutamate receptor antagonist, glutaminase inhibitor",,,,"N[C@@H](CCC(=O)C[N+]#N)C(O)=O, N[C@@H](CCC(=O)C[N+]#N)C(O)=O",Preclinical
6-iodo-nordihydrocapsaicin,TRPV antagonist,TRPV1,,,"CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I",Preclinical
6-thio-2'-deoxyguanosine,telomerase inhibitor,TERT,oncology,non-small cell lung cancer (nsclc),OC[C@@H]1[C@H](C[C@H](N2C=NC3=C2NC(N)=NC3=S)O1)O,Preclinical
"7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one",,,,,O=C1N2CCCCC=C2Nc2ccccc12 |c:7|,Preclinical
7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate,,,,,N[C@@H](C(=O)NC1C2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1,
7-aminocephalosporanic-acid,beta lactamase inhibitor,,,,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|",Preclinical
7-chlorokynurenic-acid,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C",,,"OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1",Preclinical
7-hydroxy-DPAT,dopamine receptor agonist,"DRD2, DRD3",,,"CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|",Preclinical
7-hydroxy-PIPAT,dopamine receptor ligand,DRD3,,,CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|,Preclinical
7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",,,"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13",Phase 2
7-keto-DHEA,steroid,,,,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|,Launched
7-methoxytacrine,acetylcholinesterase inhibitor,ACHE,,,"COc1ccc2nc3CCCCc3c(N)c2c1, COc1ccc2nc3CCCCc3c(N)c2c1",Phase 2
7-methylxanthine,adenosine receptor antagonist,,,,"Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12",Phase 2
7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",,,"[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12",Preclinical
8-bromo-cAMP,PKA activator,,,,"Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|",Preclinical
8-bromo-cGMP,PKA activator,PRKG1,,,"Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|",Preclinical
8-hydroxy-DPAT,serotonin receptor agonist,"HTR5A, HTR7",,,"CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|",Preclinical
8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",,,"CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|",Preclinical
8-M-PDOT,melatonin receptor agonist,"MTNR1A, MTNR1B",,,"CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|",Preclinical
80841-78-7,,,,,Cc1oc(=O)oc1CCl,Preclinical
9-aminoacridine,,,,,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
9-aminocamptothecin,topoisomerase inhibitor,TOP1,,,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O",Phase 2
9-anthracenecarboxylic-acid,,"ANO1, CLCN1",,,"OC(=O)c1c2ccccc2cc2ccccc12, OC(=O)c1c2ccccc2cc2ccccc12",Preclinical
9-ing-41,gsk3b inhibitor,"GSK3B, MARK2",hematologic malignancy,myelofibrosis,Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12 |t:4|,Phase 2
